monday, april 20 at-a-glance - American Association for Cancer

Transcription

12_15AM_Mon_Layout 1 3/27/15 12:23 PM Page 293
MONDAY, APRIL 20 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
295-298
7:00 a.m.-8:00 a.m.
NCI/NIH-Sponsored Session
299
7:00 a.m.-12:00 p.m.
Poster Sessions
300-332
8:00 a.m.-12:00 p.m.
Late-Breaking and Clinical Trials Poster Sessions
333
8:15 a.m.-10:15 a.m.
Plenary Session
334
8:15 a.m.-10:15 a.m.
WICR Professional Advancement Session
335
9:15 a.m.-10:15 a.m.
AMC Career Conversations
336
9:30 a.m.-11:30 a.m.
Forum
337
10:00 a.m.-11:00 a.m.
Meet the AACR PCWG Chairperson
338
10:00 a.m.-11:00 a.m.
Meet the CEBP Editor-in-Chief
339
10:30 a.m.-12:00 p.m.
340
10:30 a.m.-12:20 p.m.
Clinical Trials Plenary Session
341
10:30 a.m.-12:30 p.m.
Major Symposia
342-345
10:30 a.m.-12:30 p.m.
Recent Advances in Diagnostics and
Therapeutics Research
346-347
10:30 a.m.-12:30 p.m.
Recent Advances in Epidemiology and
Prevention Research
348
10:30 a.m.-12:30 p.m.
Recent Advances in Organ Site Research
349
10:30 a.m.-12:30 p.m.
Regulatory Science and Policy Session
350
11:00 a.m.-12:00 p.m.
Meet the Research Icon: Dr. Charles L. Sawyers
351
11:15 a.m.-12:15 p.m.
Career Conversations
352
11:30 a.m.-12:30 p.m.
Meet the Charlotte Friend Lecturer
353
12:00 p.m.-1:00 p.m.
354
12:00 p.m.-1:30 p.m.
355
12:00 p.m.-1:30 p.m.
CICR Town Meeting
356
12:30 p.m.-2:00 p.m.
TME Working Group Special Session
357
12:30 p.m.-2:30 p.m.
SU2C Special Session
358
12:45 p.m.-2:00 p.m.
AACR Business Meeting
359
1:00 p.m.-2:00 p.m.
360
1:00 p.m.-2:00 p.m.
Meet the CAPR Editor-in-Chief
361
1:00 p.m.-3:00 p.m.
Major Symposia
362-365
April 18-22, 2015 • Philadelphia, PA
293
MONDAY, APRIL 20 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
1:00 p.m.-3:00 p.m.
Recent Advances in Diagnostics and
Therapeutics Research
366
1:00 p.m.-3:00 p.m.
Recent Advances in Epidemiology and
Prevention Research
367
1:00 p.m.-3:00 p.m.
Recent Advances in Organ Site Research
368-369
1:00 p.m.-5:00 p.m.
Poster Sessions
370-402
1:00 p.m.-5:00 p.m.
Late-Breaking Poster Sessions
403
1:30 p.m.-3:30 p.m.
404
2:00 p.m.-2:45 p.m.
405
2:00 p.m.-3:00 p.m.
Meet the Research Icon: Dr. Wan Ki Hong
405
2:30 p.m.-3:30 p.m.
Meet the 2015-2016 AACR President
406
3:00 p.m.-4:00 p.m.
Meet the Jane Cooke Wright Lecturer
407
3:00 p.m.-4:30 p.m.
AMC Meet and Greet
408
3:00 p.m.-5:00 p.m.
SU2C Special Session
409
3:00 p.m.-5:00 p.m.
Clinical Trials Minisymposium
410
3:00 p.m.-5:00 p.m.
AACR/JCA Joint Symposium
411
3:00 p.m.-5:00 p.m.
Minisymposia
412-416
3:30 p.m.-4:30 p.m.
AACR Princess Takamatsu Lectureship
417
3:30 p.m.-5:00 p.m.
418
3:30 p.m.-5:30 p.m.
Regulatory Science and Policy Session
419
4:00 p.m.-5:00 p.m.
Meet the MCR Editor-in-Chief
420
4:30 p.m.-5:30 p.m.
AACR-Rosenthal Award Lecture
421
5:00 p.m.-6:30 p.m.
Forums
422-423
5:00 p.m.-6:30 p.m.
AACR/ASCO Joint Session
424
5:00 p.m.-6:30 p.m.
Science Policy Session
425
5:00 p.m.-6:30 p.m.
Radiation Oncology Task Force Special Session
426
5:00 p.m.-6:30 p.m.
MICR Town Meeting
427
5:30 p.m.-6:30 p.m.
AACR-G. H. A. Clowes Lecture
428
6:00 p.m.-8:00 p.m.
CIMM and TME Working Groups Special Session
429
6:30 p.m.-8:00 p.m.
MEG Town Meeting
430
6:30 p.m.-8:45 p.m.
Professional Advancement Session
431
294
AACR ANNUAL MEETING 2015
MEET-THE-EXPERT SESSIONS
Monday, 7:00 a.m.-8:00 a.m.
Room 121, Pennsylvania Convention Center
At the Intersection of Chemistry, Genomics,
and Biology: Identifying New Targeted
Approaches in Leukemia
Kimberly Stegmaier, Dana-Farber Cancer Institute,
Boston, MA
This talk will focus on the integration of chemical and
functional genomic approaches to identify and validate
new targets in acute leukemias. In acute lymphoblastic
leukemia (ALL), a new approach to targeting mutated
Notch1 will be discussed from presentation of an initial
small-molecule library screen, through compound
validation and mechanism of action, to development and
testing of a more leukemia-selective derivitization strategy.
In the case of acute myeloid leukemia (AML), novel targets
of myeloid differentiation will be presented.
genetic alterations that occur in bladder cancer, yet the
specific functional drivers of these processes are only now
beginning to be understood. This functional delineation is
critical in providing targets for therapeutic intervention. We
used a new functional genomic screen in experimental
tumors and human specimens and found AGL, a glycogen
debranching enzyme deficient in glycogen storage disease,
is a new suppressor of in vivo bladder cancer growth and
patient prognostic. Metabolic and transcriptional profiling
coupled with gene targeting studies showed that reduced
AGL enhances tumor growth by inducing hyaluronic acid
synthesis. Surprisingly, low AGL also makes cells vulnerable
to molecular blockade of glucose import and autophagy.
This work is the first to show an enzyme implicated in
congenital liver disease also regulates cancer growth and
provides hitherto unappreciated biomarker and therapeutic
opportunities.
Terrace Ballroom II-III (400 Level), Pennsylvania
Convention Center
Basic Science Insights to Guide PI3K
Pathway Targeting in Cancer
The Cancer Epigenome
Bart Vanhaesebroeck, UCL Cancer Institute, London,
United Kingdom
Peter A. Jones, Van Andel Research Institute,
Grand Rapids, MI
Deregulation of PI3K pathway components is very common
in cancer, and therapeutic interference with PI3K signaling
is high on the pharma agenda. Current basic science
insight into the roles of PI3K and downstream signaling in
cancer biology will be reviewed. This includes the roles of
the different PI3K isoforms, the existence of feedback
loops, and the emerging evidence for an important role of
PI3K in regulation of the tumor stroma, such as through
the regulation of angiogenesis and immunomodulation.
Epigenetic processes are reinforced by interactions between
covalent chromatin marks such as DNA methylation, histone
modifications, and variants. These marks ultimately specify
the locations of nucleosomes particularly with respect to
transcriptional start sites and other regulatory regions.
Importantly, many of these enzymes which catalyze these
processes are now known to be mutated in human cancers.
We have developed a new methodology to simultaneously
map nucleosomal positioning and DNA methylation on
individual DNA molecules and have combined this approach
(NOMe-seq) with ChIP-seq to obtain a comprehensive view
of the chromatin states at transcription start sites (TSS), and
also at enhancers, CTCF sites, and gene bodies. The results
elucidate a key role for DNA methylation in the down
regulation of TSSs and enhancers, no visible role in the
overall structure of CTCF sites, and up regulation of
expression when located in gene bodies. Whole epigenome
analysis also shows altered chromatin structural alterations
in cancer which might help explain the macropscopic
changes visible to pathologists in cancer cells.
Bladder Cancer: Functional Genomics
Leading to Targeted Therapy
Dan Theodorescu, University of Colorado Cancer Center,
Aurora, CO
Bladder cancer is the most common malignancy affecting
the urinary system with an estimated 72,570 new cases
and 15,210 deaths in 2013 in the United States. Significant
advances have occurred since 2011 in the delineation of the
295
Monday, 7:00 a.m.-8:00 a.m.
Head and Neck Cancer: Translational
Research Strategies
Jennifer Rubin Grandis, University of California,
San Francisco, CA
Head and neck squamous cell carcinoma (HNSCC) is a
common malignancy worldwide. HNSCC arising from
tobacco exposure is frequently lethal despite intensive
multimodality therapy. HNSCC linked to infection with the
human papilloma virus (HPV) is rapidly increasing in
incidence and is generally associated with a more favorable
prognosis compared with HPV[-] HNSCC. The EGFR
targeted antibody cetuximab is the only FDA-approved
molecular targeting agent for HNSCC. Even though most
HNSCCs express relatively high levels of EGFR, relatively
few individuals are cured with cetuximab therapy. The
ability to prevent and treat HNSCC is primarily limited by
an incomplete understanding of the biological
underpinnings of the disease. Major gaps in knowledge
include a lack of predictive biomarkers to any treatment
modality and a paucity of HPV-selective therapies, despite
increasing evidence that HPV[+] HNSCC is a distinctly
different cancer from HNSCC[-] disease. The wealth of
genomic and epigenomic data emerging from large-scale
studies demonstrates the heterogeneity of HNSCC and
underscores the need for a more rational selection of
preclinical models for translational research. This
presentation will discuss bidirectional translational research
approaches in HNSCC to most efficiently achieve the
promise of precision head and neck cancer medicine.
Melanoma - Basic Science
David E. Fisher, Massachusetts General Hospital, Boston, MA
This session will review aspects of the molecular
pathogenesis of melanoma. Topics include the role of MITF,
a master transcriptional regulator of melanocyte
development, and also a key survival factor in melanoma.
MITF is an amplified or mutated melanoma oncogene, and
its functions within melanoma are becoming increasingly
appreciated. In addition, aspects of melanoma formation
will be reviewed. These will include the roles of UV in skin
signaling, the role of intercellular communication in
mediating UV pigmentation effects of skin. Studies will also
review behavioral consequences of UV irradiation, such as
296
UV addictive behaviors, through analyses of genetic models
and signaling paradigms. Collectively these studies will span
early steps in melanoma formation, risk factors, modulators
of treatment responses, and novel therapeutic approaches.
Molecular Pathology in Oncology
Massimo Loda, Dana-Farber Cancer Institute, Boston, MA
Pathology connects basic research to clinical practice to
make informed decisions about patient care. Molecular
pathologists play an essential role in the analysis of
genomic data, combining cutting-edge molecular tools with
deep understanding of tissue architecture. Linking
molecular and morphologic annotation is essential for the
identification of prognostic and predictive biomarkers,
monitor drug resistance, and to provide a detailed
classification of tumors. This is because molecular
alterations need to be analyzed in the context of cell of
origin, tissue heterogeneity, and tumor microenvironment.
Decreasing amounts of neoplastic tissue (e.g., diagnostic
biopsies) and increasing demands for material for molecular
analyses requires the adaptation of molecular techniques to
formalin-fixed paraffin-embedded tissue as well as
approaches such as multiplexing in situ technologies for the
simultaneous assessment of several biomarkers and ex vivo
propagation of tumors. Molecular data need to be
interpreted in a context-dependent manner for accurate
personalization of diagnosis and treatment.
Post-GWAS Studies of Epithelial Ovarian
Cancer: Now What?
Thomas A. Sellers, Moffitt Cancer Center and Research
Institute, Tampa, FL
Genome-wide association studies (GWAS) have identified
roughly 20 loci for risk of epithelial ovarian cancer. In
general, the allele frequencies are common and effect sizes
are modest. Some loci are associated with all histologic
subtypes of ovarian cancer, whereas others are associated
in a subtype-specific manner. GWAS success requires large
sample sizes to reach the accepted statistical significance
threshold, which becomes problematic for a rare cancer.
Innovative approaches are required to sift through the large
number of potential candidates to identify true risk loci.
Prior to the GWAS era, genetic epidemiology relied on highrisk pedigrees or sibling-pairs. Inevitably, the responsible
disease-causing alteration was a nonsense mutation in a
gene-coding region. A major surprise that has emerged
from GWAS studies is that the vast majority of risk regions
are not in exons. This requires the development of novel
assays and a systematic approach to try to identify
candidate target genes, the functional variant, and how
they interact to influence disease risk. The translational
implications from GWAS are numerous, spanning risk
prediction, early detection, more precise diagnostics, novel
therapeutic targets, and risk reduction interventions.
based analysis of genes with significant hazard ratios, we
have identified a biological process (immune function) that
predicts response to trastuzumab. We are now using
multisite annotated clinical trials samples to validate, both
analytically and clinically, a genomic profile that predicts
response to adjuvant trastuzumab in patients with earlystage HER2-positive breast cancer, and exploring other
promising predictive biomarkers in this setting.
Therapy of Lymphoma Inspired by
Functional and Structural Genomics
Louis M. Staudt, National Cancer Institute, Bethesda, MD
Prognostic and Predictive Biomarkers for
Anti-HER2 Therapy
Edith A. Perez, Mayo Clinic, Ponte Vedra Beach, FL
The EGFR family member HER2 (ERBB2) is overexpressed
in 15-20% of breast tumors. Although the prognosis for
such patients was traditionally generally poor, the addition
of the humanized monoclonal anti-HER2 antibodies, such
as trastuzumab, has resulted in long-term (10 yr.) diseasefree survival in about 80% of patients with early-stage
HER2+ disease. However, about 20% of such patients are
refractory to adjuvant trastuzumab-containing regimens
and develop tumor relapse within 10 years. The challenge
being addressed is to identify this subset of patients, who
can then be enrolled in future clinical trials to test the
efficacy of emerging HER2-targeted therapies. In short,
although we may know how to cure most HER2+ patients,
we need to identify patients most likely to benefit from
existing therapies while focusing our efforts upon the
patients who are unresponsive to the current standard of
care. We have completed a comprehensive set of
biomarker analyses over the years, culminating in a whole
transcriptome analysis of >1,200 patients with early-stage
HER2+ disease that led us to three central concepts: 1) that
the clinical behavior of HER2+ tumors was linked to
biological functions; 2) that these biological functions
could be identified using a systems biology approach that
focused on networks of genes with significant associations
with clinical outcome (Cox hazard ratios); and 3) that
different subsets of these genes might govern the relevant
biological processes in individual tumors. Using a networkApril 18-22, 2015 • Philadelphia, PA
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous
diagnostic category that is comprised of two prominent
molecular subtypes, termed activated B cell-like (ABC) and
germinal center B cell-like (GCB). Constitutive activation of
the B cell receptor (BCR) and MYD88 pathways by genetic
and non-genetic mechanisms will be discussed, including
the role of self-antigens in BCR activation. To attack
chronic active BCR signaling therapeutically, we initiated
clinical trials in DLBCL of ibrutinib, an irreversible and
highly selective inhibitor of BTK. Ibrutinib monotherapy
induced a high rate of complete and partial responses in
ABC DLBCL, while GCB DLBCL tumors rarely responded.
To extend the efficacy of ibrutinib, we have identified
additional therapeutic targets in the oncogenic signaling
pathways in ABC DLBCL including: 1) ubiquitin ligases,
such as LUBAC, 2) the kinase IRAK4, 3) the PI3 kinase
pathway, and 4) BCL2. Several synergistic, mechanismbased drug combinations that exploit these redundant
survival pathways will be discussed.
297
Monday, 7:00 a.m.-8:00 a.m.
Terrace Ballroom I (400 Level), Pennsylvania
Convention Center
Terrace Ballroom IV (400 Level), Pennsylvania
Convention Center
Through the Eyes of a Mouse:
The p53 Pathway
Understanding Cancer: Microenvironment
Interactions at Multiple Scales
Guillermina Lozano, The University of Texas MD Anderson
Cancer Center, Houston, TX
Joe W. Gray, Oregon Health and Science University,
Portland, OR
Mutations in the p53 tumor suppressor are common in
human cancers. In particular, p53 missense mutations
represent approximately 80% of alterations in tumors.
Missense mutations have additional activities, termed gain
of function, that result in highly invasive tumors. We and
others have generated mouse models to examine the
consequences of p53 mutations in tumor development. I
will discuss lessons learned from these studies and a new
mouse that models somatic inactivation of p53.
Revolutionary advances in nucleic acid and protein
profiling and multiscale imaging make it possible to
identify (epi)genomic abnormalities in cancer and to learn
how these abnormalities compromise protein, cell, and
tissue molecular architecture at scales ranging from
nanometers to centimeters. This presentation will describe
a) the use of correlative light and electron microscopy and
workflows to define the multiscale molecular architectures
of breast and pancreatic cancers, b) high-throughput
biological models and analytical processes to assess the
functional importance of specific molecular abnormalities
and cell-microenvironment interactions, and c) integrative
computational approaches. Emphasis will be on
understanding how tumor intrinsic changes and cancer
cell-microenvironmental interactions influence cancer
progression and response to therapy.
Tumor Dormancy and Metastatic
Recurrence
Ann F. Chambers, London Regional Cancer Program,
London, ON, Canada
Most cancer deaths are due to metastatic disease, which is
treatable but generally incurable. Metastases can recur
long after successful treatment of a primary tumor, even
for cancers diagnosed at an early stage. Late recurrences
can occur years or decades after initial diagnosis, and
some cancers may be considered “chronic relapsing
diseases.” Dormant cancer has been shown experimentally
and clinically to be a therapeutic target, in groups of
patients at risk. However, we do not know which individual
patients will benefit from antidormancy therapy, or even
the extent of micrometastatic burden in individuals. We
also do not know well how to prevent dormant cells from
reinitiating growth or how to kill them. We need to identify
individuals who harbor dormant disease and develop
appropriate long-term therapeutic strategies. We also need
to learn if lifestyle interventions or host features vs.
properties of the primary tumor affect regrowth of
dormant cells.
298
NCI/NIH-SPONSORED SESSION (not eligible for CME credit)
Monday, 7:00 a.m.-8:00 a.m.
The NCI PREVENT Cancer Preclinical Drug Development Program
Chemoprevention research in the Division of Cancer Prevention (DCP) was restructured in 2011,
creating the PREVENT Cancer Preclinical Drug Development Program. This Program provides for peerreview of proposals from the general research community for development of small molecules or
biologicals, including vaccines, for cancer prevention or biomarkers to facilitate clinical evaluation of
prevention strategies. The process for applying to the Prevent Program is described at:
http://prevention.cancer.gov/programs-resources/programs/prevent. Applications are submitted twice
yearly and reviewed by a panel of experts from the extramural community and NIH Scientists outside
DCP and scored for scientific merit, feasibility, etc. Top scoring applications undergo secondary review
and prioritization by a panel of DCP and other NIH scientists. Applications with potential for near-term
clinical translation are given highest priority. Approved projects are implemented as Task Orders via a
system of contracts with academic and nonprofit, independent research institutions that provide the
full range of preclinical studies, including good laboratory practice toxicology, needed to support
Investigational New Drug Applications. Twenty-five Task Orders addressing a range of intervention
strategies have been awarded in the first two years of the Program. Small molecules targeting classic
aspects of inflammation as well as newer molecular-targeted agents (n=16) are under study.
Pharmacodynamic assays are coupled to efficacy studies. Immunoprevention strategies targeting
tumor-associated antigens as well as antigens from cancer-associated infectious agents (n=6) are
being pursued. Preliminary data from current projects will be presented. The PREVENT Cancer
Program has engaged a broad cross-section of investigators, supporting preclinical development of
agents addressing a wide variety of cancer prevention strategies.
Speaker:
Robert H. Shoemaker, National Cancer Institute, Bethesda, MD
299
POSTER SESSION
Poster Section 1 • Monday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Cell Death and Survival
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
988 Triple negative breast cancer cells have higher
dependence on mitophagy for their survival as compared to
hormone positive breast cancer cells. Bhawana Dikshit,
Aakansha Rai, Soumya S. Roy.
2.
989 Regulation of metastatic potential through
adiponectin-stimulated induction of autophagy. Emily Falk
Libby, Jianzhong Liu, Monica J. Lewis, Andra R. Frost, Wendy
Demark-Wahnefried, Douglas R. Hurst.
3.
990 Saxifragifolin D induces autophagy via activating
IRE1␣/ JNK pathway in breast cancer cells. Liang-Liang Bai,
Jun-Min Shi, Min-Feng Chen, Dong-Mei Zhang, Ying Wang, WenCai Ye.
4.
991 Role of autophagy as potential molecular mechanism
in trastuzumab-induced cardiotoxicity. Nishant Mohan, Yi
Shen, Wen Jin Wu.
5.
992
Significance of an autophagy protein, microtubuleassociated protein light chain 3 (LC3), in gastric cancer. Go
Masuda, Masakazu Yashiro, Hiroaki Kasashima, Haruhito
Kinoshita, Tatsunari Fukuoka, Tamami Morisaki, Tsuyoshi
Hasegawa, Katsunobu Sakurai, Takahiro Toyokawa, Naoshi Kubo,
Hiroaki Tanaka, Kazuya Muguruma, Masaichi Ohira, Kosei Chung.
6.
993 The relationship between autophagy, senescence, and DNA
repair. Moureq R. Alotaibi, Lawrence Povirk, Daivd Gewirtz.
7.
994 PU.1 inhibition confers resistance to TRAIL- and
anthracycline-mediated apoptosis through NF-␬B activation
and TRAIL receptor downregulation in acute myeloid leukemia
cells. Aladin Haimovici, Thomas Kaufmann, Mario P. Tschan.
Poster
Board
1
Abstract
Number
17.
1004 Novel adjuvants from seaweed impede autophagy
signaling in therapy-resistant residual pancreatic cancer.
Sheeja Aravindan, Satish Kumar Ramraj, Faizan H. Khan, Terence
S. Herman, Somasundaram T. Somasundaram, Natarajan
Aravindan.
18.
1005 Dual targeting of MEK/MAPK1/2 and pro-survival
autophagy to optimize antiestrogen treatment toward the
eradication of antiestrogen resistant breast cancer. Mathew
Manning, Suchreet Takhar, Sudharsan Periyasamy-Thandavan,
Michael Cheng, Thomas Barrett, William Hill, Darren Browning,
Muthusamy Thangaraju, Meghan McGee-Lawrence, Patricia V.
Schoenlein.
19.
1006 Celastrol modulated Taz and induced cell apoptosis
in vitro. Shuren Wang.
20.
1007 Elucidating a role for the translation initiation factor,
eIF4G1, in resistance to therapy in inflammatory breast cancer
(IBC). Arianna Price, Courtney M. Edwards, Myron K. Evans,
Gayathri Devi.
21.
1008 Cytoplasmic p53 protects against MG132-induced
apoptosis in a cell state-dependent manner. Ho Wa (Jacky)
Cheng, Aster Legesse-Miller.
22.
1009 Cytotoxic effect of ginsenosides C-K and PPD on
glioblastoma cells through cell cycle arrest and downregulation of cell adhesion proteins. Eunsoo Kim, Cheryl
Wanderi, Chulhee Choi, Kyungsun Choi.
23.
1010 Synergistic antitumor effects of luteolin and silibinin
with overexpression of miR-7-1-3p inhibited autophagy and
promoted apoptosis in glioblastoma. Mrinmay Chakrabarti,
Walden Ai, Swapan K. Ray.
8.
995 Regulation of radiation by autophagic modulator.
Keun Ho Lee, Yoon Kyung Lee.
9.
996 Retinoic acids activate autophagy in breast cancer
cells through the FOXO3A-RARA pathway and blocking
autophagy enhances retinoic acid-mediated cell death. Anna
M. Schlaefli, Enrico Garattini, Mario P. Tschan.
24.
1011 Quercetin inhibited starvation-induced autophagy to
increase apoptosis in CD133+ neuroblastoma stem cells in
vitro and in vivo. Mrinmay Chakrabarti, Angela Murphy, Swapan
K. Ray.
10.
997 Loss of Miz-1 increases latency of T-ALL by preventing
induction of autophagy. Marissa Rashkovan, Charles Vadnais,
Julie Ross, Jennifer Fraszczak, Tarik Moroy.
25.
11.
998 Induction of non-protective autophagy by radiation in
tumor cells: Implications for autophagy inhibition as a
therapeutic strategy. Shweta Chakradeo, Khushboo Sharma,
Aisha Alhaddad, Duaa Bakhshwin, Ngoc Le, Hisashi Harada, W.
Andrew Yeudall, Suzy Torti, Frank Torti, David Gewirtz.
1012 Discovery and synthesis of novel autophagy
inhibitors with anti-proliferative activity in lung and
pancreatic cancer cells. Juan Sironi, Lars Ulrik Nordstroem,
Evelyn Aranda, Marina Shcherba, Roman Perez-Soler, Peng Wu,
Edward L. Schwartz.
26.
1013 Understanding the molecular pathways underlying
radio-sensitization of non-small cell lung cancer (NSCLC) by
vitamin D (EB1089). Khushboo Sharma, Theresa Thekkudan,
David Gewirtz, Hisashi Harada, Frank Torti, Suzy Torti.
27.
1014 Dihydrotanshione I induces caspase-independent
cell death and autophagy in lung cancer cells. Sung-Hoon Kim,
Gunho Won, Myoung Seok Jeong, Sang Wook Yoon, Jihyun Lee,
Bonglee Kim, Eun Jung Sohn.
28.
1015 Misaponin B induces G2-M arrest and autophagy via
upregulation of miR1290 in non-small cell lung cancer
(NSCLC) A549 cells. Gunho Won, Eun Jung Sohn, Myoung Seok
Jeong, Sang Wook Yoon, Jihyun Lee, Bonglee Kim, Sung H. Kim.
29.
1016 Caveolin-1-dependent and -independent uPAR
signaling pathways contribute to ganglioside GT1b-induced
early apoptosis in A549 lung cancer cells. Hyun-Jin Jang,
Young-Ho Chung, Junsoo Park, Ik-Soon Jang.
30.
1017 Silencing of apoptosome regulating genes, HSP70
and TRIAP1, induces apoptosis in MM cell lines. Veruska L. Fook
Alves, Daniela B. Zanatta, mariana B. oliveira, angela I. eugenio,
rodrigo C. fernando, Bryan E. Strauss, Gisele W. Colleoni.
12.
999 Utilization of catastrophic autophagy in ovarian
cancer. Joe R. Delaney, Chandni Patel, Dwayne G. Stupack.
13.
1000
Tyrosine kinase receptor EGFR regulates the switch
between cell survival and cell death induced by autophagy
under hypoxia in cancer cells. Spencer B. Gibson, Yongqiang
Chen, Elizabeth S. Henson, Daniel Huang.
14.
1001
Protein Kinase D1 induces autophagic cell death
through activation of endoplasmic reticulum stress in prostate
cancer cells. Rishi K. Gara, Sonam Kumari, Sheema Khan, Neeraj
Chauhan, Aditya Ganju, Subhash C. Chauhan, Meena Jaggi.
15.
1002
Molecular characterization of aggresome formation
in choroid plexus carcinoma. Marwa Nassar, Heba Samaha,
Myret Ghabriel, Maha Yehia, Hala Taha, Dina Yassin, Sherine
Salem, Khaled Shaaban, Mariem Omar, Shahenda M. El-Naggar.
16.
1003
300
S-nitrosylation of Bcl-2 negatively affects autophagy
in malignantly transformed lung epithelial cells. Clayton A.
Wright, Anand K. Iyer, Yogesh Kulkarni, Neelam Azad.
1
POSTER SESSION
Poster
:LJ[PVU
2
2
Cell Signaling in Cancer 2
Poster
Board
Abstract
Number
1.
1018 Role of Stat3 vs Stat5 in the differentiation of
HC11, mouse breast epithelial cells. Jamaica Cass,
Maximilian Niit, Rozanne Arulanandam, Bruce Elliott, Leda
Raptis.
2.
1019 hnRNPA2/B1 upregulates COX-2 expression and
tumor growth and predicts poor prognosis in human lung
cancers. Jingshu Wang, Yang Xuan, Wei Guo, Guangwei Du,
Wuguo Deng.
3.
4.
1020 Latent membrane protein 1 N-C interaction of EBV
facilitates (nuclear factor kappa-light-chain-enhancer of
activated B cells transcriptional activity. Cheng-Lung Hsu, HsinPai Li, Yung-Chia Kuo, Ngan-Ming Tsang, Yu-Sun Chang.
1021 Superoxide anion (O2.-) mediated activation of
mTORC2 by estrogen receptor in breast cancer cells: Role
of acetylation dependent inhibition of MnSOD. Mehraj U.
lone, Ranjana K. Kanchan, Khemraj S. Baghel, Chakrapani
Tripathi, Brij N. Tewari, Smrati Bhadauria.
5.
1022 DYRK1A kinase regulates mTOR signaling via
modulating the TSC complex. Vijay R. Menon, Larisa Litovchick.
6.
1023 Duration of signaling through IgM and IgD
receptors differentially influences cell survival and BCL6regulated CCL3/4 chemokine production in Chronic
Lymphocytic Leukemia (CLL). Elisa ten Hacken, Cristina
Scielzo, Susan O’Brien, William G. Wierda, Michael J. Keating,
Paolo Ghia, Federico Caligaris-Cappio, Jan A. Burger.
7.
1024 Targeting PAK1 activity in breast cancer:
Inhibition of cell growth, survival, motility, and signaling.
Alexandra M. Fajardo, Tristan Browne, Hannah Graff, Kelly
Kleier, Kyle Neltner, Courtney McCall, Brad Meyer, Larry
Douglass, Julia Carter.
8.
1025 Protein kinase D2 promotes the proliferation of
glioma cells by regulating golgi phosphoprotein 3. Xiuping
Zhou, Pengfei Xue, Minglin Yang, Hengliang Shi, Dong Lu,
Qiong Shi, Jinxia Hu, Rutong Yu.
9.
1026 Role of Group I Paks in MPNST cell proliferation,
migration and invasion. Galina Semenova, Jonathan
Chernoff.
10.
1027 Apoptotic resistance in arsenic transformed cells
attributed to decreased SIRT3-FOXO3A signaling. Ram V.
Roy, Xinglin Shi.
11.
1028 Prostaglandin E2 activates the mTORC1 pathway
through an EP4/cAMP/PKA and EP1/calcium-mediated
mechanisms in human pancreatic carcinoma cells. Hui-Hua
Chang, Steven Young, James Sinnett-Smith, Caroline E. Chou,
Oscar J. Hines, Enrique Rozengurt, Guido Eibl.
12.
1029 Receptor-interacting protein kinase 1 regulates
survival of human melanoma cells upon endoplasmic
reticulum stress through autophagy. Xu Guang Yan, Qi
Luan, Lei Jin, Chen Chen Jiang, Kwang Hong Tay, Fritz Lai,
Xiao Ying Liu, Yi Lun Liu, Su Tang Guo, Hsin-Yi Tseng, Xu
Dong Zhang.
13.
1030 Loss of PHLPPs protects against colitis by
inhibiting epithelial apoptosis through upregulating AKT
activity. Yang-an Wen, Xin Li, Tatiana Goretsky, Terrence A.
Barrett, Tianyan Gao.
14.
1031 Cadherin-11 function is required for full
neoplastic transformation of mouse fibroblasts by
activated Src. Stephanie Guy, Patrick Magee, Mulu Geletu,
Rozanne Arulanandam, Leda Raptis.
April 18 –22, 2015 • Philadelphia, PA
Poster
Board
Abstract
Number
15.
1032 The acetylcholine signaling pathway: A novel
molecular target for lung cancers. Kathleen C. Brown, Jamie
K. Lau, Haley E. Perry, Brent A. Thornhill, Cathryn D.
Stevenson, William D. Rollyson, Cody A. Stover, Dennie V.
Jones, Joseph F. Pulliam, Piyali Dasgupta.
16.
1033 Alternative tumor suppressor mechanisms in lung
carcinomas - modulation of senescence by growth factorinduced signaling. Boyka Markova, Frank Breitenbuecher,
Martin Schuler.
17.
1034 Comparing the effects of Akt-1 and 2 inhibition on
NSCLC tumour suppression. Ritesh Briah, Roger Moorehead.
18.
1035 An angiogenic role of E-cadherin-positive
exosomes in ovarian cancer. Maggie K. S. Tang, Alice S.
Wong.
19.
1036 A muscle specific protein “myoferlin” modulates
IL-6/STAT3 signaling by chaperoning activated STAT3 to
nucleus. Arti Yadav, Bhavna Kumar, Theodoros N. Teknos,
Pawan Kumar.
20.
1037 Inverse regulation of p53 by atypical PKC
inhibitors in ovarian cancer cells. Minjel Shah, Christopher
Apostolatos, Hercules Apostolatos, Mildred Acevedo-Duncan.
21.
1038 Cell-based screening identifies gene expression
signature correlated with sensitivity to PI3K-mTOR dual
inhibitor BEZ235. Jing Zhang, Sheng Guo, Zhengzheng Bao,
Limei Shang, Xiao Wen, Jean-Pierre Wery, Jinying Ning.
22.
1039 Leucine-rich ␣2 glycoprotein modulates the
effect of TGF␤1 on the growth of lewis lung carcinoma
cells. Norihiko Takemoto, Satoshi Serada, Minoru Fujimoto,
Hidenori Inohara, Tetsuji Naka.
23.
1040 mTOR pathway status in vulvar carcinomas: One
more step in the biological knowledge of this tumor. André
M. Lavorato-Rocha, Laura G. Anjos, Beatriz M. Maia, Iara S.
Rodrigues, Glauco Baiocchi, Isabela C. Werneck, Jose
Vassallo, Fernando A. Soares, Rafael M. Rocha.
24.
1041 PTHrP(12-48) localization is intracellular and it
inhibits cell proliferation and osteoclastogenesis. Varinder
Kaur, Archana Kamalakar, Nisreen Akel, Kim Leitzel, Allan
Lipton, Larry J. Suva.
25.
1042 Suppression of colorectal cancer cell proliferation
by resveratrol involves upregulation of the non-canonical
ligand Wnt9a. Irshad Ali, Bani M. Fagla, Donald P. Braun.
26.
1043 Blocking constitutive aryl hydrocarbon receptor
(AhR) signaling attenuates androgen receptor activity.
Maryam Ghotbaddini, Aaron Hemphill, Joann B. Powell.
27.
1044 A combination of cisplatin and 2-deoxy-dglucose results in synergistic cell death in both normoxia
and hypoxia by the attenuation of autophagy. Akansha
Jalota, Bhudev C. Das, Ajay K. Yadav, Kunzang Chosdol,
Subrata Sinha.
28.
1045 A snapshot of pan-cellular PTM in response to
Sorafenib-mediated multikinase inhibition. Christian M. Loch.
29.
1046 The role of NF-kB activation in the
immortalization of nasopharyngeal epithelial cells. George
S. Tsao, Dan Dan Zhu, Jun Zhang, Wen Deng.
30.
1047 A role for the free beta subunit of human
chorionic gonadotropin in sensitivity of epithelial ovarian
cancer cells to platinum-based chemotherapeutics. Snega
M. Sinnappan, Robert C. Baxter, Deborah J. Marsh.
301
POSTER SESSION
DNA Methylation 1
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
1048 Chromatin remodelers are frequently disrupted
by epigenetic and genetic alterations at an early stage of
carcinogenesis. Hideyuki Takeshima, Tohru Niwa, Takamasa
Takahashi, Takayuki Ando, Hirokazu Taniguchi, Hitoshi Katai,
Toshiro Sugiyama, Toshikazu Ushijima.
2.
1049 Prognostication of patients with clear cell renal
cell carcinomas based on quantification of DNA
methylation levels of CpG island methylator phenotype
marker genes using anion exchange high performance
liquid chromatography. Takuya Yotani, Yuriko Yamada, Eri
Arai, Ying Tian, Masahiro Gotoh, Motokiyo Komiyama,
Hiroyuki Fujimoto, Michiie Sakamoto, Yae Kanai.
3.
1050 Effects of 5-hydroxymethylcytosine epigenetic
modification on G-quadruplex and i-motif structure and
stability within the VEGF promoter. Rhianna Morgan, Randy
Wadkins, Tracy Brooks.
4.
1051 An assay to detect hypomethylation in circulating
cell free DNA and monitor cancer burden. Cassie A.
Schumacher, Sukhinder Sandhu, Vladimir Makarov.
5.
1052 Variable expression of 5-alpha reductase 2 in the aging
adult prostate is regulated by DNA methylation. Ge Rongbin,
Zongwei Wang, Seth Bechis, Alexander Otsetov, Shengyu
Hua, Shulin Wu, Chin-Lee Wu, Shahin Tabatabaei, Aria Olumi.
6.
1053 Potential utility of DNA methytlation as a
biomarker for prediction of ulcerative colitis associated
colitic cancer (UCAC). Tomomitsu Tahara, Naoko Nakano,
Mitsuo Nagasaka, Yoshihito Nakagawa, Tomoyuki Shibata,
Naoki Ohmiya, Ichiro Hirata.
7.
1054 Aberrant TET1 methylation closely associated with CpG
island methylator phenotype in colorectal cancer. Norihisa
Ichimura, Keiko Shinjo, Fumiharu Ohka, Keisuke Katsushima,
Akira Hatanaka, Masayuki Tojo, Yasuhiro Shimizu, Eiichiro
Yamamoto, Hiromu Suzuki, Yutaka Kondo.
Poster
Board
3
Abstract
Number
14.
1061 Clinico-pathological significance of LINE-1 and
ESR1 methylation levels in sporadic colorectal cancer.
Tomofumi Noguchi, Yuji Toiyama, Koichiro Mori, Shozo Ide,
Hiroki Imaoka, Hiroyuki Fujikawa, Junichiro Hiro, Susumu
Saigusa, Minako Kobayashi, Masaki Ohi, Koji Tanaka, Yasuhiro
Inoue, Yasuhiko Mohri, kenichiro ishii, Masato Kusunoki.
15.
1062 Hypermethylation of BARHL2 gene is useful as a
molecular marker in early stage of gastric cancer. Yoshiyuki
Watanabe, Ritsuko Oikawa, Hiroyuki Yamamoto, Fumio Itoh.
16.
1063 Transcriptional implications of intragenic DNA
methylation in the estrogen receptor alpha gene in breast cancer
cells and tissues. NATALIE S. SHENKER, Kirsty J. Flower,
Charlotte Wilhelm-Benartzi, Wei Dai, Emma Bell, Mona El
Bahrawy, Gillian Weaver, James M. Flanagan, Robert Brown.
17.
1064 RASSF10 suppresses colorectal cancer growth by
activating p53 signaling and sensitizes colorectal cancer
cell to docetaxel. Jing Guo, Yage Yang, Yunsheng Yang,
Enqiang Linghu, Qimin Zhan, Malcolm V. Brock, James G.
Herman, Bingyong Zhang, Mingzhou Guo.
18.
1065 RASSF- 1A methylation in squamous cell
carcinoma of the lower lip using pyrosequencing
technique. Estela Kaminagakura, Cláudia Coutinho-Camillo,
Luciana Strieder, Danyel Perez, Fernando Soares, Kátia
Oliveira, Luiz Paulo Kowalski.
19.
1066 Racial disparities of genome-wide DNA
methylation profiles and association with breast tissues
biomarkers in healthy women. Min-Ae Song, Catalin Marian,
Theodore M. Brasky, Daniel Weng, Cenny Taslim, Jo L.
Freudenheim, Peter G. Shields.
20.
1067 Characterization of DNA hypermethylation in two cases
of peritoneal mesothelioma. Ritsuko Oikawa, Yoshiyuki
Watanabe, Ryota Hama, Hiroyuki Yamamoto, Fumio Itoh.
21.
8.
1055 Genome-wide DNA methylation analysis in
precancerous conditions associated with hepatitis B virus and
hepatitis C virus infection. Eri Arai, Ying Tian, Masahiro Gotoh,
Yoriko Takahashi, Hidenori Ojima, Tomoo Kosuge, Yae Kanai.
1068 Correlation of DNA methylation pattern between
peripheral blood cell and normal breast tissue. Xingyi Guo,
Xiao-Ou Shu, Chun Li, Jirong Long, Bingshan Li, Yu-Tang Gao,
Wei Zheng, Qiuyin Cai.
22.
9.
1056 Impact of host methylome on cervical cancer
pathogenesis. Shrinka Sen, Samsiddhi Bhattacharjee,
Indranil Mukhopadhyay, Paramita Mandal, Sweta Sharma,
Rahul Roy Chowdhury, Sharmila Sengupta.
1069 DNA methylation in circulating free DNA as a new
biomarker for pancreatic cancer. Keiko Shinjo, Fumiharu
Ohka, Keisuke Katsushima, Akira Hatanaka, Norihisa
Ichimura, Zhao Juan, Kenji Yamao, Yutaka Kondo.
23.
10.
1057 Characterization of methylation patterns in
cancer tissue shown by targeted Next-Gen bisulfite
sequencing. Jessica Alexander, Ryan Drennan, Ann Meyer,
Jessica Xu, Matthew L. Poulin, Winston Timp.
1070 Epigenetic silencing of galectin-12 in colorectal
cancer. Eva-Maria Katzenmaier, Johannes Gebert, Matthias
Kloor, Jürgen Kopitz.
24.
1071 Age-dependent DNA methylation in normal breast
epithelium and breast cancer. Shoghag B. Panjarian, Carolyn Slater,
Jozef Madzo, Jaroslav Jelinek, Xiaowei Chen, Jean-Pierre Issa.
25.
1072 DNA methylation profile analysis of gliomas revealed a
change in methylation status during malignant progression.
Mukasa Akitake, Kuniaki Saito, Koki Aihara, Genta Nagae,
Mayu Omata, Ryohei Otani, Shunsaku Takayangi, Shota
Tanaka, Yoshitaka Narita, Keisuke Ueki, Ryo Nishikawa,
Motoo Nagane, Hiroyuki Aburatani, Nobuhito Saito.
26.
1073 KRAS-mediated epigenetic reprogramming
upregulates RELB-dependent CXCR2 expression to
promote transformation. Joel Durand, Albert Baldwin.
27.
1074 Epigenetic silencing of DACH1 in triple negative
breast cancer contributes to the tumorigenesis. Qian Chu,
Na Han, Yan Dong, Xun Yuan, Mingzhou Guo, Hanxiao Xu,
Shiying Yu, Kongming Wu.
11.
12.
13.
302
1058 Novel insights into the genetic and epigenetic
regulation of the MLH1 CpG island and shore in colorectal cancer.
Andrea J. Savio, Mathieu Lemire, Miralem Mrkonjic, Steven
Gallinger, Brent W. Zanke, Thomas J. Hudson, Bharati Bapat.
1059 Analysis of promoter methylation levels of COX2
gene in Turkish patients with head and neck cancer. Semra
Demokan, Cansu Ozkoklesen, Zubeyde Yalniz, Necati Enver,
Murat Ulusan, Nejat Dalay.
1060 Epigenome-wide DNA methylation profiling of
lung tumors from asbestos-exposed patients. Eeva M.
Kettunen, Hector Hernandez-Vargas, Marie-Pierre Cros,
Geoffroy Durand, Florence Le Calvez-Kelm, Henrik Wolff,
Kaisa Salmenkivi, Sisko L. Anttila, Zdenko Herceg, Kirsti
Husgafvel-Pursiainen.
3
POSTER SESSION
Poster
:LJ[PVU
4
4
Examination of Cancer Pathways Using Computational Approaches
Poster
Board
Abstract
Number
1.
1075 Multiple alternative promoters and a long noncoding RNA constitute the complex regulatory region of
the cancer and drug resistance associated gene B4GALT1.
MOHAMMED A. AlOBAIDE, Hytham Alobydi, Abdelsalam
Abdelsalam, Ruiwen Zhang, Kalkunte S. Srivenugopal.
3.
1077 Use of the SVClassify algorithm to classify
pediatric solid tumor translocation variant calls as likely
true or false positives. Jo Lynne Harenza, Hemang M. Parikh,
Jun S. Wei, Xinyu Wen, Sivasish Sindiri, Rajesh Patidar, Marc
Salit, Paul S. Meltzer, Javed Khan, Justin Zook.
4.
1078 TGF-␤ and TNF-␣ activate gene transcription
programs associated with poor breast cancer prognosis.
Yuan Qi, Kazuharu Kai, Chad J. Creighton, Bedrich Eckhardt,
Hideyuki Saya, Debu Tripathy, Naoto T. Ueno.
5.
1079 Transcriptional profiling reveals uterine
leiomyoma subtypes with distinct pathways and
biomarkers of tumorigenesis. Miika Mehine, Eevi Kaasinen,
Esa Pitkänen, Nanna Sarvilinna, Hanna-Riikka Heinonen,
Netta Mäkinen, Jari Sjöberg, Lauri A. Aaltonen.
6.
1080 Computational and biochemical discovery of
RSK2 as a novel target for epigallocatechin gallate
(EGCG). Hanyong Chen, Ke Yao, Xiaoyu Chang, Jung-Hyun
Shim, Hong-Gyum Kim, Margarita Malakhova, Dong-Joon
Kim, Ann M. Bode, Zigang Dong.
7.
1081 Non-random genomic alterations in BRCA1related breast cancer. Sheida Nabavi, Kristina M. Holton,
Ashish Juvekar, Nicholas Wang, Olivier Elemento, Lewis C.
Cantley, Gerburg M. Wulf.
9.
1083 Expression of an estrogen-regulated variant
transcript of the peroxisomal branched chain fatty acid
oxidase, ACOX2, in breast cancer. Sunniva Bjørklund,
Vessela N. Kristensen, Michael Seiler, Grethe I. Grenaker
Alnaes, Yao Ming, John Kerrigan, Bjørn Naume, Ravi
Sachidanandam, Gyan Bhanot, Anne-Lise Børresen-Dale,
Shridar Ganesan.
10.
1084 An EMT-like gene expression profile
differentiates helical from kinase domain PIK3CA
mutations. Christina Yau, Joe Garay, Stephen Benz, Joe Gray,
Ben Park, Christopher C. Benz.
11.
1085 A bioinformatics approach to evaluate the
involvement of CDH1/E-cadherin in solid tumors and to
identify breast cancer biomarkers. Maria F. Abascal, Maria J.
Besso, Evangelina Aparicio, Marina Rosso, Victoria Mencucci,
Laura I. Furlong, Monica H. Vazquez-Levin.
12.
1086 CTNNB1-mutated desmoid tumors have different
gene expression patterns compared to wild-type ones.
Chiara Colombo, Loris De Cecco, Antonino Belfiore, Silvana
Canevari, Marco Fiore, Silvia Stacchiotti, Elena Palassini,
Alessandro Gronchi, Silvana Pilotti, Federica Perrone.
13.
1087 Genomic analysis reveals evidence of clonality in
premalignant colonic polyps. Kyle Chang, Ester Borras,
Anthony San Lucas, Jerry Fowler, Ernest T. Hawk, Gabriel
Capella, Paul Scheet, Eduardo Vilar.
Poster
Board
Abstract
Number
14.
1088 Exploration of the human peptidome for cancerspecific peptide-MHC targets. Ankur Dhanik, Wen Zhang,
Jessica Kirshner, Douglas MacDonald, Susan Croll, Calvin Lin,
Gavin Thurston, Andrew Murphy.
15.
1089 Dissecting the potential distinct role/s of the four
RNA binding domains in a phosphoprotein nucleolin using
bioinformatics tools. Ruchama C. Steinberg, Shaneen Singh,
Anjana D. Saxena.
16.
1090 Evolutionary, structural, and functional insights
into the seven-transmembrane GPCR superfamily through
NCBI’s Conserved Domain Database. James S. Song, Noreen
R. Gonzales, Roxanne A. Yamashita, Aron Marchler-Bauer,
Stephen H. Bryant.
17.
1091 A new image processing approach for functional
context-based analysis of tryptase positive mast cells in
cutaneous T-cell lymphomas. Radu Rogojanu, Johanna
Eder, Waltraud Jerey, Gabriele Klosner, Verene Paulitschke,
Isabella Ellinger, Theresia Thalhammer, Dan Kolmer, Franz
Trautinger.
18.
1092 Interpreting and navigating the TCGA in the
context of the RAS pathway. Ming Yi, Bailey Kessing, Robert
Stephens.
19.
1093 Sensitive detection of somatic mutations in class I
HLA genes reveals enrichment for functional events in
cancer. Sachet A. Shukla, Mohini Rajasagi, Philip Dixon, Grace
Tiao, Michael S. Lawrence, Carrie Sougnez, Vladimir Brusic,
Kristian Cibulskis, Adam Kiezun, Catherine J. Wu, Gad Getz.
20.
1094 Deciphering driver mechanisms for tumorigenesis
in BRAF/NRAS double wild-type melanoma through
integration of heterogeneous genome-wide datasets. Amit
Mandal, Maria R. Girotti, Amaya Viros, Gabriela Gremel, Elena
Galvani, Rebecca Lee, Kok Haw J. Lim, Simon J. Furney, Paul
Lorigan, Richard Marais.
21.
1095 In silico mapping of oncogene networks implicate
the WNT pathway in the glioblastoma MES subtype. Anna
M. Joy, Ivan Smirnov, Mark Reiser, Seungchan Kim, Burt
Feuerstein.
22.
1096 Murine mammary carcinoma produce more CCL2
in response to TLR agonist treatment than dendritic cells
because of differences in NF-kB levels. Tiffany Phuong,
Carli B. Jones, Robert A. Kurt, Chun Wai Liew.
23.
1097 Knockdown of splicing factor ESRP1 affects
multiple splicing factors. Yesim Gökmen-Polar, Yaseswini
Neelamraju, Xiaoping Gu, Gouthami Nallamothu, Sarath C.
Janga, Sunil Badve.
24.
1098 Epistasis analysis of the PTHLH region in
European subjects of the iCOGS breast cancer GWAS
suggest multiple genes may be implicated in its role in
breast cancer. Adam N. Freeman, Michael A. Henderson, T
John Martin, Enes Makalic, Miroslaw K. Kapuscinski, Daniel
Schmidt, John Hopper.
303
POSTER SESSION
Functional Genomics
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
304
Abstract
Number
1099 High-throughput engineering and functional
annotation of cancer fusion genes. Hengyu Lu, Angeliki
Pantazi, Turgut Dogruluk, Armel Dogruluk, Chad Creighton,
Gordon B. Mills, Raju Kucherlapati, Kenneth L. Scott.
1100 Functional genomics to investigate the genetic
determinants of cell death induced by oxidative stresses.
Chien-Kuang C. Ding, Xiaohu Tang, So Young Kim, Jen-Tsan
A. Chi.
1101 Functional genomics of HER2 and HER3 mutations
and response to neratinib. Aphrothiti J. Hanrahan, David M.
Hyman, John Sfakianos, Alexis Jones, Ricardo Ramirez,
Hannah Johnsen, Gopakumar Iyer, Hikmat A. Al-Ahmadie,
Dean Bajorin, Bernard H. Bochner, Jonathan A. Coleman,
Jonathan E. Rosenberg, Michael F. Berger, Sarat
Chandarlapaty, Jose Baselga, David B. Solit.
1102 Integrated genomic analysis of clear-cell ovarian
cancer identifies PRKCI as a therapeutic target. Tsun Yee
Tsang, Gayatry Mohapatra, Hiroaki Itamochi, Samuel C. Mok,
Michael J. Birrer.
1103 Human tumorigenesis induced by endogenous
DNA transposase. Anton Henssen, Amy Eisenberg, Eileen
Jiang, Elizabeth Henaff, Richard Koche, Melissa Burns,
Julianne R. Carson, Gouri Nanjangud, Eric Still, Jorge
Gandara, Paolo Cifani, Avantika Dhabaria, Xiaodong Huang,
Elisa de Stanchina, Elizabeth Mullen, Hanno Steen, Elizabeth
Perlman, Jeffrey Dome, Cristina Antonescu, Cedric Feschotte,
Christopher E. Mason, Alex Kentsis.
1104 Identification of genes required for glioblastoma
stem cell growth and survival using pooled RNAi screening
with next generation sequencing. Shreya Kulkarni, Surbhi
Goel-Bhattacharya, Sejuti Sengupta, Brent Cochran.
1105 Clinical associations between altered bladder
cancer genes. Michael L. Nickerson, Kate M. Im, Sevilay
Turan, Lee E. Moore, Michael Dean, Dan Theodorescu.
1106 Genome-wide CRISPR-Cas9 screens reveal
candidate therapeutic targets and tumor suppressor genes
for human glioma. Yu Ding, Chad Toledo, Pia Hoellerbauer,
Ryan Basom, Emily Girad, Eunjee Lee, Philip Corrin, Qi Lin,
Xiao-Nan Li, Do-Hyun Nam, Jeongwu Lee, Jun Zhu, Steven
Pollard, Jeffery Delrow, Jim Olson, Patrick J. Paddison.
1107 In whole-exome sequencing analysis,
alternations of P-selectin glycoprotein ligand 1 (SELPLG)
significantly associates with inflammation and survival
outcomes. Sunghoon Cho, Chansu Lee, Hyun Choi, KwangSung Ahn, Yongil Koh, Sung-Soo Yoon.
1108 SPOP mutation leads to genomic instability in
prostate cancer. Gunther Boysen, Christopher E. Barbieri,
Davide Prandi, Sung-Suk Chae, Srilakshmi Nataraj, Mirjam
Blattner, Clarisse Marotz, Limei Xu, Paola Lecca, Sagar
Chhangawala, Pengbo Zou, Andrea Sboner, Francesca
Demichelis, Yariv Houvras, Mark A. Rubin.
1109 In vivo loss of function screening reveals carbonic
anhydrase IX (CAIX) as a key modulator of tumor initiating
potential in primary pancreatic tumors. Nabendu Pore,
Sanjoo Jalla, Brandon Higgs, Roger Liu, David A. Tice, Robert
Hollingsworrth, Emil Michelotti, Claudio Sorio, Aldo Scarpa.
1110 Functional genomics reveals genetic
dependencies in gastric cancer. Meghana M. Kulkarni,
Sushma Gurumurthy, Oleg Schmidt-Kittler, Jason Berglund,
Christopher H. Hulton, David J. Wilson, David Jakubosky,
Daniel Michaud, Robert E. Jones, Nicole M. Sjoblom, Russell
McSweeney, Hongwei Zhou, Annapurna Venkatakrishnan,
Karin J. Jensen, Jingxin Zhang, Parminder K. Mankoo, Jack
Pollard, Christopher Winter, Pasi A. Jänne, Kwok-Kin Wong,
Victoria M. Richon, Jessie M. English, Mark A. Bittinger.
Poster
Board
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
5
Abstract
Number
1111 Altered inflammatory and death pathways in
head and neck cell lines model genomic and expression
signatures identified in The Cancer Genome Atlas. Xinping
Yang, Hui Cheng, Anthony Saleh, Shaleeka Cornelius, Emine
Guven-Maiorov, Ruth Nussinov, Carter Van Weas, Zhong
Chen, Ozlem Keskin, Attila Gursoy.
1112 Loss-of-function genetic screening with shRNA
and CRISPR libraries. Donato Tedesco, Mikhail Makhanov,
Sylvain Baron, Dmitry Suchkov, Alex Chenchik.
1113 Novel recurrent glycosylation-associated gene
mutations in colon cancer. Srividya Venkitachalam, Leslie
Revoredo, Lakshmeswari Ravi, James Lutterbaugh, Sanford
Markowitz, Thomas Gerken, Kishore Guda.
1114 Genomics in cancer patient care: Bench to
bedside and beyond. Sharanya Raghunath, David
Loughmiller, Aimee Shamo, Jackie Wayne, Patrick Bradley,
Jason Gillman, Gary Stone, Derrick Haslem, Lincoln Nadauld,
Pravin J. Mishra.
1115 Targeted RNA sequencing improves transcript
analysis in cancer samples. Ling Lin, Ryan Abo, Deniz
Dolcen, Rachel Paquette, Angelica Laing, Luc de Waal, Aaron
Thorner, Matthew Ducar, Liuda Ziaugra, Bruce Wollison, Marc
Breneiser, William Hahn, Matthew Meyerson, Paul Van
Hummelen, Laura MacConaill.
1116 Oncogene signatures identify novel therapeutic
targets and combinatorial strategies in breast cancer.
Stephen Guest, Zachary Kratche, Jonathan Irish, Aliccia
Bollig-Fischer, Elizabeth Garrett-Mayer, Stephen Ethier.
1117 Who’s in the driver’s seat? Identifying causative
variants of colorectal cancer. Nicole Coggins, Luis CarvajalCarmona, David Segal.
1118 Activation of MET via diverse exon 14 skipping
mutations occurs in multiple tumor types and confers
clinical sensitivity to MET inhibitors. Garrett M. Frampton,
Siraj Ali, Juliann Chmielecki, Mark Rosenzweig, Timothy
Brennan, Zachary Chalmers, Julia Elvin, Alex Fichtenholtz,
Kyle Gowan, Joel Greenbowe, Adrienne Johnson, Lily Khaira,
Doron Lipson, Caitlin McMahon, Steven Roels, Roman
Yelensky, Deborah Morosini, Philip Stephens, Vincent Miller.
1119 Subclonal structure of breast cancer subtypes
determined by quantitative analyses of activating
mutations. Meagan B. Myers, Malathi Banda, Karen L. McKim,
Barbara L. Parsons.
1120 Glioblastoma whole transcriptome analysis:
molecular mechanisms related to recurrence-free survival
(RFS). Sara Franceschi, Francesca Lessi, Paolo Aretini,
Francesco G. Carbone, Cristian Scatena, Marco La Ferla,
Valerio Ortenzi, Riccardo Vannozzi, Generoso Bevilacqua,
Antonio G. Naccarato, Chiara M. Mazzanti.
1121 Analysis of gene expression changes as a function
of PBRM1, BAP1, and SETD2 mutation status clear cell
renal cell carcinoma in TCGA tumors. Philip H. Abbosh, Ilsiya
Ibragimova, Michael Slifker, Paul Cairns.
1122 Personalized oncogenomics in advanced stage
breast cancer. Sophie Sun, Karen A. Gelmon, Stephen Chia,
Caroline Lohrisch, Tamara Shenkier, Diego Villa, Yaoqing
Shen, Martin Jones, Erin Pleasance, Katayoon Kasaian, Peter
Eirew, Sreeja Leelakumari, Yusanne Ma, Tony Ng, Stephen
Yip, Steven J. Jones, Marco A. Marra, Janessa J. Laskin.
5
POSTER SESSION
Poster
:LJ[PVU
6
6
Metabolic Pathways and Signaling Pathways That Regulate Metabolism
Poster
Board
Abstract
Number
Poster
Board
1.
1123 Glutaminase inhibitors suppress pyrimidine
synthesis and promote DNA replication stress in VHL-deficient
human renal cancer cells. Arimichi Okazaki, Paulo Gameiro,
Gregory Stephanopoulos, Othon Iliopoulos.
15.
2.
1124 Transcriptional control of B cell identity restricts
metabolic fitness in human leukemia. Lai N. Chan, Daniel Braas,
Christian Hurtz, Seyedmehdi Shojaee, Huimin Geng, Valeria
Cazzaniga, Carina Ng, Behzad Kharabi Masouleh, Yi H. Qiu,
Nianxiang Zhang, Kevin R. Coombes, Thomas Ernst, Giovanni
Cazzaniga, Andreas Hochhaus, Steven Kornblau, Thomas
Graeber.
16.
3.
Oncogenic PIK3CA mutations reprogram glutamine
metabolism in colorectal cancers. Yujun Hao, Yardena Samuels,
Qingling Li, Dawid Krokowski, Henri Brunengraber, Maria
Hatzoglou, Guo-Fang Zhang, Bert Vogelstein, Zhenghe Wang.
4.
1126 Differential effects of metformin and phenformin vs.
other complex 1 inhibitors in vitro and in vivo. Carolyn Algire,
Alexander Ehrmann, Sven Christian, Roland Neuhaus, Stephan
Menz, Wolfgang Schwede, Michael Haerter, Andrea Haegebarth.
18.
1125
5.
1127 Small molecule SIRT3 inhibitor 4’-bromo-resveratrol
inhibits proliferation, promotes apoptosis and causes
metabolic reprograming of human melanoma cells. Jasmine
George, Minakshi Nihal, Chandra K. Singh, Nihal Ahmad.
6.
1128
7.
17.
TET1-mediated epigenetic reprogramming switches
metabolism and promotes malignant phenotypes of ovarian
cancer. Lin-yu Chen, Rui-Lan Huang, Pearlly S. Yan, Tien-Shuo
Huang, Yu-Ping Liao, Jian-Liang Chou, Jora M.J. Lin, Tai-Kuang
Chao, Michael W.Y. Chan, Wun-Shaing Wayne Chang, HungCheng Lai.
1129 How to develop ACC1 inhibitors targeting lipid
metabolism and oncogenic signaling pathways effectively and
safely. Ningshu Liu, Wilhelm Bone, Sendhil S. Velan, Krishnarao
Doddapuneni, Jadegoud Yaligar, Kai Thede Thede, Ursula
Moenning, Xiaohe Shi, Xianfeng Tian, Elissaveta Petrova1, Franz
V. Nussbaum, Dominik Mumberg, Michael Brands, Karl
Ziegelbauer.
19.
20.
21.
22.
23.
24.
8.
1130 Unveiling the metabolic response of BRAF mutant
melanoma cells to BRAF inhibition. Teresa Delgado-Goni,
Slawomir Wantuch, Paul Workman, Richard Marais, Martin Leach,
Mounia Beloueche-Babari.
25.
9.
1131 Disruption of the NAD+- binding site affects GAPDH
interactions in the nuclei of cancer cells outside glucose
metabolism. Evgeny Krynetskiy, Manali Phadke, Natalia
Krynetskaia, Anurag Mishra, Carlos Barrero, Salim Merali, Scott A.
Gothe.
26.
1132
27.
10.
Gluconeogenesis, lipogenesis, and HBV replication
are commonly regulated by PGC-1␣-dependent pathway.
Wei-Hsiang Hsu, Hong-Jhih Jhuang, Chi-Ying Huang.
11.
1133 Plk1 phosphorylation of PTEN causes a tumorpromoting metabolic state. zhiguo li, li jie, Liu xiaoqi.
12.
1134
N-Myc promotes glutamine anaplerosis and
aggressive tumor progression through direct GLS2 activation.
Daibiao Xiao, Ping Ren, Hexiu Su, Ming Yue, Ruijuan Xiu, Lei Gan,
Hudan Liu, Guoliang Qing.
13.
1135 Loss of HSulf-1 promotes defective autophagy and
increased lipid droplet biogenesis in ovarian cancer. Debarshi
Roy, Susmita Mondal, Ashwani Khurana, Xiaoping He, Edward
Hammond, Keith Dredge, Viji Shridhar.
14.
1136 Regulation of AMPK by androgen receptor signaling
and its role in promoting prostate cancer through the use of
autophagy. Yan Shi, Efrosini Tsouko, Alicia M. Blessing, Jayantha
Tennakoon, Jenny J. Han, Michael M. Ittmann, Daniel E. Frigo.
28.
29.
30.
Abstract
Number
1137 Mitochondrial targeting of EGFR-VIII in
temozolomide resistant glioblastoma models. Kiran Kumar
Velpula, Swapna Asuthkar, Sarah E. Martin, Justin D. Lathia,
Andrew J. Tsung.
1138 AMPK promotes survival of breast cancer cells by
modulating metabolic stress. Katie L. Sullivan, Stavros
Kopsiaftis, Kathryn N. Phoenix, Melissa M. Fox, Kevin P. Claffey.
1139 Tumor-associated fibroblasts facilitate head and
neck cancer metabolism. Dhruv Kumar, Partha Kasturi, Bennett
V. Houten, Sufi Thomas.
1140 PI3K/Akt inhibition decreases oxygen consumption
In tumor cells by phosphorylating and inactivating pyruvate
dehydrogenase PDH E1␣ subunit. George J. Cerniglia, Souvik
Day, Shannon M. Gallagher-Colombo, Natalie Daurio, Stephen
Tuttle, Theresa M. Busch, Theresa M. Busch, Alexander Lin,
Tatiana V. Esipova, Sergei A. Vinogradov, Constantinos
Koumenis, Amit Maity.
1141 LPA stimulates glycolytic shift of ovarian cancer cells
via gip2 oncogenes. Ji Hee Ha, Rangasudhagar Radhakrishnan,
Danny Dhanasekaran.
1142 COP1 functions as a sensor of cellular lipids and
regulator of lipogenesis in human cancer cells. Chenfei Huang,
Yiwen Bu, Deliang Cao.
1143 EGF induces epithelial to mesenchymal transition
and cancer stem-like cell properties in human head and neck
cancer cells via promoting Warburg Effect. Qilin Xu, Qunzhou
Zhang, Ahn D. Le.
1144 Antioxidant enzyme-mediated survival of ECMdetached breast cancer cells requires AMPK activation. Sienna
M. Durbin, Calli Versagli, Daniel Pape, Zachary Schafer.
1145 The TDP-43 confers resistance to metabolic stress
condition via activating autophagy in GBM cells. Tzu-Wei Lin,
Chen-Wen Wu.
1146 Global profiling of SPARC-regulated metabolic
pathways in ovarian cancer. Sherine Taylor, Christian Sanchez,
Amna Adrees, Hale N. Ozbek, Harjapjit Sahni, Neveen A. Said.
1147 Differential expression of enzymes associated with
glycine metabolism in ovarian cancer stem like cell. So-Jin
Shin, Hye-Won Chung, Hyun-Gyo Lee, Eun Som Choi, Chi-Heum
Cho.
1148 Ang-(1-7) decreases HIF-1␣ and migration of oral
squamous cell carcinoma. Andre L. Guimaraes, Carlos A. Fraga,
Lucyana C. Farias, Talita A. Guimarães, Alfredo M. De Paula,
Amanda Mota, Lais Santiago, Ricardo S. Gomez, Sergio H. Santos,
Robson A. Santos, Michael Bader.
1149 Consistency between genomic and proteomic
profiles reveals novel molecular mechanisms of fasting
antitumor activity. Lizzia Raffaghello, Giovanna Bianchi, Roberto
Martella, Danilo Marimpietri, Andrea Petretto, Elvira Inglese,
Adriana Amaro, Vito Pistoia, Ulrich Pfeffer, Valter Longo.
1150 mTORC2 enhances flux through the hexosamine
biosynthetic pathway by regulation of GFAT1 expression.
Estela Jacinto, Joseph Moloughney, Thomas Lynch, Chang-Chih
Wu, Olufunmilola Ibironke, Aixa Navia, Po-Chien Chou, Sisi
Zhang, Joshua Rabinowitz, Guy Werlen.
1151 Overexpression of Fatty Acid Synthase is associated
with inhibition of autophagy under conditions of metabolic
stress in colorectal cancer cells. Yekaterina Y. Zaytseva, Jennifer
W. Harris, Ji T. Kim, Tianyan Gao, Eun Y. Lee, Heidi L. Weiss, B M.
Evers.
1152 The regulatory effect of fructose-bisphosphate
aldolase C in oral squamous cell carcinoma progression. Yueju
Li, Tse-Hung Huang, Been-Ren Lin, Cheng-Chi Chang.
305
POSTER SESSION
Metabolism and Cancer 1
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
7
Abstract
Number
1.
1153 Effective treatment of cancer associated cachexia
by AV-380, a GDF15 inhibitory antibody. Lorena Lerner,
Nianjun Tao, Brian Krieger, Richard Nicoletti, Bin Feng,
Nesreen Ismail, William Winston, Yanyu Zhang, Jinwei Jiang,
Solly Weiler, Jeno Gyuris.
15.
1167 Inhibition of WNT/ß-catenin signaling-related
glutamine metabolism but not the Warburg effect in
denervation-induced suppression of gastric tumorigenesis.
Gøran Andersen, Riyas Vettukattil, Yoku Hayakawa, Jon Erik
Grønbech, Timothy C. Wang, Duan Chen, Chun Mei Zhao.
2.
1154 Serum and urine markers of metabolic
dysfunction in colorectal cancer: A pilot study. Katarzyna J.
Jerzak, Marissa Laureano, Peter A. Kavsak, Sukhbinder
Dhesy-Thind, Kevin Zbuk.
16.
1168 Impact of some common organics on cellular
glycolysis and the differential survival of lung fibroblast
and lung carcinoma cell lines. Ibrahim O. Farah, Veshell L.
Lewis, Zikri Arslan.
3.
1155 Regulation of glutamine metabolism: Allosteric
activation and inhibition of mitochondrial glutaminase.
Clint Stalnecker, Scott Ulrich, Jon Erickson, Sekar
Ramachandran, Ralph DeBerardinis, Rick Cerione.
17.
1169 Growth regulation of bladder cancer cells by
compounds that affect glucose metabolism. Michael A. Lea,
Charles desBordes.
18.
4.
1156 Widespread deficiency of ASS1 in uveal melanoma and
sensitivity to pegylated arginine deiminase. Ramsay S. Khadeir,
Melissa M. Phillips, Mandeep S. Sgoo, Amit Arora, Victoria
Cohen, Caroline Thaung, Peter W. Szlosarek.
1170 TTP inhibits insulin receptor signals in cancer cell.
Ji Eun Yoon, VO MAI TRAM, Nal Ae Yoon, Jin Ho Back, Young
Joo Min, Wha Ja Cho.
19.
1171 Increased expression of PDK4 in bladder cancer
cells. Dharamainder Choudhary, Andrew Mikhalyuk, Carol
Pilbeam, John Taylor.
20.
1172 (R,R’)-4’-Methoxy-1-naphthylfenoterol
decreases glycolytic activity in the PANC-1 pancreatic
cancer cell line. Nagendra S. Singh, Jonathan Catazaro,
Michel Bernier, Robert Powers, Irving Wainer.
21.
1173 Extracellular ATP is internalized through not only
macropinocytosis but also other endocytic process and
promotes growth of human lung cancer cells with Ras
mutations. Yanrong Qian, Xuan Wang, Yunsheng Li, Yanyang
Cao, Shiyong Wu, Xiaozhuo Chen.
22.
1174 Exploiting glioma stem cell metabolism to
abrogate radioresistance in glioblastomas. Elizabeth I.
Spehalski, Keita Saito, Tamalee Kramp, Anita Tandle, Barbara
Rath, Murali Cherukuri, Kevin Camphausen.
23.
1175 Curcumin may have anticancer effect by normalizing
cancer metabolic pathway. Hideaki Takeyama, Hiromitsu
Hayashi, Takayoshi Kaida, Kota Arima, Katsunobu Taki,
Takaaki Higashi, Hirohisa Okabe, Hidetoshi Nitta, Daisuke
Hashimoto, Akira Chikamoto, Toru Beppu, Hideo Baba.
24.
1176 The effect of resveratrol combined with dichloroacetate
(DCA) on breast cancer cell lines and
MCF-10a noncancerous cells. Sarah Piepenbrink, Dan Sisler,
Russ Feirer.
25.
1177 Ketogenic diet sensitizes FaDu human head and
neck cancer xenografts to cisplatin as well as ionizing
radiation combined with cetuximab. Daniel C. Ma, Samuel
N. Rodman, John M. Buatti, Carryn Anderson, Bryan G. Allen,
Douglas R. Spitz, Melissa A. Fath.
26.
1178 Loss of PHLPP expression promotes glycolysis in colon
cancer cells. Xiaopeng Xiong, Yang-an Wen, Tianyan Gao.
27.
1179 Unique metabolic profile of Vemurafenibresistant melanoma cells: a quantitative proteomics
approach. Deeba N. Syed, Rahul K. Lall, Iram Majeed, Feng
Liu, Frank L. Meyskens, Hasan Mukhtar.
28.
1180 Hexokinase II plays a pivotal role in colorectal
cancer cell proliferation and survival. Nelson Ho, Brenda L.
Coomber.
5.
6.
1157 Potential mechanism for mitochondrial
uncoupling protein 2 promotes skin carcinogenesis.
Chunjing Zhang, Yunfeng Zhao.
1158 Real-time assessment of uptake and utilization of
lactate in intact human breast cancer cells using a 1HNMR-based assay. Emily G. Wholey, Harold G. Parkes, Paul
Workman, Martin O. Leach, Mounia Beloueche-Babari.
7.
1159 Ketosis and hyperbaric oxygen elicit potent anticancer effects in vitro and in vivo. Angela Poff, Nathan
Ward, Thomas Seyfried, Dominic D’Agostino.
8.
1160 CtBP1 is the molecular link that associates breast
cancer and metabolic syndrome. Paola De Luca, Nicolás
Dalton, Cristian P. Moiola, Carolina Flumian, Georgina Scalise,
Juliana Porretti, Cintia Massillo, Edith Kordon, Laura Todaro,
Elba Vazquez, Roberto Meiss, Adriana De Siervi.
9.
1161 Metformin has an inhibitory effect on cell
proliferation but does not induce death in colorectal
cancer. Angela Mogavero, Maria Valeria Maiorana, Claudia
Bertan, Fabio Bozzi, Marco A. Pierotti, Manuela Gariboldi.
10.
1162 Investigating the NAD metabolome in Ewing
Sarcoma. Cornelia N. Mutz, Raphaela Schwentner, Maximilian
O. Kauer, Jozef Ban, Dave N. Aryee, Sophie Erhardt, Dietmar
Fuchs, Andreas Heitger, Heinrich Kovar.
11.
1163 Phosphoserine aminotransferase 1 (PSAT1) as a
novel anti-tumor target in hepatocellular carcinoma.
Zhaobing Ding, Kenneth Wee, Eung-Sam Kim, Animesh
Samanta, Michael Steckel, Marian Raschke, Sendhil Velan,
Young-Tae Chang, Andrea Haegebarth, Karl Ziegelbauer,
Sylvia Gruenewald, Weiping Han.
12.
1164 Metabolic responses in cancer cells with differential
susceptibility to GLUT1 inhibition. Sylvia Gruenewald, Ulrike
Rennefahrt, Sandra G. Maldonado, Alexander Walter, Heike
Petrul, Mélanie Héroult, Iring Heisler, Maria Quanz, Patrick
Steigemann, Bernd Buchmann, Andrea Haegebarth.
13.
1165 Identification of a cholesterol onco-metabolite,
promoter of tumor in breast cancers, and of the enzyme
involved in its biosynthesis. Maud Voisin, Philippe de
Medina, Michael R. Paillasse, Magali Lacroix-Triki, Florence
Dalenc, Marc Poirot, Sandrine Silvente-Poirot.
14.
1166 ASCT2: A novel metabolic target for cancer therapy.
Nabendu Pore, Wanda King, Kristen Lekstrom, Susan Wilson,
Robert Hollingsworth, David A. Tice, Emil Michelotti.
306
7
POSTER SESSION
Poster
:LJ[PVU
8
8
Metabolism and Cancer 2
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
1182 Metformin affects breast cancer cell growth and
disturbs an IGF1/insulin related gene network that
correlates with breast cancer progression. Alessia I.
Esposito, Adriana Amaro, Giovanna Angelini, Laura Emionite,
Alessandra Gennari, Stefano Indraccolo, Davide Maggi,
Cecilia Marini, Barabara Salani, Gianmario Sambuceti, Maria
Pia Sormani, Ulrich Pfeffer.
1183 Metabolic characterization of follicular lymphoma
transformation. Brad Poore, Ana Ortega-Molina, Christopher
Nguyen, Liang Zhao, Anne Blackwell, Thomas Hartung, HansGuido Wendel, Anne Le.
1184 The tumor suppressor klotho: a master regulator
of metabolism in breast cancer. Riva Shmulevich, Tammi
Rubinstein, Taly Scherf, Ido Wolf, Tami Rubinek.
1185 Regulation of neutral amino acid transporters
gene expression profile in non-small cell lung cancer.
Pierre P. Massion, Maria Senosain, Mohamed Hassanein,
Xiangming Ji, Jun Qian, Megan hoeksema.
1186 Regulatory role of lactate dehydrogenase A
during head and neck carcinogenesis. Tsai-Ying Chen,
Wan-Jung Chang, Chang-Yi Chen, Wan-Chun Li.
1187 Functional genomic screening reveals asparagine
dependence as a metabolic vulnerability in sarcoma.
Simone Hettmer, Anna C. Schinzel, Daria Tchessalova, Nigel
G. Richards, William C. Hahn, Amy J. Wagers.
1188 HIF-1␣/NDUFA4L2 promotes hepatocellular
carcinoma progression through reducing oxidative stress.
Kit Ho Lai, Ming Jing Xu, Pui Wah Tse, Kung Chun Chiu, Wei
Lai, Chun Ming Wong, Pik Wong, Oi Lin Ng, Chak Lui Wong.
1189 The impact of metformin on progression-free survival
in patients with advanced pancreatic well differentiated
neuroendocrine tumor receiving everolimus plus somatostatin
analogue treatment. sara pusceddu, Roberto Buzzoni, laura
Concas, cristina bregant, livia leuzzi, massimo milione, ettore
seregni, barbara formisano, paola consonni.
1190 Prognostic significance of serine synthesis pathwayrelated protein expression in patients with resected colon cancer.
Byung Woog Kang, Jong Gwang Kim, Yee Soo Chae, Soo
Jung Lee, Shinkyo Yoon, Ghil Suk Yoon.
1191 The RNA binding protein, HuR, regulates pancreatic
cancer cell metabolism. Fernando F. Blanco, Mahsa Zarei,
Jonathan R. Brody, Laszlo G. Boros, Jordan M. Winter.
1192 Glutamic acid and glutaminolysis mark aggressive
tumorigenesis in head and neck squamous cell carcinoma. Adam
D. Banda, Mercedes Bermudez Cortes, Pachiyappan
Kamarajan, Thekkenlnaycke Rajendiran, Arul M. Chinnaiyan,
Yvonne L. Kapila.
1193 LSR transcript variant iota drives nuclear
localization and altered transcriptome regulation in breast
cancer. Katerina D. Fagan-Solis, David A. McDonald, Lynnelle
W. Thorpe, Jodie M. Fleming.
1194 O-GlcNAcylation regulates breast cancer lipid
metabolism via sterol regulatory element binding protein 1.
Valerie L. Sodi, Zachary Bacigalupa, Christina Ferrer, Mauricio
Reginato.
1195 Ethanolamine kinase-1 and
phosphoethanolamine are potential diagnostic markers
and therapeutic targets in breast cancer. Tariq Shah, Balaji
Krishnamachary, Flonne Wildes, Jannie Wijnen, Kristine
Glunde, Zaver M. Bhujwalla.
1196 Enhancement of anti-melanoma effect of BRAF
and MEK inhibition by metformin. Yanping Zhang,
Guangyong Peng, Eddy C. Hsueh.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1197 Selenium-binding protein 1-mediated tumor
suppression is associated with alterations of lipid/glucose
metabolic pathways in vivo. Qi Ying, Emmanuel Ansong,
Alan M. Diamond, Zhaoxin Lu, Xiaomei Bie, Wancai Yang.
1198 Molecular benefit of dietary alterations in breast
cancer controlled via microRNAs 188 and 669. Joshua D.
Palmer, Sunny Y. Han, Huang-Wen Chen, Isidore Rigoutsos,
Nicole L. Simone.
1199 Systems-based approach identifies altered
carbohydrate metabolism as a predictor of a malignant
phenotype in ovarian cancer. Rebecca A. Previs, Tyler J. Moss,
Behrouz Zand, Rajesha Rupaimoole, Heather J. Dalton, Jean
M. Hansen, Guillermo Armaiz-Pena, Susan Lutgendorf, Robert
L. Coleman, Pratip Bhattacharya, Prahlad Ram, Anil K. Sood.
1200 1,25-Dihydroxyvitamin D regulation of glutamine
metabolism in Harvey-ras transformed MCF10A human
breast epithelial cells. Xuanzhu Zhou, Wei Zheng, Fariba
Tayyari, G.A.Nagana Gowda, Daniel Raftery, Shawn S.
Donkin, Brian Bequette, Dorothy Teegarden.
1201 Characterization of the effects of IDH2 mutations
and (R)-2-HG in cancer progression. Kevin Kotredes, Ana
M. Gamero.
1202 Thrombospondin-1 regulates energy metabolism
to increase carcinogenesis in an in vivo model of colorectal
cancer. David R. Soto-Pantoja, John M. Sipes, Nicole Morris,
Nancy J. Emmenaker, David D. Roberts.
1203 Metastasis-associated oncogene RhoC as a
regulator of glutamine metabolism in the inflammatory
breast cancer cell line SUM149. Joel A. Yates, Michelle L.
Wynn, ZhiFen Wu, Charles R. Evans, Charles Burant, Santiago
D. Schnell, Sofia D. Merajver.
1204 Design of phenotype-driven flux analysis
approach for personalized metabolic models of cancer
patients. Abhinav Achreja, Lifeng Yang, Tyler Moss, Vasudha
Sehgal, Juan Marini, Prahlad T. Ram, Deepak Nagrath.
1205 Identification of a novel adjuvant therapeutic
agent for obesity related pancreatic cancer. Adriana
Harbuzariu, Robin C. Garrison, Danielle S. Daley-Brown,
Derrick J. Beech, Frederick D. Cason, Tia L. Harmon, Lily Yang,
Ruben R. Gonzalez-Perez.
1206 Cisplatin resistant non small cell lung cancer is
sensitive to arginine deprivation therapy. Medhi
Wangpaichitr, Chunjing Wu, Dao M. Nguyen, Min You, Ying
Ying Li, Shumei Chen, Lynn G. Feun, Niramol Savaraj.
1207 Nrf2 suppression results in growth inhibition and
enhances response to chemotherapy and radiation therapy in
triple-negative breast cancer cells. Yuzhe Yang, Douglas Yee.
1208 Glutamine modulates cellular NAD+/NADH
homeostasis thereby regulating cancer metastasis, drug
sensitivity in cancer cells. Lifeng Yang, Abhinav Achreja,
Tyler Moss, Joelle Baddour, Katherine Stilles, Lisa Chiba, Sun
Hye Kim, Josh Morse, Juan Marini, Anil K. Sood, Prahlad T.
Ram, Deepak Nagrath.
1209 Dissecting by 13C tracers the utilization of
glucose and glutamine for the synthesis of fatty acids in
triple negative breast cancer cells. Alexander Strigun,
Regina Reszka, Hans-Joerg Schiewe, Jean-Philippe Laine,
Ulrike Rennefahrt.
1210 Biopterin metabolism drives tumor progression.
Christopher Rabender, Asim Alam, Mike Waters, Ross
Mikkelsen.
1211 Metabolite assays to illuminate cellular energy
networks. Mary Sobol, Jolanta Vidugiriene, Donna Leippe,
Gediminas Vidugiris, Wenhui Zhou, James Cali.
307
POSTER SESSION
Nuclear Tumor Suppressors
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
308
Abstract
Number
1212 Mutant p53 stabilizes and protects the
transcription factor ETS2 from proteasomal degradation
by the ubiquitin ligase COP1/DET1. Zunamys I. Carrero,
Madhusudhan Kollareddy, Krishna M. Chauhan,
Gopalakrishnan Ramakrishnan, Luis A. Martinez.
1213 Endogenous p53 affinity tagging with CRISPR.
Chen Yang, Cortney L. Lawrence, Charles E. Lyons, Shirley M.
Taylor, Richard G. Moran.
1214 TP53 affects SOX2 copy number alterations and
expression in non-small cell lung cancer. Johanna SamulinErdem, Vidar Skaug, Per Bakke, Amund Gulsvik, Aage
Haugen, Shanbeh Zienolddiny.
1215 Small molecule Prodigiosin-mediated p53
pathway restoration and inhibition of self-renewal in
colorectal cancer involves c-Jun-mediated ⌬Np73
inhibition and p73 activation. Varun Vijay Prabhu,
Shengliang Zhang, Bo Hong, Joshua E. Allen, Amriti Lulla,
David T. Dicker, Wafik S. El-Deiry.
1216 Thiol-modification induced reactivation of
mutant p53 protein in human cancers using a nontoxic
stabilized homoglutathione disulfide. Debasish Basak,
Kalkunte S. Srivenugopal.
1217 Determining the impact of CRPC-specific p53
mutation on therapeutic response and prostate tumor
progression. Jeffry L. Dean, Jennifer K. Jones, Jonathan F.
Goodwin, Karen E. Knudsen.
1218 A biological crosstalk between p53 and MYCN/
MYC in neuroblastoma. Naohiko Ikegaki, Xao Tang.
1219 ID4 and p53 cross-talk promotes restoration of
mutant-p53 transcriptional activity. Derrick J. Morton,
Divya Patel, Jugal Joshi, Pankaj Sharma, Ashley Knowell,
Aisha Hunt, Jaideep Chaudhary.
1220 MDM2 promotes p53-independent breast cancer
metastatic phenotypes. Chong Gao, Nandini Kundu, Jill
Bargonetti.
1221 Pontin, a new mutant p53 binding protein,
promotes gain-of-function of mutant p53. Yuhan Zhao, Cen
Zhang, Xuetian Yue, Xiaoyan Li, Juan Liu, Haiyang Yu, Qifeng
Yang, Zhaohui Feng, Wenwei Hu.
1222 p53 downregulates CRKL proto-oncogene protein
through miR-200 family. Yasushi Sasaki, Miyuki Tamura,
Kenta Kobashi, Kousuke Takeda, Takafumi Nakagaki, Masashi
Idogawa, Takashi Tokino.
1223 LIF is a novel negative regulator of p53 in
colorectal cancers. Wenwei Hu, Haiyang Yu, Xuetian Yue,
Yuhan Zhao, Cen Zhang, Ken Young, Juan Liu, Zhaohui Feng.
1224 Identification of novel p53 targets by RNA
sequencing in mice liver tissues. Tomoyuki Koguchi, Chizu
Tanikawa, Yoshiyuki Kojima, Hidewaki Nakagawa, Yusuke
Nakamura, Koichi Matsuda.
1225 Proteome-wide analysis of gain-of-function
mutant p53 targets in breast cancer implicates PARP,
PCNA and MCM4 as oncogenic drivers. Alla Polotskaia, Gu
Xiao, Katherine Reynoso, Che Martin, Wei-Gang Qiu, Ronald
Hendrickson, Jill Bargonetti.
1226 Association of p53 codon72 polymorphism with
susceptibility to hepatocellular carcinoma in Chinese
population of Northeast Sichuan. Jiajing Cai, Yan Cai, Qiang
Ma, Dongsheng Wang, Guoyuan Zhang, Xiaolan Guo.
1227 Differential efficacy of p53 restoration in
induction and maintenance of senescence in premalignant
and malignant cells. Mohammad Harajly, Hassan Zalzali,
Sandra Ghayad, Farrah Ghamloush, Mark Jabbour, Hussein
Basma, Ayman Tawil, Zafar Nawaz, Raya H. Saab.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
9
Abstract
Number
1228 Identification of a novel p53 target regulating
p53-induced apoptotic pathway. Jinichi Mori, Paulysally Lo,
Chizu Tanikawa, Yusuke Nakamura, Koichi Matsuda.
1229 E3 ubiquitin ligase TRIM32 negatively regulates
tumor suppressor p53 to promote tumorigenesis. Cen
Zhang, Juan Liu, Xiaolong Wang, Ken H. Young, Wenwei Hu,
Zhaohui Feng.
1230 Detection of increased O-GlcNAcylated p53 levels
in MCF-7 cells after O-GlcNAcase inhibitor treatment using
antibodies specific for Ser-149-O-GlcNAcylated p53
proteins. Hyesook Kim, So Hee KIm, Aby Joiakim, David
Kaplan, Sung Hun Bae, David Putt.
1231 Live cell and in vitro analysis of p53 interactions.
Larisa Yurlova, Andrea Buchfellner, Benjamin Ruf, Sebastien
Gabriel Michel Jo, Jean-Christophe Bourdon, Farid J.
Ghadessy, Christopher J. Brown, David P. Lane, Tina Romer.
1232 Regulation of ARHI and p53 gene on the
programmed cell death of oral cancer cells. Yi Li, Shan-Wei
Shi, Chun-Jie Li, Bo Han, Long-Jiang Li.
1233 Impairment of TFF3 induces cellular apoptosis in
prostate cancer cell lines and overexpression of TFF3 may
be a prognostic biomarker in human prostate cancers.
So-Youn Kim, Ji-Ying Liu, Yeun-Jun Chung.
1234 Impact of cancer-associated mutations on MDM2
function. Krishna M. Chauhan, Luis A. Martinez.
1235 Inducible overexpression of bHLH transcriptional
regulator Id4 abrogates tumorigenicity of prostate cancer
xenografts. Divya Patel, Derrick J. Morton, Maxwell KorangYeboah, Yamini Gorantla, Sushma Bhosle, Perri Nagappan,
Nathen Bowen, Jaideep Chaudhary.
1236 Combined transfer of p19Arf and interferon-beta
genes to mouse melanoma cells causes LC3B- and
caspase-3-independent cell death and alters the
expression of critical genes. Aline H. Ribeiro, Paulo R. Del
Valle, Ruan F. Medrano, Daniel G. Ferrari, Daniela B. Zanatta,
Bryan E. Strauss.
1237 Antitumor studies of an E2f1 promoter sequence
binding peptide - penetratin conjugate as a molecule
targeting E2f in prostate cancer. Tazeem Shaik, Nitu Bansal,
Nadine J. Farley, John Kerrigan, Olga Garbuzenko, Tamara
Minko, Emine Abali, Zoltan Szekely, Kathleen Scotto,
Debabrata Banerjee, Joseph Bertino.
1238 Effects of MLH1 on prostate cancer cell function.
Shinichiro Fukuhara, Inik Chang, Yozo Mitsui, Soichiro
Yamamura, Takeshi Chiyomaru, Shahana Majid, Sharanjot
Saini, Hiroshi Hirata, Guoren Deng, Ankurpreet Gill, Darryn K.
Wong, Hiroaki Shiina, Norio Nonomura, Rajvir Dahiya,
Yuichiro Tanaka.
1239 CDKN2B loss promotes progression from benign
melanocytic nevus to melanoma. Andrew McNeal, Kevin
Liu, Vihang Nakhate, Christopher Natale, Brian Capell, Tzvete
Dentchev, Shelley Berger, Meenhard Herlyn, John Seykora,
Todd W. Ridky.
1240 Boric acid inhibits cell proliferation through RB1
protein in head and neck cancer. Esra Gunduz, Omer F.
Hatipoglu, Sadık Cigdem, Kubra Erdogan, Mustafa S. Elitok,
Reidar Grenman, Husamettin Erdamar, Mehmet Gunduz.
1241 A large prostate cancer tissue microarray showed
significant downregulation of hZIP1 in African American as
compared to Caucasian men. Andre= Kajdacsy-Balla, Omar
Bagasra, Vicky Y. Marcias, Katy Rezaei.
9
POSTER SESSION
Poster
:LJ[PVU
10
10
Unfolded Protein Response and Oxidative Stress
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
1242 Modulating the cellular redox state by targeting
the NAD glycohydrolase CD38: A novel therapeutic
approach for chemosensitizing B-cell malignancies. Davide
Botta, Tulin Dadali, Betty Mousseau, Anna Manouvakhova,
Melinda I. Sosa, Sara N. MKellip, LaKeisha Woods, Nichole A.
Tower, Larry J. Ross, Lynn Rasmussen, E. L. White, James R.
Bostwick, Frances E. Lund.
1243 Therapeutic ER stress induced by tunicamycin is
anti-angiogenic/anti-tumorigenic and signals through
unfolded protein response. Dipak K. Banerjee, Aditi
Banerjee, Krishna Baksi, Usha Katiyar, Jesus Santiago,
Neysharie Sanchez, Dipak K. Banerjee.
1244 Hyperthermia and chemotherapy mediated
effects on tumor cell proliferation and heat shock protein
expression in human colon cancer. Tanja Grimmig, Rebeca
Thumm, Romana Moench, Eva M. Moll, Christoph T. Germer,
Ana Maria Waaga-Gasser, Martin Gasser.
1245 Peroxiredoxin induction in breast cancer. Valerie
Buurma, Brendan Freeman, Akosua Adzenyah, Gregory
Pettit, Felicitas Heinen, Jillian Muhlbauer, Shelley A. Phelan.
1246 c-Myc is critical for apoptosis in 4hyroxynonenal-treated colorectal cancer cells. Christina T.
Wales, Rachel Gristock, Nadine So, Aaron T. Jacobs.
1247 Reduction of oxidative stress promotes
daunorubicin resistance in acute lymphoblastic leukemia
cells. Xia Sheng, Jonathan Tucci, Steven D. Mittelman.
1248 Environmental factors (heavy metal, alcohol)
enhance tumor malignant behaviors. Siying Wang.
1249 MLN4924, a protein neddylation inhibitor,
induces apoptosis via endoplasmic reticulum (ER)-stress
in human cervical cancer. Kuan-Lin Kuo, Yeong-Shiau Pu,
I-LIN Ho, Chen-Hsun Hsu, Ju-Ton Hsieh, Wei-Chou Lin, ChienTso Chou, Kuo-How Huang.
1250 Role of mitochondria elongation in p53-induced
cellular senescence. Young Yeon Kim, Hye Jin Jee, Na Young
Jeong, Jeanho Yun.
1251 Expression of NADPH oxidase 5 (Nox5) modulates
cellular morphology, proliferation and invasiveness of
human melanoma UACC-257 cells. Smitha Antony,
Yongzhong Wu, Guojian Jiang, Jennifer L. Meitzler, Han Liu,
Agnes Juhasz, Jiamo Lu, Miriam R. Anver, Krishnendu K. Roy,
James H. Doroshow.
1252 Arginylation as a new link between oxidative
stress response and prostate cancer progression. Fangliang
Zhang, Michael D. Birnbaum, Akhilesh Kumar, William M.
Morgan.
1253 Selectivity of regulated IRE1 dependent decay of
RNA controls pro-oncogenic signaling in glioblastoma. Eric
Chevet.
1254 Mitochondrial SOD2 regulates EMT and cancer
stem cell-like cell populations. Kelly A. Whelan, Hideaki
Kinugasa, Koji Tanaka, Satish Srinivasan, Manti Guha, Daret
St. Clair, Andres Klein-Szanto, Narayan Avadhani, Alan Diehl,
Anil Rustgi, Hiroshi Nakagawa.
1255 Mifepristone causes endoplasmic reticulum
stress, triggers the unfolded protein response, and
increases autophagic flux in ovarian cancer cells. Lei
Zhang, Alicia Goyeneche, Rekha Srinivasan, Carlos Telleria.
1256 MUC4 is negatively regulated by hypoxia in ROSdependent manner in pancreatic cancer. Suhasini Joshi,
Sushil Kumar, Moorthy P. Ponnusamy, Surinder K. Batra.
1257 In vivo inhibition of GRP78 potentiates
antiestrogen therapy effectiveness in ER+ breast tumors.
Katherine L. Cook, Robert Clarke.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1258 The unfolded protein response may contribute to
racial disparity in endocrine responsiveness in breast
cancer. Ahreej E. Eltayeb, Diane M. Demas, Robert Clarke,
Ayesha N. Shajahan-Haq.
1259 Identification of p97 as a prime target to inhibit
cancer growth and stemness. Chuang Li, Meng Nie,
Hongyang Quan, Qianqian Fan, Nan Zhang, Quancai Cui, Lin
Wang.
1260 Divergent androgen regulation of unfolded
protein response pathways drives prostate cancer. Yke J.
Arnoldussen, Margrethe Storm, Xia Sheng, Martina Tesikova,
Yang Jin, Hatice Z. Nenseth, Sen Zhao, Ian G. Mills, Ladan
Fazli, Paul Rennie, Bjørn Risberg, Håkon Wæhre, Håvard E.
Danielsen, Gökhan S. Hotamisligil, Fahri Saatcioglu.
1261 Comprehensive failure of intracellular protein
homeostasis kills myeloma and solid cancer cells following
VCP/p97 inhibition. Katarzyna Parzych, Sandra Loaiza,
Tamara M. Chinn, Philippa May, Florentina Porsch, Anastasios
Karadimitris, Christoph Driessen, Heather P. Harding, David
Ron, Holger W. Auner.
1262 The transcription factor ATF4 regulates resistance
to anoikis and promotes metastasis in fibrosarcoma via
cooperative upregulation of Heme Oxygenase-1 with Nrf2.
Souvik Dey, Carly M. Sayers, Stacey L. Lehman, Yi Cheng,
George J. Cerniglia, Stephen W. Tuttle, Michael D. Feldman,
Paul J. Zhang, Serge Y. Fuchs, J. A. Diehl, Constantinos
Koumenis.
1263 Cellular senescence in Hodgkin’s lymphoma.
Jacob Gopas, Udi Zurgil, Estee Zeev, Daniel Benharoch, Jodi
Ezratty, Giora Shubinsky, Etta Livneh.
1264 Conditional mouse and zebrafish models of INK4mediated tumor suppression reveal ARF-independent
regulation of cellular senescence. Kathleen Flaherty, Daniel
Jones, Shamila Yussuf, Stephani Davis, Eric Huselid, Wei
Wang, Monica Bartucci, Hatem E. Sabaawy.
1265 LAMP2 overexpression in the plasma membrane
of breast cancer cells in response of chronic acidosis as a
new imaging and therapeutic target. Mehdi Damaghi,
Robert Sprung, Narges Tafreshi, Veronica Estrella, John
Koomen, David Morse, Robert Gillies.
1266 Autophagy-mediated degradation of nuclear
envelope proteins during oncogene-induced senescence.
Christelle Lenain, Olga Gusyatiner, Sirith Douma, Daniel S.
Peeper.
1267 The senescence-associated secretory phenotype
requires the histone variant macroH2A1 and is
antagonized by ATM in a novel ER stress response.
Hongshan Chen, Penelope D. Ruiz, Wendy McKimpson,
Leonid Novikov, Richard N. Kitsis, Matthew J. Gamble.
1268 Anoikis evasion in inflammatory breast cancer
cells is mediated by Bim-EL sequestration. Cassandra
Buchheit, Brittany Angarola, Allison Steiner, Kelsey Weigel,
Zachary Schafer.
1269 Role of ribosomal protein, Rpl22 in regulating
leukemic transformation. Nehal S. Patel, Noa G. Kushnir,
Shuyun Rao, Suraj Peri, Michele Rhodes, Panduka
Nagahawatte, Charles Mullighan, David L. Wiest.
1270 Ribosome biogenesis is reduced by oncogenic
stress in normal cells and is sufficient to trigger cellular
senescence. Frédéric Lessard, Véronique Bourdeau,
Sebastian Igelmann, Xavier Deschênes-Simard, Marinieve
Montero, Gerardo Ferbeyre.
1271 MDM2 small molecule inhibitors synergize with
chemotherapeutics to attenuate senescence-driven
inflammatory secretion. Nicholas Schaum, Fatouma
Almirah, Gary Scott, Christopher Benz, Judith Campisi, Albert
R. Davalos.
309
POSTER SESSION
Immunology
Human Immunity and Immune Correlates
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
310
Abstract
Number
1272 Upregulation of mRNA of CD80, FOXP3, NKG2D and
PD-L1 in peripheral blood mononuclear cells is associated with
metastatic breast cancer patients. Ayane Yamaguchi, Kosuke
Kawaguchi, Eiji Suzuki, Mariko Nishie, Masakazu Toi.
1273 Relation between tumor-associated macrophage (TAM)
subsets and CD47 expression on squamous cell carcinoma of the
head and neck (SCCHN) in tumor microenvironment. Koichi
Sakakura, Hideyuki Takahashi, Kazuaki Chikamatsu.
1274 Hallmark of immune responses to multiple tumorassociated antigens (TAAs) in immunodiagnosis of hepatocellular
carcinoma (HCC) and other solid tumors. Liping Dai, Pei Li,
Weihong Liu, Chenglin Luo, Eng M. Tan, Jianying Zhang.
1275 Chemotactic factors underlying tumor infiltration by
immunocompetent cells in colorectal cancer. Eleonora Cremonesi,
Francesca Amicarella, Elisabetta Padovan, Manuele G. Muraro,
Valentina Mele, Paul Zajac, Christian Hirt, Raoul Droeser, Daniel Oertli,
Markus Zuber, Michel Adamina, Raffaele Rosso, Jesus G. Garzon,
Lubor Borsig, Giulio C. Spagnoli, Giandomenica Iezzi.
1276 CD169-positive sinus macrophages in regional lymph
nodes are associated with better survival in patients with
malignant melanoma. Yoichi Saito, Koji Ohnishi, Azusa Miyashita,
Satoshi Nakahara, Yukio Fujiwara, Hasita Horlad, Takanobu
Motoshima, Satoshi Fukushima, Masatoshi Jinnin, Hironobu Ihn,
Motohiro Takeya, Yoshihiro Komohara.
1277 Tumor-specific human monoclonal antibodies isolated
from cancer patients that bind antigens expressed on the outer
plasma membrane of cancer cells. Baron Heimbach, Cezary Swider,
Huiwu Zhao, Paul Simon, R. Katherine Alpaugh, Michael Walker,
David Krag, David Knight, Tung Chan, Hossein Borghaei, Scott
Dessain.
1278 Accumulation of tolerogenic human 6-sulfo LacNAc+
dendritic cells in renal cell carcinoma is associated with poor
prognosis. Marieta I. Toma, Rebekka Wehner, Anja Kloß, Kati
Erdmann, Susanne Fuessel, Barbara Seliger, Dorothee Brech, Elfriede
Noessner, Knut Schaekel, Manfred Wirth, Gustavo Baretton, Marc
Schmitz.
1279 Expression of B7-H5 in human pancreatic caner. Yuwen
Zhu, Joshua Byers, Alessandro Paniccia, Jeffrey Kaplan, Michelle
Koenig, Richard Schulick, Barish Edil.
1280 Clinical features of transcriptional factor Helios
expression on regulatory T cells in patients with non-small cell
lung cancer. Satoshi Muto, Yuki Owada, Takuya Inoue, Yuzuru
Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki
Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori
Higuchi, Hiroyuki Suzuki, Mitsukazu Gotoh.
1281 Serum levels of the immunomodulatory protein, the
progesterone induced blocking factor (PIBF) are not higher in
women with progesterone (P) receptor (R) positive vs. negative
breast cancer. Jerome H. Check, Anne Rosenberg, Ann DiAntonio,
Hallgeir Rui, Rachael Cohen, Gabrielle DiAntonio.
1282 Comparison of serum progesterone levels of the
immunomodulatory protein, the progesterone induced blocking
factor, in people with BRCA-2 mutations associated with and not
associated with a high risk of cancer. Jerome H. Check, Michael P.
Dougherty, Gabrielle DiAntonio, Jamie Vaniver, Marie Duroseau, Maya
D. Srivastava.
1283 In situ activity of tumor specific CTL is a prognostic
factor in colorectal cancer. Slava Stamova, Christoph Reissfelder,
Christina Gossmann, Marion Braun, Andreas Bonertz, Ute Walliczek,
Moritz Koch, Axel Benner, Dirk Jäger, Niels Halama, Khashayarsha
Khazaie, Jürgen Weitz, Philipp Beckhove.
1284 Analysis of the immune suppression mechanism in
extra-hepatic cholangiocarcinoma. Satoshi Wada, Mariko
Tsukagoshi, Akira Watanabe, Norio Kubo, Kenichiro Araki, Hideki
Suzuki, Hiroyuki Kuwano.
1285 Production of interleukin-17 is increased in patients with
gastrointestinal cancer and correlates with immune suppression
involving MDSC, nutritional impairment, and poor prognosis.
Masahiko Shibata, Kenji Gonda, Takahiro Nakajima, Shinji Ohki, Izumi
Nakamura, Tatsuo Shimura, Koji Kono, Seiichi Takenoshita.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
11
Abstract
Number
1286 Macrophages in the breast tumor microenvironment as a
prognostic factor among race/ethnicity. Ana M. Santander, Tulay
Koru-Sengul, Feng Miao, Merce Jorda, Stephan Gluck, Consuelo
Alvarez, Clara Milikowski, Osvaldo Perez, Mehrdad Nadji, Roberto
Carrio, Omar Lopez-Ocejo, Marta Torroella-Kouri.
1287 Characterization of B cells infiltrating human breast
cancer. Soizic Garaud, Laurence Buisseret, Céline Naveaux, Anaïs
Boisson, Jean-Nicolas Lodewyckx, Hugues Duvillier, Ligia Craciun,
Denis Larsimont, Karen Willard-Gallo.
1288 Does an increased underlying immune/inflammatory
response in healthy females put them at a higher risk for thyroid
cancer. Karnika Singh, Melanie Jones, Augustine Moscatello, Edward
Shin, Raj Tiwari, Jan Geliebter.
1289 Renal cell carcinoma patients have altered HLA
expression patterns which show correlations to clinical parameter.
Steffen Goebel, Karen Bluemke-Anbau, Wolfgang Altermann, Udo
Bilkenroth, Axel Meye, Susanne Fuessel, Astrid Kehlen, Christine
Lautenschlaeger, Andres Melchior, Paolo Fornara, Helge Taubert.
1290 Distinct immune cell composition for lung squamous cell
carcinoma (SCCA) and adenocarcinoma (ADCA). Julia Kargl,
Kyoung-Hee Kim, Stephanie E. Busch, Mark L. Hanke, Heather E. Metz,
Martin W. McIntosh, A M. Houghton.
1291 Tumor-infiltrating FOXP3+ T-regulatory (Treg) cells in
early-stage human lung cancer exhibit enhanced suppressive
function when compared to blood or lymph node (LN) Treg cells.
Tatiana Akimova, Evgeniy B. Eruslanov, Pratik S. Bhojnagarwala, Jon
G. Quatromoni, Jacqueline Morgen, Sunil Singhal, Steven M. Albelda,
Wayne W. Hancock.
1292 Validation study on quantitative analysis method of
interrelationships between immune cells and prostate epithelial
and cancer cells. Gero Kramer, Lukas Kenner, Thomas Szekeres,
Shahrokh Shariat, Sarah Schwarz.
1293 Ocular adnexal lymphomas and chlamydia association:
an Indian scenario. Mansi Bhardwaj, Anjana Sharma, Seema Sen, Gita
Satpathy, Neelam Pushker, Seema Kashyap, Lalit Kumar.
1294 Identification of tumor-specific antigens associated with
RET/PTC3 expression. Laura Sponton, Gabriela Cosma, Mark
Mendonca, Mirella Giovarelli, Laurence C. Eisenlohr.
1295 Role of glycine N-methyltransferase in the regulation of
T cell responses in experimental autoimmune encephalomyelitis.
Chung-Hsien Li, Ming-Hong Lin, Yen-Fu Chen, Shih-Han Chu, PangHsien Tu, Cheng-Chieh Fang, Chia-Hung Yen, Peir-In Liang, Jason C.
Huang, Yu-Chia Su, Huey-Kang Sytwu, Yi-Ming A. Chen.
1296 The phosphoproteome as a new target for
immunotherapy against hepatocellular carcinoma. Nico Buettner,
Sarah A. Penny, Paisley D. Trantham, Lora G. Steadman, Stuart
Curbishley, David Adams, Donald F. Hunt, Mark Cobbold.
1297 Increases in the numbers of myeloid-derived suppressor
cells in Egyptian children with acute lymphoid leukemia. Mohamed
L. Salem.
1298 The effect of adipocyte-derived factors on lung cells:
Exploring the protective nature of excess weight on lung cancer
risk. Rosalind B. Penney, Daniel Sappington, Eric Siegel, Gunnar
Boysen, Susan Kadlubar.
1299 Tumor-infiltrating B cells are predictive of human lung
squamous cell survival. Sara Centuori, Samuel Kim, Cecil Gomes,
Charles Putnam, David Mount, Linda Garland, Jesse Martinez.
1300 Breast cancer-associated macrophages undergo
proliferation at different rates across ethnicities: results of a pilot
study. Lidia G. Sanchez, Jorge E. Torrez-Munoz, Ana M. Santander,
Tan A. Ince, Marta Torroella-Kouri.
1301 Inter- and intra-tumoral immune and genomic
heterogeneity in patients with metastatic melanoma. Alexandre
Reuben, Zachary A. Cooper, Whijae Roh, Yu Cao, Jacob AustinBreneman, Hong Jiang, Rodabe N. Amaria, Pei-Ling Chen, Michael T.
Tetzlaff, Lynda Chin, Andrew Futreal, Michael A. Davies, Jennifer A.
Wargo.
11
POSTER SESSION
Immunology
Poster
:LJ[PVU
12
12
Immune Monitoring/Biomarkers
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Abstract
Number
1302 High complexity flow cytometry panels to monitor
target expression, T-cell activation and suppresssion by novel
immunotherapies in hematomalignancy clinical trials. Ghanashyam
Sarikonda, Devika Ashok, Anil Pahuja, Jelveh Lameh, Shabnam
Tangri, Naveen Dakappagari.
1303 Quantification of natural killer cell-mediated
cytotoxicity using Celigo imaging cytometry. Leo L. Chan, Kelsey
Rosbach, Srinivas S. Somanchi, Dean Lee.
1304 Identification of responders for Anti-CTLA4 in refractory
colorectal cancers using CANScript™ platform. Biswanath
Majumder, Baraneedharan Ulaganathan, Allen Thayakumar,
Saravanan Thiyagarajan, Nilesh Brijwani, Biplab Tewari, Basavaraja U.
Santhappa, Padhma Radhakrishnan, Pradip K. Majumder.
1305 In vitro analysis of T cells effector vs regulatory function
in patients with metastatic melanoma and its correlation to
patient outcome. Upendra P. Hegde, Sidharth S. Jha, Nitya G.
Chakraborty.
1306 Biomarker results from a clinical trial of nivolumab in
patients (pts) with metastatic renal cell carcinoma (mRCC)
(CA209-009): Gene expression, serum profiling for immune
markers, and multiplex tissue immunohistochemistry (IHC). Toni
K. Choueiri, Mayer N. Fishman, Bernard Escudier, Walter M. Stadler,
Scott Chasalow, Petra Ross-Macdonald, Maria Jure-Kunkel, Mario
Sznol, Jason S. Simon.
1307 Assessment of gene expression in peripheral blood from
patients with advanced melanoma using RNA-seq before and after
treatment with anti-PD-1 therapy with pembrolizumab (MK3475). Mark D. Ayers, Michael Nebozhyn, Heather A. Hirsch, Razvan
Cristescu, Erin E. Murphy, S. Peter Kang, Scot W. Ebbinghaus, Terrill
K. McClanahan, Andrey Loboda, Jared K. Lunceford.
1308 Depressed anti-HER2 CD4 Th1 responses correlate with
residual disease following neoadjuvant therapy in HER2+ breast
cancer patients and can be restored by dendritic cell vaccination.
Jashodeep Datta, Erik Berk, Shuwen Xu, Elizabeth Fitzpatrick, Lea
Lowenfeld, Noah Goodman, David Lewis, Robert E. Roses, Angela
DeMichele, Brian J. Czerniecki.
1309 Fitness of T cells for use in cellular therapy of pediatric
malignancies. Nathan Singh, Jessica Hulitt, Stephan A. Grupp, David
M. Barrett.
1310 Programmed death ligand-1 (PD-L1) heterogeneity in
non-small cell lung cancer (NSCLC). Joseph McLaughlin, Kurt A.
Schalper, Daniel E. Carvajal-Hausdorf, Vasiliki Pelekanou, Vamsidhar
Velcheti, Herbert Haack, Matthew R. Silver, Roy Herbst, Patricia
LoRusso, David L. Rimm.
1311 The frequency of circulating V⌬1-positive but not V⌬2positive ⌫/⌬ T cells correlates positively with survival in latestage melanoma and may be increased by ipilimumab treatment.
Kilian Wistuba-Hamprecht, Benjamin Weide, Alex Martens, Graham P.
Pawelec.
1312 Transcriptional signatures associated with lack of
response to anti-PD-1 therapy in patients with renal cell
carcinoma. Maria Libera Ascierto, Tracee McMiller, Alan Berger,
Robert A. Anders, Chris Cheadle, Haiying Hu, Charles Drake, Drew
Pardoll, Janis Taube, Suzanne L. Topalian.
1313 Characterization and isolation of antigen-responding T
cells in Sipuleucel-T treated patients. Jeff Pufnock, Tuyen Vu, James
Trager, Nadeem Sheikh.
1314 Evaluation of PD-L1 mRNA and protein expression in
non-small cell lung and hepatocellular carcinoma. Savina Jaeger,
Benjamin H. Lee, Rebecca Mosher, Olga Shebnova, Yan Wang,
Yenyen Yu, David Yang, Masato Murakami, Joel Greshock, Robert
Schlegel, Anthony Boral, Zhu A. Cao.
1315 High IFN␥ and perforin and low GM-CSF and sCD40L
production correlate with CD8 TIL growth in breast cancer. Hitoe
Torisu-Itakura, Yueqin Quan, Myung Shin Sim, Maggie L. DiNome,
Peter A. Sieling, Delphine J. Lee, Mark B. Faries.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
1316 Evaluation of immune cell subsets of cancer patients
treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C)
capable of mediating ADCC of human tumor cells. Lauren M.
Lepone, Renee N. Donahue, Benedetto Farsaci, Italia Grenga,
Benjamin Boyerinas, Caroline Jochems, Kwong-Yok Tsang,
Christopher R. Heery, Ravi A. Madan, Geraldine O’Sullivan Coyne,
Harpreet Singh, James L. Gulley, Jeffrey Schlom.
1317 Biomarker evaluation for PD-1 targeted therapies in
non-small cell lung cancer (NSCLC) patients. Alice O. Kamphorst,
Rathi N. Pillai, Shu Yang, Rama Akondy, Lydia Koenig, Ke Yu, Megan
McCausland, Gabriel Sica, Fadlo R. Khuri, Taofeek K. Owonikoko,
Suresh S. Ramalingam, Rafi Ahmed.
1318 A protein microarray signature of autoantibody
biomarkers for the detection of HER2+ breast cancers. Benjamin A.
Katchman, Rizwan Alam, Matthew S. Field, Jennifer Viloria, Garrick
Wallstrom, Joshua LaBaer, Paul Engstrom, Karen S. Anderson.
1319 Monitoring inflammasome activation with a
bioluminescent caspase-1 assay. Martha O’Brien, Danielle Moehring,
Raúl Muñoz-Planillo, Gabriel Núñez, Justin Callaway, Jenny Ting, Mike
Scurria, Tim Ugo, Laurent Bernad, James Cali, Dan Lazar.
1320 PD-L1: the hand brake of immune responses in cervical
intraepithelial neoplasia and cancer. Leonel F. Maldonado Gonzalez,
Christopher VandenBussche, Richard Roden, T.C. Wu, Benjamin
Tycko, Cornelia L. Trimble.
1321 The use of proteomics to analyze whole tumors and
identify unique immuno-oncology targets for antibody-based
therapeutics. Jim Ackroyd, Arnima Bisht, Jason Allen, Lindsey
Hudson, Martin Barnes, Christian Rohlff, Keith Wilson, Robert Boyd,
Dee Aud.
1322 Expression of programmed cell death ligand 1/2 and
BCG immunotherapy in bladder cancer. Jun Hyeok Heo, Ki Chung
Park, Kang Su Cho, Sung Joon Hong, Kyung Seok Han.
1323 Both programmed cell death protein 1 and programmed
death-ligand 1 molecules can be expressed on the cell surface of
small-cell lung cancer. Hiromichi Yamane, Hideko Isozaki, Nobuaki
Ochi, Kenichiro Kudo, Yoshihiro Honda, Tomoko Yamagishi, Toshio
Kubo, Katsuyuki Kiura, Nagio Takigawa.
1324 A translational platform to design antibodies targeting
triple negative breast cancer-specific antigens for cancer
immunotherapy. Kristina M. Ilieva, Rebecca Marlow, Anthony
Cheung, Erika Francesch, Panagiotis Karagiannis, Matthew Fittall,
Silvia Crescioli, Andrew Tutt, Sophia Karagiannis.
1325 Evaluation of immuno-oncology related treatment in
syngenic and human reconstituted immune systems. Marc Hillairet
de Boisferon, Francis Bichat, Caroline Mignard, Xavier Tizon, Damien
France, Jean-François Mirjolet.
1326 Elevated levels of plasma VEGF associated with the
attenuation of whole blood IFN-␥ production and QOL impairment
in patients with advanced gastric cancer. Naoyuki Sakamoto,
Takeshi Ishikawa, Tetsuya Okayama, Tomoyo Yasuda, Toshifumi Doi,
Hideyuki Konishi, Satoshi Kokura, Mari Tanigawa, Kazuko Uno, Yuji
Naito, Yoshito Ito, Toshikazu Yoshikawa.
1327 Variable impact of chemotherapy +/- cetuximab on
immune modulation in a prospective cohort of 163 cancer
patients. Cristiana Lo Nigro, Martino Monteverde, Marie-Christine
Etienne-Grimaldi, Giuliana Strola, Laura Lattanzio, Daniela Vivenza,
Federica Tonissi, Annalisa Ghiglia, Marco Merlano, Gerard Milano.
1328 Molecular characterization of mouse syngeneic tumor
models in response to treatment with anti-PD-1 immunotherapy.
Heather A. Hirsch, Elaine M. Pinheiro, Mingmei Cai, Yanhong Ma,
Manjiri Sathe, Mark Ayers, Terrill K. McClanahan.
1329 Identification of neoantigens recognized by
autoantibodies in chemotherapy-treated pancreatic cancer
patients. Giorgia Mandili, Emanuela Mazza, Michela Capello, Daniele
Giordano, Paola Cappello, Francesco Novelli.
1330 The influence of anticancer agents and heat treatment
on PD-L1 expression on human and murine pancreatic cancer cell
lines. Toshifumi Doi, Tetsuya Okayama, Takeshi Ishikawa, Kaname
Oka, Naoyuki Sakamoto, Tomoyo Yasuda, Yuji Naito, Yoshito Itoh.
311
POSTER SESSION
Immunology
Tumor Immunology
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
312
Abstract
Number
1331 Targeting CD47 triggers macrophage-dependent
brain tumor destruction in a clinical relevant model. Huaiyang
Zhu, Ning Yang, Lina Leiss, Cecilie B Rygh, Siddhartha S Mitra,
Samuel H Cheshier, Bin Huang, Rolf Bjerkvig, Per Ø Enger, Irving L
Weissman, Xingang Li, Jian Wang.
1332 Interleukin-15 enhances rituximab-dependent
cytotoxicity ex vivo and in vivo against a mouse lymphoma
expressing human CD20. Bernard Wen, Meili Zhang, David Dilillo,
Jeffrey V. Ravetch, Thomas A. Waldmann.
1333 CD4 Th1 cytokines and HER-2/HER-3 blockade
induces tumor apoptosis in breast cancer. Cinthia Rosemblit,
Jashodeep Datta, Erik Berk, Brian J. Czerniecki.
1334 Chemotherapy regulated microRNA-125/HER2
pathway as a novel therapeutic target for trastuzumabmediated cellular cytotoxicity in small-cell lung cancer.
Shigehiro Yagishita, Yu Fujita, Yuichi Fujimoto, Fumiyuki
Takahashi, Kazuhisa Takahashi, Tomohide Tamura, Fumiaki
Koizumi.
1335 Dissecting the mechanisms of anti-tumor protection
mediated by an antibody targeting the transferrin receptor 1.
Lai Sum Leoh, Tracy R. Daniels-Wells, Otoniel Martinez-Maza,
Manuel L. Penichet.
1336 Novel immunotherapeutic activity of JAK and PI3K␦
inhibitors in a model of pancreatic cancer. Holly K. Koblish,
Michael Hansbury, Liang-Chuan S. Wang, Gengjie Yang, Taisheng
Huang, Chu-Biao Xue, Yun-Long Li, Eddy Yue, Andrew Combs,
Wenqing Yao, Reid Huber, Peggy Scherle.
1337 Up-regulation of mannose 6-phosphate receptor
induced by BRAF inhibitor PLX4720 is linked to
phosphatidylserine externalization and shows positive effects
for combination therapies. Sergio Lavilla-Alonso, Rolf Brekken,
Dmitry Gabrilovich.
1338 Novel implications of histone deacetylase 6 selective
inhibition in melanoma T-cell immunotherapy. Andressa S.
Laino, David M. Woods, Amod Sarnaik, Esteban Celis, Jeffrey
Weber, Eduardo M. Sotomayor.
1339 Preclinical combination activity of SGN-CD19A and
CVAD in patient-derived B-lineage acute lymphoblastic
leukemia models. Ivan J. Stone, Tina Albertson, Che-Leung Law.
1340 Antitumor effector B cells directly kill tumor cells
involving the CXCL12/CXCR4 pathway and their therapeutic
efficacy is enhanced by IL-2. Yang Xia, Huimin Tao, Yangyang Hu,
Li Zhou, Yangyi Bao, Steven K Lundy, Shiang Huang, Qiao Li, Alfred
E Chang.
1341 Endocrine deprivation therapy increases the
sensitivity of breast cancer cells to T cell-mediated lysis
independently of estrogen receptor or androgen receptor
status. Anna R. Kwilas, Andressa Ardiani, Sofia R. Gameiro, James
W. Hodge.
1342 A new approach to cancer therapy based on dynamic
anchor-mediated activation of tumor-specific T cells. Chih-Ping
Mao, Chien-Fu Hung, TC Wu.
1343 Abcc3 up-regulation confers protection from
chemotherapy to NK cells in a murine model of malignant
glioma. Serena Pellegatta, Sara Pessina, Gabriele Cantini,
Emanuela Cazzato, Dimos Kapetis, Gaetano Finocchiaro.
1344 The ketogenic diet enhances immunity in a mouse
model of malignant glioma. Eric C. Woolf, John L. Johnson,
Danielle M. Lussier, Kenneth S. Brooks, Joseph N. Blattman,
Adrienne C. Scheck.
1345 Antitumor and antimetastatic response of melanomabearing normal and alcoholic mice to Sunitinib and ALT-803
treatment. Kari A. Gaither, Alexander A. Little, Alisha A. McBride,
Savanna Castillo, Kiran K. Brar, Amity Platt, Zhaohui Zhu, Faya
Zhang, Dung Luong, Hui Zhang, Gary G. Meadows.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
13
Abstract
Number
1346 Immunotherapy against breast cancer based on Stat3
blockade. Mara De Martino, María F. Mercogliano, Mercedes Tkach,
Leandro Venturutti, Patricia V. Elizalde, Roxana Schillaci.
1347 Genomic stress in antigen experienced Tlymphocytes. Shashank Patel, Madhusudhanan Sukumar, Douglas
Palmer, Rahul Roychoudhari, Rabindra Roy, Andre Nussenzweig,
Nicholas Restifo.
1348 CD4 T cells targeting citrullinated vimentin reject
advanced tumors. Lindy G. Durrant, Victoria A. Brentville, Rachael
L. Metheringham, Ian Daniels, Peter Symonds, Mohamed Gijon, Wei
Xue.
1349 Tim-3/galectin-9 interaction might be associated with
the immunosuppression of gastrointestinal stromal tumor
(GIST). HIDEO KOMITA, Sigeo Koido, Hisao Tajiri, Masafumi Suzuki,
Sadamu Homma.
1350 The combination of a murine iNKT cell-activating
antibody and IL-12 exhibits antitumor activity in a mouse
melanoma model. Weiming Yuan, Xiangshu Wen.
1351 Post-transplantation cyclophosphamide depletes
vaccine primed donor T cells and compromises graft-versustumor effects in alloBMT model. Han-Hsuan Fu, Jie Fu, Jie Wang,
Richard J. Jones, Ephraim Fuchs, Hyam Levitsky.
1352 Identifying pre-diagnostic breast cancer antigens in
transgenic mouse mammary tumor models for preventative
vaccine development. Sasha E. Stanton, Ekram Gadd, Lauren
Rastetter, James Annis, Jianning Mao, John Ladd, Samir Hanash,
Mary L. Disis.
1353 Alleviation of sepsis in osteosarcoma-bearing mice via
immunomodulatory cytokine interleukin-30 treatment. Jun Yan,
Abhisek Mitra, Jiemiao Hu, Jeffery J. Cutrera, Xueqing Xia, Lopa
Mishra, Shulin Li.
1354 Comparison of pomalidomide dosing strategies in
lenalidomide-refractory myeloma: Impact on clinical outcome,
immune activation and cereblon targets. Rituparna Das, Kartik
Sehgal, Lin Zhang, Rakesh Verma, Yanhong Deng, Mehmet
Kocoglu, Juan Vasquez, Srini Koduru, Yan Ren, Maria Wang,
Suzana Couto, Mike Breider, Donna Hansel, Stuart Seropian, Dennis
Cooper, Anjan Thakurta, Xiaopan Yao, Kavita M. Dhodapkar,
Madhav V. Dhodapkar.
1355 Functional inactivation of LKB1 increases the
production of pro-inflammatory cytokines and governs
response to immune modulation. Esra A. Akbay, Shohei Koyama,
Yvonne Li, Grit S. Herter-Sprie, Tran C. Thai, Amir R. Aref, Margaret
Soucheray, Takeshi Shimamura, David A. Barbie, Glenn Dranoff,
Peter S. Hammerman, Kwok-Kin Wong.
1356 Chemotherapy and agonistic CD40 cooperate to
regress pancreatic adenocarcinoma independently of TLR4 and
MyD88. Katelyn T. Byrne, Robert H. Vonderheide.
1357 Preferential expression of CD99 isoform variant 5
(CD99v005) in Ewing sarcoma compared to normal tissues.
Sabine Heitzeneder, John F. Shern, Javed Khan, Crystal L. Mackall.
1358 Generation of induced pluripotent stem cells from
tumor-infiltrating lymphocytes. Hidehito Saito, Keisuke Okita,
Noemi Fusaki, Michael Sabel, Alfred Chang, Fumito Ito.
1359 Co-expression of ULBP1 and NKG2D are related to
better overall survival in patients with gastric cancer. Kiyoshi
Yoshimura, Moeko Inoue, Ryoji Kamei, Shigehisa Kitano.
1360 Combination therapy of reovirus and PD-1 blockade
effectively establishes tumor control via innate and adaptive
immune responses. Karishma Rajani, Christopher Parrish, Kevin
Shim, Liz Ilett, Fiona Errington-Mais, Jill Thompson, Tim Kottke,
Rosa Maria-Diaz, Peter Selby, Hardev Pandha, Kevin Harrington,
Alan Melcher, Matt Coffey, Shane Zaidi, Richard Vile.
13
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
14
14
Angiogenesis Inhibitors
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
1361 The decoy receptor interleukin-1 receptor type 2
acts as an angiogenic factor in human colorectal cancer.
Ai-Chung Mar.
1362 Distinct binding mode of lenvatinib to VEGFR2
revealed by biochemical characterization. Kiyoshi
Okamoto, Megumi I. Kawada, Anja Jestel, Konstanze von
König, Yasuhiro Funahashi, Tomohiro Matsushima, Akihiko
Tsuruoka, Atsushi Inoue, Junji Matsui.
1363 VEGF reduction facilitates angiogenesis by
CXCR2. Mary A. Kosir, Donghong Ju.
1364 Blocking of S100A9 with tasquinimod
demonstrates a potent anti-myeloma activity. Indu
Ramachandran, Cindy Lin, Dmitry I. Gabrilovich, Yulia
Nefedova.
1365 Visualizing the effect of BIBF1120 in lung cancer
cells by imaging-massspectrometry (MS). Daisuke Arai,
Kenzo Soejima, Hiroyuki Yasuda, Kota Ishioka, Shizuko
Kagawa, Junko Hamamoto, Katsuhiko Naoki, Katsura Emoto,
Yuki Sugiura, Makoto Suematsu, Tomoko Betsuyaku.
1366 Mdm2 antagonist RG7388 does not interfere with
tumor angiogenesis in vitro and in vivo. Christian Lehmann,
Thomas Friess, Erica Lorenzon, Frank Herting, Markus Dangl.
1367 Anti-angiogenesis promotes venous
thromboembolism through inducing PAI-1 in a mouse
xenograft model of human lung carcinoma. Ni Chen,
Meiping Ren, Rong Li, Xin Deng, Yongjie Li, Kai Yan, Lamei
Xiao, Yan Yang, Liqun Wang, Mao Luo, Jianbo Wu.
1368 The impact of bevacizumab on combination lowdose afatinib and cetuximab therapy in lung cancer cells
harboring activated EGFR mutations. Kenichiro Kudo,
Kadoaki Ohashi, Eiki Ichihara, Daisuke Minami, Hisao Kubo,
Akiko Sato, Yuka Kato, Hideko Isozaki, Hiroe Kayatani,
Tomoki Tamura, Mitsune Tanimoto, Katsuyuki Kiura.
1369 Inhibition of Notch- and EGFR signaling reduces
cell viability and angiogenesis in glioblastoma multiforme.
Mikkel Staberg, Signe R. Michaelsen, Louise S. Olsen, Mette K.
Nedergaard, Mette Villingshøj, Hans S. Poulsen.
1370 Activin receptor-like kinase 1 ligand trap reduces
microvascular density and improves chemotherapy
efficiency to various solid tumors. Lukas J. Hawinkels,
Amaya Garcia de Vinuesa, Madelon Paauwe, Marianna
Kruithof-de Julio, Renier Heijkants, Marie-Jose Goumans,
Timo ten Hagen, Peter ten Dijke.
1371 Systems biology analysis to identify biomarkers
for lenvatinib in the preclinical cancer cell line panels.
Zoltan Dezso, Mitsuhiro Ino, Yukinori Minoshima, Osamu
Tohyama, Naoko H. Sugi, Sergei Agoulnik, Yoshiya Oda,
Yasuhiro Funahashi.
1372 Acquired resistance to sunitinib is not associated
with functional re-vascularization in 786-O renal cell
carcinoma xenografts. Simon P. Robinson.
1373 Insight into the mechanisms of anti-angiogenesis
mediated by phosphaplatins. Lu Yang.
1374 Lenvatinib, tri-specific targeted therapy to
VEGFR/FGFR/RET, suppresses angiogenesis through the
inhibition of both VEGFR and FGFR signaling pathways.
Kenji Ichikawa, Saori W. Miyano, Yusuke Adachi, Yuji
Yamamoto, Yoichi Ozawa, Yasuhiro Funahashi, Kiyoshi
Okamoto, Kenichi Nomoto, Junji Matsui.
1375 Development of synthetic heparan sulfate
oligosaccharides as anti-angiogenic agents. Gordon C.
Jayson, Steen U. Hansen, Gavin J. Miller, Claire Cole, Graham
Rushton, John M. Gardiner, Egle Avizienyte.
1376 Receptor tyrosine kinase (RTK) signaling
pathway in preclinical thyroid cancer models: Antitumor
and antiangiogenic activity of lenvatinib to target VEGFR/
FGFR/RET. Osamu Tohyama, Junji Matsui, Kotaro Kodama,
Naoko H. Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori
Minoshima, Masao Iwata, Yasuhiro Funahashi.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
1377 Chemical probe-based approach clarifies binding
of receptor tyrosine kinases (RTKs) to lenvatinib in
preclinical models. Takayuki Kimura, Noboru Yamamoto,
Hiroshi Kamiyama, Megumi I. Kawada, Akihiko Yamamoto,
Yoshihiko Kotake, Yasutaka Takase, Yasuhiro Funahashi,
Yoshiya Oda.
1378 Evasive resistance to VEGF blockade mediated by
autocrine IL-6/STAT3 signaling in xenograft models of
human cancer. Alexander P. Adler, Alexandra Eichten, Li
Zhang, Jia Su, Ella Ioffe, George D. Yancopoulus, Douglas
MacDonald, Christopher Daly, Xunbao Duan, Gavin Thurston.
1379 IKK␤ is a potential anti-angiogenic therapeutic
target in KRAS-induced lung cancer. Tatiana C. Lobo, Leila
Magalhães, Laura Cardeal, Ricardo Giordano, Albert Baldwin,
Daniela Bassères.
1380 The in vivo activity of a novel anti-angiogenic
compound, JFD-WS, in human breast adenocarcinoma
xenograft implanted athymic nude mice. Thanigaivelan
Kanagasabai, Janelle Alvarez, Meera Bhalani, Sivanesan
Dhandayuthapani, Appu Rathinavelu.
1381 The vascular targeted and antitumor effects of
gene electrotransfer of plasmid silencing endoglin with
tissue specific and constitutive promoter. Monika Stimac,
Tanja Dolinsek, Ursa Lampreht, Maja Cemazar, Gregor Sersa.
1382 2-Deoxy-glucose downregulates endothelial Akt
and Erk via interference with N-linked glycosylation,
induction of endoplasmic reticulum stress, and GSK-3␤
activation. Krisztina Kovacs, Christina Decatur, Dien G. Pham,
Huaping Liu, Yuqi Jing, Timothy G. Murray, Theodore J.
Lampidis, Jaime R. Merchan.
1383 Phenotype-based development of novel
therapies for the treatment of colorectal cancer. Clare T.
Butler, Adrian Murphy, William M. Gallagher, Jacintha
O’Sullivan, Breandán Kennedy.
1384 CRLX101, an investigational camptothecincontaining nanoparticle-drug conjugate, reverses the HIF1␣-mediated increase in cancer stem cells caused by
bevacizumab in a preclinical model of triple-negative
breast cancer. Sarah J. Conley, Trenton L. Baker, Joseph P.
Burnet, Rebecca L. Thiesen, Douglas Lazarus, Christian G.
Peters, Shawn G. Clouthier, Scott Eliasof, Max S. Wicha.
1385 TGF beta regulates tumor resistance to
antiangiogenic therapy through POSTN in glioma stem cell
models. Soon Young Park, Yuji Piao, Ningyi Tiao, Verlene
Henry, Jianwen Dong, John F. de Groot.
1386 KLF5 inhibits angiogenesis in PTEN-deficient
prostate cancer by attenuating AKT activation and
subsequent HIF1␣ accumulation. Xinpei Ci, Changsheng
Xing, Baotong Zhang, Zhiqian Zhang, Jenny Jianping Ni, Wei
Zhou, Jin-Tang Dong.
1387 Enhanced recruitment of tumor microenvironment
components in A549 xenografts with acquired resistance to
sorafenib. Qingyu S. Zhou, Xiaofang Guo.
1388 Inhibition of VEGF and angiopoietin-2 to reduce
brain metastases of breast cancer burden. Kaci A. Bohn,
Emily R. Sechrest, Chris E. Adkins, Rajendar K. Mittapalli,
Mohamed I. Nounou, Tori B. Terrell-Hall, Afroz S. Mohammad,
Paul R. Lockman.
1388A Assessment of the anti-angiogenic effect of
VEGFR2 siRNA in HUVEC using the Lonza 4D-Nucleofecto
system. Srinivasan Kokatam, Kanchan Tiwari, Jenny
Schroeder, Andrea Toell, Lubna Hussain, Preeti Kapoor.
313
POSTER SESSION
Tumor Biology
Cancer Stem Cell Identification
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
1389 Study on cancer stem cell marker CD90 in liver cancer.
Wei-Ching Chen, Ming-Derg Lai.
2.
1390 Combination of carbon ion beam and gemcitabine
causes unrepairable DNA damage and death of radioresistant
pancreatic cancer stem-like cells in vitro and in vivo. Sei Sai,
Toshifumi Wakai, Guillaumes Vares, Shigeru Yamada, Takehiko
Kamijo, Eun Ho Kim, Tadashi Kamada, Toshiyuki Shirai.
3.
1391 Single cell analysis of Lin-CD34-CD45- cells from
primary AML samples reveals leukemia clones with stem celllike properties distinct from CD34+CD38-CD123+ LSC.
Christopher B. Benton, Ahmed Al Rawi, Taejin Min, Rui-Yu Wang,
Wendy Schober, Zhiqiang Wang, Zhihong Zeng, Jeffrey Hokanson,
Zhu Zhu, Xiaoping Su, Xiaofeng Zheng, Karen Lu, Bing Carter,
Richard E. Davis, Hagop Kantarjian, Marina Konopleva, Michael
Andreeff.
4.
1392
ALDH1A1 is the best marker by a composite approach
for cancer stem cells in ovarian cancer whose integrity is
controlled by the hedgehog pathway. Rohit P. Nagare, S Sneha, S
Krishnapriya, Trivadi S. Ganesan.
5.
CD44v3-positive (CD44v3+) and CD24-negative
(CD24 ) cells possess cancer stem cell (CSC)-like properties in a
human oral squamous cell carcinoma cell line. Keita Todoroki,
Sachiko Ogasawara, Jun Akiba, Masamichi Nakayama, Yoshiki
Naito, Jingo Kusukawa, Hirohisa Yano.
1393
Poster
Board
16.
17.
18.
19.
20.
-
6.
CD44 isoform expression illuminates multiple CSC
subpopulations in PC3. James R. Hernandez, Steven M. Mooney,
Gonzalo Torga, James E. Verdone, Kenneth J. Pienta.
7.
1395
Conversion to stem cell state in response to
microenvironmental cues is regulated by balance between
epithelial and mesenchymal features in lung cancer. Francesca
Andriani, Giulia Bertolini, Federica Facchinetti, Erika Baldoli,
Massimo Moro, Patrizia Casalini, Roberto Caserini, Roberto
Caserini, Ugo Pastorino, Gabriella Sozzi, Luca Roz.
8.
1396
9.
10.
11.
12.
Unraveling the cellular hierarchywithin human
tonsillar crypt epithelium and oropharyngeal squamous
cellcarcinoma tumors. Vivian F. Wu, Tennison Yu, Brette Harding,
Robert Bruno.
1397 Identification of a hepatocellular carcinoma cell line
capable of monitoring the differentiation of CD13(+)CD166(-)
cancer stem cells and effects of sorafenib. Takeshi Yamada,
Masato Abei, Inaho Danjoh, Ryoko Shirota, Taro Yamashita, Shinji
Endo, Ichinosuke Hyodo, Yukio Nakamura.
22.
23.
24.
25.
26.
1398
Metastatic neuroblastoma cancer stem cells exhibit
flexible plasticity and adaptive stemness signaling. Satish
Kumar Ramraj, Faizan H. Khan, Sheeja Aravindan, Mohan
Natarajan, Terence S. Herman, Natarajan Aravindan.
1399 Characterization of cancer stem cell properties and
identification of invasion as well as metastatic process in head
and neck cancer. Mehmet Gunduz, Omer F. Hatipoglu, Esra
Gunduz, Elif N. Cetin, Eyyup Uctepe, Sadık Cigdem, Reidar
Grenman, Muradiye Acar.
1400 Evaluation of tumor-initiating cell populations in the
KPC mouse model of pancreatic cancer. Joseph S. Dosch,
Elizabeth K. Ziemke, Amrith Shettigar, Alnawaz Rehemtulla, Judith
S. Sebolt-Leopold.
13.
1401 Low proteasome activity and cancer stemness in
colorectal cancer. Mamoru Uemura, Koji Munakata, Junichi
Nishimura, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima,
Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori.
15.
1403
314
21.
1394
SOX2 as a marker of oral cancer stem-like cells: Cell
division patterns and chromosomal instability. Hatem Kaseb,
Dale Lewis, Sussane Gollin.
27.
28.
29.
30.
15
Abstract
Number
1404 A red-shifted fluorescent substrate for aldehyde
dehydrogenase, AldeRed 588-A, for labeling viable ALDHpositive cells. Vi Chu, Konstantin Taganov, D Ramesh, Nick
Asbrock, Martin Pomper.
1405 Novel biomarkers for gastric cancer stem cells utilizing
comparative proteomics analysis. Masakazu Yashiro, Tamami
Morisaki, Tsuyoshi Hasegawa, Anna Kakehashi, Haruhito Kinoshita,
Tatsunari Fukuoka, Hiroaki Kasashima, Go Masuda, Katsunobu
Sakurai, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Masaichi
Ohira, Hideki Wanibuchi, Kosei Hirakawa.
1406 High expression of DPD and ALDH1 are associated
with poor prognosis in pancreatic cancer. Kota Arima, Hirohisa
Okabe, Daisuke Hashimoto, Takayoshi Kaida, Takaaki Higashi,
Katsunobu Taki, Hideaki Takeyama, Hidetoshi Nitta, Hiromitsu
Hayashi, Akira Chikamoto, Toru Beppu, Hideo Baba.
1407 Identification of sialylated glycoproteins in
doxorubicin-treated hepatoma cells with glycoproteomic
analyses. Eiji Miyoshi, Kanako Azuma, Shinji Takamatsu, Naoko
Terao, Satoshi Serada, Tetsuji Naka, Yoshihiro Kamada.
1408 Generation of 3D-microtissues suitable for drug
screening with lentivirally GFP-labelled CD44+CD24- breast
cancer cells enriched by irradiation. Ines Höfig, Michael
Rosemann, Michaela Albrecht, Yashodhara Ingawale, Jens M. Kelm,
Michael J. Atkinson, Christian Thirion, Natasa Anastasov.
1409 Whole-cell and local viscoelasticity of stem-like and
non-stem-like breast cancer cells. Amina Alipour, Monica M.
Burdick, David F. Tees.
1410 Evaluation of the immunogenicity of ALDHhigh human
head and neck squamous cell carcinoma cancer stem cells in
vitro. Mark E. Prince, Li Zhou, Yang Xia, Huimin Tao, Jeffrey S.
Moyer, Lin Lu, John Owen, Alfred E. Chang, Jianchuan Xia, Gregory
Wolf, Max S. Wicha, Xiubao Ren, Yangyi Bao, Shiang Huang, Qiao
Li.
1411 An analysis on the usefulness of ALDH in esophageal
squamous cell carcinoma. Kentaro Murakami.
1412 Utilizing cell surface markers to define osteosarcoma
and the stages of osteoblast differentiation. Pratistha Koirala,
Vincent Poon, Sajida Piperdi, Amy Park, Michael Fremed, Michael
Roth, Jonathan Gill, Richard Gorlick.
1413 Significance of KIFC1 in spheroid formation of gastric
cancer cells. Naohide Oue, Shoichiro Mukai, Trang Pham T.B.,
Kazuhiro Sentani, Reiko Ito, Wataru Yasui.
1414 Molecular and functional characterization of ovarian
cancer stem cells. Michela Lupia, Giovanni Bertalot, Nicoletta
Colombo, Stefano Confalonieri, Pier Paolo Di Fiore, Ugo Cavallaro.
1415 Telomere shortening in centroacinar-acinar region of
the pancreas: relationships with aging, cancers and tissue stem
cells. Yoko Matsuda, Naotaka Izumiyama-Shimomura, Toshiyuki
Ishiwata, Mutsunori Fujiwara, Ken-ichiro Tomita, Naoki Hiraishi,
Hideki Hamayasu, Ken-ichi Nakamura, Naoshi Ishikawa, Steven
Poon, Junko Aida, Kaiyo Takubo, Tomio Arai.
1416 Granulocyte-colony stimulating factor (G-CSF)
enhances stemness by inducing myeloid-derived suppressor
cell (MDSC) in cervical cancer. Hiromasa Kuroda.
1417 Clonal succession in pancreatic cancer progression is
not driven by genetic instability. Karl R. Ehrenberg, Claudia R.
Ball, Felix Oppel, Naveed Ishaque, Taronish D. Dubash, Sebastian
M. Dieter, Christopher M. Hoffmann, Ulrich Abel, Moritz Koch, Jens
Werner, Frank Bergmann, Manfred Schmidt, Christof von Kalle,
Wilko Weichert, Jürgen Weitz, Benedikt Brors, Hanno Glimm.
1418 Screening and identification of key surface markers of
mesenchymal stem cell osteogenic differentiation and
osteosarcoma development. Tingting Ren, Sajida Piperdi, Amy Y.
Park, Richard Gorlick.
15
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
16
16
Epithelial-Mesenchymal Transition, Mesenchymal-Epithelial Transition,
and Related Behaviors
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
1419 Glypican-3 (GPC3) inhibits metastatic
dissemination in a preclinical human breast cancer model.
Lilian F. Castillo, Rocio Tascon, Elisa Bal de Kier Joffé, Maria
G. Peters.
1420 MITF regulates proliferative subpopulation tumor
architecture and modifies invasion and characteristics of
the epithelial to mesenchymal transition within
melanoma. Crystal A. Tonnessen, Kimberley A. Beaumont,
David S. Hill, Sheena M. Daignault, Andrea Anfosso, Russell J.
Jurek, Wolfgang Weninger, Nikolas K. Haass.
1421 The spontaneous generation of GD2+ breast
cancer stem-like cells is directly proportional to tumor
progression and mediated by epithelial to mesenchymal
transition and NF␬B activation. Jeffrey Sun, Gabriel N.
Hortobagyi, Michael Andreeff, Venkata Lokesh Battula.
1422 Neutrophil Elastase plays a key role in epithelialmesenchymal transition and metastasis in triple-negative
breast cancers. Kavitha Balaji, Chun-Hui Su, Said Akli, Kelly
K. Hunt, Khandan Keyomarsi.
1423 SSX-2 expression and function in metastatic
prostate cancer. Jordan E. Bloom, Douglas G. McNeel.
1424 F-box protein fbxl5 nuclear retention by specific
inhibitors of nuclear export induces snail ubiquitination
leading to reversal of EMT. Irfana Muqbil, Amro
ABOUKAMEEL, Yosef Landesman, Michael Kauffman, Sharon
Shacham, Ramzi M. Mohammad, Asfar S. Azmi.
1425 FBXO11 suppresses epithelial plasticity and
proliferation by ubiquitinating the Snail family of
transcription factors. Jianrong Lu, Yue Jin, Anitha K. Shenoy,
Hao Chen, Huacheng Luo,Lizi Wu, Kamal A. Mohammed.
1426 Lung epithelial cells induce both phenotype
alteration and senescence in breast cancer cells. Masashi
Furukawa, Alan Wells, Sarah Wheeler, Amanda M. Clark.
1427 Embigin is overexpressed in pancreatic ductal
adenocarcinoma and regulates cell motility through
epithelial to mesenchymal transition via the TGF-␤
pathway. Dawoon E. Jung, Jeong Mi Kim, Chanyang Kim, Si
Young Song.
1428 Targeting RRM2 by siRNA inhibits cellular
invasion and represents a rational approach for inhibition
of metastasis of head and neck and lung cancers.
Mohammad A. Rahman, A.R.M. R. Amin, Jun Zhang,
Sreenivas Nannapaneni, Nabil F. Saba, Zhuo G. Chen, Dong M.
Shin.
1429 Contribution of membrane-bound
carboxypeptidase M to tumor growth and metastasis by
regulating epithelial mesenchymal transition in
esophageal squamous carcinoma. Yuji Kudo, Junki Fukuda,
Ritsuko Harigai, Kazunori Kato.
1430 Transcriptional regulatory loops among SNAI1,
TWIST1, ZEB1, and ZEB2 defines the epithelialmesenchymal transition (EMT) spectrum in epithelial
ovarian cancer (EOC). Ming Tan, Vin Yee Chuang, Tuan Zea
Tan, Jean Paul Thiery, Ruby Yun-Ju Huang.
1431 Id4 inhibits cancer metastasis through EMT
regulation in lung cancer. Szu-Hua Pan, Yuan Ling Hsu, PeiFang Hung, Chia-Jen Wang, Chi-Chung Wang.
1432 Role of ubiquitin-specific proteases 47 in
epithelial-mesenchymal transition. Bae-Jung Choi, YoungJoon Surh.
1433 CDKL2 promotes epithelial-mesenchymal
transition and breast cancer progression. Linna Li, Jeffrey
Chang, Guangwei Du, Robert Amato, Wenliang Li.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1434 MDM2 promotes tumor cell migration through the
induction of epithelial to mesenchymal transition. Lin
Zheng, Yeping Wu, Tianyi Zhou, Hong Zhu, Qiaojun He, Bo
Yang.
1435 Role of PRKD2 in HSP90- and hypoxia-mediated
epithelial-to-mesenchymal transition. Ninel Azoitei,
Alexander Becher, Kristina Diepold, Susanne Bobrovich,
Cornelia Brunner, Gabriela Chiosis, Stefan Fröhling, van Lint
Johan, Claudia Scholl, Thomas Seufferlein.
1436 The SxxSS motif of T-cell Factor-4 isoforms
regulates Wnt5a expression and EMT in human liver cancer
cells. Hironori Koga, Toru Nakamura, Mitsuhiko Abe, Yu
Ikezono, Fumitaka Wada, Hirohisa Yano, Takuji Torimura.
1437 The activity of plasma membrane V-ATPases is
critical for the invasion of breast cancer cells. Kristina
Cotter, Joseph Capecci, Souad Sennoune, Markus Huss,
Martin Maier, Raul Martinez-Zaguilan, Michael Forgac.
1438 Opposing influence of activin and TGF␤ on PI3K
and MEK/ERK signaling in colon cancer. Jessica I. Bauer,
Naomi Akagi, Ozkan Ozden, Daniel R. Principe, Timothy
Carroll, Seung Hyun Baik, Martina E. Spehlmann, Lars
Eckmann, Paul J. Grippo, Barbara Jung.
1439 RANK expression by osteosarcoma cells increases
lung metastasis in Nude mouse while has no effect in
immune-competent mouse. Benjamin Navet, Kosei Ando,
Hideo Yagita, Christopher G. Mueller, Dominique Heymann,
Frederic Lezot.
1440 Mitochondrial superoxide dismutase (Sod2)
modulates ovarian clear cell carcinoma transcoelomic
metastatic pathway. L.P. Madhubhani P. Hemachandra,
Usawadee Dier, Nadine Hempel.
1441 Adapting the Syngraft mouse model to study
metastatic recurrence of pancreatic cancer. Crissy
Dudgeon, Ashley Tsang, Neil Campbell, Eric Collisson, Darren
Carpizo.
1442 Understanding the role of autophagy during
cancer metastasis. Maegan M. Lim, Ziqiang Teo, Chee Chong
Choo, Pengcheng Zhu, Nguan Soon Tan.
1443 BMP-2 induces motility and invasiveness of colon
cancer through upregulation of cancer stem cell. Bo Ram
Kim, Jung Lim Kim, Seong Hye Park, Yoon A Jeoung, Sun Il
Lee, Byoung-Wook Min, Sang Cheul Oh.
1444 Docosahexaenoic acid reduces cancer cell
migration may link with actin binding proteins and miRNA
17-92 cluster expressions changes. Mehboob Ali, Kathryn
M. Heyob, Lynette K. Rogers.
1445 Overexpression of angiotensin II type 1 receptor
induces epithelial-mesenchymal transition and promotes
tumorigenesis of human breast cancer cells. Eunhye Oh, Ji
Young Kim, Youngkwan Cho, Nahyun Lee, Hyunsook An, Jun
Suk Kim, Jae Hong Seo.
1446 Induction of epithelial-to-mesenchymal
transition (EMT) by SL-15 knockdown contributes to
anoikis resistance in human colorectal cancer metastases.
Soo Young Jun, Hyun-Soo Cho, Jeong-Ju Lee, Jun-Ho Ahn,
Ji-Yong Yoon, Jae-Hye Lee, Min Hyuk Choi, Nam-Soon Kim.
1447 Functional genomics identifying a TIS1-HIFNOTCH signaling orchestrating epithelial-mesenchymal
transition for tumor invasion. Sen-Yung Hsieh.
1448 Dynamic chromatin modification by tumor
secreted Hsp90 modulates EMT and tumor invasion. Krystal
D. Nolan, Michael W. Hance, Omar E. Franco, Simon W.
Hayward, Jennifer S. Isaacs.
315
POSTER SESSION
Tumor Biology
Human-in-Mouse Models of Cancer 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
316
Abstract
Number
1449 The valuable experimental model system “Cancer
Xenopatient” established in NOG mice. Tsuyoshi Chijiwa, Kenji Kawai,
Akira Noguchi, Hidemitsu Sato, Akimune Hayashi, Haruhiko Cho, Manabu
Shiozawa, Takeshi Kishida, Soichiro Morinaga, Tomoyuki Yokose, Makoto
Katayama, Nobuo Takenaka, Hiroshi Suemizu, Roppei Yamada, Yoshiyasu
Nakamura, Yasuo Takano, Kohzoh Imai, Yohei Miyagi, Masato Nakamura.
1450 Autopsy derived orthotopic xenograft (ADOX) mouse
models for terminal pediatric brain tumors. Lin Qi, Baxter A. Patricia,
Kogiso Mari, Du Yuchen, Lindsay Holly, Liu Zhigang, Xiumei Zhao, Yujing
Zhang, Jack M. Su, Adekunle Adesina, Andrew W. Walter, Jeffery Murray,
Rene McNall-Knapp, Javad Nazarian, Will Parsons, Murali Chintagumpala,
Susan Blaney, Xiao-Nan Li.
1451 Modeling patient-derived lung cancer in mice: Preclinical
tool for drug development. Prafulla C. Gokhale, Sangeetha Palakurthi,
Man Xu, Antonio Calles, Shruti D. Shah, Allison O’Connell, Melissa
Messineo, Yanan Kuang, Masahiko Yanagita, Mosab Ali, Cam Anh Tran,
Jihyun Choi, Atsuko Ogino, Mohit Butaney, Amanda J. Redig, Cloud
Paweletz, Paul T. Kirschmeier, Pasi A. Jänne.
1452 In vivo TK-NOG liver-humanized model to predict patient
pharmacological profile of anti-cancer agents. Caroline Mignard, Olivier
Duchamp, Fariba Nemati, Nathalie Cassoux, Sergio Roman-Roman,
Yasuyuki Ohnishi, Hiroshi Suemizu.
1453 Methods for developing patient derived xenografts in
athymic nude mice. Laura A. Marlow, James L. Miller, Brandy Edenfield,
Adam C. Mathias, Louis K. Dawson, William F. Durham, Robert J. Mullin,
Daniel L. Small, Aidan J. Synnott, Kevin Wu, John A. Copland.
1454 Patient-derived xenograft model using peritoneal fluid of
gastric cancer patients. Jeong Min Kim, Won Suk Lee, Woo Sun Kwon,
Han Na Park, Hye Rin Lee, Hyun Myong Kim, Tae Soo Kim, Hyunki Kim, Jae
Kyung Roh, Hyun Cheol Chung, Sun Young Rha.
1455 Next generation sequencing of human tumor xenografts is
significantly improved by prior depletion of mouse cells. David Agorku,
Stefan Tomiuk, Kerstin Klingner, Stefan Wild, Silvia Rüberg, Lisa Zatrieb,
Andreas Bosio, Julia Schueler, Olaf Hardt.
1456 Efficacy of photo-immunotherapy in combination with
surgical resection on a pancreatic cancer patient derived orthotopic
xenograft (PDOX). Yukihiko Hiroshima, Ali Maawy, Takashi Murakami,
Nzola D. Magalhães, Daisuke Kawaguchi, Kenichi Matsuo, Kuniya Tanaka,
Michael Bouvet, Robert M. Hoffman, Itaru Endo.
1457 Genomic characterization of a PDX model of
T-DM1-resistant HER2+ invasive ductal carcinoma using augmented
exome sequencing. Elena Helman, Michael J. Wick, Michael J. Clark,
Lizette Gamez, Sean Boyle, Kyriakos P. Papadopoulos, Shujun Luo,
Anthony W. Tolcher, Parin Sripakdeevong, Mirian Karbelashvili, Deanna
Church, Richard Chen, John West.
1458 Characterization of novel thyroid PDX models and their
response to combination therapies. Laura A. Marlow, Adam C. Mathias,
Louis K. Dawson, William F. Durham, Kenneth A. Meshaw, Robert J. Mullin,
Daniel L. Small, Aidan J. Synnott, Dragana Milosevic, Brian C. Netzel, Stefan
K. Grebe, Kevin Wu, Robert C. Smallridge, John A. Copland.
1459 Patient-derived xenograft models of breast cancer with
human immune components. Rebecca Marlow, Kristina Ilieva, Erika
Francesch, Fernanda Kyle, Panagiotis Karagiannis, Adrian Hayday, Sophia
Karagiannis, Andrew Tutt.
1460 Establishment and characterization of a panel of patientderived soft tissue sarcoma (STS) xenograft models for in vivo testing
of novel therapeutic approaches. Haifu Li, Jasmien Cornillie, Agnieszka
Wozniak, Thomas Van Looy, Yemarshet Gebreyohannes, Jasmien Wellens,
Ulla Vanleeuw, Daphne Hompes, Marguerite Stas, Friedl Sinnaeve, Maria
Debiec-Rychter, Raf Sciot, Patrick Schöffski.
1461 A panel of patient derived gastrointestinal stromal tumors
(GIST) xenograft models for in vivo preclinical drug testing. Agnieszka
Wozniak, Thomas Van Looy, Giuseppe Floris, Yemarshet K.
Gebreyohannes, Jasmien Wellens, Haifu Li, Jasmien Cornillie, Ulla
Vanleeuw, Daphne Hompes, Marguerite Stas, Maria Debiec-Rychter, Raf
Sciot, Patrick Schoffski.
1462 Characterization of patient-derived bladder cancer
xenografts: role of xCT in response to cisplatin. May F. Elbanna, Eric
Ciamporcero, Swathi Ramakrishnan, Remi Adelaiye, Li Shen, Ashley
Orillion, Sheng-Yu Ku, Sreenivasulu Chintala, Roberto Pili.
1463 Engraftment of patient derived xenografts on mice with a
humanized immune system. Annika Wulf-Goldenberg, Maria Stecklum,
Klaus Eckert, Diana Behrens, Iduna Fichtner, Jens Hoffmann.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
17
Abstract
Number
1464 Patient-derived tumor xenograft are susceptible to formation of
B-cell lymphoma after initial transplantation of human carcinoma to
immunodeficient mice. Gennadiy Bondarenko, Andrey Ugolkov, Piotr
Kulesza, Stephen M. Rohan, Oleksii Dubrovskyi, Demirkan Gursel, Jeremy
V. Mathews, Thomas V. O’Halloran, Jian-Jun Wei, Andrew P. Mazar.
1465 Development of patient-derived platform to assess activity
of anticancer agents in pancreatic cancer. Vladimir Khazak, Natalia
Skobeleva, Natalia Beglyarova, Eugenia Banina, Elena Lysenko, Igor
Astsaturov, Sandra A. Jablonski, Louis M. Weiner, Ilya Serebriiskii, David A.
Proia.
1466 Patient-derived xenograft models for pancreatic
adenocarcinoma demonstrate retention of tumor morphology through
the incorporation of murine stromal elements. Daniel Delitto, Kien Pham,
Adrian C. Vlada, George A. Sarosi, Ryan M. Thomas, Kevin E. Behrns, Chen
Liu, Steven J. Hughes, Shannon M. Wallet, Jose G. Trevino.
1467 Feasibility and relevance of “animal clinical trials” using
breast cancer patient-derived xenografts (PDX) in mice. Michael T.
Lewis, Lacey E. Dobrolecki, Ivana Petrovic, Susan G. Hilsenbeck.
1468 Characterization of patient-derived xenograft (PDX) models to
evaluate clinical and therapeutic responses of glioblastoma multiforme. Dioval
A. Remonde, Brett L. Carlson, Mark A. Schroeder, Brock Armstrong, Sen
Peng, Lisa Evers, Paul A. Decker, Jeanette Eckel Passow, Michael E. Berens,
Nhan L. Tran, Robert B. Jenkins, Jann N. Sarkaria.
1469 Patient derived xenograft (PDX) models: improving
predictability of experimental cancer therapies. Edward Rosfjord, Xin
Han, Danielle Leahy, Erik Upeslacis, Justin Lucas, Jonathon Golas, Andrea
Hooper, Fred Immermann, Bingwen Lu, Jeremy Myers, Zhengyan Kan,
James Hardwick, Eric Powell, Puja Sapra, Paul Rejto, Hans-Peter Gerber,
Judy Lucas.
1470 Ovarian cancer PDXs preserve preexisting genetic
oligoclonality. Pierre-Emmanuel Colombo, Stanislas du Manoir, Beatrice
Orsetti, Rui Bras-Goncalves, Alan MacKay, Maryou Lambros, Tuan T.
Nguyen, Florence Boissiere, Didier Pourquier, Jorge Reis-Filho, Charles G.
Theillet.
1471 Establishment, characterization, and clinical correlation of a
platform of ovarian patient-derived xenograft (PDX) models.
Sangeetha S. Palakurthi, Joyce F. Liu, Qing Zeng, Shan Zhou, Wei Huang,
Elena Ivanova, Cloud Paweletz, John R. Murgo, Justin Evangelista, Melissa
Buttimer, Jennifer Curtis, Huiying Piao, Prafulla Gokhale, Colin Pritchard,
Jessie M. English, Paul Kirschmeier, Kwok-Kin Wong, Ursula A. Matulonis,
Ronny Drapkin.
1472 Building comprehensive and fully annotated patient tumor
derived xenogragft (PDX) library mirroring cancer patient population.
Jie Cai, Dawei Chen, Rajendra Kumari, Sheng Guo, Jie Yang, Mengmeng
Yang, Andrew McKenzie, Zhun Wang, Xuesong Huang, Xiaoyu An, Jinping
Liu, Jean-Pierre Wery, Henry Li.
1473 Are the genomic gene expression profiles maintained
between the original donor and patient-derived xenograft tumors.
Leopoldo J. Fernandez, Aaron R. Wolen, Amy L. Olex, Mikhail Dozmorov,
David A. Fenstermacher, Kazuaki Takabe.
1474 Characterization of 148 ovarian cancer tumografts (Avatars)
using BROCA-HR deep sequencing. Kunal A. Lodhia, Marc A. Becker,
Xiaonan Hou, Kimberly R. Kalli, Maria I. Harrell, Elizabeth M. Swisher, John
S. Weroha, Paul Haluska.
1475 Therapeutic responses in a novel patient-derived xenograft
mouse model for rare acinar cell pancreatic carcinoma. Laura A. Marlow,
Adam C. Mathias, Louis K. Dawson, William F. Durham, Kenneth A.
Meshaw, Robert J. Mullin, Aidan J. Synnott, Ricardo Paz-Fumagalli, Murli
Krishna, Daniel Von Hoff, Daniel L. Small, Gerardo Colon-Otero, John A.
Copland.
1476 Effect of target therapies in liver cancer PDX tumor models:
Response, resistance and predictive biomarkers. Tengfei Yu, Ying Yan,
Wei Du, Liang Hua, Xuqin Yang, Tingting Tan, Jiali Gu, Jingjing Jiang, Xin K.
Ye, Zhenyu Gu.
1477 Pharmacodynamic response and anti-tumor activity of the
MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived
xenograft models. Alwin Schuller, Evan Barry, Rhys Jones, Melanie
Frigault, Garry Beran, Ryan Henry, David Linsenmayer, Maureen
Hattersley, Aaron Smith, Joanne Wilson, Ammar Adam, Michael Zinda,
Corinne Reimer, Stephen Fawell, Edwin Clark, Celina D’Cruz.
1478 Development of novel Mi-HTX in vivo platform by
reconstituting autologous immune components in patient tumorderived xenografts. Saravanan Thiyagarajan, Padhma Radhakrishnan,
Vinod D Radhakrishna, Dency D Pinto, Biswanath Majumder.
17
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
18
18
Preclinical and Clinical Imaging of Molecular Events in Tumors
Poster
Board
1.
Abstract
Number
1479 Investigation of the permeation and retention of
biocompatible low-retention superparamagnetic iron
oxide nanoclusters in tumors with magnetic resonance
imaging. Yushuang Wei, Liang Shan, Paul Wang, Qibing
Zhou.
Poster
Board
Abstract
Number
14.
1492 Trastuzumab-induced normalization in a HER2+
murine model of breast cancer. Anna G. Sorace, Jennifer G.
Whisenant, J. O. McIntyre, Thomas E. Yankeelov.
15.
1493 18F-misonidazole PET (FMISO-PET) monitors
vascular normalization (VN) and predicts benefit from
antiangiogenic treatment plus chemotherapy in pancreas
cancer. Tamara Mondejar, Elena Hernadez-Agudo, Marisa
Soto-Montenegro, Diego Megias, David Cebrian, Jesus
Sanchez, Francisca Mulero, Ramon Colomer, Manuel Hidalgo,
Manuel Desco, Miguel Quintela-Fandino.
2.
1480 Hot spot 19F MR imaging of inflammation
predicts colitis-associated cancer. Soo-Hyun Shin, Deepak
K. Kadayakkara, Jeff W. Bulte.
3.
1481 Development of theranostic mesoporous silica
nanoparticles for pancreatic cancer. Dillon S. Pender, Anil
Khanal, Michael E. Egger, Lacey R. McNally.
16.
4.
1482 Early detection and longitudinal imaging of
breast cancer metastatic microlesions using short-wave
infrared light emitting rare-earth nanoprobes. Margot
Zevon, Vidya Ganapathy, Harini Kantamneni, Marco Mingozzi,
Paul Kim, Derek Adler, Mark Pierce, Richard Riman, Charles
Roth, Prabhas Moghe.
1494 Non-invasive prediction of molecular subtype in
glioblastoma using multi-parametric magnetic resonance
imaging pattern analysis and machine learning. Jared
Pisapia, Lukasz Macyszyn, Hamed Akbari, Xiao Da, Mark
Attiah, Yingtao Bi, Sharmistha Pal, Ramana Davaluri, Laura
Roccograndi, Nadia Dahmane, Ronald Wolf, Donald M.
O’Rourke, Christos Davatzikos.
17.
5.
1483 Lipid oxidation via CPT1 as a target for prostate
cancer imaging and therapy. Isabel R. Schlaepfer, Maren
Salzmann-Sullivan, Lih-Jen Su, L.Michael Glode, Thomas
Flaig.
1495 Quantification of blood perfusion in
rhabdomyosarcoma xenograft in 3D using contrastenhanced ultrasound imaging. Abbas Shirinifard, Suresh
Thiagarajan, András Sablauer.
18.
6.
1484 Pancreatic cancer and normal pancreas water
content and its impact in metabolite quantification. MarieFrance Penet, Balaji Krishnamachary, Tariq Shah, Yelena
Mironchik, Anirban Maitra, Zaver M. Bhujwalla.
1496 Quantification of tumor blood perfusion of an
orthotopic mouse model of neuroblastoma using nonlinear
contrast-enhanced ultrasound imaging. Suresh
Thiagarajan, Abbas Shirinifard, Megan O. Jacus, Abigail D.
Davis, Yogesh T. Patel, Stacy L. Throm, Vinay Daryani, Clinton
F. Stewart, András Sablauer.
7.
1485 Pilot study of VPAC1 targeted PET imaging of
prostate cancer. Edouard J. Trabulsi, Pradeep Kumar, Sushil
Tripathi, Ruth Birbe, Peter McCue, Eric Wickstrom, Charles
Intenzo, Sung Kim, Robert Den, Leonard Gomella, Mathew L.
Thakur.
19.
8.
1486 Fatty acid and phospholipid profiling of liver
tumor tissue: correlation with in vivo molecular PET
imaging of phosphocholine synthesis. Sandi A. Kwee,
Adrian A. Franke, Laurie J. Custer, Xingnan Li, Linda L. Wong.
1497 In vivo discrimination of tumor modifications
during antiangiogenic and cytotoxic therapy using
ultrasonography modalities: Shear Wave Elastography
(SWE), Contrast Enhanced Ultrasound (CEUS) and
Quantitative Ultrasound (QUS). Alexandre Dizeux, Thomas
Payen, Guillaume Barrois, Michele Lamuraglia, Capucine
Baldini, Delphine Le Guillou, Eva Comperat, Jean-Luc
Gennisson, Mickael Tanter, Michael Oelze, S. Lori Bridal.
20.
9.
1487 Rotating 3D projections of prostate lesions
imaged by Cu-64-VPAC1 ligand PET and CT. Matthew E.
Wampole, Bishnuhari Paudyal, Edouard J. Trabulsi, Mathew
L. Thakur, Eric Wickstrom.
1498 Feasibility of 2-hydroxyglutarate 1H-MR
spectroscopy for routine clinical glioma imaging. Macarena
I. de la Fuente, Robert Young, Jennifer Rubel, Jamie Tisnado,
Samuel Briggs, Andrei I. Holodny, Joseph Deasy, Lisa M.
DeAngelis, Justin Cross, Ingo K. Mellinghoff, Sunitha Thakur.
10.
1488 In vivo magnetic resonance elastography in
pediatric brain tumor models. Jin Li, Jessica K. Boult, Maria
Vinci, Sergey Popov, Karen Barker, Zai Ahmad, Yann Jamin,
Craig Cummings, Suzanne A. Eccles, Jeffrey C. Bamber, Ralph
Sinkus, Louis Chesler, Chris Jones, Simon P. Robinson.
21.
1499 SUPR peptides as novel targeted molecular
imaging agents for Her2. Lindsay Kelderhouse, Amanda
Hardy, Terry T. Takahashi, Argentina Ornelas, Seth Gammon,
Shannon Howell, Peiying Yang, Pin Wang, Richard W.
Roberts, Steve Fiacco, Steven W. Millward.
11.
1489 MRI assessment of changes in tumor oxygenation
post hypoxia-targeted therapy. Shubhangi Agarwal, Rohini
V. Shankar, Landon J. Inge, Vikram D. Kodibagkar.
22.
12.
1490 Matrigel rescues breast cancer cells from the
growth inhibitory effects of HIF-1␣ and HIF-2␣ silencing.
Santosh K. Bharti, Balaji Krishnamachary, Wenlian Zhu,
Flonne Wildes, Yelena Mironchik, Samata M. Kakkad, Dmitri
Artemov, Zaver M. Bhujwalla.
1500 Syndecan-1 targeted mesoporous silica-coated
gold nanorods act as theranostic agents for in vivo
detection of orthotopic pancreatic tumors using
multispectral optoacoustic tomography. Anil Khanal,
Charles W. Kimbrough, Nichola C. Garbett, Joseph A.
Burlison, William E. Grizzle, Lacey R. McNally.
23.
1501 Evaluation of tumor vascularity in colorectal
cancer using contrast enhanced ultrasonograpy in
comparison with microvessel density. Takaomi Okawa,
Hiromi Nogami, Munenori Takaoka.
24.
1501A Detecting lung metastases by hyperpolarized
NMR technique: A pilot study. He N. Xu, Mehrdad Pourfathi,
Hoora Shaghaghi, Stephen Kadlececk, Harrilla Profka, Rahim
Rizi, Lin Z. Li.
13.
1491 Targeting radiation-inducible cell surface TIP-1
using HVGGSSV peptide as a novel imaging and
therapeutic strategy for tumors. Vaishali Kapoor, David
Dadey, Kim Nguyen, Hua Li, Buck Rogers, Dinesh Thotala,
Dennis Hallahan.
317
POSTER SESSION
Tumor Biology
Solid Tumor Stem Cells
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
318
Abstract
Number
1502 DCLK1 labeling a unique pancreatic cellular
lineage contributes to intraductal papillary mucinous
neoplasm development. Wanglong Qiu, Gloria Su.
1503 HP1-gamma’s expression correlates with glioma
grade and survival and is a putative marker of glioma stem
like cells. Uros Rajcevic, Sabrina Fritah, Petr V. Nazarov,
Mara Popovic, Rajko Kavalar, Tadej Strojnik, Neza Podergajs,
Jaco C. Knol, Thang V. Pham, Sander R. Piersma, Connie R.
Jimenez, Simone P. Niclou.
1504 Quantification of dedifferentiation rates in breast
cancer using fluorescent reporter constructs and lineage
tracing. Michael D. Brooks, Max S. Wicha.
1505 Suppression of triple-negative breast cancer
tumorigenesis by targeting cancer stem cells through JNK/
Notch1 signaling inhibition. Xuemei Xie, Tamer S. Kaoud,
Ramakrishna Edupunganti, Tinghu Zhang, Takahiro Kogawa,
Gaurav B. Chauhan, Dionysios N. Giannoukos, Yuan Qi, Debu
Tripathy, Nathanael S. Gray, Kevin N. Dalby, Chandra
Bartholomeusz, Naoto T. Ueno.
1506 Frequent loss of function mutations in TGF〉R1
and TGF〉R2 identify hair follicle bulge stem cells as the
cell of origin for cutaneous squamous cell carcinoma.
Patrizia Cammareri, Aidan M. Rose, David F. Vincent, Silvana
Libertini, Rachel A. Ridgway, Dimitris Athineos, Philip Coates,
Angela McHugh, Celine Pourreyron, Jonas Larsson, Lindsay C.
Spender, Gopal Sapkota, Karin Purdie, Charlotte Proby,
Catherine A. Harwood, Irene M. Leigh, Hans Clevers, Nicholas
Barker, Stefan Karlsson, Catrin Pritchard, Richard Marais,
Andrew P. South, Owen J. Sansom, Gareth J. Inman.
1507 Heterogeneity of CD34 and CD38 expression in
adult acute B lymphoblastic leukemia cells is reversible
and not hierarchically organized. Zhiwu Jiang, Manman
Deng, Yi Lu, Bing Xu, Peng Li.
1508 UV-induced Wnt7a in the human skin
microenvironment specifies the fate of neural crest -like
cells via suppression of Notch. Mizuho Fukunaga-Kalabis,
Denitsa Hristova, Joshua Wang, Ling Li, Markus Heppt, Zhi
Wei, Alexandra Gyurdieva, Marie Webster, Masahiro Oka,
Ashani Weeraratna, Meenhard Herlyn.
1509 Leptin drives mammary stem cell self-renewal via
the mTOR pathway. Ray Esper, Michael Dame, Shannon
McClintock, Becky Simon, Max Wicha, Dean Brenner.
1510 The sonic hedgehog pathway as a therapeutic
target in bladder cancer. Peter A. Raven, Summer
Lysakowski, Yoshiyuki Matsui, Shintaro Narita, Alan I. So.
1511 Identification of metastatic subsets of pancreatic
cancer stem cells possessing metabolic features of
pluripotent stem cells. Chi-Che Hsieh, Wen-Ying Liao, ChihLung Chen, Pei-Yu Lin, Chia-Ning Shen.
1512 Cancer stemness property incurred by
inflammatory cytokine confers poor prognosis of
hepatocellular carcinoma. Te-Sheng Chang, Yu-Chih Wu,
Ying-Huang Tsai, Yen-Hua Huang.
1513 ALDH1 and podoplanin expression in oral
leukoplakia: Correlate with malignant transformaion risk.
Umma Habiba, Masanobu Shindoh.
1514 Acquired differentiation and loss of malignancy of
pulmonary metastases in breast cancer. Huiping Liu.
1515 Inhibition of the IKK/NF-␬B pathway impairs
glioma stem cell function. Amanda L. Rinkenbaugh, Patricia
C. Cogswell, Albert S. Baldwin.
1516 YAP1 regulates Oct4 activity and Sox2
expression, facilitating self-renewal and vascular mimicry
of stem-like cells. Namrata Bora Singhal, Jonathan Nguyen,
Courtney Schaal, Deepak Perumal, Sandeep Singh, Domenico
Coppola, Srikumar Chellappan.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
27.
28.
29.
30.
19
Abstract
Number
1517 G0-like cells support an oral cancer stem cell pool
by transitioning to a JARID1B-high state. Nicole Facompre,
Zachary Belden, Phyllis Gimotty, Anil Rustgi, Meenhard
Herlyn, Hiroshi Nakagawa, Devraj Basu.
1518 Multiethnic triple negative breast cancer
comparisons of gene expression shows enrichment of
distinct pathways in ALDH1+ subpopulations compared to
CD44+/CD24-/EpCAM+. Evelyn M. Jiagge, Qingxuan Song,
Shukmei Wong, Tahra Luther, Michele Dziubinski, Shawn
Clouthier, Sean McDermott, Lisa Newman, John Carpten, Jun
Li, Max WIcha, Sofia Merajver.
1519 Cantrixil targets ovarian cancer stem cells and prevents
recurrence in a cisplatin-resistant animal model. Gil G. Mor, Eydis
Lima, Natalia Sumi, Mary Pitruzzello, Yang Yang-Hartwich,
David Brown, Andrew Heaton, Ayesha B. Alvero.
1520 Plasticity of CD44+ colorectal cancer stem cells
depends on TGF-beta-induced epithelial mesenchymal
transition (EMT): evidences from ex vivo culture system.
Michitaka Nakano, Hioshi Ariyama, Shingo Tamura, Taichi
Isobe, Kohta Miyawaki, Yuta Okumura, Hitoshi Kusaba,
Takashi Ueki, Eishi Baba, Koichi Akashi.
1521 High-throughput molecular profiling of Multiple
Myeloma clonotypic CD19+ B cells highlights pathways
potentially involved in the disease endurance. Marina
Martello, Angela Flores Dico, Daniel Remondini, Barbara Santacroce,
Enrica Borsi, Mauro Procacci, Lucia Pantani, Elena Zamagni, Paola
Tacchetti, Anna Maria Brioli, Serena Rocchi, Giulia Marzocchi,
Giovanni Martinelli, Michele Cavo, Carolina Terragna.
1522 Survival of skin cancer tumor initiating cells
requires the Ezh2 polycomb group protein. Gautam
Adhikary, Dan Grun, Candace Kerr, Sivaprakasam
Balasubramanian, Ellen Rorke, Wen Xu, Richard Eckert.
1523 Prostaglandin E2 promotes colorectal cancer
stem-like cell expansion and metastasis. Dingzhi Wang,
Lingchen Fu, Haiyan Sun, Raymond N. DuBois.
1524 Establishing long-term circulating tumor cells
(CTCs) in a 3D culture system in vitro. Marina C. Cabrera,
Elaine Hurte.
1525 FAK and PI3K/mTOR inhibitors target cancer stem
cells: Implications for SCLC treatment strategies. Vihren N.
Kolev, Qunli Xu, Jonathan A. Pachter, David T. Weaver.
1526 HOXA5 inhibits cell plasticity and stemness in
breast cancer cells by reinforcing epithelial traits. Wei Wen
Teo, Vanessa Merino, Sean Cho, Preethi Korangath, Neil M.
Neumann, Andrew J. Ewald, Saraswati Sukumar.
1528 GD2+ breast cancer stem cell growth is
dependent on NF␬B signaling and suppressed by the IKK
inhibitor BMS345541 in vitro and in vivo. Venkata Lokesh
Battula, Jeffrey Sun, Gabriel N. Hortobagyi, Michael Andreeff.
1529 MYC and HIF-2alpha cooperates in oral squamous
carcinoma cell self-renewal during hypoxia. Hong Li,
Joyeeta Talukdar, Sora Sandhya, Seema Bhuyan, Sukanya
Gayan, Anupam Sarma, Reza B. Mokhtari, Dean W. Felsher,
Herman Yeger, Bikul Das.
1530 Therapeutic efficacy of cancer stem cell vaccine in
an adjuvant setting. Yangyang Hu, Lin Lu, Alfred E. Chang,
Martin Egenti, John Owen, Jeffrey S. Moyer, Mark E. Prince,
Jianchuan Xia, Shiang Huang, Max S. Wicha, Qiao Li.
1531 Distinct roles of CXCR3 isoforms in promoting
breast cancer stem-like cell properties and metastasis.
Yanchun Li, Jocelyn C. Reader, Xinrong Ma, Namita Kundu,
Tyler Kochel, Amy M. Fulton.
19
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
20
20
Therapeutic Targeting of the Microenvironment
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
1532 A Microbiomic analysis in African American with colonic
lesions reveals bacterial markers with potential diagnostic value.
Hassan Brim, Sudhir Varma, Adeinko Laiyemo, Zaki Sharif, Edward L.
Lee, Hassan Ashktorab.
16.
1547 The clinical implication of MMP-1 and TIMP-1 on
prognosis in patients with non-small cell lung cancer. Ho Jung An,
Jin-Hyoung Kang, Yoon-Jin Lee, Soon Uk Hong, Kyo Young Lee,
Jeong-Oh Kim.
2.
1533 16S rRNA saliva analysis unveils differences in the head
and neck squamous cell carcinoma microbiome before and after
surgical resection. Rafael E. Guerrero-Preston, Filipa Godoy-Vitorino,
Herminio González, Christina Michailidi, Anne Jedlicka, Amanda
Dziedzic, Rajagowthamee Thangavel, Tal Hadar, Maartje G.
Noordhuis, William Westra, Wayne Koch, David Sidransky.
17.
3.
1534 The microbiome of cancer as seen through the lens of
public genome sequence data. Kelly M. Robinson, Karsten B. Sieber,
Kathleen E. Anderson, David R. Riley, Julie C. Dunning Hotopp.
1548 Baseline serum levels of osteopontin and
thrombospondin-1 predict shorter overall survival in primary
resected non-small cell lung cancer. Mathieu Rouanne, Julien Adam,
Aïcha Goubar, Angélique Robin, Caroline Ohana, Emilie Louvet,
Jiemin Cormier, Olaf Mercier, Peter Dorfmüller, Soly Fattal, Vincent
Thomas de Montpreville, Elie Fadel, Benjamin Besse, Ken André
Olaussen, Christian Auclair, Jean-Charles Soria.
18.
4.
1535 Omentin: A novel adipokine linking visceral obesity to
ovarian cancer progression. Chi Lam Au Yeung, Ngai Na Co,
Michaela Onstad, Tsz-Lun Yeung, Cecilia S. Leung, Rosemarie
Schmandt, Karen H. Lu, Samuel C. Mok.
1549 Development and validation of a biomarker for
prospective selection of Notch1 activation in patients with certain
advanced solid tumors in a first-in-human phase1 study of the
cancer stem cell targeting antibody OMP-52M51 (anti-Notch1).
Belinda Cancilla, Raymond Tam, Chun Zhang, Steve Anderson, John
Lewicki, Tim Hoey, Bryan McCune, Lori Johnson, Esohe Idusogie, Ann
M. Kapoun.
5.
1536 Effect of ascites on tumor response in advanced stage
ovarian cancer. Soochi Kim, Anna Kim, Hee Seung Kim, HyeRan
Gwak, UnTek Jo, Yong Sang Song.
19.
1550 Significance of ectopic lymph node-like structures in
neuroendocrine tumors of the small bowel. Mauro Cives, Jonathan
Strosberg, Stacey A. Simons, Domenico Coppola.
6.
1537 Tumor stroma in serous ovarian cancer; inter and intra
patient heterogeneity and impact on survival. Sara Corvigno, Bea
Wisman, Ate G.J. Van der Zee, Hans W. Nijman, Artur Mezheyeuski,
Elisabeth Åvall Lundkvist, Arne Östman, Hanna Dahlstrand.
20.
7.
1538 Levels and enzyme activity of CD73 in primary samples
from cancer patients. Qihui Huang, Nicholas M. Durham, Erin Sult,
Yuling Wu, Jenny Liu, Nicholas Holoweckyj, Laurie Iciek, Robert
Hollingsworth, Brett Hall, Ronald Herbst, Ching Ching Leow, Kris
Sachsenmeier.
1551 Identification of plasma biomarker concentration
changes resulting from the administration of the Vascular
Disrupting Agent BNC105 across 3 clinical trials in mesothelioma,
ovarian and renal cancer. Gabriel Kremmidiotis, Annabel Leske,
Jeremy Simpson, Elizabeth Doolin, Jose Iglesias.
21.
1552 Image-based microchip sorting of pure, immunophenotypically defined subpopulations of tumor cells from tiny
formalin-fixed paraffin embedded (FFPE) samples reveals their
distinct genetic features. Chiara Bolognesi, Anna Doffini, Genny
Buson, Rossana Lanzellotto, Giulio Signorini, Valeria Sero, Alex
Calanca, Francesca Fontana, Rita Romano, Stefano Gianni, Giulia
Bregola, Gianni Medoro, Raimo Tanzi, Giuseppe Giorgini, Hans
Morreau, Massimo Barberis, Willem E. Corver, Nicolo Manaresi.
22.
1553 Biomarker evaluation in a randomized phase 2 study of
MEHD7945A (MEHD) versus cetuximab (Cet) in >2 line recurrent/
metastatic (R/M) squamous cell carcinomas of the head and neck
(SCCHN) [MEHGAN]. Elicia Penuel, Amy V. Kapp, An Do, Rachel Tam,
Teiko Sumiyoshi, Chaitra Marathe, Susan Sa, Franklin Peale, Mark
Lackner, Scott Holden, Tanguy Seiwert, Andrea Pirzkall.
24.
1555 An automated cage-based method of randomized group
distribution in pre-clinical in vivo studies. Eric M. Ibsen, Jeffrey L.
Kumer.
25.
1556 Role of Klotho in age-related melanoma progression.
Reeti Behera, Amanpreet Kaur, Katie Marchbank, Vanessa Dang,
Marie Webster, Xiaowei Xu, Ashani T. Weeraratna.
26.
1557 The iron-overload genetic disease hemochromatosis
potentiates colonic inflammation and colon carcinogenesis.
Vadivel Ganapathy, Ashish Gurav, Jaya P. Gnanaprakasam, Ellappan
Babu, Yangzom D. Bhutia, Cynthia Reinoso Webb, Matthew B.
Grisham.
27.
1558 Association of ErbB/HER biomarkers with antitumor
activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in
SCCHN. Diego Alvarado, Jerry Wallweber, Scott Seibel, Ahmed
Chenna, Roy Ravanera, Weidong Huang, David Stathas, Paul
Theobald, Theresa M. LaVallee.
28.
1559 Progranulin A9D mutation functionally leads to the
cytoplasm retardation of angiogenin. Jinghao Sheng, Yongdui
Chen, Siqi Li, Haojie Dong, Guangdi Chen, Zhengping Xu.
29.
1560 FGFR4 is expressed in the tumor and stromal
compartments of human gliomas of all grades and histologies.
Christiane H. Gjerde, Ercan Mutlu, Lina Leiss, Bjarne W. Kristensen,
Mohummad A. Rahman, Per Ø. Enger.
8.
9.
1539 Analysis of differential protein profiles in co-culture
models of pancreatic cancer cells and fibroblasts. Elena PrietoGarcía, M. Teresa Agulló-Ortuño, C. Vanesa Díaz-García, Inés GarcíaConsuegra, Jorge Adeva, M. Carmen Riesco, Lucía Parrilla, Carlos
Gómez, Laura Lema, Luis Robles, Hernán Cortés-Funes, José A.
López-Martín.
1540 Effect of IGF1 on cancer and stromal cells of human
pancreatic tumors. Marina R. Kopantseva, Eugenia Usova, Arsen
Mikaelyan, Maria Kostina, Olga Melekhina, Vyacheslav Egorov,
Eugene P. Kopantzev.
10.
1541 Secreted serglycin in tumor microenvironment promotes
tumor malignancies in a CD44-dependent manner. Jing-You Guo,
Shiaw-Wei Tyan, Han-Shui Hsu, Fen-Yau Li, Jeou-Yuan Chen.
11.
1542
Targeting KIF3a and primary cilia differentially affects
sonic hedgehog sensitivity and the rate of glioblastoma
progression. Lan Hoang-Minh, Dorit Siebzehnrubl, Loic Deleyrolle,
George Ugartemendia, Hunter Futch, Benjamin Griffith, Joshua
Breunig, Susan Semple-Rowland, Brent Reynolds, Matthew Sarkisian.
12.
1543 Wogonin suppresses the production of breast cancerderived osteolytic factors. Hyungkeun Kim, Kwang-Kyun Park,
Won-Yoon Chung.
13.
1544
Association of tumor location with the breast and
clinicopathological characteristics. Seth Rummel, Nick Costantino,
Matthew T. Hueman, Craig D. Shriver, Rachel E. Ellsworth.
14.
1545 Cytokine profiling of drug-disrupted tumor
cell/fibroblast crosstalk provides insights to understand the
protective role of the stroma. Natalia Guillen Díaz-Maroto, Samuel
Gonçalves, Ramon Salazar, Flavien Carpentier, Eric Mennesson, Nadia
Normand, David Garcia Mollevi.
15.
1546
Immunosuppressive activity of cancer-associated
fibroblasts in head and neck squamous cell carcinoma. Hideyuki
Takahashi, Koichi Sakakura, Kazuaki Chikamatsu.
319
POSTER SESSION
Clinical Research
Biomarkers for Early Detection
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
1561 Detection of colorectal cancer-associated genetic
and epigenetic alterations in urine of patients with CRC.
Adam W. Clemens, Selena Lin, Surbhi Jain, Ying-Hsiu Su, Wei
Song.
2.
1562 Proteomic changes observed in colon cancer
tumors by label-free differential profiling of paired tumor
versus normal FFPE samples. Lokesh Agrawal, Fiona
McAlister, Sushmita Roy, Florian Unger, Kerstin David,
Harmut Juhl, Daniel Chelsky, Helen Moore.
3.
1563 Stool proteomics reveals novel candidate
biomarkers for colorectal cancer screening. Linda J. Bosch,
Meike de Wit, Annemieke C. Hiemstra, Sander Piersma,
Thang Pham, Gideon Oudgenoeg, George Scheffer, Sandra
Mongera, Malgorzata Komor, Jochim Terhaar Sive Droste,
Frank A. Oort, Sietze van Turenhout, Ilhame Ben Larbi, Chris
J. Mulder, Beatriz Carvalho, Remond J. Fijneman, Connie
Jimenez, Gerrit A. Meijer.
4.
1564 Evaluation and characterization of anti-RalA
autoantibody as a potential biomarker in human prostate
cancer. jitian li, Liping Dai, Carlos A. Casiano, Jianying Zhang.
5.
1565 Magnetic bead-based serum peptidome profiling
for identifying potential biomarkers in esophageal
squamous cell carcinoma. Kun Jia, Wei Li, Feng Wang, Fang
Liu, Xiaofei Liu, Yuanyuan Qiao, Yang Xu, Lanping Zhou, Yulin
Sun, Qingwei Ma, Xiaohang Zhao.
6.
1566 Association of a serum HPV16 IgG signature and
risk of oropharyngeal cancer. Karen S. Anderson, Hilde
Langseth, Garrick Wallstrom, Marshall Posner, Julia N. Cheng,
Rizwan Alam, Diego Chowell, Jon Mork.
7.
1567 A mass spectrometry based serum test for the
detection of hepatocellular carcinoma (HCC) in high risk
patients. Devalingam Mahalingam, William K. Washburn,
Glenn Halff, Leonidas Chelis, Stylianos Kakolyris, Stylianos
Vradelis, Julia Grigorieva, Carlos Oliveira, Heinrich Roder,
Joanna Roder.
8.
1568 Detection of HBV-host junction DNA sequences in
urine of patients with HBV-infected HCC. Selena Lin,
Benjamin Song, Evan Trauger, Malcolm Hoffman, Emilie
Thompson, Rebecca Zhou, Surbhi Jain, Wei Song, Ying-Hsiu
Su.
9.
320
1569 Development of a noninvasive and sensitive urine
screening test for liver cancer targeting circulationderived cancer DNA biomarkers. Surbhi Jain, Sitong Chen,
Selena Y. Lin, Adam Clemens, Hei-won L. Hann, Ting-Tsung
Chang, Chi-Tan Hu, Shun-Hua Chen, Wei Song, Ying-Hsiu Su.
Poster
Board
22
Abstract
Number
10.
1570 Early Detection Research Network (EDRN)
validation of circulating ovarian cancer biomarkers. Steven
J. Skates, Karen S. Anderson, Tao Liu, Vathany Kulasingam,
Dustin Rabideau, Chaochao Wu, Michael Gillette, Andrew K.
Godwin, Nicole Urban, Anna Lokshin, Jeffrey Marks,
Eleftherios Diamandis, Zhen Zhang, Sudhir Srivastava, Jacob
Kagan, Christos Patriotis, Karin Rodland.
12.
1572 Sensitive and robust targeted sequencing of
pancreatic precancer and tumors using microfluidic singlemolecule enrichment. Angelina I. Londoño-Joshi, Erica Pratt,
Robert W. Cowan, Michael L. Samuels, Steve Kotsopoulos,
Jeff Olson, Francis Long, Michelle A. Anderson, Diane
Simeone, Andrew D. Rhim.
13.
1573 miR-Test: a blood test for lung cancer early
detection. Francesca Montani, Matteo Jacopo Marzi, Fabio
Dezi, Elisa Dama, Rose Mary Carletti, Giuseppina Bonizzi,
Raffaella Bertolotti, Massimo Bellomi, Cristiano Rampinelli,
Patrick Maisonneuve, Lorenzo Spaggiari, Giulia Veronesi,
Francesco Nicassio, Pier Paolo Di Fiore, Fabrizio Bianchi.
14.
1574 Leveraging bronchial airway gene expression to
develop a nasal biomarker for lung cancer detection.
Joseph Perez-Rogers, Joseph Gerrein, Christina Anderlind,
Xiaohui Xiao, Hanqiao Liu, Rebecca Kusko, Joshua Campbell,
Teresa Wang, Yuriy Alekseyev, Gang Liu, Kate Porta, Duncan
Whitney, Avrum Spira, Marc Lenburg.
15.
1575 Serum circulating miR–Test application:
Standardized protocol for miR–Test clinical application.
Francesca Montani, Matteo Marzi, Fabio Dezi, Elisa Dama,
Rose Mary Carletti, Giulia Veronesi, Francesco Nicassio, Pier
Paolo Di Fiore, Fabrizio Bianchi.
16.
1576 Analysis of HSP10 as a putative biomarker of
breast cancer. Sadr-ul Shaheed, Andreas Hadjisavvas,
Kleitos Sokratous, Paul Loadman, Chris Sutton, Kyriacos
Kyriacou.
17.
1577 Levels of Fibroblast Growth Factor 21 (FGF21) in
serum as diagnostic biomarker in patients with breast
cancer. Maria E. Knott, Stella M. Ranuncolo, Myriam Nuñez,
Eduardo Armanasco, Lydia I. Puricelli, Mariana S. De Lorenzo.
18.
1578 Identification of type X collagen as a pan-cancer
serum biomarker. Maria J. Prendes, Karen B. Chapman,
Orlena Tam, Joseph Wagner.
19.
1579 Circulating cell-free DNA as a diagnostic marker
for epithelial ovarian cancer and an association with
epithelial-mesenchymal transition. Yu-Jin Koo, Kyung-Jin
Min, Jin-Hwa Hong, Jae-Kwan Lee.
22
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
23
23
Circulating Tumor Cells
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
1580 MET expression in circulating tumor cells (CTCs) isolated on
the ISET platform correlates with MET expression in matched tumor
tissue in advanced NSCLC patients. Marius Ilie, Edith Szafer-Glusman,
Veronique Hofman, Rebecca Suttman, Walter Darbonne, Charles-Hugo
Marquette, David S. Shames, Elizabeth Punnoose, Paul Hofman.
1581 A study of pulmonary and peripheral vein blood as sources
of circulating tumor cells in early lung cancer. Vasudha Murlidhar,
Rishindra M. Reddy, Ebrahim Azizi, Lili Zhao, Svetlana Grabauskiene, Zhuo
Zhang, Nithya Ramnath, Jules Lin, Andrew C. Chang, Philip W. Carrott,
William R. Lynch, Mark B. Orringer, Max S. Wicha, Nallasivam Palanisamy,
David G. Beer, Sunitha Nagrath.
1582 Isolation of circulating tumor cells and evaluation of PD-L1
expression in metastatic lung cancer. Manjima Dhar, James Che, Jessica
M. Wong, Edward Pao, Victor S. Yu, Melissa Matsumoto, Jonathan
Goldman, Edward Garon, Elodie Sollier, Rajan Kulkarni, Dino Di Carlo.
Poster
Board
16.
17.
18.
19.
1583
Circulating tumor cells isolated from non-small cell lung
cancer patients using the in vivo CellCollector Technology. Thomas
Krahn, Lukasz Gasiorowski, Wojciech Dyszkiewicz, Grzegorz
Dworacki, Maciej Zabel, Dave S. Hoon, Stefanie Herold, Bjoern
Nowack, Johannes Tucholsky, Christian Schumann, Klaus Lücke.
1584 Analytical and clinical validation of the Epic Circulating
Tumor Cell (CTC) Platform: enrichment-free CTC detection and
biomarker characterization. Ryon P. Graf, David T. Valenta, Mark
Landers, Bryan Taggart, Stephanie Greene, Shannon L. Werner, Ryan
Dittamore, Dena Marrinucci.
1585 Application of a graphene oxide based microfluidic
device (GO Chip) to prostate cancer circulating tumor cell capture
and analysis. Molly Kozminsky, Hyeun Joong Yoon, Nallasivam
Palanisamy, Kathleen Cooney, Maha Hussain, Ajjai Alva, Todd
Morgan, Sunitha Nagrath.
1586 Recovery and characterization of circulating tumor cells
(CTCs) in cryopreserved metastatic castrate-resistant prostate cancer
(mCRPC) patient samples. David Lu, Melissa Harvey, Ravi Madan,
Christopher Heery, Jennifer Marte, Sharon Beasley, Mark Landers, Rachel
Krupa, Jessica Louw, Justin Wahl, Natalee Bales, Dena Marrinucci, Jeffrey
Schlom, James Gulley, Ryan Dittamore.
1587 Targeted sequencing of prostate cancer circulating tumor
cells in comparison with matched cell free DNA and prostate tumors.
Brian Hu, Stephen Liu, Yucheng Xu, Paul Dempsey, William Strauss,
Kristopher Wentzel, Tong Xu, Jacek Pinski, Tanya Dorff, Jessamine WinerJones, David I. Quinn, Amir Goldkorn.
1588 Single cell analysis of AR N terminal, AR C terminal and the
ARv7 splice variant in the CTCs of metastatic castration resistant
prostate cancer (mCRPC) patients. James Kelvin, David Lu, Davin Packer,
Richard Bambury, Dana Rathkopf, Nicole Schreiber, Zaina Arslan, Natalie
Prigozhina, David Brown, Rachel Krupa, Edward Swangren, Mark Landers,
Florence Lee, Dena Marrinucci, Ryan Dittamore, Howard I. Scher.
1589 Investigation of circulating tumor cells from head and neck
cancer patients undergoing radiation therapy: A pilot study. Michael J.
Eblan, Ja H. Myung, Joseph M. Caster, Bhishamjit S. Chera, Seungpyo
Hong, Andrew Z. Wang.
1590 CD133-expressing circulating tumor cells might predict poor
prognosis in patients with head and neck cancer. Jason Chia-Hsun Hsieh,
Harber H. Shiao, Bill Y. Chao, Ming-Jung Lin, John Wen-Cheng Chang,
Hung-Ming Wang, Tyler Min-Hsien Wu.
1591 Comprehensive molecular profiling of circulating tumor cells
from metastatic breast cancer patients. Mark Jesus M. Magbanua, Louai
Hauranieh, Ritu Roy, Praveen Pendyala, Eduardo Sosa, Janet Scott, Hope
Rugo, John Park.
1592 CXCR4 pathways in CTCs: from bioinformatics to
immunophenotype. G. Kallergi, V. Tsintari, S. Sfakianakis, M. Zervakis, D.
Mavroudis, V. Georgoulias.
1593 Label-free high throughput microfluidic device for the
isolation of circulating tumor cells from breast cancer patients. Eric Lin,
Lianette Rivera, Hyeun Joong Yoon, Shamileh Fouladdel, Jacob Wieger,
Stephanie Guthrie, Yadwinder S. Deol, Shawn G. Clouthier, Tahra K. Luther,
Diane M. Simeone, Monika L. Burness, Ebrahim Azizi, Max S. Wicha,
Sunitha Nagrath.
1594 Application of label-free microfluidic technologies for the
enrichment, expansion and characterization of circulating tumor cells in
pancreatic cancer. Lianette Rivera-Baez, Eric Lin, Hyeun Joong Yoon,
Meghna Waghray, Shamileh Fouladdel, Ebrahim Azizi, Max Wicha, Diane
Simeone, Sunitha Nagrath.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1595 Analysis of circulating epithelial and EMT-like CTCs in
pancreatic cancer using a sensitive microfluidic CTC capture device.
Mina Zeinali, Vasudha Murlidhar, Shamileh Fouladdel, Mathius Hafner,
Shimeng Shao, Ebrahim Azizi, Max S. Wicha, Kyle Cuneo, Diane M.
Simeone, Sunitha Nagrath.
1596 Detection of PD-L1 in cell surface vimentin positive
circulating tumor cells is associated with poor survival in cancer
patients. Arun Satelli, Zachary Brownlee, Hyangsoon Noh, Qing H. Meng,
Scott Kopetz, Michael Overman, Shulin Li.
1597 A novel method for isolation and genetic analysis of pure
populations of circulating plasma cells from multiple myeloma
patients. Greg Brittingham, Chandra Rao, Peter Vulfson, Denis Smirnov,
Brad Foulk.
1598 Isolation and characterization of circulating melanoma cells
by size filtration and fluorescent in situ hybridization. Masahiko
Yanagita, Jason J. Luke, Cloud P. Paweletz, Elena Ivanova, Paul T.
Kirschmeier, Stephen F. Hodi, Pasi A. Jänne.
1599 Potential values of circulating tumor cell enumeration for
clinical management of patients with papillary thyroid carcinoma.
Hung-Chih Lin, Jen-Der Lin, Ching-Ping Tseng.
1600 A multiplexed marker-based algorithm for diagnosis of
carcinoma of unknown primary using circulating tumor cells. Elizabeth
M. Matthew, Lanlan Zhou, Namrata Vijayvergia, David T. Dicker, Karen S.
Gustafson, Harry S. Cooper, Eric A. Ross, Bora Lim, Ramdane Harouaka,
Si-Yang Zheng, Nicholas E. Lamparella, Joseph J. Drabick, Cristina I. Truica,
Zhaohai Yang, Wafik S. El-Deiry.
1601 Clinical performance of the AccuCyte® - CyteFinder® System,
a dual-technology platform for comprehensive collection and high
resolution imaging of circulating tumor cells. Jackie L. Stilwell, Nick
Drovetto, Arturo B. Ramirez, Daniel Campton, Joshua Nordberg, Paulina
Varshavskaya, Alisa Clein, Steve Quarre, Barry Friemel, Daniel E. Sabath,
Eric P. Kaldjian.
1602 Development and validation of an NGS-based assay to
detect all classes of genomic alterations in circulating tumor cells
(CTCs) from patients with solid tumors. Allison Welsh, Garrett M.
Frampton, Zachary R. Chalmers, Jamie Sperger, Roman Yelensky, Doron
Lipson, Geoff Otto, Lindsay Strotman, Scott Berry, Hannah Pezzi, Anne
Traynor, David J. Beebe, Vincent A. Miller, Joshua M. Lang, Philip J.
Stephens.
1603 High purity isolation of circulating tumor cells for nextgeneration sequencing. Nur Lina Mohd Salleh, Yi Fang Lee, Mei Hui Tan,
Michelle A. Rosario, Ross A. Soo, Ali A. Bhagat, Richie C. Soong.
1604 IMI CANCER-ID: Validation of novel blood-based biomarker
technologies in clinical settings. Thomas Schlange, Thomas Krahn,
Sabrina Pleier, Klaus Pantel, Leon W. Terstappen, Barbara Baggiani.
1605 Dielectrophoretic microwell array system for detection
circulating tumor cells in patients with solid tumors and single cell
analysis of detected circulating tumor cells. Takeshi Sawada, Atsushi
Morimoto, Tatsu Shimoyama, Toshinari Yamashita, Toshifumi Mogami,
Kazuki Iijima, Mayu Yunokawa, Shintaro Kanda, Yasuyuki Akiyama, Koji
Katayama, Masaru Watanabe, Yasuhiro Koh, Kenji Tamura, Tomohide
Tamura, Toru Futami, Fumiaki Koizumi.
1606 Single cell isolation and DNA analysis from circulating tumor
cells using self-sorting nanowell plates. Joost F. Swennenhuis, Arjan G.
Tibbe, Michiel Stevens, Nikolas H. Stoecklein, Rui Neves, Hien D. Tong,
Cees J. van Rijn, Leon W. Terstappen.
1607 Identification of low number circulating tumor cells (CTCs)
for cancer treatment monitoring. Thomas J. George, Weian Sheng, Jose I.
Varillas, Chen Liu, Z. H. Fan.
1608 CTC categorization: Subpopulations of CTCs and their
potential clinical significance. Chengsen Xue, Thomas W. Mc Closkey.
1609 Comprehensive multi-omic analysis of circulating tumor
cells isolated from a metastatic triple-negative breast cancer patient to
identify pathogenic genomic aberrations. Kellie Howard, Sharon Austin,
Arturo Ramirez, Leila Ritter, Debbie Boles, James Cox, Fang Yin Lo, Kerry
Deutsch, Christopher Subia, Tuuli Saloranta, Nicole Heying, Heather
Collins, Amanda Leonti, Lindsey Maassel, Jackie Stilwell, Eric Kaldjian,
Michael Dorschner, Anthony Blau, Marcia Eisenberg, Steven Anderson,
Anup Madan.
321
POSTER SESSION
Clinical Research
Pediatric Cancer: Clinical Investigations / Regulatory Science and Policy
Poster
Board
Abstract
Number
1.
1610 Development of meta-[211At]astatobenzylguanidine
([211At]MABG) as an alpha particle emitting systemic targeted
radiotherapeutic for neuroblastoma. Vandana Batra, Pietro Ranieri, Mehran
Makvandi, Matthew Tsang, Catherine Hou, Yimei Li, Ganesan Vaidyanathan,
Daniel A. Pryma, John M. Maris.
2.
1611
3.
4.
5.
6.
7.
8.
9.
10.
11.
322
The FACT histone chaperone complex is highly expressed in
aggressive drug refractory childhood cancers and the anti-FACT
compound CBL0137 represents a highly promising therapeutic approach
in this setting. Michelle Haber, Jayne Murray, Laura Gamble, Ashleigh
Carnegie-Clark, Hannah Webber, Michelle Ruhle, Michelle
J. Henderson, Shiloh Middlemass, Daniel Carter, Maria Tsoli, Anahid
Ehteda, Sandy Simon, Andre Oberthuer, Matthias Fischer, Katerina
Gurova, Catherine Burkhart, Andrei Purmal, Richard B. Lock, David
Ziegler, Glenn M. Marshall, Andrei V. Gudkov, Murray D. Norris.
1612 Identification of mithramycin analogs with improved
targeting of the EWS/FLI1 transcription factor. Christy Osgood,
Nichole Maloney, Christopher G. Kidd, Meti Gebregiorgis, Luz E.
Nunez, Javier Gonzalez-Sabin, Lee J. Helman, Francisco Moris, Patrick
J. Grohar.
1613 ␤-lapachone: a novel targeted therapy for atypical
teratoid rhabdoid tumors (ATRTs). Zachary R. Moore, Sarai Stuart,
Agnieszka Cholka, Ashwin Venkataraman, Jingying Xu, Anat
Erdreich-Epstein, Dinesh Rakheja, David A. Boothman, James F.
Amatruda, Theodore W. Laetsch.
1614 Inhibition of MDM2 by RG7388 confers hypersensitivity
to X-radiation in xenograft models of childhood sarcoma. Peter J.
Houghton, Doris A. Phelps, Kathryn Bondra, Star Seum, Christopher
Chronowski, Justin Leasure, Raushan T. Kurmasheva, Stephen
Middleton, Dian Wang, Xiaokui Mo.
1615 Initial testing (stage 1) of the Curaxin, CBL0137, by the
Pediatric Preclinical Testing Program (PPTP). Malcolm A. Smith,
Min Kang, Patrick C. Reynolds, Richard B. Lock, Hernan Carol, Richard
Gorlick, Anders E. Kolb, John M. Maris, Stephen T. Keir, Catherine A.
Billups, Raushan Kurmasheva, Peter J. Houghton.
Poster
Board
1621 Tolcapone, a catechol-O-methyltransferase inhibitor, alone
and in combination with oxaliplatin induces cell death in neuroblastoma.
David E. Hayes, Ping Zhao, Austin Voydanoff, Abhinav Nagulapally,
Jeff Bond, Giselle Sholler.
13.
1622 The AKT inhibitor reverses protein trafficking and
inhibits tumor cell motility of p27-mislocalized osteosarcoma
cells. Xiang Chen, Yiting Li, Manjula Nakka, Tsz Kwong Man.
1623 Targeted therapy of Ewing’s Sarcoma and childhood
leukemia (ALL) by hybrid polymerized liposomal nanoparticles
(HPLN). Hyunggyoo Kang, Violette Shahbazian, Ryan Holly, Jon
Nagy, Timothy Triche.
1624 Methotrexate resistance in relation to treatment outcome in
childhood acute lymphoblastic leukemia. Anna Wojtuszkiewicz,
Godefridus J. Peters, Nicole L. van Woerden, Boas Dubbelman,
Gabrielle Escherich, Kjeld Schmiegelow, Edwin Sonneveld, Rob
Pieters, Peter M. van de Ven, Gerrit Jansen, Yehuda G. Assaraf,
Gertjan J. Kaspers, Jacqueline Cloos.
1625 Ureidomustine, a novel DNA-crosslinking agent shows
activity in sarcoma preclinical models and lacks toxicity in normal
tissues. Srikanth R. Ambati, Shieh JaeHung, Benet Pera, Elissa W.
Wong, Eloisi Caldas Lopes, Elizabeth Peguero, Tsann-Long Su,
Malcolm A. Moore.
1626 Evaluation of the expression of neuroblastomaassociated genes for bone marrow (BM) involvement and minimal
residual disease (MRD) detection. Alexander E. Druy, Egor V.
Shorikov, Grigory A. Tsaur, Alexander M. Popov, Leonid I. Saveliev,
Larisa G. Fechina.
1627 Phenotypic and functional evaluation of peripheral
blood cell subsets in children at the completion of induction
therapy for acute lymphoblastic leukemia. Nina Rolf, Amina
Kariminia, Kinga K. Smolen, Caron Strahlendorf, Gregor S. Reid.
1628 Neuropeptide Y (NPY) and its receptor expression in
neuroblastoma patients - associations with disease prognosis and
patients’ survival. Susana Galli, Jason Tilan, Arlene Naranjo, Collin
Van Ryn, Chao Yang, Jessica Tsuei, Emily Trinh, Joanna B. Kitlinska.
1629 Prednisone versus dexamethasone acute toxicity and
cumulative doses variations in childhood acute lymphoblastic
leukemia. Sophie Marcoux, Aurélie Chapdelaine, Philippe Robaey,
Daniel Sinnett, Maja Krajinovic, Caroline Laverdière.
1630 Effects of rhBMP-2 on osteosarcoma tumorigenesis.
Sajida Piperdi, David Geller, Amy Park, So Hak Chung, Richard Gorlick.
1631 Bioluminescence imaging enhances analysis of drug
response in a patient-derived xenograft model of pediatric acute
lymphoblastic leukemia. Luke Jones, Jennifer Richmond, Kathryn
Evans, Richard B. Lock.
1632 Microsomal prostaglandin E synthase 1: a novel
therapeutic target of neuroblastoma. Anna Kock, Karin Larsson,
Raouf Joan, Marina Korotkova, John-Inge Johnsen, Per-Johan
Jakobsson, Per Kogner.
1633 Calorie and fat restriction during chemotherapy
improves survival in obese mice with syngeneic acute
lymphoblastic leukemia. Jonathan Tucci, Waseem Alhushki, Xia
Sheng, Steven D. Mittelman.
1634 A comprehensive guide for managing large-scale
collaborative genomics research projects. Margi Sheth, Jiashan
Zhang, Jean C. Zenklusen.
1635 Mechanistic investigation of neutropenia associated
with palbociclib. Wenyue Hu, Tae Sung, Bart Jessen, Aida Sacaan.
1636 A model-based approach toward clinical pipeline optimization.
Jackson Burton, William Antebi, Christopher J. Zopf, Dean Bottino,
Shu-Wen Teng, Ryan Nolan, Arijit Chakravarty.
15.
16.
17.
18.
19.
1616 Pharmacodynamic and genomic markers associated
with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a
report from the Pediatric Preclinical Testing Program. Malcolm A.
Smith, Richard Lock, Hernan Carol, John M. Maris, Richard Gorlick,
E. A. Kolb, Stephen T. Keir, Jianrong Wu, Yosef Landesman, Sharon
Shacham, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton.
20.
1617 Analysis of single mouse tumor response results from
the Pediatric Preclinical Testing Program (PPTP). Brendan Murphy,
Han Yin, John M. Maris, Anders E. Kolb, Richard Gorlick, Patrick C.
Reynolds, Min Kang, Stephen T. Keir, Raushan Kurmasheva, Igor
Dvorchik, Jianrong Wu, Catherine Billups, Malcolm A. Smith, Peter J.
Houghton.
22.
1618 Carboplatin therapeutic monitoring in preterm and full-term
neonates. Gareth J. Veal, Julie Errington, James Hayden, David Hobin,
Dermot Murphy, Rachel A. Dommett, Deborah A. Tweddle, Helen
Jenkinson, Susan Picton.
1619 The next-generation ALK inhibitor PF-06463922
overcomes primary resistance to crizotinib in neuroblastoma.
Nicole Infarinato, Jin Park, Renata Sano, Kateryna Krytska, Hannah
Ryles, Helen Zou, Nathan Lee, Tod Smeal, Mark A. Lemmon, Yael P.
Mosse.
21.
23.
24.
25.
26.
1620
In vivo and in vitro efficacy of birinapant in preclinical
models of Ph-like pediatric acute lymphoblastic leukemia. Jennifer
Richmond, Kathryn Evans, Alissa Robbins, Raushan T. Kurmasheva,
Peter J. Houghton, Malcolm A. Smith, Richard B. Lock.
24
Abstract
Number
12.
14.
27.
Poster
:LJ[PVU
24
POSTER SESSION
Experimental and Molecular Therapeutics
Poster
:LJ[PVU
28
28
Cell Cycle, DNA, and Transcription Targets
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
1638 Preclinical characterization of the novel TTK kinase inhibitor
S81694 for the treatment of triple negative breast cancer. Riccardo
Colombo, Mike Burbridge, Marianne Rodriguez, Frédérique Cantero,
Marina Caldarelli, Maria Laura Giorgini, Francesco Sola, Dario Ballinari,
Marina Ciomei, Roberta Bosotti, Alessia Montagnoli, Antonella Isacchi,
Daniele Donati, Arturo Galvani.
1639 Strong synergy with APR-246 and DNA-damaging drugs in
primary ovarian cancer cells. Åsa Fransson, Daria Glaessgen, Jessica
Alfredsson, Klas G. Wiman, Svetlana Bajalica Lagercrantz, Nina Mohell.
1640 Exploiting the cytoskeletal filaments of neoplastic cells to
potentiate a novel therapeutic approach. Matthew Trendowski.
1641 Tivantinib (ARQ 197) exhibits antitumor activity by directly
interacting with tubulin and overcomes ABC transporter-mediated
drug resistance. Aki Aoyama, Ryohei Katayama, Yasushi Okuno, Naoya
Fujita.
1642 Antitumor activity of lurbinectedin toward ovarian clear cell
carcinoma. Ryoko Takahashi, Seiji Mabuchi, Yuri Matsumoto, Mahiru
Kawano, Tomoyuki Sasano, Hiromasa Kuroda, Katsumi Kozasa, Kenjirou
Sawada, Tadashi Kimura.
1643 Discovery of 1-benzylquinazoline-2,4(1H,3H)-diones as
novel and potent PARP inhibitors. SAR of the benzyl group. Sui Xiong
Cai, Qingbing Xu, Lizhen Wu, Feng Yin, Xiuhua Hu, Xiaozhu Wang,
Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Xiuyan Zhang, Ye Edward
Tian.
1644 VX-970, the first-in-class inhibitor of the DNA damage
repair enzyme ATR. John Pollard, Philip Reaper, Julie Jones, Christopher
Barnes, Scott Gladwell, Stuart Hughes, Adele Peak, Hakim Djeha, Amy
Hall, David Newsome, Yuxin Wang, Diane Boucher, Brenda Eustace, Yong
Gu, Brian Hare, Mac Johnson, Sean Milton, Cheryl Murphy, Darin Takemoto,
Crystal Tolman, Mark Wood, Brinley Furey, Marina Penney, Howard Li,
Christopher Defranco, Mohammed Asmal, Scott Fields.
1645 DNA-damaging compound 0404 effectively inhibits
hepatocellular carcinoma by upregulation of miR-34a and miR-200c
expression. Caixia Xia, Yanning Liu, Guohua Lou, Xiao Xu, Long Mao, Min
Zheng.
1646 ZYTP1, a novel efficacious and safe poly (ADP-ribose)
polymerase (PARP) and tankyrase inhibitor for treatment of various
types of solid tumors. Mukul R. Jain, Abhijit Chatterjee, Jogeswar
Mohapatra, Debdutta Bandhyopadhyay, Krishnarup Ghoshdostidar,
Upendra Bhatnagar, Harilal Patel, Vikram Ramanathan, Brijesh Srivastava,
Pankaj R. Patel, Ranjit Desai.
1647 Novel transcriptional inhibitors for the inhibition of
melanoma growth. Kylie M. Taylor, Ahmad M. Alhendi, Gary Halliday,
Lionel Prado-Lourenço.
1648 Targeting ETS factor ETV4 as a novel therapeutic for the
management of breast and prostate cancer. Miriam S. Butler, Michael
Hsing, Mani Roshan Moniri, Desmond Lau, Paul Yen, Ari Kim, Scott Lien,
Marta Mroczek, Fariba Ghaidi, Eric LeBlanc, Lawrence McIntosh, Michael
Cox, Artem Cherkasov, Paul S. Rennie.
1649 Potent anticancer activity of an orally bioavailable small
molecule, ON 013100, and its water soluble derivative, briciclib, a
clinical-stage eIF4E-targeted agent. Neel Jasani, Bina Desai, Justine M.
Betzu, Tanmay Dichwalkar, Samhita Bapat, V. J. Rajadhayksha, Benjamin
S. Hoffman, Manoj Maniar, Vikas Sehdev.
1650 CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic
studies, determinants of sensitivity and synergistic combinations.
Chiara Saladino, Sheelagh Frame, Susan Davis, David Blake, Daniella
Zheleva.
1651 BGB-290, a novel PARP inhibitor with unique brain
penetration ability, demonstrated strong synergism with
temozolomide in subcutaneous and intracranial xenograft models.
Zhiyu Tang, Bin Jiang, Zhenyan Shi, Wenfeng Gong, Yong Liu, Xing Wang,
Yajuan Gao, Fenglong Yu, Changyou Zhou, Lusong Luo, Min Wei, Lai
Wang.
1652 Therapeutic targeting of ETS factor ERG for the treatment of
prostate cancer. Mani Roshan-Moniri, Michael Hsing, Miriam S. Butler,
Desmond Lau, Peter Axerio-Cilies, Paul Yen, Ari Kim, Scott Lien, Marta
Mroczek, Dennis Ma, Huifang Li, Yubin Guo, Fuqiang Ban, Fariba Ghaidi,
Eric LeBlanc, Lawrence McIntosh, Michael Cox, Artem Cherkasov, Paul S.
Rennie.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1653 BGB-290: A highly potent and specific PARP1/2 inhibitor
potentiates anti-tumor activity of chemotherapeutics in patient biopsy
derived SCLC models. Zhiyu Tang, Ye Liu, Qin Zhen, Bo Ren, Hexiang
Wang, Zhenyan Shi, Wenfeng Gong, Yong Liu, Xing Wang, Yajuan Gao,
Fenglong Yu, Yiyuan Wu, Bing Jiang, Xuebing Sun, Min Wei, Changyou
Zhou, Lusong Luo, Zhengxiang Li, Jiangyong Yu, Jun Zhao, Jie Wang, Lai
Wang.
1654 The small molecule YK-4-279 shows anti-lymphoma activity
in pre-clinical models. Elain Y. Chung, Valdemar Priebe, Eugenio Gaudio,
Ivo Kwee, Chiara Tarantelli, Andrea Rinaldi, Laura Carrassa, Monica
Testoni, Luciano Cascione, Massimo Broggini, Jeffrey A. Toretsky,
Emanuele Zucca, Francesco Bertoni.
1655 Targeting RFX-1 as a novel therapeutic strategy in
hepatocellular carcinoma. Jung-Chen Su.
1656 MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair
deficient pancreatic cancer cells. Shruti Lal, Saswati N. Chand, Emanuela
Dylgjeri, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody.
1657 The role of Noxa/MCL-1 axis in solid tumors treated with
DNA damaging agents. Wataru Nakajima, Kanika Sharma, Mark A. Hicks,
June Y. Lee, Nobuyuki Tanaka, Hisashi Harada.
1658 Proteolytic processing pathways for topoisomerase covalent
complexes. Yilun Sun, Karin C. Nitiss, John L. Nitiss.
1659 The non-cardiotoxic anticancer drug pixantrone targets
topoisomerase II. Brian B. Hasinoff, Xing Wu, Daywin Patel, Jack C.
Yalowich.
1660 Impact of antioxidants on myeloperoxidase (MPO)dependent DNA damage and genotoxicity induced by etoposide (VP16): implications for therapy-induced second malignancies. Jason
Goodspeed, Soumendra Karmahapatra, Ragu Kanagasabai, Alex Klausing,
Jack C. Yalowich.
1661 Development of lipid-based nanosuspension formulation of
first-in-class PLK2 inhibitor GBO-006 to treat triple-negative breast
cancer. Vijaya G. Tirunagaru, Arnab Roy Chowdhury, Jeyaraj A.
Duraiswamy, Srinivasa R. Maddi, Sayan Mitra, Chandra Deb, Ram S. Adluri,
Jang B. Gupta.
1662 Therapeutic relevance of the Rad6/translesion synthesis
pathway in BRCA1-related triple-negative breast cancer cells. Brittany
Haynes, Hend Kothayer, Andrew Westwell, Malathy Shekhar.
1663 Selective CDK8 inhibitor SEL120-34A alters expression of
interferon-related DNA damage resistance signature genes in
colorectal cancer. Tomasz Rzymski, Michał Mikula, Małgorzata SzajewskaSkuta, Eliza Żyłkiewicz, Łukasz Sapała, Izabela Dolata, Agata Kitlińska,
Krzysztof Goryca, Aleksandra Grochowska, Aleksandra Cabaj, Agnieszka
Dreas, Katarzyna Kucwaj, Artur Białas, Adam Radzimierski, Aniela Gołas,
Renata Windak, Jerzy Ostrowski, Krzysztof Brzózka.
1664 New moieties mimicking the trimethoxyphenyl (ring A) of
combretastatin A-4: Synthesis and biological evaluation. Mathieu
Gagné-Boulet, Sébastien Fortin, Jacques Lacroix, Carole-Anne Lefebvre,
Marie-France Côté, René
C-Gaudreault.
1665 Design, synthesis, biological evaluation of
cyclopenta[d]pyrimidines as antitubulin agents and discovery of N-(4methylthiophenyl) and N-(4-dimethylaminophenyl) substituted N,2dimethyl-cyclopenta[d]pyrimidines as long acting and potent
antimitotic agents. Aleem Gangjee, Weiguo Xiang, Susan L. Mooberry,
Ernest Hamel.
1666 Increased sensitivity of ␤III tubulin-containing microtubules
to cabazitaxel compared with docetaxel: A possible role of ␤III tubulin
in specifying good efficacy of cabazitaxel for docetaxel-resistant
tumors. Leslie Wilson, Olga Azarenko, Gregoriy Smiyun, Herbert Miller,
Mary Ann Jordan.
1667 Targeting acute myelogenous leukemia with novel
combrestatin analogs and development of predictors of response.
Hongliang Zong, Narsimha R. Penthala, Vijayakumar N. Sonar, Paraskevi
Giannakakou, Gail J. Roboz, Peter A. Crooks, Monica L. Guzman.
323
POSTER SESSION
Growth Factor Receptors and Other Surface Antigens as Targets for Therapy
Poster
Board
1.
2.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
324
Abstract
Number
1668 Effective targeting of colorectal cancer with a recombinant
antibody mixture against EGFR, HER3 and IGF1R. Christina Egebjerg,
Camilla Fröhlich, Karsten W. Eriksen, Thomas T. Poulsen, Klaus Kofoed,
Thomas Bouquin, Andrea Bretotti, Livio Trusolino, Ivan D. Horak, Michael
Kragh, Mikkel W. Pedersen.
1669 Preclinical efficacy of Sym004, novel anti-EGFR antibody, in
esophageal squamous cell carcinoma cell lines. Shota Fukuoka, Takashi
Kojima, Yoshikatsu Koga, Mayumi Yamauchi, Rie Komatsuzaki, Kazuhiko
Aoyagi, Hiroki Sasaki, Masahiro Yasunaga, Yasuhiro Matsumura, Toshio
Kuronita, Toshihiko Doi, Atsushi Ohtsu.
1671 Fibroblast growth factor receptor 3 enhances progression of
hepatocellular carcinoma. Jakob Paur, Lisa Nika, Christiane Maier, Julia
Kostka, Petra Heffeter, Sonja Kappel, Daniela Kandioler, Klaus Holzmann,
Brigitte Marian, Walter Berger, Michael Grusch, Bettina Grasl-Kraupp.
1672 Structural basis for inhibition of ligand-dependent and independent ErbB3 activation by KTN3379. Diego Alvarado, Sangwon
Lee, Etienne Greenlee, Gwenda F. Ligon, Jay S. Lillquist, Edward J. Natoli,
Theresa M. LaVallee, Joseph Schlessinger.
1673 Galunisertib combined with sorafenib affects proliferation,
EMT and delays tumor growth in mice and in hepatocellular carcinoma
(HCC) patient samples ex vivo. Annemilai Tijeras-Raballand, Maria
Serova, Cindy Neuzillet, Miguel Albuquerque, Nathalie Colnot, Matthias
Barral, Anthony Dohan, Matthias Barral, Philippe Bonnin, Marc Pocard,
Valérie Paradis, Eric Raymond, Sandrine Faivre, Armand de Gramont.
1674 HER3 inhibition potentiates anti-tumor effects of PI3K
inhibitors in pre-clinical models of HNSCC. Kara S. Davis, Nayel Khan,
Carolyn Kemp, Sucheta Kulkarni, Diego Alvarado, Theresa LaVallee,
Jennifer R. Grandis, Umamaheswar Duvvuri.
1675 MEF2 plays a significant role in the tumor inhibitory effects
of agarose encapsulated RENCA cells through the EGF receptor. Prithy
C. Martis, Melissa A. Laramore, Atira Dudley, Barry H. Smith, Lawrence S.
Gazda.
1676 An agonistic antibody to EphA2 exhibits anti-tumor effect to
human melanoma. Kazunori Kato, Atsushi Sakamoto, Taro Kojima, Toshio
Hasegawa, Shigaku Ikeda.
1677 Annexin A2 antibody inhibits the progression of triplenegative and herceptin-resistant breast cancer by blocking epidermal
growth factor receptor functions. Pankaj Chaudhary, Lee D. Gibbs,
Jamboor K. Vishwanatha.
1678 Bioavailability and anti-tumor activity of capsaicin in human
small cell lung cancer. John D. Hurley, William D. Rollyson, Cody A.
Stover, Kathleen C. Brown, Haley E. Perry, Cathryn D. Stevenson, Clayton
M. Crabtree, Aaron M. Dom, Jamie K. Lau, Theodore R. Witte, W E.
Hardman, Piyali Dasgupta.
1679 Immunotherapeutic strategies targeting CXCR4 axis plus
␥/␦ T cells in treating ovarian cancer. Chao Lien Liu, Tsui Lien Mao.
1680 In vitro and in vivo activity of a highly potent and novel
FGFR2/FGFR4 dual targeting antibody-drug conjugate. Matthew J.
Meyer, David Jenkins, David Batt, Rebecca Mosher, Randi Isaacs, Tiancen
Hu, Vladimir Capka, Xiamei Zhang, Dongshu Chen, Lujia Tang, Mike Daley,
Patrycja Nowakowski, Yeonju Shim, Wei Jiang, Seth Ettenberg, Emma
Lees.
1681 Inhibition of tumor growth in vivo through neutralization of
the interaction of MCAM with laminin alpha 4. Ken Flanagan, Lauri W. Li,
Carlos Lorenzana, Stephen J. Tam, Yue Liu, Philip J. Dolan, Lana Alexander,
Josh Salmans, Robin M. Barbour, Jeffrey N. Higaki, Tarlochan Nijjar,
Wagner Zago, Ted A. Yednock, Gene Kinney.
1682 Development and activity of a novel antibody-drug
conjugate for the treatment of P-cadherin expressing cancers. Daniel
Menezes, Tinya J. Abrams, Christopher Karim, Yan Tang, Chi Ying, Kathy
Miller, Christie Fanton, Majid Ghoddusi, Zhen Wang, Montesa Patawaran,
Nancy Pryer, Emma Lees, Jason Damiano.
Poster
Board
16.
17.
18.
19.
20.
21.
23.
24.
25.
26.
27.
28.
29.
30.
Poster
:LJ[PVU
29
Abstract
Number
1683 Pharmacokinetic/pharmacodynamic (PK/PD) and
toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of
FGFR2-ADC (BAY 1187982) to guide dosing in phase 1. Sabine
Wittemer-Rump, Anette Sommer, Charlotte Kopitz, Hung Huynh,
Christoph Schatz, Ruprecht Zierz, Manuela Braun, Kirstin Meyer, Dirk
Laurent, Jörg Lippert, Klaas Prins.
1684 Preclinical anti-tumor efficacy of FGFR2-ADC BAY 1187982
in patient-derived gastric, breast and ovarian cancer models. Anette
Sommer, Charlotte Kopitz, Christoph Schatz, Ruprecht Zierz, Joachim
Schuhmacher, Sabine Wittemer-Rump, Klaas Prins, Manuela Braun, Frank
Reetz, Bertolt Kreft, Hung T. Huynh, Karl Ziegelbauer.
1685 In vivo efficacy of PSMA ADC in combination with
enzalutamide in castration-resistant prostate cancer. Vincent A.
DiPippo, Holly M. Nguyen, Lisha G. Brown, William C. Olson, Robert L.
Vessella, Eva Corey.
1686 CD70 as a target in non-Hodgkin lymphoma (NHL) and renal
cell carcinoma (RCC). Kenneth W. Wood, Elaina M. Gartner, Mechthild
Jonas, Maureen Ryan, Dana A. Kennedy.
1687 Vandetanib as a potential new treatment for ER negative
breast cancers. Elisabetta Marangoni, Rana Hatem, Dalila Labiod, Sophie
Chateau-Joubert, Rania El Botty, Jean-Luc Servely, Ludmilla De Plater,
Ivan Bièche.
1688 A novel anti-CEACAM5 maytansinoid-antibody-drug
conjugate for the treatment of colorectal, lung and gastric tumors.
Stéphanie Decary, Pierre-François Berne, Céline Nicolazzi, Anne-Marie
Lefebvre, Tarik Dabdoubi, Beatrice Cameron, Catherine Devaud, Catherine
Prades, Hervé Bouchard, Alhassan Cassé, Christophe Henry, Céline Amara,
Paul Ferrari, Laetitia Maçon, Eric Lacoste, Cécile Combeau, Eric Beys,
Souad Naimi, Francis Blanche, Carlos Garcia-Echeverria, Jean-François
Mayaux, Véronique Blanc.
1690 Mechanistic characterization of MM-131, a bispecific
antibody that blocks c-Met signaling through concurrent targeting of
EpCAM. Adnan O. Abu-Yousif, Jessica B. Casaletto, Kristina Masson, Aaron
Fulgham, Melissa Geddie, Birgit Schoeberl, Ulrik Nielsen, Gavin MacBeath.
1691 SL-401 activity against AML blasts correlates with CD123
levels and does not down-regulate CD123 expression. Rajeswaran Mani,
Bhavani Gopalakrishnan, Xiaokui Mo, Chris Brooks, William Blum, Gerard
Lozanski, Sumithira Vasu, Natarajan Muthusamy.
1692 Antibody-drug conjugates to target cell surface TACEcleaved amphiregulin in breast cancer. Edmund C. Jenkins, Kelly S.
Levano, Eric H. Jung, Matthew Levy, Paraic A. Kenny.
1693 ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug
conjugate, causes complete regression in multiple solid tumor models.
Roger A. Smith, Nitin K. Damle, Sanjeeva P. Reddy, Alex Yurkovetskiy,
Natalya Bodyak, Mao Yin, Dmitry Gumerov, Elena Ter-Ovanesyan, Liu Qin,
Peter U. Park, Timothy B. Lowinger, Sandeep Gupta.
1694 Preclinical evaluation of a novel bispecific targeted toxin for
the treatment of sarcomas. Antonella Borgatti, Amber Winter, Kathleen
Stuebner, Joseph Koopmeiners, Jaime F. Modiano, Daniel Vallera.
1695 Development of a novel antibody-drug conjugate for the
treatment of c-Kit expressing solid tumors and AML. Tinya J. Abrams,
Xiaohong Niu, Millicent Embry, Janine Kline, Montesa Patawaran, Christie
Fanton, Marjorie Ison-Dugenny, Tracy Schneider, Kathy Miller, Zhen Wang,
Majid Ghoddusi, Steven Cohen, E. Erica Hong, Emma Lees, Siew Schleyer.
1696 Blocking activity of a novel anti-MET humanized monoclonal
antibody, KTN0216, is enhanced by IgG2 isotype in HGF-dependent and
Met-amplified tumors. Sreekala Mandiyan, Brett S. Robinson, Lida
Kimmel, Gerald McMahon, Yaron Hadari, Yan Yang.
1697 Therapeutic targeting the NOTCH3 receptor with antibody
drug conjugates. Kenneth G. Geles, Yijie Gao, Latha Sridharan, Andreas
Giannakou, Ting-Ting Yamin, Jonathan Golas, Judy Lucas, Manoj Charati,
Xiantang Li, Magali Guffroy, Tim Nichols, Kai Wang, Max Follettie, Andreas
Maderna, Lioudmila Tchistiakova, Hans-Peter Gerber, Puja Sapra.
29
POSTER SESSION
Poster
:LJ[PVU
30
30
In Vitro and In Vivo Models and New Targets
Poster
Board
1.
2.
Abstract
Number
1698 Systems pathology for characterization of cancer model
systems in a multicenter IMI-PREDECT project. Sami Blom, Yinhai Wang,
Tauno Metsalu, Tiina Vesterinen, Teijo Pellinen, Anne Grote, Nina Linder,
Jenni Säilä, Katja Välimäki, Ruusu-Maria Kovanen, Outi Monni, Panu
Kovanen, Emma Davies, Kristin Stock, Marta Estrada, Georgios Sflomos,
Sylvia Grünewald, Catarina Brito, Julia Schüler, Ronald de Hoogt, Cathrin
Brisken, Heiko van der Kuip, Wytske van Weerden, Simon Barry, Wolgang
Sommergruber, Elizabeth Anderson, Matthias Nees, Juha Klefström, Jaak
Vilo, Emmy Verschuren, Ralph Graeser, John Hickman, Johan Lundin, Olli
Kallioniemi.
1699 Differential aggregation rates and therapeutic response of
pancreatic cancer cell lines to sigma-2 receptor activation in 3D
culture. Timothy Chou, Michaela Jacobs, Hilary Nicholson, Wayne D.
Bowen.
Poster
Board
15.
16.
17.
18.
3.
1700 Dasatinib and everolimus show synergistic growth inhibition
with paclitaxel in an ovarian granulosa cell tumor model. Ulla-Maija
Haltia, Noora Andersson, Bhagwan Yadav, Evgeny Kulesskiy, Anniina
Färkkilä, Annika Riska, Leila Unkila-Kallio, Krister Wennerberg, Tero
Aittokallio, Mikko Anttonen.
19.
4.
1701 Identification of epigenetic modifiers able to suppress
growth of pancreatic ductal adenocarcinoma: A patient-oriented in
vivo functional platform. Alessandro Carugo, Giannicola Genovese, Sahil
Seth, Luigi Nezi, Johnathon L. Rose, Andrea Viale, Piergiorgio F.
Pettazzoni, Angelo Cicalese, Daniela Bossi, Wantong Yao, Jason B.
Fleming, Luisa Lanfrancone, Timothy P. Heffernan, Giulio F. Draetta.
20.
5.
1702 Effect of aspirin on BIRC7/livin protein expression on
colorectal cancer cells: a putative report. Sirajo M. Aminu, Ahmed
Adamu, Sani Ibrahim, Yawale Iliyasu, John Idoko, Atara Ntekim, Abdullahi
J. Randawa, Khalid Shah, Adamu Abdullahi, Mohammed Faruk*.
6.
1703 A 3D tissue culture-based utra-high content screening
platform that uses phenotypic profiling of cancer tissues to identify
selective inhibitors of receptor tyrosine kinases. Leo S. Price, Tijmen
Booij, Maarten Klop.
8.
1705 Classification of colorectal PDX into transcriptomic subtypes
associated with distinct genomic alteration profiles and in vivo
response patterns to therapies. Anne-Lise Peille, Christina Gredy, Bruno
Zeitouni, Armin Maier, Kerstin Klingner, Tim Kees, Julia Schüler, Thomas
Metz, Heinz. Herbert Fiebig, Vincent Vuaroqueaux.
9.
1706
Whole exome sequencing of pre and post treatment diffuse
large B cell lymphoma reveals the mutation spectrum of the relapse/
refractory patient population. Danielle Greenawalt, Kate Byth, Zhongwu
Lai, Justin Johnson, Ambar Ahmed, Brian Dougherty, Kenneth Thress,
Michael Zinda, Winnie S. Liang, John Carpten, Stephen Fawell, J. Carl
Barrett.
10.
1707 PACE4-dependent cellular uptake and retention of the MultiLeucine peptide inhibitor into cancer cells. Frédéric Couture, Kevin Ly,
Christine Levesque, Anna Kwiatkowska, Roxane Desjardins, Brigitte
Guérin, Robert Day.
11.
1708 Identification of triple negative breast cancer (TNBC)
subtypes by an immunohistochemistry (IHC) panel with impact on
clinical outcomes. Elaine M. Walsh, Aliaa Shalaby, Laura Murillo, Mark
Webber, Michael Kerin, Sharon Glynn, Grace Callaghy, Helen Ingoldsby,
Maccon Keane.
12.
1709 Quantification of biologically relevant vascular phenotypes
in human prostate cancer: automated image analysis using
hyperplexed immunofluorescence. Chris Sevinsky, Alberto SantamariaPang, Jingyu Zhang, Christina Lowes, Dipen Sangurdekar, Beverly Falcon,
Qing Li, Bronek Pytowski, Laura Benjamin, Jeremy Graff, Fiona Ginty,
Aejaz Nasir, Mark T. Uhlik.
13.
1710 Xanthohumol suppresses estrogen-signaling in endocrine
resistant breast cancer through the specific inhibition of BIG3-PHB2
interactions. Toyomasa Katagiri.
14.
1711 SLC6A15, a novel potential metabolic target for non-small
cell lung cancer. PALLEVI SRIVASTVA, Hyuntae Yoo.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1712 CAMKV as an immunotherapy target in MYCN-amplified
neuroblastoma. Robyn T. Sussman, Kevin Huang, Pichai Raman, John M.
Maris.
1713 IL-24 inhibits lung cancer cell migration and invasion by
disrupting the SDF-1/CXCR4 signaling axis. Janani Panneerselvam,
Jiankang Jin, Manish Shanker, Jason Lauderdale, Jonathan Bates, Qi Wang,
Daniel Zhao, Stephen Archibald, Timothy Hubin, Rajagopal Ramesh.
1714 The role and mechanism of JAB1 as a therapeutic target in
biliary tract cancer. Ah-Rong Nam, Kyo Hwa Kang, Ji Eun Park, Ju-Hee
Bang, Ling Jin, Mei Hua Jin, Tae Yong Kim, Sae-Won Han, Sang-Hyun
Song, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang.
1715 IRES-transactivating factors (ITAFs) as therapeutic targets
in breast and colorectal cancer. Toby M. Ward, Jessica Bockhorn, J C.
Harrell, Xiaofei Liu, Mark D. Pegram.
1716 Acquisition of estrogen independence induces TOB1-related
mechanisms supporting breast cancer cell proliferation. Yong-Wei
Zhang, Rochelle E. Nasto, Rency Varghese, Sandra A. Jablonski, Ilya G.
Serebriiskii, Rishi Surana, Valerie S. Calvert, Ionut Bebu, Joseph Murray, Lu
Jin, Michael Johnson, Rebecca Riggins, Habtom Ressom, Emmanuel
Petricoin III, Robert Clarke, Erica A. Golemis, Louis M. Weiner.
1717 Selective induction of breast adenocarcinoma cell death via
inhibition of the transient receptor potential melastatin-2 (TRPM2)
cation channel. David W. Koh, Daniel P. Powell, Steven D. Blake, Joy L.
Hoffman, Xiaoxing Feng.
1718 The importance of clinically relevant rapid autopsy
specimens and LuCaP patient-derived xenograft models to interrogate
the heterogeneous and evolving treatment resistance of castrationresistant prostate cancer. Colm Morrissey, Ming H. Lam, Tia S. Higano,
Lawrence D. True, Martine Roudier, Robert B. Montgomery, Peter S.
Nelson, Paul H. Lange, Evan Y. Yu, Robert L. Vessella, Eva Corey.
1719 Highly adaptable triple-negative breast cancer cells as a
suitable model for testing epigenetic therapies. Balraj Singh, Ryan D.
Milligan, Hannah E. Kinne, Anna Shamsnia, Anthony Lucci.
1720 HO-3867, a selective inhibitor of stat3, suppress ovarian
tumor growth and metastasis in human tissue culture and in an
orthotopic mouse model. Shan Naidu, Uksha Saini, Adam C. ElNaggar,
Hemant K. Bid, Ross Wanner, Kristin Bixel, Adrian A. Suarez, Chelsea
Bolyard, Balveen Kaur, Paul J. Goodfellow, Periannan Kuppusamy, David
Cohn, Karuppaiyah Selvendiran.
1721 Moving beyond in vitro models and addressing the
challenges of pooled RNAi screens in mouse xenografts. Paul Diehl,
Donato Tedesco, Kyle Bonneau, Mikhail Makhanov, Debbie Deng, Peiqing
Sun, Alex Chenchik.
1722 Effectiveness of predictive simulation in identifying
potential patient-specific therapeutic targets in multiple myeloma-a
pilot study. Sathish Kumar, Shireen Vali, Kabya Basu, Saji Gera, Neeraj
Singh, Ansu Kumar, Taher Abbasi, Shazib Pervaiz.
1723 IKZF1/CDKN2A co-deletion predicts shorter survival in adult
B-ALL. Shiven Patel, Clinton C. Mason, Martha J. Glenn, Christian N.
Paxton, Sara T. South, Melissa H. Cessna, Julie Asch, Erin F. Cobain, Dale L.
Bixby, Lauren B. Smith, Joshua D. Schiffman, Rodney R. Miles.
1724 Integrated functional RNAi screening and structural
genomics identify inverse co-modulators of TP53 family and NF-␬B
transitional activation as potential therapeutic targets in head and neck
squamous cell carcinoma. Anthony Saleh, Shaleeka Cornelius, Scott
Martin, Pinar Ormanoglu, Hui Cheng, Rita Das, Xinping Yang, Zhong Chen,
Carter Van Waes.
1725 The tyrosine phosphatase PRL3 as a novel drug target in
T-cell acute lymphoblastic leukemia. Jessica S. Blackburn, Aleksey
Molodstov, Riadh Lobbardi, Finola Moore, David Langeau.
1726 CRM1 is overexpressed in lung tumorigenesis and represents
an adjuvant target for lung cancer treatment. Weimin Gao, Chuanwen
Lu, Lixia Chen, Phouthone Keohavong.
1727 DNA-binding domain as an alternative target site on
androgen receptor for prostate cancer therapy: Pre-clinical in vivo
study of a novel small molecule for drug development. Mohamed D.
Hassona, Leslie G. Chan, Gray R. Meckling, Huifang Li, Eric LeBlanc,
Fuqiang Ban, Artem Cherkasov, Paul S. Rennie, Emma Guns.
325
POSTER SESSION
Inhibitors of UPS and HSP90 Pathways and Other Targets
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
326
Abstract
Number
1728 Discovery of highly selective DUB inhibitors with in vivo
pre-clinical anti-tumor activity. Xavier Jacq, Niall M. Martin, Lisa
Smith, Jeanine Harrigan, Charlotte Knights, Helen Robinson, Yaara
Ofir-Rosenfeld, Aaron Cranston, Mark I. Kemp, Stephen P. Jackson.
1729 Discovery of a synthetic small molecule inhibitor of
HSP90 for cancer therapy. Rudi Bao, Zhongzong Pan, Zhiming Zhao,
Hongping Yu, Yaochang Xu.
1730 TAS4464, a novel highly potent NEDD8 activating
enzyme inhibitor, demonstrates antitumor activity in multiple
myeloma through the inactivation of NF-␬B pathways. Hiromi
Muraoka, Chihoko Yoshimura, Shingo Tsuji, Takamasa Suzuki, Akihiro
Hashimoto, Takashi Mizutani, Shuichi Ohkubo, Kenichi Matsuo,
Yoshikazu Iwasawa, Teruhiro Utsugi.
1731 Preclinical testing demonstrates strong activity of STA12-8666, an HSP90 inhibitor-SN-38 conjugate, in small cell lung
cancer (SCLC). Anna Gaponova, AS Nikonova,A Deneka,BL
Egleston,S Litwin,JS Duncan,K Duncan,H Borghaei ,R Mehra,DA
Proia,Y Boumber, Erica Golemis.
1732 Effect of 19-substituted benzoquinone ansamycin Hsp90
inhibitors on Hsp90/Cdc37/co-chaperone complexes and casein
kinase 2 (CK2) activity. Chuan-Hsin Chang, David Ross, David Siegel,
Christopher J Moody, Russell Kitson.
1733 Development of chemical tools to study the endogenous
Hsp70 interactome in malignant cells. Anna A. Rodina, Tony
Taldone, Yanlong Kang, Pallav Patel, John Koren, Pengrong Yan,
Erica DaGama Gomes, Chenghua Yang, Maulik Patel, Liza Shrestha,
Stefan Ochiana, Ronnie Maharaj, Alexander Gozman, Marc Cox,
Hediye Erdjument-Bromage, Ronald Hendrickson, Leandro Cerchietti,
Ari Melnick, Monica Guzman, Gabriela Chiosis.
1734 Preclinical study of HSP-90 inhibitor drug, AUY922
showed good efficacy in treatment of nasopharyngeal cancer.
Timothy T.C. Yip, Roger K.C. Ngan, Wai-Tong Ng, Lewis T.C. Chan,
William C.S. Tai, Wai-Wai Cheng, Victor W.S. Ma, Kwok-Wai Lo, YaPing Li, Michael B.H. Yang, Eric C.H. Wong, Brigette B.Y. Ma, Nai-Ki
Mak, George S.W. Tsao, Maria Li-Lung.
1735 Identification of novel synthetic lethal interactions in
small cell lung cancer with the proteasome inhibitor carfilzomib.
Vincent B. Masto, Alana G. Lerner, Shirin Arastu-Kapur.
1736 The anticancer activity of the DUB inhibitor
b-AP15 is associated with accumulation of proteasome bound
ubiquitin and oxidative stress. Magdalena Mazurkiewicz, Slavica
Brnjic, Mårten Fryknäs, Chao Sun, Xiaonan Zhang, Rolf Larsson,
Pádraig D’Arcy, Stig Linder.
1737 Carfilzomib transcriptionally regulates CIP2A/PP2A/pAkt signaling and induces apoptosis in leukemia cells. Chun-Yu Liu,
Wen-Chun Tsai, Man-Hsin Hung, Yuan-Bin Yu, Po-Shen Ko, ChengHwai Tzeng, Chung-Wai Shiau, Kuen-Feng Chen.
1738 Decreases in ubiquitin levels post proteasome inhibition
identify FKBP4 immunophilin as a novel target for potentiating the
anti-myeloma activity of carfilzomib. Eric Lowe, Shirin ArastuKapur.
1739 A novel HSP90 inhibitor induces metabolic oxidative
stress in head and neck squamous cancers and prevents migration
and stem cell EMT even under hypoxic conditions. Chitra
Subramanian, Qing Zhu, Eileen Brandes, Peter T. White, Barbara N.
Timmermann, Mark S. Cohen.
1740 Allosteric Hsp70-family inhibitors as targeted anticancer
therapeutics. John Koren, Chao Xu, Anna Rodina, Liza Shrestha, Tony
Taldone, Gabriela Chiosis.
1741 GRP78 / BiP / HSPA5 expression and those of other
chaperone proteins is rapidly degraded by OSU-03012 and Viagra
exposure: Implications for anti-cancer and anti-pathogen
therapies. Laurence A. Booth, Jane L. Roberts, Paul Dent.
Poster
Board
15.
16.
18.
19.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31
Abstract
Number
1742 Ibrutinib plus proteasome or MALT1 inhibitors overcome
resistance to BCR antagonists in CARD11 mutant-expressing Blymphoma cells. Ling Xue, Mutiah Apatira, Mint Sirisawad, Betty
Chang.
1743 Pharmacological sequestration of Skp1 causes
degradation of oncogenic E3 ligases and mitotic blockade.
Guangbiao Zhou, Yong-Qiang Liu, Jinsong Liu.
1745 NPY1 receptor specific peptide-drug-conjugates as
novel treatment for metastatic breast cancer. Lutz Weber, Robert
Rennert.
1746 Discovery and evaluation of a small molecule KIFC1
inhibitor for breast cancer treatment. Wei Zhang, Ling Zhai,
Wenyan Lu, Yimin Wang, Vandana V. Gupta, Indira Padmalayam,
Robert J. Bostwick, Lucile White, Ross Larry, Joseph Maddry, Sam
Ananthan, Mark Suto, Bo Xu, Rongbao Li, Yonghe Li.
1748 Usp9x as a novel therapeutic target in human pancreatic
cancer. Anupama Pal, Marina P. Di Magliano, Diane Simeone, Luke
Peterson, Harish Potu, Moshe Talpaz, Nicholas Donato.
1749 Bortezomib and JQ1 hold promise for human and canine
osteosarcoma. Yating Yang, Vilma Yuzbasiyan-Gurkan.
1750 Preclinical efficacy of Hsp90 inhibition by using PF04942847 in osteosarcoma. Marc Baud’Huin, Benjamin Ory, Franck
Verrecchia, Dominique Heymann, Francoise Redini, Francois
Lamoureux.
1751 Y15 and Pyridoxal 5’ Phosphate enhances the cytotoxic
profile of Cisplatin and Paclitaxel in platinum resistant ovarian
cancer cells. Monique P. Reboe, Terry-ann Waite, Arkene S. Levy,
Sivanesan Dhandayuthapani, Appu Rathinavelu.
1752 6-Methoxyethylamino-numonafide (MEAN) inhibits
hepatocellular carcinoma as a single agent or in combination with
sorafenib. Yanning Liu, Guohua Lou, John Norton, Chen Wang,
Irawati Kandela, Shuai Tang, Min Huang, Michael Avram, Richard
Green, Andrew Mazar, Daniel Appella, Zhi Chen, Sui Huang.
1753 XIAP maintains the characteristics of cancer stem cells
and is a therapeutic target in nasopharyngeal carcinoma. jiao ji,
Rong Deng, Wen-Dan Chen, Gong-Kan Feng, Xiao-Feng Zhu, Da-Jun
Yang.
1754 BPR2P001S0, a Coumarin derivative, induced cell cycle
arrest in A549 through inhibiting PDPK1 activity. Pi-Han Lin, TzuMing Jao, Yu-Lin Hung, Hsing-Pang Hsieh, Ya-Chien Yang, Sui-Yuan
Chang.
1755 TORK/DNA-PK inhibitor CC-115 is effective as a single
agent in a subset of glioblastoma patient-derived cancer stem
cells and xenografts and potentiates temozolomide therapy.
Kimberly Bergman, Susan M. Irtenkauf, Laura A. Hasselbach, Claudius
Mueller, Emanuel Petricoin, Heather Raymon, Tom Mikkelsen, Ana C.
Decarvalho.
1756 Preclinical activity in non-Hodgkin’s lymphoma of
Selinexor, a selective inhibitor of nuclear export (SINE), is
enhanced through combination with standard-of-care therapies.
Asfar S. Azmi, Amro Aboukameel, Robert O. Carlson, Sivan Elloul,
Sharon Shacham, Michael Kauffman, Ran Frenkel, Ramzi M.
Mohammad.
1757 The new molecular target therapy of Hsp90 inhibition in
esophageal squamous cell carcinoma. Masahiro Yamamura,
Tsutomu Nohno, Akira Yamauchi, Naoki Katase, Makoto Okawaki,
Akira Sawaki, Hideo Matsumoto, Toshihiro Hirai, Yoshiyuki
Yamaguchi.
31
POSTER SESSION
Poster
:LJ[PVU
32
32
Novel Agents and Mechanisms of Action
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
1758 Deconstructing protein and gene expression
pathways to define the anticancer effects of XPO1
inhibition in ovarian cancer. Brad R. Evans, Thomas R.
Silvers, Ying A. Chen, Jason Garcia, Catalina Camacho,
Andrew J. Sharp, Paras Garag, Srinivas V. Koduru, Jean-Noel
Billaud, Peter R. Dottino, Yosef Landesman, Sharon Shacham,
John A. Martignetti.
1759 Preclinical activity of selinexor, an inhibitor of
XPO1/CRM1, in sarcoma. Robert Nakayama, Yi-Xiang
Zhang, Alex Anatone, Ewa Sicinska, George Demetri, Andrew
Wagner.
1760 Single cell longitudinal studies reveal cell cycle
specific effects of selective inhibitors of nuclear export
(SINE). Russell T. Burke, Joshua M. Marcus, John DeSisto,
Yosef Landesman, James D. Orth.
1761 Small molecule restoration of wildtype structure
and function of mutant p53 using a novel zinc
metallochaperone based mechanism. Xin Yu, Adam R.
Blanden, Sumana Narayanan, Lalithapriya Jayakumar, David
Lubin, David J. Augeri, S. David Kimball, Stewart N. Loh,
Darren R. Carpizo.
1762 Verbascoside promotes apoptosis by regulating
HIPK2-p53 signaling in human colorectal cancer. Lihong
Zhou, Yuanyuan Feng, Yongjie Jin, Xuan Liu, Hua Sui, Ni Chai,
Xingzhu Chen, Ningning Liu, Yan Wang, Qi Li.
1763 Activation of p53/miR-34a tumor suppressor
network by Chinese herbal recipe JP-1 in human lung
cancer cells. Chih-Jung Yao, Peter Sheng, Tsai-Shu Hu,
Jacqueline Wang-Peng, Gi-Ming Lai.
1764 Galeterone and its novel analogs induce profound
anti-cancer activities in human pancreatic cancer cell lines:
Implications for pancreatic cancer therapy. Andrew K.
Kwegyir-Afful, Puranik Purushottamachar, Marlena S. Martin,
Vincent C. Njar.
1765 Creating novel translation inhibitors to target
pro-survival proteins in chronic lymphocytic leukemia.
Rong Chen, Mingzhao Zhu, Yuling Chen, Wesley Skillern,
William G. Wierda, Ken Hull, Daniel Romo, William Plunkett.
1766 Effects of lovastatin on the PRL-3 cascade of
events in prostate cancer. Allison K. Palmer, Gnanasekar
Munirathinam.
1767 Anti-proliferative and anti-invasive action of
omega-3 polyunsaturated fatty acids in stomach cancer
cells. Soyeon Shin, Soyeon Jeong, Soyeon Kim, Jun-Young
Heo, Gi-Ryang Kweon, Seung-Kiel Park, Jong-Il Park, Kyu
Lim.
1768 Chloroquine potentiates carfilzomib but not
bortezomib effects on myeloma cells. Kristine Misund,
Katarzyna A. Baranowska, Toril Holien, Kristian Starheim, Ida
Johansson, Glenn Buene, Anders Waage, Geir Bjørkøy,
Anders Sundan.
1769 Rottlerin induces ER stress-mediated cell death in
pancreatic stellate cells. Hsin-Yuan Su, Richard Waldron,
Raymond Gong, Stephen Pandol, Aurelia Lugea.
1770 A role of nicotinamide phosphoribosyltransferase
in growth of KRAS mutant non-small cell lung cancer.
Shunsuke Okumura, Takaaki Sasaki, Yoshinobu Ohsaki.
1771 Metabolic reprogramming in KRAS mutant cancer
cells may cause sensitivity to the histone deacetylase
(HDAC) inhibitor romidepsin. Agnes Basseville, Carole
Sourbier, Robert W. Robey, Dan L. Sackett, W. M. Linehan,
Susan E. Bates.
1772 Circadian control of cell death in glioma cells
treated with curcumin. Ashapurna Sarma, Michael E. Geusz,
Karunakar Samuel.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1773 MHY-449 induces apoptotic cell death through
ROS- and caspase-dependent pathways in AGS human
gastric cancer cells. Yung Hyun Choi, Yong Jung Kang, Seon
Hee Kim, Bokyung Sung, Dong Hwan Kim, Seong Yeon
Hwang, Minjung Kim, Hyun Sook Lim, Jeong-Hyun Yoon,
Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim.
1774 The effects of diarylthiourea analogs on triple
negative breast cancer cell growth. Deborah Nambi, Maggie
C. Louie, Shengquan Liu.
1775 Inhibition of breast cancer cell proliferation by
diarylthiourea analog, SL1-18. Maryam Fallatah, Maggie C.
Louie, Shengquan Liu.
1776 Synergistic anticancer effects of triptolide with
celastrol, two main compounds from Thunder God Vine.
Qi-Wei Jiang, Ke-Jun Cheng, Xing Wei, Zhi Shi.
1777 The characterization of the effects of the
strigolactones on the heat shock response. Victor S. Wang,
Nu Nu Kyin, Claire Pollock, Hyjoung Lee, Xin Li, Cristina
Prandi, Yoram Kapulnik, Hinanit Koltai, Luke Whitesell, Ronit
Yarden.
1778 Selectively targeting the DNA-binding domain of
the androgen receptor as a prospective therapy for
prostate cancer. Kush Dalal, Mani Roshan-Moniri, Aishwariya
Sharma, Huifang Li, Fuqiang Ban, Mohamed D. Hassona,
Michael Hsing, Kriti Singh, Eric LeBlanc, Scott Dehm, Emma
Tomlinson Guns, Artem Cherkasov, Paul S. Rennie.
1779 Bromodomain inhibitor JQ1 inhibits
cholangiocarcinoma tumor growth in patient-derived
xenograft models. Patrick L. Garcia, Aubrey L. Miller, Kelly
Kreitzburg, Tracy L. Gamblin, Leona N. Council, John D.
Christein, Pablo Arnoletti, Marty Heslin, Sushanth Reddy,
Joseph H. Richardson, Eddy S. Yang, Jun Qi, James E.
Bradner, Karina J. Yoon.
1780 Targeted inactivation of CRL4-CDT2 E3 ubiquitin
ligase as a novel therapeutic strategy for malignant
melanoma. Mouadh Benamar, Fadila Guessous, Patrick
Corbett, Craig L. Slingluff, Tarek Abbas.
1781 G1 phase melanoma cells escape proteasome
inhibitor cytotoxicity. Sheena M. Daignault, David S. Hill,
Kimberley A. Beaumont, Andrea Anfosso, Penny E. Lovat,
Wolfgang Weninger, Nikolas K. Haass.
1782 Post-translational regulation of cyclins by Aspirin
through 26S proteasome: Implications in
chemoprevention. Rakesh Dachineni, Guoqiang Ai,
Hemachand Tummala, Jayarama B. Gunaje.
1783 Pharmacological inhibition of CDK4/6 induces G1
arrest, autophagy and senescence in ER+ breast cancer.
Smruthi Vijayaraghavan, Khandan Keyomarsi.
1784 Pre-clinical characterization of G1T28-1, a novel
CDK 4/6 inhibitor for protection of bone marrow from
cytotoxic chemotherapies. John E. Bisi, Hannah S. White,
Jessica A. Sorrentino, Patrick J. Roberts, Jay C. Strum.
1785 Chemical inhibition or transient knockdown of
wild-type p53 induced phosphatase 1 (WIP1/PPM1D)
potentiates the response to MDM2 inhibitors in a p53dependent manner. Arman Esfandiari, Nicola J. Curtin, John
Lunec.
1786 Role of Euphorbia tirucalli terpenes cocktail
extracts in the regulation of molecular cell death:
implications in gynecological cancer progression. Mpho
Choene, Lesetja Motadi.
1787 Imipramine blue: a novel NOX inhibitor as potent
therapeutic agent to treat triple-negative breast cancers.
Subapriya Rajamanickam, Panneerdoss Subbarayalu,
Santhosh Timilsina, Michael T. Drake, Zhenze Zhao, Hung I.
Chen, Yidong Chen, Jack L. Arbiser, Manjeet K K. Rao.
327
POSTER SESSION
Translational Radiation Oncology
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
33
Abstract
Number
1.
1788 Converting radiation-mediated tumor control to tumor
cure by manipulating the macrophage response to dying cells.
Marka R. Crittenden, Jason R. Baird, Talicia Savage, Benjamin Cottam,
David Friedman, Kristina Young, Pippa Newell, Cynthia Nguyen,
Andrew M. Jackson, Michael J. Gough.
15.
1802 Application of small animal image-guided irradiation to
preclinical in vivo models, such as patient-derived xenografts, to
inform on combination strategies. Andrew Mckenzie, Nektaria
Papadopoulou, Yinfei Yin, Lucy Page, Jason King, Henry Li, Martin
Page, Ian Wilson, Rajendra Kumari.
2.
1789 Drug repurposing: Sulfasalazine sensitizes gliomas to
gamma knife surgery by blocking cystine uptake through System
XC-, leading to gluthatione depletion. Linda Sleire, Bente Sandvei
Skeie, Inger Anne Netland, Hilde Elise Førde, Ernest Dodoo, Frode
Selheim, Lina Leiss, Jian Wang, Jan Heggdal, Paal-Henning Pedersen,
Per Øyvind Enger.
16.
1803 A truncated Plasminogen Activator Inhibitor-1 protein
protects from pulmonary fibrosis mediated by irradiation in a
murine model. Eunjoo Chung, Ayla White, Bradley T. Scroggins,
Grace B. McKay-Corkum, Mary Jo Mulligan-Kehoe, Deborah E. Citrin.
17.
1790 Caloric restriction can increase the efficacy of radiation
in both hormone-sensitive and hormone-resistant prostate
cancers by downregulating the IGF-1R pathway. Sunny Y. Han, Tu
D. Dan, Tiziana De Angelis, John Y. Han, Mak Sarich, Peter Carroll,
Karen Knudsen, Adam Dicker, Nicole L. Simone.
1804 The role of adipose derived stromal cells for reversal of
radiation fibrosis. Xiao Zhao, Ju Hee Lee, Kenneth Yip, Laurie Ailles,
Fei-Fei Liu.
18.
1791 Targeting radiation-inducible cell surface GRP78 using
GIRLRG peptide as a novel imaging and therapeutic strategy for
tumors. Vaishali Kapoor, David Dadey, Kim Nguyen, Hua Li, Buck
Rogers, Dinesh Thotala, Dennis Hallahan.
1805 DUOX2: The key player for hyper-radiosensitivity in
gastric cancer cells with low dose fractionation radio therapy
(LDFRT). Duc Nguyan, Palak R. Parekh, Elizabeth T. Chang, Navesh
Sharma, France Carrier.
19.
1792 Radiation-induced downregulation of GLT-1 glutamate
transporter mRNA expression is reversed by renin-angiotensin
system inhibitors. Mitra Kooshki, Christine Naczki, Michael E.
Robbins, Linda J. Metheny-Barlow.
1806 Local chemotherapy and chemoradiation therapy using
INCeRT brachytherapy implants in cancer models. Rajiv Kumar,
Jodi Belz, Houari Korideck, Robert Cormack, Mike Makrigiorgos,
Srinivas Sridhar.
20.
1807 Nuclear targeted gold nanoparticles for radiation
enhancement. James F. Hainfeld, Henry M. Smilowitz.
21.
1808 Enhancing the Stupp regimen in glioblastoma cancer
cells with a T-type calcium channels inhibitor. Jaroslaw
Dziegielewski, Barbara Dziegielewska, Lloyd S. Gray.
22.
1809 Next-generation brachytherapy: a preclinical study of a
thermally stabilized biopolymer gel for delivering intratumoral
radionuclide therapy in a pancreatic tumor mouse model. Jeffrey L.
Schaal, Wenge Liu, Ashutosh Chilkoti, Xinghai Li, Eric Mastria, Michael
R. Zalutsky.
23.
1810 Three-dimensional microtissues as phenotypic
screening model to identify radiation modifiers for breast cancer.
Natasa Anastasov, Ines Höfig, Vanja Radulovic, Sabine Richter, Jan
Lichtenberg, Jens M. Kelm, Christian Thirion, Michael J. Atkinson.
24.
1811 Correlations of COX2 expressions in circulating tumor
cells (CTCs) and response to radiotherapy in head and neck
squamous cell carcinoma (HNSCC). Feng Wang, Xiaoqi Xie, Zhen
Wang, Ping Li.
25.
1812 Ultrasound-stimulated microbubble based
biomechanical enhancement of radiation cell death: Role of acid
sphingomyelinase and ceramide. Gregory J. Czarnota, Ahmed El
Kaffas, Anoja Giles, Azza Al Mahrouki, Amr Hashim.
26.
1813 Tumor and normal tissue localization of trastuzumabmodified with a metal chelating polymer for auger electron
radioimmunotherapy in HER2-positive xenografts. Ghislaine Ngo
Ndjock Mbong, Yijie Lu, Conrad Chan, Zhongli Cai, Mitchell A. Winnik,
Raymond Reilly.
3.
4.
5.
6.
1793 Novel radiation mitigators and anticancer drugs. Robert
H. Schiestl, Michael Davoren, Yelena Rivina.
7.
1794 Preclinical evaluation of radiotherapy in combination
with radio-sensitizing telomerase-specific oncolytic virus for
human bone and soft tissue sarcomas. Toshinori Omori, Yasuaki
Yamakawa, Joe Hasei, Hiroshi Tazawa, Shuhei Osaki, Tusyoshi Sasaki,
Kazuhisa Sugiu, Tomohiro Fujiwara, Toshiyuki Kunisada, Yasuo Urata,
Toshifumi Ozaki, Toshiyoshi Fujiwara.
8.
1795 Potent anti-tumor activity of talazoparib (BMN673) in
combination with radiation for squamous cell carcinoma of the
head and neck. Deborah J. Wong, David D. Shin, Josephine Ratikan,
Meenal Chalukya, Kanthinh Manivong, Leonard Post, Dörthe Schaue,
Richard S. Finn, Yuqiao (Jerry) Shen, William McBride, Dennis J.
Slamon.
9.
1796 Targeting the microenvironment and vasculature of
tumors to improve response to radiation administered using a
dose and schedule equivalent to those of a stereotactic radiation
treatment. Michael R. Horsman, Thomas R. Wittenborn.
10.
Downregulation of ribosomal protein S6 overcomes
radioresistance in prostate cancer. Suleman S. Hussain, Paul Rivas,
Roble G. Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H.
Pollock, Daniel C. Chan, Rita Ghosh, Addanki P. Kumar.
11.
1798
Targeted therapy of osteosarcoma with radiolabeled
monoclonal antibody to an insulin-like growth factor-2 receptor.
David S. Geller, Ekaterina Revskaya, Mani Khan, Jonathan Morris,
Richard Gorlick, Ekaterina Dadachova.
12.
1799 Mithramycin A as a radiation sensitizer. Bradley T.
Scroggins, Jeffery F. Burkeen, Eun Joo Chung, Ayla O. White, Su I.
Chung, Kathryn E. Hudak, Deborah E. Citrin.
27.
1814 Effective auger electron radioimmunotherapy using
modified anti-HER2 antibody with nuclear localizing signal. Huizi
Li, Sumitaka Hasegawa, Tadashi Kamada, Tsuneo Saga.
13.
1800 The PARP inhibitor, rucaparib enhances the antitumor
activity of 177Lu-DOTA-octreotate radionuclide therapy in
preclinical models of neuroendocrine tumor. Carleen Cullinane,
Kelly Waldeck, Peter Eu, Rodney J. Hicks.
28.
14.
1801 Biological validation of a novel high-throughput
irradiator for predictive radiation sensitivity bioassays. Alison
Bailey, Tyler Fowler, Kwangok P. Nickel, Bryan Bednarz, Randall J.
Kimple.
1815 Bystander effect and genomic instability in human cells
and their progeny after irradiation with X rays, protons or carbon
ions: role of gap junction communication. Narongchai
Autsavapromporn, Ianik Plante, Cuihua Liu, Teruaki Konishi, Noriko
Usami, Tomoo Funayama, Yukio Uchihori, Tom K. Hei, Edouard I.
Azzam, Sirikan Yamada, Takeshi Murakami, Masao Suzuki.
29.
1816 Impact of 5FU and radiation on replication of interferonexpressing adenovirus. Jordan Sell.
328
1797
33
POSTER SESSION
Chemistry
Poster
:LJ[PVU
35
35
Proteomic and Metabolomic Investigations in Cancer
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
Abstract
Number
1817 Quantitative proteomics identifies unique
signaling phenotypes in NSCLC. Melissa Martinez, Bin Fang,
Jiannong Li, Y. A. Chen, Stephen Brantley, Wei Guan, Fumi
Kinose, Eric Welsh, Steven A. Eschrich, Eric B. Haura, John M.
Koomen.
1818 Analytical platform evaluation for quantification
of ERG oncoprotein in prostate cancer using protein and
mRNA detection methods. Jintang He, Athena Schepmoes,
Anshu Rastogi, Shyh-Han Tan, Wusheng Yan, Wei Huang,
Sreedatta Banerjee, Tujin Shi, Chaochao Wu, Thomas
Fillmore, Yuqian Gao, Jacob Kagan, Sudhir Srivastava,
Richard Smith, Wei-Jun Qian, David McLeod, Gyorgy
Petrovics, Albert Dobi, Alagarsamy Srinivasan, Shiv
Srivastava, Karin Rodland, Tao Liu, David Camp.
1819 Profiling of extracellular matrix proteins in
pancreatic ductal adenocarcinoma progression and
metastasis. Chenxi Tian, Daniel Ohlund, Karl Clauser, Steven
A. Carr, David A. Tuveson, Richard O. Hynes.
1820 Phosphoproteomics of a panel of AML cell lines
reveals oncogenic signaling and candidate drivers.
Carolien van Alphen, Jacqueline Cloos, Sander R. Piersma,
Jaco C. Knol, Thang V. Pham, Gert J. Ossenkoppele, Henk
Verheul, Jeroen J. Janssen, Connie R. Jimenez.
1821 FFPE preanalytical variables: Investigating the
effect of delayed times to fixation on the proteome and
phosphoproteome for FFPE kidney tumor samples and a
comparison of tumor versus normal for matching FFPE and
OCT frozen tissue. Fiona E. McAllister, Rachana Agarwal,
Bich Nguyen, Yiyong Zhou, Sushmita Roy, Daniel Chelsky,
Ping Guan, Mary Barcus, Hana Odeh, Lararsha Carithers,
Helen Moore.
1822 Proteome signatures distinguish lung cancer
subtypes, define metabolism states, and have prognostic
impact. Wen Zhang, Paul Taylor, Lei Li, Yuhong Wei, Jiefei
Tong, Vladimir Ignatchenko, Nhu-An Pham, Thomas
Kislinger, Ming-sound Tsao, Michael Moran.
1823 A novel web interface to facilitate pathology
directed mass spectrometry. Erin H. Seeley, R. Ryan
Dunkerley, Andre L. Moreira, Robert J. Downey, Greg W.
Kilby.
1824 Predictive value of neutrophil-lymphocyte ratio
for the efficacy of preoperative chemotherapy in triplenegative breast cancer. Yuka Asano, Shinichiro Kashiwagi,
Tamami Morisaki, Satoru Noda, Hidemi Kawajiri, Tsutomu
Takashima, Naoyoshi Onoda, Kosei Hirakawa.
1825 Carbonylation and degradation of cardiac myosin
binding protein C serves as an indicator of doxorubicininduced cardiotoxicity. Baikuntha P. Aryal, Jinsook Jeong,
V. Ashutosh Rao.
1826 Characterization of HPV-positive head and neck
cancer cell lines as preclinical models for targeted therapy.
Nene N. Kalu, Tuhina Mazumdar, Lixia Diao, Patrick K. Ng,
Jing Wang, Jeffery Myers, Faye M. Johnson, Lauren Averett
Byers.
1827 Detection of recurrent renal cell carcinoma
biomarkers by metabolite ratios. Beatriz Sanchez-Espirdion,
Nizar M. Tannir, Surena F. Matin, Jose A. Karam, Maosheng
Huang, Christopher G. Wood, Xifeng Wu, Jian Gu.
1828 Proteomic analysis of the effect of E6 star
expression on cellular pathways in HPV positive SiHa and
HPV negative C33A cervical carcinoma cells. Whitney
Evans, Maria Filippova, Robert Aragon, Valeri Filippov, Mark
E. Reeves, Penelope Duerksen-Hughes.
Poster
Board
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Abstract
Number
1829 Comparative surface proteomics of NCI-H2122
cells reveals distinct cell surface phenotype of a metastatic
NSCLC cell line expressing oncogenic KRASG12C. Xiaoying
Ye, Thomas J. Turbyville, Rachel Bagni, Franck McCormick,
Gordon Whiteley, Josip Blonder.
1830 Untargeted metabolomics reveals smokers’
characteristic profiles. Ping-Ching Hsu, Renny S. Lan,
Theodore Brasky, Catalin Marian, Amrita K. Cheema, Habtom
W. Ressom, Christopher A. Loffredo, Wallace Pickworth,
Peter G. Shields.
1831 Identification of alpha-enolase and annexin as
candidate tumor-associated antigens by
immunoseroproteomic profiling of autoantibodies in
African American and Caucasian men with prostate cancer.
Tino W. Sanchez, Kwame Agyeman, Saied Mirshahidi, Nathan
Wall, Colwick Wilson, Susanne Montgomery, Carlos A.
Casiano.
1832 Quantification of metabolic changes by magnetic
resonance and mechanism of cell death in ovarian cancer.
Louiza Belkacemi.
1833 KRAS-regulated P4HA1 in pancreatic tumor and
its hydroxylated peptide as a serum biomarker for early
diagnosis. Zaian Deng, Karen M. Mann, Eugene J. Koay,
Mauro Ferrari, Xifeng Wu, Paul J. Chiao, Tony Hu.
1834 Sex hormone receptor expression affects ovarian
cancer survival. Jenny-Maria Jönsson, Nicolai Arildsen,
Susanne Malander, Anna Måsbäck, Linda Werner Hartman,
Mef Nilbert, Ingrid Hedenfalk.
1835 In-depth quantitative analysis of protein
glycoforms in human prostate cancer plasma. Sarah M.
Totten, Majlinda Kulloli, Cheylene Tanimoto, James D. Brooks,
Sharon J. Pitteri.
1836 Triple negative breast cancer: Metabolomics and
flux analysis to identify targets for drug development.
Delisha A. Stewart, Jason Winnike, Susan McRitchie, Wimal
Pathmasiri, Susan Sumner.
1837 Quantitative analysis of AKT/mTOR pathway
using immunoprecipitation and targeted mass
spectrometry. Bhavinkumar Patel, Suzanne Smith, Ryan
Bomgarden, Kay Opperman, Barbara Kaboord, John Rogers.
1838 MUC1 serves as metabolic regulator in triple
negative breast cancer. Gennifer D. Goode.
1839 Development of urinary pseudo-targeted LC-MS
based metabolomics method and its application in
hepatocellular carcinoma biomarker discovery. Zhenzhen
Yao, Yaping Shao, Guowang Xu.
1840 Metabolomic profiling of gastrointestinal stromal
tumor (GIST) T1 cell lines in response to imatinib therapy.
Vered Marks, Gregory Tiesi, Ana Paz Mejia, Jonathan Trent,
Jamie Walls, Alan Livingstone, Danny Yakoub.
1841 Enrichment of IGF1R-AKT-mTOR pathway
proteins using immunoprecipitation and proteomic
analysis by mass spectrometry. Suzanne Smith, Bhavin
Patel, Ryan Bomgarden, Kay Opperman, John Rogers,
Barbara Kaboord.
1842 Identification of a novel binding partner of
hnRNPD/AUF1 in oral cancer and its association with poor
disease prognosis. Manish Kumar, Jatinder Kaur, Alok
Thakar, Nootan K. Shukla, Ajoy R. Chaudhary, Mehar C.
Sharma, Ajay Matta, Ranju Ralhan, KW M. Siu, Shyam S.
Chauhan.
329
POSTER SESSION
Endocrinology
Molecular Endocrinology of Cancer 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
330
Abstract
Number
1843 Novel actions of next-generation taxanes benefit
advanced stages of prostate cancer. Renee de Leeuw, Lisa
Berman-Booty, Matthew Schiewer, Stephen Ciment, Robert
Den, Adam Dicker, William Kelly, Edouard Trabulsi, Costas
Lallas, Leonard Gomella, Karen Knudsen.
1844 Genome wide analysis of AR-cell cycle interplay
reveals novel functions in cancer. Christopher McNair,
Jonathan Goodwin, Michael Augello, Alfonso Urbanucci,
Matthew Schiewer, Clay Comstock, Adam Ertel, Liguo Wang,
Qianben Wang, Ian Mills, Wei Li, Jason Carroll, Karen
Knudsen.
1845 Chloroquine demonstrates limited effectiveness
in an autochthonous preclinical model of prostate cancer.
Yurie Kura, Marco A. De Velasco, Naomi Ando, Emiko
Fukushima, Barry R. Davies, Dennis Huzdar, Yutaka
Yamamoto, Yuji Hatanaka, Takashi Oki, Nobutaka Shimizu,
Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa,
Kazuto Nishio, Hirotsugu Uemura.
1846 Catalytic topoisomerase II inhibitors suppress the
androgen receptor signaling and prostate cancer
progression. Haolong Li, Ning Xie, Martin Gleave, Xuesen
Dong.
1847 AR-V7 regulation during epithelial plasticity.
Kathryn E. Ware, Daneen Schaeffer, Tian Zhang, Mariano A.
Garcia-Blanco, Andrew J. Armstrong.
1848 PPAR␥ function is attenuated by full length
androgen receptor and the AR-V7 variant in human
prostate cancer cells. Emuejevoke Olokpa, Lamonica V.
Stewart.
1849 Androgen receptor transcriptionally represses
genes mediating DNA synthesis and repair in prostate
cancer. Yanfei Gao, Shuai Gao, Housheng He, Xiaming Liu,
Sen Chen, Fen Ma, X. Shirley Liu, Myles Brown, Steven P.
Balk, Shaoyong Chen, Changmeng Cai.
1850 Evaluation of Pim-1 kinase inhibition in a
preclinical model of mouse prostate cancer. Marco A. De
Velasco, Takashi Oki, Yurie Kura, Naomi Ando, Emiko
Fukushima, Barry R. Davies, Dennis Huszar, Yutaka
Yamamoto, Yuji Hatanaka, Nobutaka Shimizu, Kazuhiro
Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto
Nishio, Hirotsugu Uemura.
1851 Estradiol-inducible dependence receptor UNC5a
restricts estrogen receptor activity and imparts estradiol
dependence to breast cancer cells. Poornima BhatNakshatri, Manjushree Anjanappa, Yangyang Hao, Howard
Edenberg, Yunlong Liu, Harikrishna Nakshatri.
1852 Merlin/NF2 is associated with elevated aromatase
expression and estrogen formation in human liver tissues
and liver cancer cells: An unifying model for hepatocellular
carcinoma development and progression. Letizia
Cocciadiferro, Vitale Miceli, Orazia M. Granata, Giuseppe
Carruba.
1853 Ovarian steroid hormones promote progression
of DCIS by increasing cancer stem cell self-renewal
through IL-6 signaling. Kelli E. Valdez, Yan Hong, Fang Fan,
Lisa May, Therese Cusick, Marc Inciardi, Mark Redick, Jason
Gatewood, Fariba Behbod.
1854 Evidence that RARs interact with Src family
kinases and that inhibition of Src family kinase activity can
affect the growth response of SKOV3 ovarian cancer cell to
atRA. Thais Acquafreda Lakind, Kenneth Soprano, Dianne
Soprano.
1855 Structural requirements for the association of the
ETS domain transcription factor Elk1 and the androgen
receptor in enabling the growth of prostate cancer cells.
Rayna Rosati, Venkatesh Chari, Mugdha Patki, Manohar
Ratnam.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
36
Abstract
Number
1856 Preclinical effects of dual AKT/MAPK inhibition in
PTEN-deficient prostate cancer. Marco A. De Velasco,
Yutaka Yamamoto, Yurie Kura, Emiko Fukushima, Naomi
Ando, Barry Davies, Yuji Hatanaka , Takashi Oki, Nobutaka
Shimizu, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuhiro
Yoshimura, Kazuto Nishio, Hirotsugu Uemura.
1857 Effects of long-term chloroquine chemotherapy in
a preclinical model of PTEN-deficient prostate cancer.
Kazuhiro Yoshikawa, Marco A. De Velasco, Yurie Kura, Naomi
Ando, Emiko Fukushima, Yutaka Yamamoto, Yuji Hatanaka ,
Takashi Oki , Nobutaka Shimizu, Kazuhiro Yoshimura, Kazuto
Nishio , Hirotsugu Uemura.
1858 Estrogen receptor beta as a tractable therapeutic
target. Carly S. Filgueira, Cindy Benod, Xiaohua Lou, Anders
Strom, Jan-Åke Gustafsson, Anders Berkenstam, Paul Webb.
1859 Discerning the molecular basis of DNA-PK protumorigenic functions and translational capacity as a
therapeutic target in prostate cancer. Emanuela Dylgjeri,
Jonathan Goodwin, Karen Knudsen.
1860 DNA-PK-mediated transcriptional regulation
drives tumor progression and metastasis. Jonathan F.
Goodwin, Vishal Kothari, Justin M. Drake, Shuang Zhao,
Emanuela Dylgjeri, Jeffry L. Dean, Matthew J. Schiewer,
Christopher McNair, Michael S. Magee, Robert B. Den, Ziqi
Zhu, Nicholas A. Graham, Ajay A. Vashisht, James A.
Wohlschlegel, Thomas G. Graeber, R J. Karnes, Mandeep
Takhar, Elai Davicioni, Scott A. Tomlins, Nima Sharifi, Owen N.
Witte, Felix Y. Feng, Karen E. Knudsen.
1861 Estrogen modulation of fibroblast growth factor
signaling in non-small cell lung cancer. Laura P. Stabile,
Natalie J. Rothenberger, Marjorie Romkes, Lisa Koodie,
Mariya Farooqui, Sanja Dacic, Jill M. Siegfried.
1862 Discerning the role of USP22 in prostate cancer
development and progression. Jennifer Jones, Jeffry L.
Dean, Randy S. Schrecengost, Karen Knudsen.
1863 Using a cell based model system to characterize
CYP17A1 genetic variants. Cameron P. Capper, Jiayan Liu,
Lauren McIntosh, José M. Larios, Michael D. Johnson, Paul F.
Hollenberg, Richard J. Auchus, James M. Rae.
1864 Selective estrogen receptor degrader (SERD)
activity in ESR1 mutant models. Wei Zhou, Robert A. Blake,
Jim Nonomiya, Jing Qian, Lorna Kategaya, Ingrid Wertz,
Anneleen Daemen, Thomas O’Brien, John Sensintaffar,
Michael Moon, Michelle A. Nannini, Jason Oeh, Deepak
Sampath, Xiaojing Wang, Nicholas Smith, Daniel Brigham,
James Joseph, Jeffrey H. Hager, Lori S. Friedman.
1865 TRIM24 acts as a transcriptional co-activator of
the androgen receptor during prostate cancer progression.
Anna C. Groner, Jonas de Tribolet-Hardy, Jean-Philippe
Theurillat, Peter J. Wild, Myles Brown.
1866 Constitutively active NF-␬B signaling switches
estrogen receptor positive breast cancer cells from a
proliferative to an invasive phenotype through luminal/
basal plasticity. Lamiaa El-Shennawy, Jonna Frasor.
1867 Enrichment of CD44high stem-cell-like cells as a
possible mechanism of progestin-dependent progression
of human breast cancer. Sandy Goyette, Benford
Mafuvadze, Matthew T. Cook, Yayun Liang, Salman M. Hyder.
1868 Expression of MAS1 in triple-negative breast
cancer. Yi Luo, Yasuhiko Kitadai, Yukiko Nishiguchi, Rina
Fujiwara, Takamitsu Sasaki, Hitoshi Ohmori, Hiroki Kuniyasu.
1868A Progesterone receptor promotes inflammatory
gene programs in breast cancer. Christy R. Hagan, Todd P.
Knutson, Carol A. Lange.
36
POSTER SESSION
Epidemiology
Poster
:LJ[PVU
37
37
Diet and Cancer Risk/Mortality
Poster
Board
Abstract
Number
1.
1869 Plasma fatty acids and colorectal cancer risk: The
Singapore Chinese Health Study. Lesley M. Butler, Woon P.
Koh, Jin Su, Renwei Wang, Choon N. Ong, Jian M. Yuan.
2.
1870 Associations among tissue vitamin D metabolites
and breast cancer risk factors in women undergoing
reduction mammoplasty. Renny S. Lan, Adana A. Llanos,
Theodore M. Brasky, Catalin Marian, Ramona G. Dumitrescu,
Bhaskar V. Kallakury, Kepher H. Makambi, Jo L. Freudenheim,
Peter G. Shields.
3.
4.
1871 Circulating cis- and trans- palmitoleic acid in
relation to prostate cancer-specific mortality among
prostate cancer patients. Meng Yang, Stacey A. Kenfield,
Hannia Campos, Howard D. Sesso, Jing Ma, Meir J. Stampfer,
Jorge E. Chavarro.
1872 Plasma carotenoids and breast cancer risk in the
Cancer Prevention Study II Nutrition Cohort. Ying Wang,
Susan M. Gapstur, Mia M. Gaudet, Jeremy D. Furtado, Hannia
Campos, Marjorie L. McCullough.
Poster
Board
Abstract
Number
12.
1880 Associations of coffee drinking with systemic
immune and inflammatory markers. Erikka Loftfield,
Meredith S. Shiels, Barry I. Graubard, Hormuzd A. Katki, Anil
Chaturvedi, Britton Trabert, Ligia Pinto, Troy Kemp, Fatma M.
Shebl, Susan T. Mayne, Nicolas Wentzensen, Mark P. Purdue,
Allan Hildesheim, Rashmi Sinha, Neal D. Freedman.
13.
1881 Dietary, supplement, and adipose tissue
tocopherol levels in relation to prostate cancer
aggressiveness among African- and European-Americans.
Samuel Antwi, Susan E. Steck, L. Joseph Su, James R. Hebert,
Hongmei Zhang, Elizabeth T. Fontham, Jeannette T. Bensen,
James L. Mohler, Lenore Arab.
14.
1882 Dietary intake of vitamin B6 and choline are
inversely associated with pancreatic cancer risk: The
Singapore Chinese Health Study. Joyce Y. Huang, Lesley M.
Butler, Renwei Wang, Ai Zhen Jin, Woon-Puay Koh, Jian-Min
Yuan.
15.
1883 Dietary nitrate and nitrite, micronutrients, and
postmenopausal breast cancer risk in the NIH-AARP Diet
and Health Study. Maki Inoue-Choi, Rashmi Sinha, Gretchen
L. Gierach, Mary H. Ward.
5.
1873 Serum vitamin D levels and prostate volume.
Richard U. Kalu, Adam B. Murphy, Yaw Nyame, Gregory A.
Jordan, Rick A. Kittles.
16.
6.
1874 Prolonged nightly fasting and breast cancer risk:
findings from NHANES (2009-2010). Catherine R. Marinac,
Loki Natarajan, Dorothy D. Sears, Linda C. Gallo, Sheri J.
Hartman, Elva Arredondo, Ruth E. Patterson.
1884 Dietary intake of phytoestrogens and the risk of
prostate cancer in the Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial. Michael Reger, Terrell
Zollinger, Ziyue Liu, Josette Jones, Jianjun Zhang.
17.
1885 Alcohol consumption and risk of breast cancer by
molecular subtype. Kelly A. Hirko, Wendy Y. Chen, Susan E.
Hankinson, Walter C. Willett, Rulla M. Tamimi, A. H. Eliassen,
for the Nurses’ Health Study research group.
18.
1886 Dietary scores and cancer incidence, mortality
and survival: Epidemiologic evidence and meta-analysis.
Marjorie L. Mccullough, Ying Wang, Roma Shah, Susan
Gapstur.
19.
1887 Calcium intake and milk product consumption in
association with risk for colorectal adenomas. Caroline Um,
Veronika Fedirko, W D. Flanders, Roberd M. Bostick.
20.
1888 Calcium, magnesium, and vitamin D metabolites
in colorectal adenoma prevention. Elizabeth A. Hibler, Peter
W. Jurutka, Qi Dai, Christine L. Sardo Molmenti, Elizabeth T.
Jacobs.
21.
1889 Paleolithic and Mediterranean diet pattern scores
and their associations with biomarkers of inflammation
and oxidative balance. Kristine Whalen, Marji McCullough,
W. Dana Flanders, Terryl J. Hartman, Suzanne Judd, Roberd
M. Bostick.
22.
1890 Dietary intake of 502 polyphenols and risk of
colorectal cancer in the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort
study. Raul Zamora-Ros, Isabelle Romieu, Augustin Scalbert,
EPIC Study group.
7.
1875 Development of a dietary inflammation score and
its association with incident, sporadic colorectal adenoma.
Ashley C. Holmes, Roberd M. Bostick.
8.
1876 Adolescent and mid-life diet: risk of pancreatic
cancer in the NIH-AARP Diet and Health Study. Kristin A.
Moy, Nancy Potischman, Frances E. Thompson, Amy Subar,
Elizabeth H. Ruder, Anne C. Thiebaut, Rachael Z.
Stolzenberg-Solomon.
9.
10.
11.
1877 Age at introduction to solids is associated with
the odds ratio of pediatric acute lymphoblastic leukemia.
Jeremy M. Schraw, Michael Scheurer, Michele R. Forman.
1878 Dietary vitamin A intake and breast cancer risk
among African American women: The AMBER Consortium.
Ting-Yuan D. Cheng, Susan E. McCann, Gary Zirpoli, Song
Yao, Elisa V. Bandera, Laurence N. Kolonel, Lynn Rosenberg,
Andrew F. Olshan, Julie R. Palmer, Christine B. Ambrosone.
1879 Prospective study of marine ␻-3 polyunsaturated
fatty acids and risk of colorectal cancer according to
microsatellite instability. Mingyang Song, Reiko Nishihara,
Kana Wu, Zhi Rong Qian, Sun A. Kim, Yasutaka Sukawa,
Kosuke Mima, Kentaro Inamura, Atsuhiro Masuda, Juhong
Yang, Charles S. Fuchs, Edward L. Giovannucci, Shuji Ogino,
Andrew T. Chan.
331
POSTER SESSION
Prevention Research
Mechanisms and Markers of Cancer Prevention
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
332
Abstract
Number
1891 Butyric acid reverts DRP1-mediated cell proliferation
and migration in colorectal cancer cells. Dhanir M. Tailor, Eun R.
Hahm, Shivendra V. Singh, Rana P. Singh.
1892 Curcumin induces apoptosis in H-Ras transformed
human mammary epithelial cells: Cysteine 259 of STAT3 as a
putative target. Young-Il Hahn, Su-Jung Kim, Bu-Young Choi, HyeKyung Na, Young-Joon Surh.
1893 Honokiol prevents colonic tumorigenesis and affects
stem cell viability by affecting oncogenic YAP1 function.
Dharmalingam Subramaniam, Sivapriya Ponnurangam, Deep Kwatra,
Gaurav Kaushik, Prabhu Ramamoorthy, Satish Ramalingam, Ossama
Tawfik, Scott J. Weir, Subhash Padhye, Dan A. Dixon, Shahid Umar,
Roy A. Jensen, Shrikant Anant.
1894 Transcriptomic profile analysis of PANC-1 cells in
response to metformin and aspirin. Wen Yue, Tao Wang, Chung S.
Yang, Qing Xu, Robert S. DiPaola, Xiang-Lin Tan.
1895 Ciclopirox prodrug for the prevention and therapy of
non-muscle invasive bladder cancer. Parthasarathy Rangarajan,
Satish Ramalingam, Dharmalingam Subramaniam, Michael J.
Baltezor, Robyn Wood, Shrikant Anant, Scott Weir.
1896 Role of reactive oxygen species in the extracellular
matrix-influenced sensitivity of various prostate cancer cell lines
to methylseleninic acid and selenite. Rayudu Gopalakrishna, Jessica
Tran, Alan Hung, Lu Tian, Karen K. Wang, William T. Zeng, Brian Lam,
Usha Gundimeda.
1897 Metformin as a chemoprevention agent for lung
squamous cancer. Michael K. Asiedu, Matthew R. Barron, Marie
Christine Aubry, Dennis Wigle.
1898 Cranberry proanthocyanidins induce autophagic cell
death via ROS generation and inhibition of AKT/mTOR/MAPK
signaling pathways in esophageal adenocarcinoma. Katherine M.
Weh, Harini S. Aiyer, Amy B. Howell, Laura A. Kresty.
1899 Anti-skin tumor promoting effects of pentacyclic
triterpenes found in Perilla frutescens. Jiyoon Cho, Okkyung Rho,
Jacob Junco, Thomas J. Slaga, Andrew M. Camelio, Dionicio Siegel,
John DiGiovanni.
1900 Mechanistic study of aspirin, folic acid and calcium
(AFAC) combinations delivered using targeted polymeric
nanoparticles in colon cancer prevention. Arvind Thakkar, Sushma
Chenreddy, Jeffrey Wang, Sunil Prabhu.
1901 Endogenous increase of omega-3 polyunsaturated fatty
acids through expression of of ␻3-desaturase gene inhibits
tumorigenicity and metastasis of prostate cancer cells in vitro and
in vivo. Soyeon Shin, Kaipeng Jing, Soyeon Jeong, Soyeon Kim, Yifan
Dai, Tong Wu, Jun-Young Heo, Seung-Kiel Park, Gi-Ryang Kweon,
Jong-Il Park, Kyu Lim.
1902 Experimental investigations on the effects of specific
berry phytochemicals and metabolites in esophageal cancer
prevention in vitro. Ni Shi, Kenneth M. Riedl, Steven J. Schwartz,
Xiaoli Zhang, Zui Pan, Steven K. Clinton, Tong Chen.
1903 Application of lipidomics to a sulindac intervention of
aromatase inhibitor-induced pain. Jessica A. Miller, Betsy
Werthiem, Jun Yang, Bruce Hammock, Denise Roe, Alison Stopeck,
Patricia A. Thompson.
1904 Randomized clinical trial testing the efficacy of the
combination of omega-3-fatty acids (n-3FA) and the antiestrogen
raloxifene in reducing breast density (BD) in postmenopausal
women. Narinder Sandhu, Susann E. Schetter, Jason Liao, Terryl J.
Hartman, John P. Richie, Karam El-Bayoumy, Bogdan Prokopczyk,
Cindy DuBrock, Carina Signori, Christopher Hamilton, Laurence M.
Demers, Andrea Manni.
1905 Galectin-3 and -4 as signature markers of lung, colon,
pancreatic and bladder tumor progression and chemopreventive
interventions. Gaurav Kumar, Venkateshwar Madka, Altaf
Mohammed, Jagan M. Patolla, Naveena B. Janakiram, Qian Li, Yuting
Zhang, Laura Biddick, Allison Gillaspy, Stanley Lightfoot,
Chinthalapally V. Rao.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
38
Abstract
Number
1906 CXCR4 is a novel target of cancer chemopreventative
isothiocyanates in prostate cancer cells. Ali I. Amjad, Kozue Sakao,
Avani R. Vyas, Sreenivasa R. Chinni, Rahul Parikh, Shivendra V. Singh.
1907 Transcriptomic signatures associated with the efficacy of
Angelica gigas (AGN) ethanol extract and its pyranocoumarins on
two lineages of carcinogenesis in TRAMP mice. Su-Ni Tang, Jinhui
Zhang, Wei Wu, Chengguo Xing, Cheng Jiang, Juxuan Lü.
1908 Evaulate biomarkers in NSCLC tumors receiving
neoadjuvant chemotherapy. Apar Pataer, Ruping Shao, Arlene M.
Correa, Carmen Behrens, Jack A. Roth, Ignacio I. Wistuba, Stephen G.
Swisher.
1909 Associations of Vitamin D related polymorphisms with
hereditary breast cancer in 1025 subjects undergoing BRCA 1/2
testing. Valentina Aristarco, Harriet Johansson, Debora Macis, Aliana
Guerrieri Gonzaga, Sara Gandini, Davide Serrano, Irene Feroce,
Monica Barile, Antonella Puccio, Lorenzo Brocca, Bernardo Bonanni.
1910 Reactivation of p53R175 mutant by dietary phenethyl
isothiocyanate (PEITC) impairs tumor growth in vivo. Monika
Aggarwal, Elizabeth Sinclair, Anna Jacobs, Ying Fu, Marcin Dyba,
Xiantao Wang, Idalia M. Cruz, Deborah Berry, Kallakury Bhaskar,
Susette C. Mueller, Maria L. Avantaggiati, Fung-Lung Chung.
1911 High MET and CA9 expressions define a subgroup of
hepatocellular carcinoma (HCC) patients with poor prognosis
candidates for MET inhibition strategy. Annemilai Tijeras-Raballand,
Cindy Neuzillet, Miguel Albuquerque, Nathalie Colnot, Friedhelm
Bladt, Manfred Klevesath, Christian Ihling, Hongxia Zheng, Maryse
Baia, Christiane Copie-Bergman, Eric Raymond, Armand de Gramont,
Valérie Paradis, Sandrine Faivre.
1912 Reduction of microRNA-21 by vitamin D compounds
during ductal carcinoma in situ transition to invasive ductal
carcinoma. Joseph Wahler, Larry C. Cheng, Hubert Maehr, Milan
Uskokovic, Nanjoo Suh.
1913 Rhamnetin inhibits prostate cancer progression in an
autochthonous mouse prostate cancer model. Christine Oak,
Natarajan Bhaskaran, Sanjay Gupta, Sanjeev Shukla.
1914 A novel celecoxib derivative that lacks COX-2 inhibition
but displays potent colon tumor cell growth and PDE5 inhibitory
activity. Sara C. Sigler, Veronica Ramirez-Alcantara, Adam B. Keeton,
Mohammad Abdel-Halim, Ashraf H. Abadi, Gary A. Piazza.
1915 Effects of carvedilol, a ␤-adrenergic receptor
antagonist, on UVB-induced skin cancer development and its
possible mechanism of action. Kevin M. Huang, Andy Chang, Kristan
H. Cleveland, Bradley T. Andresen, Ying Huang.
1916 Proanthocyanidins from grape seeds inhibit growth of
head and neck squamous cell carcinoma by decreasing dna
methylation and reactivation of silenced tumor suppressors.
Santosh K. Katiyar, Ram Prasad.
1917 Targeting wildtype and L858R/T790M mutant EGFR by
isoliquiritigenin induces apoptosis and Inhibits tumor growth of
NSCLC. Mee-Hyun Lee, Sung Keun Jung, Do Young Lim, Yong-Yeon
Cho, Cheol-Jung Lee, Ji-Hong Song, Myoung Ok Kim, Sung-Hyun Kim,
Ann M. Bode, Zigang Dong.
1918 Type 2 cGMP-dependent protein kinase activates
antineoplastic signaling in the colon. Allison Bridges, Bianca Islam,
Sarah Sharman, Rui Wang, Subbaramiah Sridhar, Darren D. Browning.
1919 Warfarin-dependent gamma-carboxylation regulates
androgen receptor activity. Ben Yi Tew, Teresa Hong, Sumanta K.
Pal, Markus Kalkum, Jeremy Jones.
1920 Novel molecular targets for chemoprevention of
squamous cell carcinoma. Vida Chitsazzadeh, Cristian Coarfa, Tri H.
Nguyen, Aaron K. Joseph, Preethi Gunaratne, Li Shen, Hui Yao,
Weimin Xiao, Xiaoping Su, Jennifer Drummond, David Wheeler, Elsa
R. Flores, Kenneth Y. Tsai.
38
LATE-BREAKING AND CLINICAL TRIALS POSTER SESSIONS
Monday, 8:00 a.m.-12:00 p.m.
Halls B-E, Pennsylvania Convention Center
Abstracts will be available online and in the Proceedings Part 2.
Section 25
Section 39
Section 40
Section 41
Clinical Trials in Progress
Late-Breaking Research: Molecular and Cellular Biology 2
Late-Breaking Research: Carcinogenesis
Late-Breaking Research: Cancer Chemistry
333
PLENARY SESSION
Monday, 8:15 a.m.-10:15 a.m.
Hall A (200 Level), Pennsylvania Convention Center
Precision Medicine Comes to Cancer Prevention and Screening
Chairperson: Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, NY
This session will include four presentations that highlight recent advances in cancer prevention. The
first presentation will focus on the use of multitarget stool DNA testing to enhance colorectal cancer
screening. The second presentation will provide an update of our understanding of the
chemopreventive properties of aspirin. The identification of molecular endpoints and pathways that
help to identify individuals most likely to benefit from aspirin will be reviewed. The third presentation
will focus on liver cancer, which remains among the top causes of cancer mortality in the world.
Evidence will be presented that liver injury is carcinogenic because it stimulates regenerative
responses that relax forces which normally constrain the inherent multipotency of adult liver cells. The
final presentation will focus on HPV-related cancers. The latest advances in reducing the burden of
HPV-related cancers through primary and secondary prevention will be reviewed.
8:15 a.m.
Stool DNA detection of colorectal neoplasia: A new high bar for
noninvasive screening [PL02-01]*
David A. Ahlquist, Mayo Clinic, Rochester, MN
8:45 a.m. Molecular risk stratification for aspirin chemoprevention
Andrew T. Chan, Massachusetts General Hospital, Boston, MA
9:15 a.m.
Early detection and prevention of liver cancer: Leveraging lessons
learned from liver repair [PL02-03]*
Anna Mae E. Diehl, Duke University School of Medicine, Durham, NC
9:45 a.m. Drastically reducing HPV-associated cancers through etiologically based
primary and secondary prevention [PL02-04]*
Douglas R. Lowy, National Cancer Institute-CCR, Bethesda, MD
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
334
PROFESSIONAL ADVANCEMENT SESSION (not eligible for CME credit)
Monday, 8:15 a.m.-10:15 a.m.
Regency Ballroom A-B (Second Floor), Loews Philadelphia
Hotel
WICR Career Mentoring Session
Organized by the Women in Cancer Research (WICR)
Council
Co-Chairpersons: Lucile L. Adams-Campbell, Georgetown
Lombardi Comprehensive Cancer Center, Washington, DC;
Pearl S. Huang, Roche, Basel, Switzerland
The WICR Career Mentoring Session has become one of
the most popular Professional Advancement Sessions at
the Annual Meeting. This session is designed for graduate
students, medical students and residents, and clinical and
postdoctoral fellows. Following a keynote address,
attendees will meet, network, and learn from many of the
leading senior scientists in cancer research. Attendees
participate in roundtable discussions and change tables
halfway through the session if they choose. This allows for
additional networking opportunities with more than one
mentor. Topics will include grant writing, work/life
integration, careers in industry, choosing a postdoctoral
position, oral presentations, and many more.
For AACR members, all 2015 Professional Advancement
Sessions are free with your Annual Meeting registration
(except for the Grant Writing Workshop) and are an added
benefit of your membership. For nonmembers, there is an
additional fee of $50 ($95 for the Grant Writing Workshop)
for attendance at each session. If you are not an AACR
member, we strongly encourage you to join and take
advantage of the many benefits of membership, which
include attendance at these sessions. Participation is on a
first-come, first-served basis, and space is limited.
Nonmembers are required to pay onsite.
8:15 a.m.
Welcome
8:20 a.m.
Keynote Speaker
Worta McCaskill-Stevens, National Cancer
Institute, Rockville, MD
8:40 a.m.
Roundtable Discussion 1
9:25 a.m.
Roundtable Discussion 2
10:10 a.m.
Closing Remarks
Time Management
Carolyn A. Buser-Doepner, GlaxoSmithKline, Collegeville,
PA
Balancing Research and Clinical Practice
Angela M. DeMichele, University of Pennsylvania,
Philadelphia, PA
Careers in Academia
Varsha Gandhi, The University of Texas MD Anderson
Survival Skills for Predocs
LaCreis R. Kidd, University of Louisville, Louisville, KY
Careers in Government
Beverly Lyn-Cook, FDA-NCTR, Jefferson, AR
Administrative Roles in Scientific Planning and the
Intramural Researcher
Pamela Marino, NIH-NIGMS, Bethesda, MD
Grant Writing - Postdoctoral Level
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA
Careers in Industry
Victoria M. Richon, Sanofi Oncology, Cambridge, MA
Mentoring and Sponsoring
Elizabeth Travis, The University of Texas MD Anderson
How to Write a CV
Sherrie Lee Wallington, Georgetown Lombardi
Comprehensive Cancer Cetner, Washington, DC
Negotiations for Jobs, Salaries, and Promotions
Danny R. Welch, University of Kansas Cancer Center,
Kansas City, KS
Interview Skills
Jonathan S. Wiest, NCI-CCT, Bethesda, MD
More to be announced
335
CAREER CONVERSATIONS (not eligible for CME credit)
Monday, 9:15 a.m.-10:15 a.m.
AACRcentral, Associate Member Resource and Career Center, Halls B-E, Booth #725
Cancer Research Outside of the U.S.: Opportunities for
International Trainees in Academia
Organized by the Associate Member Council (AMC)
Career Conversations, organized by the Associate Member Council, are informal networking and
discussion sessions designed to allow early-career scientists the opportunity to interact with junior
faculty and recently transitioned peers from various employment sectors. The topics change year to
year to offer a broad array of information that could be relevant to the diverse Annual Meeting earlycareer attendees. This peer-to-peer session will focus on the unique challenges that international
trainees face that will impact their career trajectory to becoming successful cancer researchers. By the
end of this hour, attendees will have obtained an overview of current resources and opportunities
available to facilitate the development of a laboratory at an international institution, addressed
effective strategies for finding funding, obtained insights on gaining independence from a mentor, and
learned how to successfully overcome general challenges when working outside of the U.S. Designed
to provide advice that can help attendees figure out their career path and potential future career
opportunities, Career Conversations are open to all graduate students, medical students, residents,
and clinical and postdoctoral fellows. All Career Conversations will take place in AACRcentral and
limited seating will be available on a first-come, first-served basis. #AACRcentral
Speakers:
Mohamed Bentires-Alj, Sr., Friedrich Miescher Institute for Biomedical Research and Basel Breast
Consortium, Basel, Switzerland
Jan O. Korbel, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
336
FORUM (not eligible for CME credit)
Monday, 9:30 a.m.-11:30 a.m.
MICR Forum: Transforming from Junior to Senior Faculty: The Unwritten
Rules and Advice for a Successful Transition
Organized by the Minorities in Cancer Research (MICR) Council
Co-Chairpersons: Malcolm V. Brock, Johns Hopkins University School of Medicine, Baltimore, MD;
John M. Carethers, University of Michigan, Ann Arbor, MI
There are challenges to undergo a successful promotion from junior faculty to senior faculty, and
strategies are not completely transparent. After the initial appointment, the new faculty must navigate
their institutions’ requirements over the ensuing handful of years, be diligent about meeting
expectations needed for promotion, and not wait until the last minute to fulfill those expectations.
Depending on their job description, performing and publishing scholarly work, acquiring external
grant support, successfully participating in the teaching mission of the institution, and satisfying any
clinical expectations are weighted. In addition, developing a national reputation is generally a
requirement. Intangibles for success will be discussed by those who have achieved promotion, which
include strategies for mentorship and the importance of networking, avoiding time-consuming
committees before promotion yet participating in the missions of the institution, protecting your
effort, suggestions for documenting activities, early strategies for leadership skills development, and
troubleshooting difficult situations. The goal of this session is to provide advice to the junior faculty
who wants to understand the path towards a successful promotion and to provide advice to set a
foundation for future leadership.
9:30 a.m.
Introduction
Malcolm V. Brock, Johns Hopkins University School of Medicine, Baltimore, MD
9:35 a.m.
Roles and relationships for success for both the mentor and mentee
Juanita L. Merchant, University of Michigan, Ann Arbor, MI
10:00 a.m.
Strategies for developing leadership skills and networking at the junior faculty level
Herbert Chen, University of Wisconsin-Madison, Madison, WI
10:25 a.m.
Staying focused for academic progression and work-life blend
John H. Stewart, IV, Wake Forest University, Winston-Salem, NC
10:50 a.m.
Panel Discussion
337
MEET AND GREET (not eligible for CME credit)
Monday, 10:00 a.m.-11:00 a.m.
AACRcentral, AACR Amphitheater, Halls B-E, Booth #725
Meet the AACR Pediatric Cancer Working Group Chairperson
Lee J. Helman, MD
National Cancer Institute-CCR, Bethesda, MD
Dr. Lee Helman is the Scientific Director for Clinical Research in the Center for Cancer Research at the
National Cancer Institute and Professor of Pediatrics and Oncology at Johns Hopkins University. His
tenure at NCI began with a fellowship after receiving his MD from the University of Maryland School of
Medicine and after completing his residency at the Barnes Hospital of Washington University.
Throughout his 31 years at NCI, Dr. Helman has served as Head, and later Chief of the Molecular
Oncology section of the Pediatric Oncology Branch, assuming the role of Scientific Director in 2007.
Dr. Helman’s laboratory currently focuses on three major themes related to the biology and treatment
of pediatric sarcomas, specifically rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, and pediatric
gastrointestinal stromal tumors (GIST). These themes are: 1) determining the pathophysiologic
consequences of IGF signaling; 2) identifying the molecular/biochemical determinants of the biology
of these sarcomas; and 3) applying preclinical laboratory findings to develop novel clinical studies for
these sarcomas.
In 2011, he was awarded the Pediatric Oncology Award and Statesman Award for his scientific
achievements in the field of pediatric oncology by the American Society of Clinical Oncology (ASCO).
He has been elected to the American Society for Clinical Investigation and the American Association
of Physicians and is a founding member and past president of the Connective Tissue Oncology
Society. He serves on the Board of Directors and is a clinical advisor to The Children’s Inn at NIH and is
a past member of the NIH Advisory Board for Clinical Research, as well as the ASCO Board of
Directors and Bylaws Committee. He also serves on the Scientific Advisory Committee of the
Children’s Oncology Group (COG).
Dr. Helman has been actively involved with the American Association for Cancer Research (AACR) for
many years. He has served on the AACR’s Science Education, Publications, and Clinical and
Translational Cancer Research Standing Committees and has also served as Chairperson of the
inaugural QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research Scientific
Review Committee. He serves on the Scientific Advisory Committee of Stand Up To Cancer and has
also served as an associate editor for the journals, Cancer Research and Clinical Cancer Research. Dr.
Helman has actively led AACR’s pediatric oncology-related initiatives since the formation of the AACR
Pediatric Oncology Task Force in 2009. In 2011, Dr. Helman oversaw the evolution of this task force
into the AACR Pediatric Cancer Scientific Working Group, whose membership now consists of over
1,800 members.
338
Monday, 10:00 a.m.-11:00 a.m.
Booth #1827 (Publications Booth), Halls B-E
Meet the Editor-in-Chief of
Cancer Epidemiology, Biomarkers & Prevention
Timothy R. Rebbeck, PhD
Professor, Biostatistics and Epidemiology
University of Pennsylvania School of Medicine
Join us at Booth #1827 at AACR Annual Meeting 2015 to meet the editors of the AACR Publications.
The Editors-in-Chief will explain the mission and scope of their journal, recent submission trends, and
other topics of interest for researchers looking to publish their work in the highly esteemed AACR
journals. Learn what Editors look for in manuscripts and participate in a unique Q&A session.
Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based
research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of
special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay
development, validation, and application; chemoprevention and other types of prevention research in
the context of descriptive and observational studies; the role of behavioral factors in cancer etiology
and prevention; survivorship studies; risk factors; and the science of cancer health disparities. Besides
welcoming manuscripts that address individual subjects in any of the relevant disciplines, the editors
encourage the submission of manuscripts with a trans-disciplinary approach.
339
Monday, 10:30 a.m.-12:00 p.m.
NCI’s Center for Strategic Scientific Initiatives (CSSI): Programs and Highlights
Moderator: Emily J. Greenspan, National Cancer Institute, Bethesda, MD
The mission of the Center for Strategic Scientific Initiatives (CSSI) is to create and uniquely implement
exploratory programs focused on the development and integration of advanced technologies,
transdisciplinary approaches, infrastructure, and standards to accelerate the creation of publically available,
broadly accessible, multidimensional data, knowledge, and tools to empower the entire cancer research
continuum for patient benefits. In this session we will highlight the programmatic objectives, research efforts,
and resources supported by the CSSI.
The Office of Cancer Nanotechnology Research (OCNR) directs the NCI Alliance for Nanotechnology in
Cancer (ANC), a program to pioneer the development and deployment of nanotechnology-based
interventions, which hold enormous promise for advancing all aspects of cancer research and medicine.
OCNR will give an overview of the goals, organization, and recent successes of the ANC program, as well as
describe interactions with other NCI initiatives to leverage their capabilities towards collaborative efforts.
There will also be a discussion of resources available to the cancer nanotechnology community, including the
Nanotechnology Characterization Laboratory (NCL), which has tested more than 300 nanomedicines
developed by over 90 research groups. This extensive experience has given NCL a unique perspective on how
to design safe and biocompatible nanomedicines for human use.
The Office for Clinical Cancer Proteomics Research (OCCPR) supports the Clinical Proteomic Tumor Analysis
Consortium (CPTAC), which is a team-based approach that focuses on identifying proteins that derive from
cancer genomes, such as those from The Cancer Genome Atlas (TCGA) program. CPTAC adds to NCI’s
ongoing initiatives in molecular biology omics-based research programs that comprehensively characterize
tumors and makes its findings publicly available. Community resources presented from OCCPR will include:
the Data Coordinating Center and Proteomic Data Portal, the Antibody Characterization Program and
Antibody Portal (greater than 300 available monoclonal antibodies), and the Proteomic Assay Portal (greater
than 500 targeted proteomic multiplex assays). The audience will hear an overview of each resource, learn
how to access each of these resources, and see a demonstration of CPTAC’s newly developed proteomic
track hubs on the UCSC genome browser.
Our session will close with an overview of the Innovative Molecular Analysis Technologies (IMAT) and
Provocative Questions (PQ) programs, including overarching goals of the initiatives, examples of supported
research and future directions.
Speakers:
Stephanie Morris, National Cancer Institute, Rockville, MD
Jennifer Grossman, Frederick National Laboratory for Cancer Research, Frederick, MD
Robert C. Rivers, National Cancer Institute, Bethesda, MD
Michelle A. Berny-Lang, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Anthony Dickherber, National Cancer Institute, Bethesda, MD
340
CLINICAL TRIALS PLENARY SESSION
Monday, 10:30 a.m.-12:20 p.m.
Clinical Trials of New Drugs in Breast Cancer
Chairperson: Fabrice Andre, Institut Gustave-Roussy, Villejuif, France
Additional chairperson to be announced
10:30 a.m.
CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor
degrader GDC-0810 (ARN-810) in postmenopausal women with ER+ HER2-,
advanced/metastatic breast cancer
Maura Dickler, Memorial Sloan Kettering Cancer Center, New York, NY
10:50 a.m.
Discussant
C. Kent Osborne, Baylor College of Medicine Cancer Center, Houston, TX
11:00 a.m.
CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with
letrozole in ER+/HER2-metastatic breast cancer
Ingrid A. Mayer, Vanderbilt University Medical Center, Nashville, TN
11:20 a.m.
CT233: A phase I study evaluating continuous and intermittent AZD2014 in
combination with fulvestrant in patients with ER+ advanced metastatic
breast cancer
Manish Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL
11:40 a.m.
Discussant to be announced
11:50 a.m.
CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin,
in patients with HER2+ metastatic breast cancer
Patricia LoRusso, Yale Cancer Center, New Haven, CT
12:10 p.m.
Discussant
Fabrice Andre, Institut Gustave-Roussy, Villejuif, France
Please refer to the online Itinerary Planner or Annual Meeting App for program updates.
341
MAJOR SYMPOSIA
Monday, 10:30 a.m.-12:30 p.m.
10:30 a.m.
Introduction
Chemical Probes for Use in Cancer
Research
10:40 a.m.
Probing the cancer genome: Opportunities
and dangers with chemical tools
Paul Workman, The Institute of Cancer
Research, London, United Kingdom
11:00 a.m.
Discussion
11:05 a.m.
Towards a chemical probe set targeting the
human bromodomain family of epigenetic
reader domains
Stefan Knapp, Oxford University, Oxford,
United Kingdom
11:25 a.m.
Discussion
11:30 a.m.
Targeting chromatin regulation for cancer
therapy: Progress towards chemical probes
for methyl-lysine readers [SY08-03]*
Stephen V. Frye, University of North Carolina
at Chapel Hill, Chapel Hill, NC
11:50 a.m.
Discussion
11:55 a.m.
Chemical probes for target validation in
cancer: A pharma perspective
Mark Bunnage, Pfizer, Inc., Cambridge, MA
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Chairperson: Paul Workman, The Institute of Cancer
Research, London, United Kingdom
The use of small-molecule chemical probes has emerged as
a highly effective strategy in modern biomedical research.
When used alongside complementary genetic
technologies, chemical probes play a key role in functional
genome annotation and in interrogating biological
pathways and phenotypes of cancer cells and their healthy
counterparts. They also make a critical contribution to
innovative target discovery and robust target validation. To
be effective, chemical tools need to be designed, assessed,
and used with a high level of critical rigor. Although there
has been a welcome increase in the availability of highquality chemical tools, there continue to be frequent
published examples where researchers use unsuitable
compounds, often suffering from clearly undesirable
chemical structures and/or insufficient potency, selectivity,
permeability, and stability – and frequently also lacking
essential biomarker evidence of specific target
engagement – resulting in misleading biological
conclusions.
This symposium will assess the state of the art in the
design, iterative optimization, and use of chemical tool
compounds in cancer research. We will review key “fitness
factors” against which chemical probes should be
assessed; describe chemical tool kits and frameworks for
their biological application; provide cutting edge examples
of high-quality chemical reagents and their innovative use
in oncology; and describe chemical biology and allied
proteomic approaches to target discovery and validation.
Specific topics will include comparative on-target and offtarget effects with both chemical and genetic approaches;
selectivity and polypharmacology in kinase research; the
rapid emergence of chemical tools for epigenetic
regulators and metabolism targets; the power of structurebased design; the increasing role of irreversible chemical
tools for use in in vitro and animal models; the application
of chemical tools in expanding the druggable cancer
genome; and contributions to overcoming the key problem
drug resistance. The value of chemical probes and
chemical biology in driving therapeutic innovation and
productivity will be discussed in the context of the current
academia-biotech-pharma ecosystem.
342
Convention Center
Convention Center
Deregulation of Cancer Hallmarks by
microRNAs and other Noncoding RNAs
Epigenetic and Transcriptional Control of
Senescence
Chairperson: Frank John Slack, BIDMC Cancer
Center/Harvard Medical School, Boston, MA
Chairperson: Emily Bernstein, Icahn School of Medicine at
Mount Sinai, New York, NY
The genome generates an increasing diversity of
noncoding RNAs. MicroRNAs (miRNAs) have led the
charge in the emergence of RNA molecules functioning in
cancer. Analysis of miRNA expression signatures have
shown promise in cancer diagnosis, and miRNAs
themselves are potential targets/agents for cancer therapy.
Playing catch-up, but of no less importance are the scores
of long noncoding RNAs (lncRNAs), many of which are
also mis-expressed in cancer and likely have important
functions. Given the sheer number of miRNA and lncRNAs
genes, thousands in humans, and our lack of
understanding of all their roles, and given the need for a
basic understanding of cancer mechanisms, this session
will provide an important synthesis of the growing role for
miRNAs and lncRNAs in multiple aspects of cancer biology.
Senescence is considered a stable form of growth arrest
that functions as a potent tumor modulating mechanism.
While evidence that senescence is a chromatin-mediated
process is gaining attention, the molecular mechanisms
underlying this process remain unclear. This session will
focus on recent advances in the epigenetic and
transcriptional regulation of cellular senescence, relevant to
aging and cancer. Subject matter will include the role of
p53 in senescence and cancer, histone modifications,
histone variants and their dedicated chaperones, as well as
epigenomic profiling studies.
10:30 a.m.
Introduction
10:40 a.m.
In vivo analysis of linear and circular
ceRNAs in tumorigenesis
Pier Paolo Pandolfi, BIDMC Cancer
11:00 a.m.
Discussion
11:05 a.m.
Mechanisms of microRNA dysregulation
in cancer
Carlo M. Croce, The Ohio State University
Comprehensive Cancer Center, Columbus, OH
11:25 a.m.
Discussion
11:30 a.m.
Quantitative analysis of miRNA regulation
Phillip A. Sharp, MIT Koch Institute for
Integrative Cancer Research, Cambridge, MA
11:50 a.m.
Discussion
11:55 a.m.
Cancer crosstalk: miR-200-containing
extracellular vesicles promote breast cancer
cell metastasis [SY09-04]*
Judy Lieberman, Boston Children’s Hospital
and Harvard Medical School, Boston, MA
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
10:30 a.m.
Introduction
10:40 a.m.
Chromatin structure change and aberrant
gene expression during senescence
[SY10-01]*
Masashi Narita, Cancer Research UK,
Cambridge, United Kingdom
11:00 a.m.
Discussion
11:05 a.m.
Novel epigenetic signatures of wild type
and mutant p53 transcriptional activity
Shelley L. Berger, University of Pennsylvania
School of Medicine, Philadelphia, PA
11:25 a.m.
Discussion
11:30 a.m.
Epigenetics of cell senescence: Unveiling
the links between aging and cancer
Peter D. Adams, University of Glasgow,
Glasgow, United Kingdom
11:50 a.m.
Discussion
11:55 a.m.
Histone tail alterations in cellular
senescence [SY10-04]*
Emily Bernstein, Icahn School of Medicine at
Mount Sinai, New York, NY
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
343
MAJOR SYMPOSIA
Monday, 10:30 a.m.-12:30 p.m.
Grand Ballroom (300 Level), Pennsylvania
Convention Center
Convention Center
Mechanisms of Tumor Immune Escape
Mechanistic Targets and Intervention
Strategies for Breaking the Obesity-Cancer
Link
Chairperson: Ton Schumacher, Netherlands Cancer
Institute, Amsterdam, The Netherlands
A number of immunotherapies, in particular immune
checkpoint targeting therapies and adoptive T cell
therapies, have started to transform the treatment of
advanced cancers. The likelihood to respond to these
immunotherapies differs strongly across tumor types.
Furthermore, also within tumor types, tumors vary with
respect to sensitivity towards immune attack. These data
make a better understanding of both intrinsic resistance
and acquired immunotherapy resistance the new frontier in
this field, with the goal to improve patient selection and
counteract immune escape. This session will deal with a
series of aspects of the dialogue between the cellular
immune system and cancer cells. Topics addressed will
range from genomic analyses that aim to uncover tumor
cell sensitivity to T cell attack, immunological analyses of
mechanisms of T cell dysfunction, and
immunohistochemical analysis of immune infiltrates that
correlate with patient outcome.
10:30 a.m.
Introduction
10:40 a.m.
What T cells see on human cancer
Ton Schumacher, Netherlands Cancer
Institute, Amsterdam, The Netherlands
11:00 a.m.
Discussion
11:05 a.m.
The immune landscape within human
tumors
Jerome Galon, INSERM U872 - Cordeliers
Research Center, Paris, France
Chairperson: Stephen D. Hursting, University of North
Carolina at Chapel Hill, Chapel Hill, NC
The prevalence of obesity, an established risk and/or
progression factor for many cancers, has more than
doubled over the past three decades in the United States,
with ~36% of adults currently obese (BMI>30 kg/m2). The
mechanisms underlying the obesity and cancer connection
are becoming increasingly clear and reveal several
potential targets and strategies for preventing obesityrelated cancers. We will focus on obesity-related host
factors that influence tumor initiation, progression, and/or
response to therapy. These host factors include
components of the secretome, including hormones, growth
factors, adipokines, and cytokines and other inflammationrelated molecules. These secreted host factors are extrinsic
to, and interact with, the intrinsic molecular characteristics
of cells (including cancer stem cells), and each will be
considered in the context of energy balance and as
potential targets for breaking obesity-cancer links.
10:30 a.m.
Introduction
10:40 a.m.
Obesity and breast cancer: Preclinical
perspectives
Stephen D. Hursting, University of North
Carolina at Chapel Hill, Chapel Hill, NC
11:00 a.m.
Discussion
11:05 a.m.
Obesity and breast cancer: Clinical
perspectives
Pamela J. Goodwin, University of Toronto
Mount Sinai Hospital, Toronto, ON, Canada
11:25 a.m.
Discussion
11:30 a.m.
Mechanisms of T cell exhaustion
Rafi Ahmed, Emory Institute, Atlanta, GA
11:25 a.m.
Discussion
11:50 a.m.
Discussion
11:30 a.m.
11:55 a.m.
Genetics of immune escape [SY11-04]*
Nir Hacohen, Massachusetts General
Hospital, Charlestown, MA; Broad Institute,
Cambridge, MA
Obesity, inflammation, and breast
cancer [SY12-03]*
Andrew J. Dannenberg, Weill Medical College
of Cornell University, New York, NY
11:50 a.m.
Discussion
12:15 p.m.
Discussion
11:55 a.m.
12:20 p.m.
General Discussion
Mechanisms of obesity-induced prostate
cancer progression
John Digiovanni, University of Texas at
Austin, Austin, TX
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
344
12:15 p.m.
Discussion
Targeted Therapies in Hematologic
Malignancies
12:20 p.m.
General Discussion
Chairperson: John C. Byrd, The Ohio State University
The evolution of basic genomic studies in leukemia have
led to development of numerous targeted therapies for
different types of hematologic malignancies. The
introduction of these targeted therapies has impacted both
the survival and also quality of life of patients over older
treatment options. Our understanding of how to best
introduce these for optimal results and also to address and
prevent resistance are evolving at a much more rapid pace
with utilization of many new technologies not previously
available to drug developers. In this session the speakers
will provide unique expert perspectives on scientific stories
related to new targeted therapies and their application to
the treatment of select hematologic malignancies.
10:30 a.m.
Introduction
10:40 a.m.
Polyclonal and heterogeneous resistance to
targeted therapy in leukemia
**Catherine C. Smith, University of California,
San Francisco, CA
Targeting Macromolecular Signaling
Complexes
Chairperson: Hao Wu, Children’s Hospital Boston-Harvard
Medical School, Boston, MA
Signal transduction is critically important for cellular
communication in numerous physiological contexts
including gene expression, cell cycle control, and
metabolism. Dysregulation in signal transduction pathways
is associated with many pathological conditions, most
notably human malignancies. This session will present
rational molecular entities as specific targets for potential
therapeutic interventions against cancer. These efforts
consist of modulation of activities of enzymes such as
kinases and caspases, as well as inhibition of proteinprotein interactions on the cell surface and inside the cell.
10:30 a.m.
Introduction
10:40 a.m.
Supramolecular signaling complexes and
their associated enzymes as potential
therapeutic targets
Hao Wu, Children’s Hospital Boston-Harvard
Medical School, Boston, MA
10:55 a.m.
Discussion
11:00 a.m.
New targeted therapies for myelofibrosis
and other myeloproliferative syndromes
Michael W. Deininger, University of Utah,
Salt Lake City, UT
11:00 a.m.
Discussion
11:15 a.m.
Discussion
11:05 a.m.
11:20 a.m.
FLT3 as a therapeutic target in AML
Neil P. Shah, UCSF School of Medicine,
San Francisco, CA
Regulation of kinase signaling complexes
with small molecule inhibitors [SY14-02]*
Arvin Dar, Mount Sinai Hospital, New York, NY
11:25 a.m.
Discussion
11:35 a.m.
Discussion
11:30 a.m.
11:40 a.m.
Novel targeted therapies in myelodysplastic
syndrome
Benjamin Ebert, Brigham and Women's
Hospital, Boston, MA
Targeted inhibitor of inv(16) acute myeloid
leukemia oncoprotein CBFb-SMMHC
Lucio Castilla, University of Massachusetts
Medical School, Worcester, MA
11:50 a.m.
Discussion
11:55 a.m.
Discussion
11:55 a.m.
12:00 p.m.
BTK as a therapeutic target: What is next?
John C. Byrd, The Ohio State University
Wnt/beta-catenin signaling
Xi He, Boston Children’s Hospital, Boston, MA
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
**NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson through a competitive application process designed
to bring more visibility to early-career scientists. Abstract can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.
345
RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH
Monday, 10:30 a.m.-12:30 p.m.
12:05 p.m.
Discussion
Dose Optimization for 21st Century
Oncology Drugs
12:10 p.m.
Panel Discussion
Chairperson: Mark J. Ratain, University of Chicago,
Chicago, IL
Oncology drug development has historically relied on the
paradigm of phase 1 studies to define a single maximally
tolerate dose, single arm phase 2 studies to estimate
activity, and phase 3 studies using the same dose defined
during early phase 1 trials. This paradigm is based on the
assumption that there is a steep dose-response curve and
that toxicity is of relatively little concern, as compared to
optimizing the probability of demonstrating efficacy. More
recently, there has been recognition that dose optimization
may be important for many, if not all, oncology drugs,
particularly for those drugs that are substantially different
from historical chemotherapy agents. The session will
include discussion of pharmacological, statistical,
commercial, and regulatory issues pertinent to dose
optimization of modern oncology drugs.
Exploiting DNA Repair Deficiencies
in Cancer
Chairperson: Alan Ashworth, UCSF Helen Diller Family
Comprehensive Cancer Center, San Francisco,CA
Inherited mutations in DNA repair genes can lead to
susceptibility to cancer. Moreover, DNA repair defects also
occur in sporadic cancers. Such defects are starting to be
exploited therapeutically, particularly through the use of
synthetic lethal approaches; the sensitivity of BRCA
mutant tumors to PARP inhibitors in the first example of
this strategy to reach the clinic. Here, recent developments
in this area will be discussed.
10:30 a.m.
PI3K-inhibitors enhance DNA damage in
tumor cells through a reduction in
nucleotide biosynthesis
Gerburg Wulf, Beth Israel Deaconess Medical
Center, Boston, MA
Discussion
10:45 a.m.
Discussion
10:55 a.m.
Challenges and opportunities for dose
optimization with today’s anticancer agents
Amita Joshi, Genentech, Inc., South
San Francisco, CA
10:50 a.m.
Extending PARP inhibitor therapy in ovarian
and breast cancer
Alan D. D'Andrea, Dana-Farber Cancer
Institute, Boston, MA
11:15 a.m.
Discussion
11:05 a.m.
Discussion
11:20 a.m.
Designing and analyzing clinical studies for
dose response estimation and dose
selection under model uncertainty
Jose Pinheiro, Janssen Research and
Development, Raritan, NJ
11:10 a.m.
SPOP mutation is associated with genomic
instability in prostate cancer
**Christopher E. Barbieri, Weill Cornell
Medical College of Cornell University,
New York, NY
11:40 a.m.
Discussion
11:25 a.m.
Discussion
11:45 a.m.
Dose-response in oncology: Why regulatory
agencies care
Jogarao Gobburu, University of Maryland
School of Pharmacy, Baltimore, MD
10:30 a.m.
The principles of dose selection: Oncology
isn’t different anymore
Mark J. Ratain, University of Chicago,
Chicago, IL
10:50 a.m.
346
11:30 a.m.
Alterations of DNA repair genes in cancer
cell lines and their predictive value for
drug activity
Yves G. Pommier, National Cancer Institute,
Bethesda, MD
11:45 a.m.
Discussion
11:50 a.m.
Targeting cell cycle checkpoint pathways
for personalized cancer therapy
H. Christian Reinhardt, University of Cologne,
Cologne, Germany
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
10:30 a.m.
Li-Fraumeni syndrome: Beyond p53
David Malkin, University of Toronto Hospital
for Sick Children, Toronto, ON, Canada
10:50 a.m.
Discussion
10:55 a.m.
The SWI/SNF complex and pediatric
rhabdoid tumors
Jaclyn Biegel, Children’s Hospital of
Philadelphia, Philadelphia, PA
11:15 a.m.
Discussion
11:20 a.m.
A mouse model of the Rothmund-Thomson
syndrome cancer predisposition syndrome
Lisa L. Wang, Baylor College of Medicine,
Houston, TX
11:40 a.m.
Discussion
11:45 a.m.
Genetic epidemiology of Ewing’s sarcoma
Joshua D. Schiffman, University of Utah
Huntsman Cancer Institute, Salt Lake City, UT
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
Germline Alterations and Susceptibility to
Childhood Cancer
Chairperson: Sharon E. Plon, Baylor College of Medicine,
Houston, TX
In this session we will highlight the new findings from
research on the inherited basis of childhood cancer that are
changing our knowledge of cancer biology. Dr. David
Malkin will describe recent insights into why cancer risk
varies so significantly among carriers of TP53 mutations
describing modifiers related to telomere length and copy
number variation and the search for additional Li-Fraumeni
syndrome loci. Dr. Jaclyn Biegel will present the range of
inherited mutations in chromatin remodeling genes of the
SWI/SHF complex such as SMARCB1 and the resulting risk
of CNS and non-CNS rhabdoid tumors. Dr. Lisa Wang will
present her development of bone specific models for the
rare recessive disorder Rothmund-Thomson syndrome to
model bone dysplasia and osteosarcoma risk. Dr. Josh
Schiffman will expand the discussion into the genetic
epidemiology of an apparently sporadic tumor, Ewing’s
sarcoma, with highly variable incidence among different
populations.
347
RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCH
Monday, 10:30 a.m.-12:30 p.m.
Lung Cancer and COPD: Commonalities
Chairperson: Avrum E. Spira, Boston University School of Medicine, Boston, MA
Independent of smoking, airflow obstruction is an established risk factor for lung cancer, and the
presence of COPD increases the risk of lung cancer by 4-6 fold. While epidemiological data has linked
COPD and lung cancer and both diseases are causally related to tobacco smoke exposure, the
molecular pathways that connect these two diseases are unclear. This session will explore recent
advances in our understanding of the cellular and molecular mechanisms that link COPD and lung
cancer along with their potential implications for the prevention, early detection, and treatment of
lung cancer among smokers with COPD.
10:30 a.m.
Immune cell phenotypes linking COPD and lung cancer
A. Mcgarry Houghton, Fred Hutchinson Cancer Research Center, Seattle, WA
10:50 a.m.
Discussion
10:55 a.m.
Epigenetic repression of CCDC37 and MAP1B links chronic obstructive pulmonary
disease to lung cancer
Steven A. Belinsky, Lovelace Respiratory Research Institute, Albuquerque, NM
11:15 a.m.
Discussion
11:20 a.m.
The airway transcriptome as a molecular link between COPD and lung cancer
Avrum E. Spira, Boston University School of Medicine, Boston, MA
11:40 a.m.
Discussion
11:45 a.m.
The combined lung cancer-COPD phenotype: Implications for risk and survival
David C. Christiani, Harvard Medical School, Boston, MA
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
348
RECENT ADVANCES IN ORGAN SITE RESEARCH
Monday, 10:30 a.m.-12:30 p.m.
Metastatic Prostate Cancer Precision
Medicine: Challenges and Solutions
Recent Advances in Skin Development and
Skin Cancers
Chairperson: Johann S. de Bono, Institute of Cancer
Research, Sutton, United Kingdom
Chairperson: Fiona M. Watt, King’s College London,
London, United Kingdom
Prostate cancer remains the commonest male malignancy
and the second commonest cause of male cancer
mortality. Although outcome from this disease has
improved with improved understanding of endocrine
treatment resistance and the successful development of
abiraterone, cabazitaxal, enzalutamide, and radium 223, all
patients still invariably die from metastatic prostate cancer.
This session will interrogate how the molecular
interrogation of castration resistant prostate cancer is
providing insights into possibilities for disease
stratification, the causality of endocrine treatment
resistance, and novel therapeutic strategies for improving
outcome from this disease.
The skin can develop a surprisingly wide range of different
tumor types that arise from specific cell populations. This
session will discuss tumors arising from skin epithelial cells,
melanocytes, and Merkel cells. Different tools for studying
tumor development will be presented, and the role of stem
cells in tumor formation will be discussed. A theme that
will emerge is the importance of cells of the immune
system in cancer modulation.
10:30 a.m.
Genomics to alter care
Arul M. Chinnaiyan, University of Michigan,
Ann Arbor, MI
10:50 a.m.
Discussion
10:55 a.m.
Elucidating treatment resistance
Jun Luo, Johns Hopkins Medical Institutes,
Baltimore, MD
11:15 a.m.
Discussion
11:20 a.m.
Functional studies of hormone-DNA repair
crosstalk to impact treatment
Karen E. Knudsen, Thomas Jefferson
University Kimmel Cancer Center,
Philadelphia, PA
11:40 a.m.
Discussion
11:45 a.m.
Novel therapeutic strategies
Johann S. de Bono, Institute of Cancer
Research, Sutton, United Kingdom
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
10:30 a.m.
Role of bone marrow-derived cells in
wound-induced skin cancer
Fiona M. Watt, King’s College, London,
United Kingdom
10:50 a.m.
Discussion
10:55 a.m.
Stem cells and tumor progression in
skin cancer
Elaine Fuchs, Howard Hughes Medical
Institute/Rockefeller University, New York, NY
11:15 a.m.
Discussion
11:20 a.m.
Cellular and signaling mechanisms of tumor
growth and regression
Valentina Greco, Yale University School of
Medicine, New Haven, CT
11:40 a.m.
Discussion
11:45 a.m.
Immune checkpoint blockade:
Turning the tide against
immunosuppression in skin cancer
Suzanne L. Topalian, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
349
REGULATORY SCIENCE AND POLICY SESSION
Monday, 10:30 a.m.-12:30 p.m.
New Drugs: Breakthrough Therapies and Beyond
Chairperson: Amy E. McKee, U.S. Food and Drug Administration, Silver Spring, MD
The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 gave the U.S. Food
and Drug Administration (FDA) statutory authority to designate medical products as a “Breakthrough
Therapy” if the therapy treats a serious or life-threatening disease or condition and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies.
Since that time, the FDA has received over 270 Breakthrough Therapy Designation (BTD) applications
and granted over 75, of which more than 20 therapies have received accelerated approval, a majority
being oncology products. This session will highlight the approval process for several recently
approved breakthrough therapies and the impact that accelerated drug access is having on patient
treatment in these disease areas.
The following drugs will be discussed:
• Nivolumab – PD-1 antibody approved to treat metastatic melanoma;
• Pembrolizumab – PD-1 antibody approved to treat metastatic melanoma;
• Ibrutinib – BTK inhibitor approved to treat chronic lymphocytic leukemia (CLL);
• Idelalisib – PI3K inhibitor approved to treat chronic lymphocytic leukemia (CLL);
• Palbociclib – CDk4/CDK6 inhibitor approved to treat metastatic ER+/Her2- breast cancer; and
• Blinatumomab - CD19-directed CD3 T-cell engager (BiTE) approved to treat acute lymphoblastic
leukemia (ALL).
A panel discussion moderated by Amy E. McKee, U.S. Food and Drug Administration, and audience
Q and A will follow the presentations.
Speakers:
Amy E. McKee, U.S. Food and Drug Administration, Silver Spring, MD
Leigh Marcus, U.S. Food and Drug Administration, Silver Spring, MD
Marc Theoret, U.S. Food and Drug Administration, Silver Spring, MD
Antoni Ribas, UCLA Janssen Comprehensive Cancer Center, Los Angeles, CA
Angelo De Claro, U.S. Food and Drug Administration, Silver Spring, MD
John C. Byrd, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Julia Beaver, U.S. Food and Drug Administration, Silver Spring, MD
Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA
Donna Przepiorka, U.S. Food and Drug Administration, Silver Spring, MD
Susan R. Rheingold, Children’s Hospital of Philadelphia, Philadelphia, PA
350
MEET THE RESEARCH ICON (not eligible for CME credit)
Monday, 11:00 a.m.-12:00 p.m.
Meet the Research Icon
Charles L. Sawyers, MD, FAACR
Memorial Sloan Kettering Cancer Center, New York, NY
Formerly known as Meet the Research Pioneer, these informal sessions, organized by the Associate
Member Council, provide early-career scientists with the special opportunity to meet and hear from a
renowned senior researcher in a small-group setting. Throughout the course of each discussion,
attendees will gain career advice relevant to each speaker’s specific field and learn about the
speaker’s professional and personal experiences, vision for the future of their field, as well as key
decisions that shaped their career path. Meet Dr. Charles L. Sawyers, chairperson of the Human
Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, professor at Weill
Cornell Graduate School of Medical Sciences, investigator at the Howard Hughes Medical Institute, and
Fellow of the AACR Academy. Dr. Sawyers also recently served as president of the AACR Board of
Directors from 2013-2014. Sessions are open to all graduate students, medical students, residents, and
clinical and postdoctoral fellows and will take place in the Associate Member Resource and Career
Center located in AACRcentral. Limited seating will be available on a first-come, first-served basis.
#AACRcentral
351
Monday, 11:15 a.m.-12:15 p.m.
Career Paths in Pancreatic Cancer Research
Diane M. Simeone, MD
University of Michigan, Ann Arbor, MI
Kenneth L. Scott, PhD
Baylor College of Medicine, Houston, TX
The pancreatic cancer research community continues to seek new investigators to join efforts in the
laboratory and clinic. This session, which focuses on career paths in the field of pancreatic cancer, will
be co-led by Dr. Diane M. Simeone, Lazar J. Greenfield Professor of Surgery and Molecular &
Integrative Physiology at the University of Michigan Medical School and Director of the Pancreatic
Cancer Center at the University of Michigan Comprehensive Cancer Center, and Dr. Kenneth L. Scott,
Assistant Professor of Molecular and Human Genetics and the Program in Integrative Molecular and
Biomedical Sciences at Baylor College of Medicine. This informal and interactive session will provide
the opportunity to interact with both a renowned established physician-scientist and a highly
successful early-career investigator and will focus on basic, translational, and clinical research paths in
the pancreatic cancer research field. Pick up new ideas and suggestions about career paths, priority
research needs for the field, postdoctoral opportunities, funding opportunities, how to start your own
laboratory, the importance of clinical trials, choosing a mentor, networking and collaborations, etc. The
forum will be an open dialogue and question and answer format. Come meet others in the field and
share your experiences.
352
Monday, 11:30 a.m.-12:30 p.m.
AACRcentral, WICR Networking and Resource Center, Halls B-E, Booth #725
Meet the Charlotte Friend Lecturer
Organized by the Women in Cancer Research (WICR) Council
Sara A. Courtneidge, PhD
Sanford-Burnham Medical Research Institute, La Jolla, CA
Please join us for informal discussion with AACR-Women in Cancer Research Charlotte Friend
Memorial Lectureship Eighteenth Annual Recipient Sara A. Courtneidge, PhD. Dr. Courtneidge’s award
lecture will be presented on Saturday, April 18, from 5:30 p.m.-6:45 p.m. The lectureship is intended to
give recognition to an outstanding female or male scientist who has made meritorious contributions
to the field of cancer research and who has, through leadership or by example, furthered the
advancement of women in science.
353
Monday, 12:00 p.m.-1:00 p.m.
In Transition: From Student to Leader
year to offer a broad array of information that could be relevant to the diverse Annual Meeting
early-career attendees. This peer-to-peer session will address key points to take away regarding
career transitions. Early-career scientists need to learn from their experiences and develop
interpersonal skills to become great mentors and leaders within the cancer research community. By
the end of this hour, participants will obtain guidelines for developing a strong set of mentoring and
leadership skills, understand what skills are necessary to progress in the field of cancer research, and
figure out how to apply these skills in the workplace. Designed to provide advice that can help
attendees figure out their career path and potential future career opportunities, Career Conversations
are open to all graduate students, medical students, residents, and clinical and postdoctoral fellows.
All Career Conversations will take place in AACRcentral and limited seating will be available on a firstcome, first-served basis. #AACRcentral
Speakers:
Andrew D. Rhim, University of Michigan Medical School, Ann Arbor, MI
Julie K. Schwarz, Washington University School of Medicine, St. Louis, MO
354
Monday, 12:00 p.m.-1:30 p.m.
The NCI SBIR Program: An Overview of New Funding Opportunities
and Strategies for Employing Lean Startup Tools to Drive Success
in Your Small Business
How do you go from idea to IP to IPO? The NCI knows that technical expertise isn’t enough to
guarantee business success, so we teamed up with leaders from across the NIH and NSF, as well as
entrepreneurial experts to develop the I-Corps™ at NIH Pilot Training Program. Based on the highly
successful NSF I-Corps™ program, the I-Corps™ at NIH curriculum is designed to provide scientists
with real-world, hands-on, immersive entrepreneurship training. NCI-funded small businesses with
technologies spanning cancer therapeutics, diagnostics, and devices all benefit from this innovative
and highly transformative entrepreneurial training program.
The first I-Corps™ at NIH cohort launched in October 2014. Through I-Corps™ at NIH, our NCI teams
experience deep learning from life science domain experts to gain true understanding of their
technologies’ value propositions and customer segments. Over the 9-week period of the course, each
company talks to at least 100 potential customers and key partners to revise and iteratively improve
their startup business model.
Leaders from the NCI SBIR Development Center have spent a year developing and tailoring the
I-Corps™ curriculum to life science and cancer-focused companies. In this panel, they will provide an
overview of the NCI SBIR program and I-Corps™ at NIH. In addition, participants from the NIH pilot
cohort will share their experiences in applying the I-Corps™ curriculum to their life science startup. An
interactive Q&A session will accompany this panel.
Panelists:
Michael Weingarten, National Cancer Institute, Bethesda, MD
Andrew J. Kurtz, National Cancer Institute, Bethesda, MD
William Plishker, IGI Technologies, Elkridge, MD
Lisa Malseed, Wild-Type Enterprise Worldwide, Wynnewood, PA
355
TOWN MEETING (not eligible for CME credit)
Monday, 12:00 p.m.-1:30 p.m.
Grand Ballroom Salons I-J (Level 5), Philadelphia Marriott Downtown
Chemistry in Cancer Research (CICR) Working Group Town Hall Meeting
The Chemistry in Cancer Research (CICR) Working Group brings together cancer-focused scientists in
chemistry and chemistry-related fields to discuss the present status and future promise of chemistry
in the advancement of the prevention and cure of cancer. All CICR members are encouraged to attend
and all interested Annual Meeting registrants are also invited. This event will provide an opportunity to
raise questions and contribute ideas to help shape future CICR initiatives. Attendees can also learn
about membership in CICR; the CICR quarterly Newsletter; meet the members of the Steering
Committee; and connect with colleagues. A networking reception will follow.
12:00 p.m.
Chairperson: Opening Remarks
Stephen A. Munk, Ash Stevens Inc., Detroit, MI
12:20 p.m.
Chairperson-Elect: Remarks
David E. Uehling, Ontario Institute for Cancer Research, Toronto, ON, Canada
12:30 p.m.
Co-Chairpersons, CICR Newsletter
Klaus Pors, University of Bradford, Bradford, United Kingdom
Billy W. Day, University of Pittsburgh, Pittsburgh, PA
12:40 p.m.
Closing Remarks
David E. Uehling, Ontario Institute for Cancer Research, Toronto, ON, Canada
356
SPECIAL SESSION (not eligible for CME credit)
Monday, 12:30 p.m.-2:00 p.m.
TME Working Group: TME Career Opportunities and
Challenges for Young Investigators
This networking session provides an opportunity for early-career investigators to interact with the
TME Working Group Leadership, experts in the field of the tumor microenvironment, to learn about
career challenges and opportunities. Come join this informative discussion, which also provides ample
time for comments and questions.
12:30 p.m.
Opening Remarks: TME Chairperson
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX
12:40 p.m.
Panel Discussion
TME Chairperson
TME Chairperson-Elect
Morag Park, Canadian Institutes of Health Research, Montréal, Quebec, Canada
TME Past Chairperson
Mary Helen Barcellos-Hoff, New York University, New York, NY
357
SU2C SPECIAL SESSION (not eligible for CME credit)
Monday, 12:30 p.m.-2:30 p.m.
SU2C Scientific Session: Translating Advances in Immunotherapy to
Patient Benefit
Chairperson: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA
A strong supporter of immunotherapy, Stand Up To Cancer (SU2C), in conjunction with its funding
partners, has awarded grants to these presenting Dream Teams and Translational Team focused on
new immune approaches against adult and childhood cancers. During this open session, which is
available to all attendees, Team members will give brief reports on their respective projects. Each
Team will discuss the science behind their current and future clinical trials. A brief Q & A will follow the
presentation of the reports.
Opening remarks from the SU2C Scientific Advisory Committee Chairperson
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
Immunologic checkpoint blockade and adoptive cell transfer in cancer therapy
SU2C-Cancer Research Institute Dream Team
Speaker: Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Baltimore, MD
Immunogenomics to create new therapies for high-risk childhood cancers
SU2C-St. Baldrick’s Foundation Dream Team
Speaker: Andrei Thomas-Tikhoneko, The Children’s Hospital of Philadelphia, Philadelphia, PA
Transforming pancreatic cancer to a treatable disease
SU2C-Lustgarten Foundation Dream Team
Speaker: Elizabeth M. Jaffee, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Baltimore, MD
Therapeutic CD8 vaccines against conserved E7 HPV epitopes identified by MS
SU2C-Farrah Fawcett Foundation Translational Team
Speaker: Ellis L. Reinherz, Dana-Farber Cancer Institute, Boston, MA
358
Monday, 12:45 p.m.-2:00 p.m.
AACR Annual Business Meeting of Members
The AACR Officers and Directors of the Board invite all AACR members to attend this Annual Business
Meeting of Members for an update on all organizational programs and initiatives, as well as to witness
the annual presidential transfer of power ceremony. This meeting will include: reports from the AACR
President, Treasurer, and President-Elect; In Memoriam for recently deceased members;
acknowledgments of new 50-year members, sustaining members, and major sponsors; recognition of
recent Officer and Board of Director election winners; induction of and remarks from the 2015-2016
AACR President; and an open discussion of any new business.
Boxed lunches will be provided for all attendees.
Speakers:
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY
Nancy E. Davidson, University of Pittsburgh Cancer Insitute, Pittsburgh, PA
Margaret Foti, American Association for Cancer Research, Philadelphia, PA
William N. Hait, Janssen Research and Development, LLC, Raritan, NJ
Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY
359
Monday, 1:00 p.m.-2:00 p.m.
Postdoc Wanted: The Hunt for the Right Postdoctoral Position
year to offer a broad array of information that could be relevant to the diverse Annual Meeting earlycareer attendees. In this peer-to-peer session, participants will learn how to choose the right
fellowship for one’s career goals. By the end of this hour, attendees will understand which
characteristics they should look for when choosing a fellowship and fellowship mentor, have gained
insight regarding when, where, and how to start looking for a fellowship position, understand whether
to start a new project or remain in their current field of study, and better comprehend the benefits and
drawbacks of larger versus smaller labs. Designed to provide advice that can help attendees figure out
their career path and potential future career opportunities, Career Conversations are open to all
graduate students, medical students, residents, and clinical and postdoctoral fellows. All Career
Conversations will take place in AACRcentral and limited seating will be available on a first-come, firstserved basis. #AACRcentral
Speakers:
Susan E. Olivo-Marston, The Ohio State University and The Ohio State University Comprehensive
Cancer Center, Columbus, OH
Trevor J. Pugh, University of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada
360
Monday, 1:00 p.m.-2:00 p.m.
Meet the Editor-in-Chief of Cancer Prevention Research
Scott M. Lippman, MD
Director, Professor of Medicine, and Associate Vice Chancellor for
Cancer Research and Care, UC San Diego Moores Cancer Center
Cancer Prevention Research is devoted exclusively to cancer prevention. The journal publishes
important original studies, reviews, and commentaries within the major topic areas of biology of
premalignancy, risk factors and risk assessment, early detection research, immunoprevention and
chemopreventive and other interventions, including the basic science behind them. Cancer Prevention
Research comprises preclinical, clinical and translational research, with special attention given to
molecular discoveries and an emphasis on building a translational bridge between the basic and
clinical sciences.
361
MAJOR SYMPOSIA
Monday, 1:00 p.m.-3:00 p.m.
The 2015 Stanley J. Korsmeyer Memorial
Symposium: Cell Death and Cancer
Therapy: Why Has Conventional
Chemotherapy Been So Successful?
Antiangiogenesis Revisited
Chairperson: Anthony G. Letai, Dana-Farber Cancer
In this current era of precisely targeted therapies and
-omics technologies, it is often forgotten that no medical
therapy has cured, and continues to cure, more people of
cancer than conventional chemotherapy. Notwithstanding
its superior performance across many cancer types, the
mechanism of the therapeutic index of conventional
agents, largely targeting ubiquitous elements like DNA and
microtubules, is poorly understood. The textbook
explanation of conventional chemotherapy’s working by
killing supposedly rapidly dividing cancer cells lacks clinical
evidence and flies in the face of many obvious clinical
counterexamples. In this session, the speakers will describe
how conventional cytotoxic chemotherapy preferentially
kills cancer cells. Moreover, they will describe how clinical
response to chemotherapy might be better predicted.
1:00 p.m.
Introduction
1:10 p.m.
Conventional chemotherapy cures people
by exploiting apoptotic priming [SY20-01]*
Anthony G. Letai, Dana-Farber Cancer
Chairperson: Donald M. McDonald, UCSF Helen Diller
Family Comprehensive Cancer Center, San Francisco, CA
Mixed results with angiogenesis inhibitors in cancer
therapy have led to reinvestigation of underlying
mechanisms and use of combinations with other
therapeutic strategies. This symposium will explore new
directions that promise greater efficacy. Some oncolytic
viruses have more potent, long-lasting actions on primary
tumors and metastases when combined with angiogenesis
inhibitors. Vascular endothelial growth factor (VEGF)
pathway inhibitors are being combined with inhibitors of
other VEGF-VEGFR family members or the angiopoietinTie2 receptor pathway. The orphan receptor Tie1 is also a
potential target in some tumors. Additional strategies are
examining immune cell actions on angiogenesis, invasion,
and immune-stimulation by antiangiogenic therapy.
Immune modulators can sensitize resistant tumors to
antiangiogenic therapy and generate more durable
responses. The therapeutic potential of targeting metabolic
pathways is another novel strategy. Agents that impact
glycolysis or lipid and amino acid metabolism can reduce
vessel sprouting and angiogenesis. The speakers will
examine the latest findings with these approaches.
1:00 p.m.
Introduction
1:10 p.m.
Synergy of oncolytic viruses and
angiogenesis inhibitors
Donald M. McDonald, UCSF Helen Diller
Family Comprehensive Cancer Center,
San Francisco, CA
1:30 p.m.
Discussion
1:35 p.m.
Using conventional chemotherapy as
targeted agents
Michael T. Hemann, MIT Koch Institute for
Integrated Cancer Research, Cambridge, MA
1:30 p.m.
Discussion
1:55 p.m.
Discussion
1:35 p.m.
2:00 p.m.
Identifying responders to chemotherapies
through functional genomics
René Bernards, Netherlands Cancer Institute,
Amsterdam, The Netherlands
Combinatorial targeting of angiogenic
growth factor pathways
Kari K. Alitalo, University of Helsinki,
Helsinki, Finland
1:55 p.m.
Discussion
2:20 p.m.
Discussion
2:00 p.m.
2:25 p.m.
A hallmark of successful cancer therapies:
Reinstatement of immunosurveillance
Guido Kroemer, INSERM U848 - Institute
Gustave-Roussy, Villejuif, France
Intertwined regulation of angiogenesis and
immune modulation in tumor progression
and therapeutic resistance
Gabriele Bergers, University of California,
San Francisco, CA
2:20 p.m.
Discussion
2:45 p.m.
Discussion
2:25 p.m.
2:50 p.m.
General Discussion
Angiogenesis revisited: Endothelial cell
metabolism as a target? [SY15-04]*
Peter Carmeliet, VIB - University of Leuven,
Leuven, Belgium
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
362
Convention Center
Interpreting the Cancer Genome in the Clinic
Chairperson: Andy Futreal, The University of Texas MD
Anderson Cancer Center, Houston, TX
This session will focus on current opportunities and
challenges to leveraging genomic data in the clinic. The
complexity and heterogeneity of cancer genomes has been
laid out in considerable detail for a large number of cancer
types over the past few years, as well as marked examples
of success in exploiting mutated genes as therapeutic
targets. As these efforts and insights gain traction, the
framework for their investigation, interpretation, and
regulation become of central importance. In this session,
we will cover aspects ranging from the potential impact of
genomic heterogeneity, the challenges of whole-exome
datasets, moving towards large-scale clinical sequencing
implementation, and regulatory challenges in the
expanding era of interpreting cancer genomes in clinical
cancer care.
1:00 p.m.
Introduction
1:10 p.m.
Somatic genetic heterogeneity in the era of
genomic medicine
Andy Futreal, The University of Texas MD
Grand Ballroom (300 Level), Pennsylvania Convention Center
Microbiome and Tumor Immunity
Chairperson: Giorgio Trinchieri, National Cancer InstituteFrederick, Frederick, MD
Commensal microorganisms colonize barrier surfaces of all
multicellular organisms. For more than 500 million years
commensal microorganisms and their hosts have
coevolved and adapted to each other. As a result, the
commensal microbiota affects many immune and nonimmune functions of their hosts, and de facto the two
together comprise one metaorganism. Microbial imbalance
may play a critical role in the development of multiple
diseases. The commensal microbiota affects the
development, progression, and immune evasion of cancer
but it also has important effects on the response to cancer
immune- and chemo-therapy. Tumor-associated myeloid
cells play a dual role inducing antitumor immune responses
but mostly promoting immune evasion, tumor progression,
and metastases formation. Myeloid cells respond to signals
derived from commensal microbes that modulate their
function and reactivity in inflammation and their ability to
act as antigen presenting cells controlling adaptive
immunity, thus affecting the tumor environment and the
response to cancer therapy.
1:00 p.m.
Introduction
1:30 p.m.
Discussion
1:10 p.m.
1:35 p.m.
Clinical whole exome interpretation for
precision cancer medicine [SY16-02]*
Eliezer M. Van Allen, Dana-Farber Cancer
The microbiota in carcinogenesis and
cancer therapy
Giorgio Trinchieri, National Cancer InstituteFrederick, Frederick, MD
1:30 p.m.
Discussion
1:55 p.m.
Discussion
1:35 p.m.
2:00 p.m.
Enterprise-wide clinical sequencing to
match patients to personalized cancer
treatments [SY16-03]*
Michael F. Berger, Memorial Sloan Kettering
Cancer Center, New York, NY
Microbial-driven cytokine expression fuels
colorectal cancer progression
Sergei I. Grivennikov, Fox Chase Cancer
Center, Philadelphia, PA
1:55 p.m.
Discussion
2:00 p.m.
Microbial activities promote development
of CRC
Christian Jobin, University of Florida,
Gainesville, FL
2:20 p.m.
Discussion
2:25 p.m.
Ipilimumab and gut microbiota: Novel
aspects of immunotherapy
Laurence Zitvogel, Institute Gustave-Roussy,
Villejuif, France
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:20 p.m.
Discussion
2:25 p.m.
Next-generation sequencing tests:
Optimizing regulatory oversight, from
cancer panels to whole genome
Zivana Tezak, U.S. Food and Drug
Administration, Silver Springs, MD
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
363
MAJOR SYMPOSIA
Monday, 1:00 p.m.-3:00 p.m.
Convention Center
Modeling the Noncoding RNA Revolution
in Cancer
Chairperson: Pier Paolo Pandolfi, BIDMC Cancer
While protein-coding genes occupy approximately 20% of
the mammalian genome, a much larger “dark matter”
fraction of our genome is transcribed in RNAs that do not
code for proteins. It is still very much debated whether
these transcripts are simply noise or represent functional
entities. Although noncoding genes vastly outnumber
protein-coding genes in our genome, they have not been
studied or sequenced systematically, if at all, in the various
“cancer anatomy efforts,” nor have they been
functionalized to determine their possible role in
tumorigenesis. In this session we will discuss the
transformative impact of the noncoding RNA dimension in
cancer research and therapy as studied in vivo in animal
models. We will discuss how current modeling efforts in
the mouse are demonstrating the critical role of the “dark
matter” and its central relevance in our ability to
comprehensively deconstruct the pathogenesis of human
cancer and to develop novel diagnostic and therapeutic
strategies.
Targeting Pathway Rewiring to Improve
Cancer Therapy
Chairperson: Michael B. Yaffe, MIT Koch Institute for
Both the emergence of malignant cells and their
subsequent resistance to killing by molecularly targeted
and cytotoxic therapies arises from rewiring of signaling
pathways that control cell growth, proliferation, invasion,
and programmed cell death. This session will review how
the continual ability of cancer cells to rewire signaling
pathways leads to the emergence of therapeutic resistance,
both through tumor cell autonomous changes and through
tumor cell manipulation of the local microenvironment.
Presenters will then demonstrate how a detailed molecular
understanding of this process can lead to novel therapeutic
strategies that can kill these resistant clones and/or
prevent their emergence. Finally, this session will show how
the inherent plasticity of signaling pathways in cancer can
also be taken advantage of therapeutically in order to
make tumor cells sensitive to drugs that they were not
previously sensitive to, through a process called
“therapeutic dynamic rewiring.”
1:00 p.m.
Introduction
1:10 p.m.
Therapeutic network rewiring of the DNA
damage response can be used to enhance
tumor killing by cytotoxic
chemotherapy [SY19-01]*
Michael B. Yaffe, MIT Koch Institute for
1:00 p.m.
Introduction
1:10 p.m.
The regulation and functions of mammalian
microRNAs in normal physiology and cancer
Joshua Mendell, UT Southwestern Medical
Center, Dallas, TX
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
A novel approach to model human cancers
using noncoding RNAs
Andrea Ventura, Memorial Sloan Kettering
1:35 p.m.
Cancer cell-state plasticity and resistance
to therapy
Rafaella Sordella, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY
1:55 p.m.
Discussion
1:55 p.m.
Discussion
2:00 p.m.
Therapeutically targeting the p53 pathway
using miRNA-based approaches in mouse
models of cancer [SY18-03]*
Elsa R. Flores, The University of Texas MD
2:00 p.m.
Rewiring of signaling associated protein
complexes in cancer [SY19-03]*
Eric B. Haura, Moffitt Cancer Center and
Research Institute, Tampa, FL
2:20 p.m.
Discussion
2:20 p.m.
Discussion
2:25 p.m.
2:25 p.m.
MicroRNA-based therapeutics in mouse
models of cancer
Frank John Slack, BIDMC Cancer
Resiliency of the kinome to targeted kinase
inhibitors: Strategies to block rewiring
Gary L. Johnson, University of North Carolina at
Chapel Hill School of Medicine, Chapel Hill, NC
2:45 p.m.
Discussion
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:50 p.m.
General Discussion
364
Convention Center
Tumor Microenvironment
Chairperson: Robert H. Vonderheide, Abramson Cancer
Center of the University of Pennsylvania, Philadelphia, PA
Immune suppressive elements in the tumor
microenvironment frustrate both natural immunity and
therapeutic attempts to mobilize the immune system to
target cancer. This session will focus several immune
aspects the tumor microenvironment and highlight how a
deeper understanding of the biology can inform the design
of novel clinical strategies. Speakers in the session will
discuss myeloid cells, thermal stress, and T lymphocytes in
the tumor microenvironment, and the interface of adaptive
and innate immune regulatory mechanisms.
1:00 p.m.
Introduction
1:10 p.m.
Insights into organ-specific metastasis
from analysis of tumor-microenvironment
interactions
Johanna A. Joyce, Memorial Sloan Kettering
1:30 p.m.
Discussion
1:35 p.m.
Modulating the tumor microenvironment to
enhance the efficacy of immunotherapies
Crystal L. Mackall, National Cancer Institute,
Bethesda, MD
1:55 p.m.
Discussion
2:00 p.m.
Calming the nervous tumor
microenvironment to improve
cancer therapy
Elizabeth A. Repasky, Roswell Park Cancer
Institute, Buffalo, NY
2:20 p.m.
Discussion
2:25 p.m.
Starting an immune response against
pancreatic cancer: Getting past the
stroma [SY21-04]*
Robert H. Vonderheide, Abramson Cancer
Center of the University of Pennsylvania,
Philadelphia, PA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
365
RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH
Monday, 1:00 p.m.-3:00 p.m.
1:00 p.m.
Mechanisms and implications of the
T cell-inflamed tumor microenvironment
Thomas Frank Gajewski, University of
Chicago, Chicago, IL
distribution. While targeting specificity is important for the
reduction of adverse effects, biodistribution is dominantly
determined by the ability of therapeutic agents to navigate
a daunting sequence of biological barriers, including
endothelia and epithelia, the reticulo-endothelial system,
the cancer stroma, target cell membranes, and subcellular
barriers such as the endosomal membrane and multidrug
resistance efflux pumps. Thus, the development of novel
therapeutics requires not only progress in their molecular
targeting specificity, but also in their delivery across
barriers, to reach desired distributions. Often, however, the
addition of specificity decreases the transport properties of
the therapeutic moiety, as for instance is the general case
in the transition from small molecule chemotherapeutics to
large biomolecular targeted therapeutics. The need to
strike a balance between these two aspects poses
problems of extraordinary complexity. In this session, four
different strategies will be presented and discussed, to
generate novel classes of cancer therapeutic agents with
favorable properties of transport, biodistribution, and
targeting specificity, drawing from the combined worlds of
nanomedicine and molecularly targeted therapeutics.
1:20 p.m.
Discussion
1:00 p.m.
1:25 p.m.
Tracking immune response through T cell
receptor sequencing
Lawrence H. Fong, University of California,
San Francisco, CA
Multistage vectors and transport
oncophysics
Mauro Ferrari, Houston Methodist Research
Institute, Houston, TX
1:15 p.m.
Discussion
1:45 p.m.
Discussion
1:20 p.m.
1:50 p.m.
Identification of mutated self-antigens as
targets for TIL therapy
Paul F. Robbins, National Institutes of Health,
Bethesda, MD
Nanoparticle albumin-bound drugs:
A journey
Neil P. Desai, Abraxis Bioscience,
Los Angeles, CA
1:35 p.m.
Discussion
2:10 p.m.
Discussion
1:40 p.m.
2:15 p.m.
Molecular correlates to clinical benefit from
T cell adoptive transfer
Patrick Hwu, The University of Texas MD
Stimuli-sensitive anticancer nanomedicines
Vladimir Torchilin, Northeastern University,
Boston, MA
1:55 p.m.
Discussion
2:00 p.m.
A novel endocytic and intercellular
transport pathway for drug delivery across
blood vessels and into nutrient-deprived
tumor cells
**Hongbo Pang, Sanford-Burnham Medical
Research Institute, La Jolla, CA
2:15 p.m.
Discussion
2:20 p.m.
Antibody-drug conjugates in the treatment
of cancer (not eligible for CME credit)
Clay B. Siegall, Seattle Genetics, Inc.,
Bothell, WA
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Biomarkers for Immunotherapy Response
Chairperson: Thomas Frank Gajewski, University of
Chicago, Chicago, IL
Novel immunotherapies for cancer are making a major
impact on clinical outcome. However, only a subset of
patients experiences therapeutic efficacy, yet the
mechanisms underlying difference in outcome to
immunotherapies are only beginning to be understood.
Viewed from the pharmacologic perspective, this question
amounts to gaining an understanding of primary resistance
mechanisms and the biologic underpinnings of interpatient
heterogeneity. This session will feature emerging data on
the biology of the tumor-host immune system interaction,
with an emphasis on novel application of genomics
technologies toward a molecular understanding of the
mechanisms of immunotherapy response.
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Novel Delivery Systems and/or
Formulations in Cancer Treatment
Chairperson: Mauro Ferrari, Houston Methodist Research
Institute, Houston, TX
The efficacy of therapeutic agents, as well as their adverse
effect profile, depends largely on their biological
366
RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCH
Monday, 1:00 p.m.-3:00 p.m.
Epidemiology of Obesity and Endometrial Cancer
Chairperson: Louise A. Brinton, National Institutes of Health, Bethesda, MD
Although obesity is a risk factor for a number of cancers, the magnitude of association is strongest for
the development of endometrial cancer, the most common gynecologic cancer in U.S. women. The
obesity epidemic in the United States and around the world raises significant concerns regarding
future increases in the incidence of endometrial cancer. Obesity may have special implications for
certain subgroups of women and/or for the development of unique subsets of tumors. The effects of
weight loss on endometrial cancer associated biomarkers and risk patterns are of obvious interest as
they may offer prevention opportunities among those at high risk. Given the strength of association of
obesity with endometrial cancer, novel options for chemoprevention in obese women warrant specific
attention.
1:00 p.m.
Obesity and its implications for changes in endometrial cancer incidence
and mortality
Louise A. Brinton, National Institutes of Health, Bethesda, MD
1:20 p.m.
Discussion
1:25 p.m.
Variations in effects of obesity on endometrial cancer risk according to ethnicity,
genetic factors, and clinical characteristics of the tumors
Veronica Wendy Setiawan, USC/Norris Comprehensive Cancer Center, Los Angeles, CA
1:45 p.m.
Discussion
1:50 p.m.
Implications of obesity and weight loss on endometrial pathology and
associated biomarkers
Faina Y. Linkov, Magee-Womens Research Institute, Pittsburgh, PA
2:10 p.m.
Discussion
2:15 p.m.
Novel options for endometrial cancer chemoprevention in obese women
Karen H. Lu, The University of Texas MD Anderson Cancer Center, Houston, TX
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
367
RECENT ADVANCES IN ORGAN SITE RESEARCH
Monday, 1:00 p.m.-3:00 p.m.
The Dharma Master Jiantai Recent
Advances in Lung Cancer Session: Progress
in Understanding Small Cell Lung Cancer
The Emerging Landscape of Epigenetic
Therapy for Lymphoid Malignancies
Chairperson: Julien Sage, Stanford University School of
Medicine, Stanford, CA
Small cell lung carcinoma (SCLC) remains the most lethal
form of lung cancer, with a dismal 5-year survival for SCLC
patients. These neuroendocrine lung tumors are often
initially responsive to first-line therapy, but relapse is
common and little can be done currently against these
recurrent tumors. No targeted therapies are approved for
SCLC. This session will present recent advances that provide
a better understanding of the molecular and cellular
underpinnings of SCLC progression. In particular, genetic and
genomic approaches (including preclinical mouse models
and cancer genomics studies) are uncovering fundamental
biological processes as well as key vulnerabilities in SCLC,
and a particular emphasis will be placed on novel candidate
targeted therapies for SCLC patients.
Chairperson: Iannis Aifantis, HHMI/NYU School of
Medicine, New York, NY
Leukemia and lymphoma and more specifically lymphoid
malignancies have been at the forefront of genomic and
epigenetic discovery in cancer. During the last decade we
have appreciated the role of the epigenome (DNA
methylation, histone methylation, nucleosome remodeling)
in the induction and progression of lymphoid neoplasms.
Indeed, a large number of mutations targeting epigenetic
factors were identified in acute lymphocytic leukemia
(ALL), chronic lymphocytic leukemia (CLL), and lymphoma.
Moreover, both DNA methylation and histone modification
alterations have been used to group and stratify patients
with distinct clinical features and treatment outcomes.
Finally, more recent work suggested key roles for enhancer
elements in lymphoid malignancies and introduced
compounds that can target enhance integrity and function
as putative therapeutics. Drs. Pasqualucci, Ferrando,
Aifantis, and Martin-Subero will present new data
connecting the epigenome to lymphoid
leukemia/lymphoma initiation, progression, and
therapeutic targeting.
1:00 p.m.
Epigenetic landscape of small cell lung cancer
Charles M. Rudin, Memorial Sloan Kettering
1:20 p.m.
Discussion
1:25 p.m.
Clonal specialization in mouse SCLC: A
paracrine role in tumor progression
Anton Berns, Netherlands Cancer Institute,
Amsterdam, The Netherlands
1:00 p.m.
Genetic basis of epigenetic changes in
diffuse large B cell lymphoma
Laura Pasqualucci, Columbia University
Medical Center, New York, NY
1:45 p.m.
Discussion
1:20 p.m.
Discussion
1:50 p.m.
Understanding the role of the MYC//MAX
and SWI/SNF pathways in small cell
lung cancer
Montse Sanchez-Cespedes, Institute
d’Investigació Biomèdica de Bellvitge,
Barcelona, Spain
1:25 p.m.
DNA methylomes of normal and neoplastic
B cells: Biological and clinical insights
Jose Ignatio Martin-Subero, University of
Barcelona and IDIBAPS, Barcelona, Spain
1:45 p.m.
Discussion
1:50 p.m.
Cytosine hydroxymethylation and the
control of lymphoid cell transformation
Iannis Aifantis, HHMI/NYU School of
Medicine, New York, NY
2:10 p.m.
Discussion
2:15 p.m.
Oncogenic and tumor suppressor
epigenetic programs in T cell acute
lymphoblastic leukemia
Adolfo Ferrando, Columbia University,
New York, NY
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
2:10 p.m.
Discussion
2:15 p.m.
Genomics of small cell lung cancer
Roman K. Thomas, University of Cologne,
Cologne, Germany
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
368
Localized Prostate Cancer:
Next-Generation Sequencing and Beyond
Translational Advances in Brain Cancer
Chairperson: Felix Y. Feng, University of Michigan Medical
Center, Ann Arbor, MI
The goal of this session is to review recent advances in
next-generation sequencing in localized prostate cancer,
with an emphasis on the clinical impact of these findings.
Presentations will review the genomic landscape of
prostate cancer, the implications of this landscape on
prostate cancer biology, the development of clinical
genomics-based assays, the challenges of implementing
genomic assays in the context of tumor heterogeneity, and
the clinical significance of noncoding aspects of the
prostate cancer genome. This session is designed to
provide the audience an overview of the clinical relevance
of prostate cancer genomics as well as novel directions of
investigation in this area.
1:00 p.m.
Molecular pathology applications in
localized prostate cancer
Scott A. Tomlins, University of Michigan
Medical School, Ann Arbor, MI
1:20 p.m.
Discussion
1:25 p.m.
New insights into primary prostate
cancer biology
Levi A. Garraway, Dana-Farber Cancer
1:45 p.m.
Discussion
1:50 p.m.
Challenges of intratumor heterogeneity in
prostate cancer
Michael C. Haffner, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
2:10 p.m.
Discussion
2:15 p.m.
Beyond protein coding genes: Long
noncoding RNAs as biomarkers and potential
therapeutic targets in prostate cancer
Felix Y. Feng, University of Michigan Medical
Center, Ann Arbor, MI
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Chairperson: Ralph J. DeBerardinis, UT Southwestern
Medical Center, Dallas, TX
Brain cancers are characterized by a number of metabolic
alterations that participate in cellular transformation and/or
support tumor cell growth. Because these alterations
distinguish tumor tissue from normal brain, some of them
present outstanding opportunities to diagnose and treat
cancer in novel ways. Important metabolic changes in brain
tumors include oncogene-induced reprogramming of
nutrient uptake and utilization and, in tumors with
mutations in isocitrate dehydrogenase-1 or -2 (IDH1, IDH2),
synthesis of the oncometabolite 2-hydroxyglutarate. This
session will explore recent progress in understanding and
exploiting these metabolic changes. Topics to be discussed
will include new discoveries of metabolic pathways that
fuel glioma cell growth in culture and in vivo; updates on
the effects of inhibiting mutant IDH isoforms on glioma cell
growth and differentiation; and recent advances in the use
of metabolic imaging techniques, particularly magnetic
resonance spectroscopy, to diagnose brain tumors and
predict their clinical course.
1:00 p.m.
Mutant IDH1 as a therapeutic target in
glioma
Paul S. Mischel, Ludwig Institute for Cancer
Research, La Jolla, CA
1:20 p.m.
Discussion
1:25 p.m.
Oncogenic regulation of metabolic
vulnerabilities in glioblastoma
Ingo K. Mellinghoff, Memorial Sloan Kettering
1:45 p.m.
Discussion
1:50 p.m.
Noninvasive metabolite detection for
predictive biomarkers in pediatric brain
cancers
Andrew C. Peet, University of Birmingham,
Birmingham, United Kingdom
2:10 p.m.
Discussion
2:15 p.m.
Substrate utilization and metabolism of
human gliomas in vivo
Elizabeth Maher, UT Southwestern Medical
Center, Dallas, TX
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
369
POSTER SESSION
Poster Section 2 • Monday, 1:00 PM-5:00 PM
Biological Conclusions from Computational Approaches
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
2
Abstract
Number
1.
1921 Unraveling the genetic basis of nasopharyngeal
carcinoma using next-generation sequencing approaches.
Hong Zheng, Wei Dai, Clara Tang, Arthur Cheung, Josephine
Ko, Pak Sham, Maria L. Lung.
10.
1930 New technology of RNA profiling at single cell
level leads to the discovery of tumor heterogeneity in
grade 1 endometrial cancer. Zhu Zhu, Samuel C. Mok,
Xiaoping Su, Ying Yuan, Karen H. Lu.
2.
1922 Target mutation comparasion of WGA circulating
tumor cell and primary tumor in epithelial ovarian cancer
cell line using NGS. Pi-Lin Sung, Chi-Ying F. Huang, Michael
Hsiao, Kuo-Chang Wen, Ming-Shyen Yen, Mong-Hong Lee.
11.
3.
1923 Distinct evolutionary and mutational patterns in
oncogenes and tumor suppressor genes. Li Liu, Yung
Chang, Jieping Ye, Sudhir Kumar.
1931 Mathematical modeling predicts exponential
growth kinetics for metastases in the lymphatic vessels in
the absence of vascularization. Ruth E. Griswold, Simona
Podgrabinska, Suvendu Das, Boyce Griffith, Charles S. Peskin,
Mihaela Skobe.
12.
4.
1924 Genes associated with histopathologic features of
triple negative breast tumors predict molecular subtypes.
Kristen Purrington, Daniel Visscher, Drakoulis Yannoukakos,
Jane Carpenter, Heli Nevanlinna, Arto Mannerma, Xianshu
Wang, Graham Giles, Wei Zheng, Angela Cox, Hiltrud Brauch,
Ute Hamann, Diana Eccles, Celine M. Vachon, Fergus J.
Couch.
1932 RNA-seq differential transcription analysis of
TCGA colorectal cancer (CRC) transcriptomes reveals
subtype-specific isoform usage. Yin Hu, Rodrigo
Dienstmann, Justin Guinney.
13.
1933 Alteration of the protein tyrosine phosphatome in
cancer. Damian Moskal, Nicholas K. Tonks, Robert Lucito.
14.
1934 Improved deconvolution of heterogeneous tumor
data to reconstruct clonal evolution from bulk genomic
samples. Theodore Roman, Russell Schwartz.
5.
1925 Streamlined analysis and interpretation of RNA
editing variants from melanoma cancer samples. Anika
Joecker, Rupert Yip, Anne Arens, Bodil Oester, Douglas
Basset, Bryant Macy.
15.
1935 Gene expression analysis reveals distinct
pathways of resistance to antiangiogenic therapy in
ovarian cancer. Bharat Kumar Devapatla, Pharavee
Jaiprasart, Sukyung Woo.
6.
1926 Patient-derived xenografts seem to have closer
global expression profile to that of the patient tumors of
the corresponding cancer types, than the equivalent cell
lines do. Sheng Guo, Wubin Qian, Jie Cai, Jean-Pierre Wery,
Henry Q. Li.
16.
1936 CoMEt: A statistical approach to identify
combinations of mutually exclusive alterations in cancer.
Hsin-Ta Wu, Mark D. Leiserson, Fabio Vandin, Benjamin J.
Raphael.
17.
7.
1927 Evolutionary novel genes expressed in fish
tumors determine progressive evolutionary characters.
Ekaterina Matyunina, Alexander Emelyanov, Andrei Kozlov.
1937 In-depth genomic analysis reveals complex
functional consequence of driver mutations in breast
cancers. Yaomin Xu, Xingyi Guo, Shilin Zhao, Eric Torstenson,
Todd Edwards, Yu Shyr.
8.
1928 High-grade serous ovarian cancer subtypes are
similar across diverse populations. Gregory P. Way, James
Rudd, Casey S. Greene, Jennifer A. Doherty.
18.
1938 Comprehesive RNA-sequencing pipeline of cancer
xenograft models. Jinha Hwang, Jong-Il Kim, Jee-Soo Choi,
Min Jung Kim, Charles Lee.
19.
9.
1929 Pan-Cancer analysis of the effects of splicealtering variants on mRNA splicing and stability. Reyka G.
Jayasinghe, Kuan-lin Huang, Jie Ning, Matthew
Wyczalkowski, Charles Lu, Mingchao Xie, Michael Wendl,
Michael McLellan, Kai Ye, Li Ding.
1939 Discovery and proteogenomic investigation of
genetic variants in human cancers. Kuan-lin Huang, Jaiyin
Wang, Song Cao, Mingchao Xie, Reyka Jayasinghe, Jie Ning,
Michael McLellan, Michael Wendl, Adam Scott, Kimberly
Johnson, Sherri Davies, David Fenyö, Reid Townsend, Feng
Chen, Jeffrey Parvin, Matthew Ellis, Li Ding.
370
2
POSTER SESSION
Poster
:LJ[PVU
3
3
Cell Signaling in Cancer 3
Poster
Board
Abstract
Number
Poster
Board
1.
1940 Dual inhibition of mTORC1/C2 and HER2 results in
maximal antitumor efficacy in preclinical model of HER2+
breast cancer resistant to trastuzumab therapy. Pradip K.
De, Yuliang Sun, Jennifer H. Carlson, Xiaoqian Lin, Nandini
Dey, Brian Leyland-Jones.
2.
1941 Distinct roles of c-Jun N-terminal kinase (JNK)
isoforms in skin cancer. Lili Du, Tinghu Zhang, Tamer Kaoud,
Nathanael Gray, Kevin Dalby, Kenneth Y. Tsai.
3.
1942 Regulation of GRNMB transcription and cellular
effects by chondroitin 4-sulfation. Joanne K. Tobacman,
Leo Feferman, Sumit Bhattacharyya.
4.
1943 Integrin ␣6␤4 promotes autocrine EGFR
signaling to stimulate migration and invasion toward HGF.
Brittany L. Carpenter, Min Chen, Teresa Knifley, Kelley A.
Davis, Susan M. Harrison, Rachel L. Stewart, Kathleen L.
O’Connor.
19.
5.
1944 NF␬B: Activation by EGF requires TLR4 and
activation by LPS requires EGFR. Sarmishtha De, Hao Zhou,
Xiaoxia Li, George Stark.
20.
6.
1945 Self-phosphorylation primes JNK2 for activation
by MKK4 in glioblastoma and non-small cell lung
carcinoma. Tamer S. Kaoud, Kevin N. Dalby.
16.
17.
18.
21.
7.
1946 Activating transcription factor 5 (ATF5) in highly
expressed in Stage 4, MYCN-amplified neuroblastoma.
Debarshi Banerjee, Shuobo Zhnag, Gonzalo Lopez, Andrea
Califano, Angela Kadenhe-Chiweshe, Darrell Yamashiro.
22.
8.
1947 Divergent effects of Smad2 and Smad3 on TGF-␤
mediated breast cancer cell growth and expression of
TMEPAI/PMEPA1. Prajjal K. Singha, Srilakshmi Pandeswara,
Manjeri A. Venkatachalam, Pothana Saikumar.
23.
9.
1948 In silico screening for novel Wnt/␤-catenin
pathway target and regulator genes in human
hepatocellular carcinoma. Hisateru Komatsu, Atsushi Niida,
Masami Ueda, Hidenari Hirata, Ryutaro Uchi, Sho Nambara,
Tomoko Saito, Shotaro Sakimura, Yuki Takano, Yoshiaki
Shinden, Tomohiro Iguchi, Hidetoshi Eguchi, Keishi
Sugimachi, Yuichiro Doki, Masaki Mori, Koshi Mimori.
10.
1949 Oncogenic signaling in amphiregulin- and EGFRexpressing PTEN-null human breast cancer. Christiana S.
Kappler, Stephen T. Guest, Ericka L. Smith, Jonathan C. Irish,
Elizabeth Garrett-Mayer, Zachary Kratche, Stephen Ethier.
11.
1950 Emerging role of CITED2 in hypoxia and TGF-beta
mediated proliferation and invasion in lung cancer. MingHan Kuo, Cheng-Han Hsieh, Yuan-Hung Wang, Cheng-Wen
Wu, Yu-Ting Chou.
12.
1951 Identification of novel molecular targets for
treatment of castration-resistant prostate cancer. Jim
Moselhy, Ram V. Roy, Suman Suman, Trinath P. Das, Murali
Ankem, Chendil Damodaran.
13.
14.
1952 Adverse effects of erythropoietin stimulates
tumor growth via EphB4. Sunila Pradeep, Jie Huang, Edna
Mora, Alpa Nick, Minsoon Cho, Sherry Wu, Rajesha
Rupaimoole, Chiyi Xiong, Chun Li, Gabriel Lopez-Berestein,
David Jackson, Anil Sood.
1953 Group I Paks as therapeutic targets in NF2deficient meningioma. Hoi Yee Chow.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
1955 IKK␧ maintains MEK activation and suppresses
non-canonical NF-␬B signaling in triple-negative breast
cancer. Carrie House, Valentina Grajales, Helmae Wubneh,
Danielle Kimble, Marianne Kim, Christina Annunziata.
1956 A subset of prostate cancer cells with loss of MST1
expression confers resistance to castration through YAP1AR interactions. Bekir Cinar, Gamze Kuser Abali, Michael
Lewis, Colm Morrissey, Isla Garraway.
1957 Negative regulation of Sox9 by glycogen
synthase kinase 3 beta phosphorylation and SCFFbw7dependent ubiquitination in cancer. Xuehui Hong, Wenyu
Liu, Hiroyuki Inuzuka, Lianxin Liu, Sharon R. Pine.
1958 Interaction between keratin intermediate
filament proteins K8/18 and cancer related signal
transduction proteins in epithelial cells. Stephanie
Lamontagne, Anne-Marie Fortier, Sophie Parent, Eric Asselin,
Monique Cadrin.
1959 15-lipoxygenase-1 suppression of colitisassociated colon cancer through inhibition of the IL-6/
STAT3 signaling pathway. Xiangsheng Zuo, Fei Mao, Min Xu,
Weiguo Xu, Rui Tian, Micheline J. Micheline J. Moussalli, Elias
Elias, Haiyan S. Li, Stephanie S. Watowich, Imad Shureiqi.
1960 Ginger consumption may delay the onset of
prostate cancer. Tonya S. Lane, Ricardo M. Richardson.
1961 Anti-endocrine therapy in breast cancerresistance
can be circumvented by targeting ribonucleotide
reductase M2 usingthe pharmaceutical agent Didox. Khyati
N. Shah, Howard L. Elford, Jesika S. Faridi.
1962 TGF-␤/SMAD2 signaling drives tumorprogression via c-KIT/STAT3-signaling in advanced HCC.
Andres Rojas, Pingyu Zhang, Ying Wang, Nina M. Munoz,
Lianchun Xiao, Jing Wang, Gregory J. Gores, Mien-Chie Hung,
Boris R. Blechacz.
1963 Analysis of aryl substitution and intramolecular
ligand H-bonding in selective inhibitors of the MEK5/ERK5
cascade. Patrick T. Flaherty, Jane C. Cavanaugh, Mohit Gupta,
Colin Vechery, Suravi Chakrabarty, Darlene Monlish, Thomas
Wright.
1964 Role of AMP kinase in TRAIL and PPAR␥ ligand
combination-induced apoptosis and ␤-catenin cleavage.
Sreevidya Santha, Aninda Basu, Ajay Rana, Basabi Rana.
1965 Hippo pathway restrains cell proliferation via
assembly of the DREAM repressor complex. Larisa
Litovchick, Siddharth Saini.
1966 Role of Wnt-Beta-Catenin signals in the control of
vascular mimicry in TNBC. Brian Leyland-Jones, Jennifer H.
Carlson, Pradip De, Nandini Dey.
1967 Elucidation of signaling pathways that mediate
gastrin-induced JNK activation and pGSK3␤/Snail
induction in gastric cancer cells. Aninda Basu, Goutam
Sondarva, Sreevidya Santha, Ajay Rana, Basabi Rana.
1968 Activation of AKT negatively regulates the proapoptotic function of death-associated protein kinase 3
(DAPK3) in prostate cancer. Trinath P. Das, Arokya M. Papu
John, Ram V. Roy, Sandhya R. Rao, Houda Alatassi, Chendil
Damodaran, Murali M. Ankhem.
1969 Regulation of cell cycle progression in
BRAFV600E inhibitor-resistant human melanoma by
histone deacetylase inhibitor. Antoni X. Toresss-Collado,
Ramin Nazarian, Ali R. Jazirehi.
371
POSTER SESSION
Deregulation of Gene Expression in Breast and Ovarian Cancer
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
4
Abstract
Number
1.
1970 The mRNA-destabilizing protein tristetraprolin
suppresses tumorigenic phenotypes in a triple-negative
breast cancer cell model via a non-canonical mechanism.
Christina R. Ross, Gerald M. Wilson.
14.
1983 Aryl hydrocarbon receptor activates NDRG1
transcription under hypoxia in breast cancer cells. En-Yu Li,
Wei-Yung Huang, Mong-Hsun Tsai, Eric Y. Chuang, LiangChuan Lai.
2.
1971 ESE-1 controls transformation properties in
HER2+ breast cancer cells, and predicts poor prognostic
status and survival in breast cancer patients. Adwitiya Kar,
Susan Edgerton, Ann Thor, Arthur Gutierrez-Hartmann.
15.
3.
1972 LIN28 gene targets are key mediators of breast
cancer disease processes. Harriet K. Kinyamu, Jun Yang,
Brian Bennett, Sara Grimm, Pierre Bushel, Trevor Archer.
1984 SOCS3 regulates IDO proteasomal degradation
and inflammatory signaling in triple negative breast
cancer. Maria Ouzounova, EunMi Lee, Ena Novakovic, Satish
Kumar Noonepalle, Raziye Piranlioglu, Huidong Shi, Max
Wicha, Hasan Korkaya.
16.
1985 PBX1 regulated lipid metabolism gene expression
and epithelial-mesenchymal transition independent of
estrogen receptor. Ali Shidfar, Liannian Liu, Vamsi Parini,
MiRan Choi, David Ivancic, Megan E. Sullivan, Demirkan B.
Gursel, Seema A. Khan, Jun Wang.
17.
1986 Effect of the PBD dimer SJG-136 on expression of
STAT3 dependent genes. Julia Mantaj, David E. Thurston,
Khondaker M. Rahman.
18.
1987 Molecular characterization of the breast cancerassociated antigen NY-BR-1. Julia Bitzer, Zeynep Kosaloglu,
Niels Halama, Claudia Ziegelmeier, Tina Lerchl, Anna Spille,
Maria Pudenz, Eva Koellensperger, Stefan Eichmueller,
Wolfram Osen, Andreas Schneeweiss, Frederik Marmé, Inka
Zoernig, Dirk Jaeger.
19.
1988 Role of N- ZEB1 in epithelial-mesenchymal
transition (EMT). M Candelaria Llorens, Ana M. Cabanillas.
20.
1989 Targeting Sin3-Pf1 complex: Novel site-specific
epigenetic therapy for triple negative breast cancer. Nidhi
Bansal, Joanna Wexler, Yeon-jin Kwon, Elena C. Gil, Boris
Leibovitch, Rajal Sharma, Arthur Zelent, Ming-Ming Zhou,
Eduardo Farias, Samuel Waxman.
4.
1973 RNA splicing events may be related to breast
cancer prevention. Julia Santucci-Pereira, Sandy Weng,
Michael Slifker, Maria Barton, Jose Russo.
6.
1975 Role and activation mechanisms of myeloid zinc
finger-1 (MZF1) in ErbB2-induced breast cancer invasion.
Tuula Kallunki, Ditte M. Brix, Knut Kristoffer B. Clemmensen,
Siri A. Tvingsholm, Bo Rafn, José Moreira, Irina Gromova,
Marja Jäättelä.
7.
1976 Oncogenic MYC induces a dependency on RNA
processing in human breast cancer. Tiffany Hsu, Lukas
Simon, Kristen Karlin, Nicholas Neill, Sarah Kurley, Chad
Shaw, Thomas F. Westbrook.
8.
1977 Elucidating heterogeneity within cancer cell
populations using single cell RNA detection. Don Weldon,
Yuko Williams, Victor Koong, Alex Ko.
9.
1978 Relationship between transcription factor TWIST1
and microRNA34a in metastatic cancer cells. Md.
Asaduzzaman Khan, Mousumi Tania, Chunli Wei, Junjiang Fu.
10.
1979 Regulation of the oncogene ZNF217 by
localization in breast cancer. Matthew J. Messana, Laurie E.
Littlepage.
22.
1980 Identification of the transcription factor ZNF217
in ER+ subset of BC: A functional relationship with the
PI3K-AKT-mTOR pathway. Nandini Dey, Casey Williams,
Amy Krie, Ben Solomon, David Starks, Luis Rojas, Jennifer H.
Carlson, Yuliang Sun, Xiaoqian Lin, Mark Abramovitz, Timea
Metzger-Nelson, Kirstin Williams, Jessica Klein, Pradip De,
Brian Leyland-Jones.
1990 The key role of MECOM complex locus and its
products in high-grade ovarian carcinoma pathogenesis
and clinical outcomes. Arsen O. Batagov, Surya P.
Yenamandra, Piroon Jenjaroenpun, Anna V. Ivshina, Vladimir
A. Kuznetsov.
23.
1981 Regulation of NF-kB signaling pathway by
glucocorticoid in breast cancer cells. Zenaida Lopez-Dee,
Jun Ling.
1991 FOXM1 expression in epithelial ovarian cancer
coincides with gene amplification and functional loss of
p53 and Rb and drives G2-M progression and target gene
expression. Carter J. Barger, Wa Zhang, Kunle Odunsi, Adam
R. Karpf.
24.
1992 Evidence for modulation of FoxM1 by p21 in
ovarian cancer. Jill Madden, Jeremy Chien.
25.
1993 Global correlation analysis of HOXC6 expression
in ovarian cancer. Pourya Naderi Yeganeh, Zahra BahraniMostafavi, Christine Richardson, David L. Tait, M. Taghi
Mostafavi.
11.
12.
13.
372
1982 The HER2 Regulon: Identification of 113 genes
that are directly controlled by HER2 and define four nodes
of cancer stem cell networks. Farah Rahmatpanah, Yuanjie
Hu, Xin Chen, Michael McClelland, Frank Jones, Dan Mercola.
4
POSTER SESSION
Poster
:LJ[PVU
5
5
New Developments in Proteomics
Poster
Board
Abstract
Number
1.
1994 Impact of laser capture microdissection on cancer
signaling proteins and phosphoproteins. Elisa Baldelli, Vienna
Ludovini, Lucio Crinò, Lance Liotta, Emanuel Petricoin, Mariaelena
Pierobon.
2.
1995
Developing integrated single-cell metabolic/proteomic
assays. Min Xue, Wei Wei, Yapeng Su, Young Shik Shin, Jungwoo
Kim, James R. Heath.
3.
1996 Surface proteomics of KRASG12V transfected MCF10A
cells reveals molecular phenotype of a model cell line expressing
oncogenic KRAS. Xiaoying Ye, King C. Chan, Thomas J. Turbyville,
Rachel Bagni, Alexander Martinko, Juan Diaz, Jim Wells, Franck
McCormick, Gordon Whiteley, Josip Blonder.
4.
1997 Label-free concentration of viable breast cancer CTCs
for single cell Western blotting. Elly Sinkala, Elodie Sollier, Corinne
Renier, James Che, Stefanie S. Jeffrey, Amy E. Herr.
5.
1998 A novel luminescent system for monitoring intracellular
protein:protein interactions. Brock Binkowski, Andrew S. Dixon,
Marie K. Schwinn, Mary P. Hall, Kris Zimmerman, Paul Otto, Thomas
Lubben, Braeden Butler, Thomas Kirkland, Monika G. Wood, Lance P.
Encell, Frank Fan, Keith V. Wood.
6.
7.
8.
1999 Proteogenomic characterization of breast cancer subtypes in patient derived xenografts. Harsha P. Gunawardena, John
A. Wrobel, Jonathon O’Brien, Ling Xie, Petra Erdmann-Gilmore, Sherri
R. Davies, Shunqiang Li, Song Cao, Michael McLellan, Kelly V.
Ruggles, David Fenyo, R. Reid Townsend, Li Ding, Bahjat F. Qaqish,
Matthew J. Ellis, Xian Chen.
2000 Proteomic features of histological compartments in
colorectal carcinoma. Robbert J. Slebos, Lisa J. Zimmerman,
Suzanne Manning, Melinda E. Sanders, Chanjuan Shi, M K.
Washington, Daniel C. Liebler.
2001 Identification of lactate dehydrogenase A (LDHA) as a
potential therapeutic target for prostate cancer radiotherapy.
Jingli Hao, Peter H. Graham, Lei Chang, Jie Ni, Valerie Wasinger, Julia
Beretov, Joseph Bucci, Paul Cozzi, Yong Li.
9.
2002 Assembling test points for quantitative proteomics to
elucidate RAS signaling. Eric Kuhn, Jeffrey R. Whiteaker, Melissa
Martinez, Matthew Holderfield, Jacob Kennedy, Jacob Jaffe, Ping Yan,
ChenWei Lin, Gordon Whiteley, Steven A. Carr, Amanda G. Paulovich,
John M. Koomen.
10.
2003 Investigating the cellular interactions of BIRB796
analogues using a novel chloroalkane capture tag. Rachel Friedman
Ohana, Robin Hurst, Thomas Kirkland, Carolyn Woodroofe, Sergiy
Levin, Paul Otto, Tetsuo Uyeda, Michael Ford, Richard Jones, Danette
Daniels, Marjeta Urh, Keith Wood.
11.
2004
12.
Phenotypic and molecular characterization of inter- and
intraclonal heterogeneity in multiple myeloma and Waldenstrom
macroglobulinemia. Jana Jakubikova, Danka Cholujova, Teru
Hideshima, Jacob Laubach, Nikhil C. Munshi, Steven P. Treon, Paul G.
Richardson, Efstathios Kastritis, David M. Dorfman, Kenneth C.
Anderson.
2005 Quantitative screening of serum protein biomarkers by
reversed phase protein serum arrays. Zhizhou Kuang, Ruochun
Huang, Shuhong Luo, Yun-Ru Chen, Zhiqiang Lv, Zhuo Zhang, RuoPan Huang.
13.
2006 Kinases and adaptive signaling contribute to drug
resistance in BRAF mutant melanoma. Ritin Sharma, Manali Phadke,
David Britton, Ian Pike, Keiran Smalley, John M. Koomen.
14.
2007
Phosphoproteomics scaled-down to tumor biopsies for
future TKI treatment selection. Mariette Labots, Johannes C. Van der
Mijn, Sander R. Piersma, Richard R. De Haas, Robin Beekhof, Thang V.
Pham, Jaco C. Knol, Inge de Reus, Nicole C. van Grieken, Gerrit A.
Meijer, Connie R. Jimenez, Henk M. Verheul.
Poster
Board
Abstract
Number
15.
2008 Proteomic analysis of SIAH2 E3 ligase complex in
oncogenic K-Ras-driven cell transformation in human cancer.
Monicah M. Njogu, Ming Lei Bian, Jamie Eisner, Amy H. Tang.
16.
2009 Flow cytometric analysis, sorting and molecular analysis
of dissociated cells from human solid tumors derived from PDX
mouse models. Rainer Blaesius, Friedrich Hahn, Eileen Snowden,
Warren Porter, Mitchell Ferguson, Frances Tong, Stewart Jurgensen,
Chang Chen, Daphne Clancy, Jamal Sirriyah, John Alianti, Perry
Haaland, Shannon Dillmore, Jeff Baker, Aaron Middlebrook, Joyce
Ruitenberg, Maria Suni, Smita Ghanekar.
17.
2010 Immunosignature technology detects stage I lung cancer
from a drop of serum. Theodore M. Tarasow, Michael W. Rowe,
Mojgan Haddad, Kathryn Sykes.
18.
2011 Feasibility of serum proteomic companion diagnostic
(CDx) test development on the microflex LT platform. Nicholas
Dupuis, Jamie Chang, Maximillian Steers, Zhigang Weng, Jeno Gyuris,
Gary Pestano.
19.
2012 Accurate measurement of free and complexed PSA
concentrations in serum of women using a novel technology with
fg/mL sensitivity. Galina N. Nikolenko, Martin K. Stengelin, Laukik
Sardesai, Eli N. Glezer, Jacob N. Wohlstadter.
20.
2013 Synthetic lectins for the determination of breast cancer
subtype. Kathleen M. O’Connell, Erin E. Gatrone, Anna A. Veldkamp,
John J. Lavigne.
21.
2014 MultiOmyxTM: A multiplexed immunofluorescent assay
capable of profiling protein expression and phosphorylation, in
combination with next-generation sequencing from a single FFPE
tissue section. Qingyan Au, Maoyong Fu, Alexander Bordwell,
Tripathi Pinky, Michael Lazare, Nam Tran, Nicholas Hoe.
22.
2015 Multiparameter flow cytometry analysis of breast cancer
cell lines MDA-MB-231 and MDA-MB-468 to simultaneously assess
cell proliferation, apoptosis, and DNA damage in response to
treatment with camptothecin. Lissette Wilensky, Stacey Roys, Mirko
Corselli, Alice Wang, Nil Emre.
23.
2016 Evaluation of prostate cancer biomarkers and
therapeutic targets in FFPE specimens using the NanoString
platform. Jocelyn Lee, Wusheng Yan, Denise Young, Yingjie Song,
Yongmei Chen, Shilpa Katta, Ahmed Mohamed, Lakshmi
Ravindranath, Alagarsamy Srinivasan, Jennifer Cullen, Jacob Kagan,
Sudhir Srivastava, Albert Dobi, Inger Rosner, David G. McLeod, Isabell
A. Sesterhenn, Shiv Srivastava, Gyorgy Petrovics.
24.
2017 Development of ultrasensitive Singulex immunoassays
for CCL3 and CCL4, important biomarkers for the BTK inhibitor
studies. Jenny Q. Wu, Luciana Burton, Rajiv Raja, Ian McCaffery, Elicia
Penuel, Walter Darbonne.
25.
2018 Elucidating the therapeutic potential of midbrain
pathways that impact breast cancer. Madeline Chandra, John Lee,
Patrick L. Sheets, Jenifer R. Prosperi.
26.
2019 Photoimmunotherapy with an anti-EGFR antibody
conjugated to an IRDye700 results in extensive and rapid cell
death in vitro and in vivo in human pancreatic cancer cell lines.
Nzola de Magalhães, Takashi Murakami, Roger Heim, Lew Makings,
Miguel Garcia-Guzman, Hisataka Kobayashi, Robert M. Hoffman,
Michael Bouvet.
27.
2020 A platform to test multiple therapies simultaneously in
the intact tumors of cancer patients: Initial clinical experience.
Alicia Moreno Gonzalez, Jason Frazier, William Kerwin, Jessica
Bertout, Joseph Casalini, Sally Ditzler, Nathan Caffo, Richard A.
Klinghoffer.
28.
2021 Integrin-alpha 8 as a potential therapeutic target in
multiple myeloma early relapse. Jiyeon Ryu, Youngil Koh, Hyun
Jung Lee, Hyun Sub Chung, Sung-Soo Yoon.
373
POSTER SESSION
Oncogenes and Tumor Suppressors 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
374
Abstract
Number
2023 MYC amplification and overexpression in
metastatic anaplastic thyroid cancer dictates response to
therapy. Emrullah Yilmaz, Marika A. Russo, Arturo Orlacchio,
Toni Forde, Antonio Di Cristofano.
2024 c-Myc driven B cell lymphomas: role of the RPL5/
RPL11/5S rRNA-MDM2 inhibitory complex (L5/L11/5SMIC). Suresh Peddigari, Carol Mercer, Sara Kozma, George
Thomas.
2025 Inverse relation of Myc and p27 in cribriform
pattern prostate cancer. Ibrahim Kulac, Jessica Hicks, Qizhi
Zheng, Helen Fedor, Toby C. Cornish, Angelo M. De Marzo.
2026 G0S2 functions as a tumor suppressor gene
through inhibition of c-Myc. Christina Y. Yim, David J.
Sekula, Sarah J. Freemantle, Ethan Dmitrovsky, Michael J.
Spinella.
2027 MECP2 is a frequently amplified oncogene with an
unusual epigenetic mechanism of action. Manish Neupane,
Allison P. Clark, Nicolai J. Birkbak, Aron Eklund, Steven E.
Schumacher, Rameen Beroukhim, Zoltan Szallasi, Marc Vidal,
David E. Hill, Daniel P. Silver.
2028 RUNX3 knockdown inhibited oral cancer-induced
bone destruction via reducing TGF-␤-dependent
responses. Junhee Park, Won-Yoon Chung, Kwang-Kyun
Park.
2029 Mcph1/Brit1 deficiency promotes genomic
instability and tumor formation in a mouse model. Yulong
Liang, Hong Gao, Shiaw-Yih Lin, John A. Goss, Chunying Du,
Kaiyi Li.
2030 FRK regulates glioma cell progression by
promoting N-cadherin/␤-catenin complex formation.
Qiong Shi, Xu Song, Haoping Yan, Jun Wang, Weijian Zhang,
Jinxia Hu, Xiuping Zhou, Rutong Yu.
2031 RRD-251 enhances retinoic acid induced
differentiation of myeloblastic leukemic cells. Aaron S.
Wallace, Wendy M. Geil, Andrew Yen.
2032 Genomic landscape survey identifies SRSF1 as a
key oncodriver in small cell lung cancer. Zheng Liu, Jiaqi
Huang, Brandon W. Higgs, Haihong Zhong, Dong Shen, Zhan
Xiao, Xin Yao, Philip Brohawn, Xiaoxiao Ge, Zhibing Hu, Yue
Jiang, Chris Morehouse, Wei Zhu, Yinong Sebastian, Meggan
Czapiga, Vaheh Oganesyan, Haihua. Fu, Xinying Su, Yi Gu,
Baohui Han, Ronald Herbst, Liayang Jiang, Hongbing Shen,
Yihong Yao.
2033 Germline mutations in ETV6 confer risk of
thrombocytopenia and acute lymphocytic leukemia. Vijai
Joseph, Michael F. Walsh, Sabine Topka, Gang Wu, Rose B.
McGee, Emily Quinn, Hiroto Inaba, Christine Hartford, ChingHon Pui, Alberto S. Pappo, Michael Edmonson, Lauren
Jacobs, Villano Danylo, Kasmintan Schrader, Pragna Gaddam,
Zsofia Stadler, Michael Zhang, Polina Stepensky, Peter
Steinherz, James Bussel, M Harit, Michael Weintraub, Akiko
Shimamura, Jinghui Zhang, James R. Downing, Kenneth Offit,
Kim E. Nichols.
2034 Amplification and overexpression of EVI1
suppresses growth inhibition mediated by TGF-␤ in
hepatocellular carcinoma. Kohichiroh Yasui, Yasuyuki Gen,
Osamu Dohi, Akira Tomie, Tomoko Kitaichi, Yoshito Itoh.
2035 Targeting the hyperactive polyisoprenylated
monomeric G-proteins functions in pancreatic cancer.
Augustine T. Nkembo, Olufisayo Salako, Rosemary Poku,
Tryphon Mazu, Byron Aguilar, Hernan Flores-Rozas, Nazarius
S. Lamango.
Poster
Board
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
6
Abstract
Number
2036 Keratin 17 mediates p27KIP1-nuclear export,
proliferative signaling and tumor growth. Luisa F. EscobarHoyos, Ruchi Shah, Lucia Roa-Peña, Nilofar Najafian,
Elizabeth Vanner, Anna Banach, Erik Nielsen, Ramsey AlKhalil, Ali Akalin, David Talmage, Kenneth Shroyer.
2037 The butyrate transporter SLC5A8 is a tumor
suppressor in colon linked to dietary fiber content. Vadivel
Ganapathy, Ashish Gurav, Nagendra Singh.
2038 A novel role for the NLRP3 inflammasome in lung
cancer. Virginie Petrilli, Mélanie Bodnar, Baptiste Guey,
Sabine Hacot, Sylvie Lantuejoul.
2039 Trim21: A novel regulator of Par-4 and oncogenic
signaling. Jeffrey Nguyen, Rosalyn Irby.
2040 Mutations in SF3B1 lead to aberrant splicing
through cryptic 3’ splice site selection and impair
hematopoietic cell differentiation. Silvia Buonamici,
Samantha Perino, Kian H. Lim, Jacob Feala, Rachel Darman,
Esther Obeng, Richard R. Furman, Suzanna Bailey, Gregg
Keaney, Pavan Kumar, Yoshiharu Mizui, Eunice Park, John
Wang, Markus Warmuth, Lihua Yu, Ping Zhu, Benjamin L.
Ebert, Peter Smith.
2041 Quantitative phosphoproteomic analysis of
EphA2 signaling in PC-3 prostate cancer cells. Carolin
Offenhäuser, Keyur A. Dave, Buddhika A. Jayakody, Jeffrey J.
Gorman, Andrew W. Boyd.
2042 Low Slit2 expression is associated with the
aggressiveness of papillary thyroid carcinoma. MinJi Jeon,
Won Gu Kim, Seonhee Lim, Eun Kyung Jang, Tae Yong Kim,
Young Kee Shong, Won Bae Kim.
2043 SATB1 (special AT-rich binding protein 1) as a
putative therapeutic target in colorectal cancer. Anja
Frömberg, Michael Rabe, Michael Linnebacher, Achim M.
Aigner.
2044 Characterization of a novel tumor suppressor
PRSS8 in colorectal cancer. Yonghua Bao, Kai Li, Qian Wang,
Yongchen Guo, Rongfei Han, Zhiguo Chen, Zexin Li, Jianguo
Wang, Weixing Zhao, Wenliang Han, Jiaqi Wang, Huijuan
Zhang, Pan He, Wancai Yang.
2045 Sleeping Beauty mutagenesis screening identifies
a novel tumor suppressor gene involved in liver tumor
development. Takahiro Kodama, Zhubo Wei, Michiko
Kodama, Nancy Jenkins, Neal Copeland.
2046 Analysis of over-expressed chromosomal regions
identifies YBX1 oncogene amplification in basal-like
breast tumors. Abbey Jebb, Sandra Fitzgerald, Sheridan
Wilson, Annette Lasham, Cristin Print.
2047 CDK10 promotes tumour growth and
chemoresistance in colorectal cancer, and is a potential
target for treatment. Louis-Bastien Weiswald, Mohammad
R. Hasan, Mahbuba Rahman, Clarissa Pasiliao, Isabella T. Tai.
2048 Evidence that MTAP acts as a genetic switch to
inhibit tumor formation. Baqing Tang, Warren Kruger.
2049 Characterization of a novel BRCA1-EGR1
interaction. Naomi A. Dickson, Nyree T. Crawford, Paul B.
Mullan.
2050 Persistent STAT3 signaling contributes to the
resistance of anti cancer drugs doxorubicin and cisplatin,
and MEK inhibitor AZD6244 in human sarcoma cells.
Xiaojuan Wu, Hui Xiao, Chenglong Li, Jiayuh Lin.
2051 Regulation of RNA processing by PADI4 pathway.
Chizu Tanikawa, Koji Ueda, Yusuke Nakamura, Koichi
Matsuda.
2052 The transcriptional co-regulator and emerging
cancer drug target C-terminal binding protein (CtBP) is a
transforming oncogene. Evan T. Sumner, Steven R.
Grossman.
6
POSTER SESSION
Poster
:LJ[PVU
7
7
Oncogenes and Tumor Suppressors 2
Poster
Board
Abstract
Number
1.
2053 Overexpressed Rab1A is associated poor
prognosis and promotes oncogenic growth and metastasis
through mTORC1 activation in hepatocellular carcinoma.
Bi-Hong Xu, Xiao-Xing Li, Hui-yun Wang, X.F. Steven Zheng.
2.
2054 In pancreatic cancer, MUC1 regulates function of
TGF-␤ and thus enhances metastasis. Priyanka Grover,
Sritama Nath, Mohammad Ahmad, Pinku Mukherjee.
3.
2055 Overexpression of nuclear met activates NF-␬B
signaling to promote tumorigenesis and metastasis in
hepatocellular carcinoma. Sze Keong Tey, Edith Yuk Ting
Tse, Frankie Chi Fat Ko, Judy Wai Ping Yam.
4.
2056 SIRT1 silencing suppresses prostate cancer growth and
metastasis in an orthotopic prostate cancer mouse model. Yan
Dai, Lijia Zhu, Elizabeth Cho, Audrey Hagiwara, Douglas
Faller, Sun-Jin Kim, Isaiah J. Fidler, Marina Amaro.
5.
2057 Protocadherin 10-mediated suppression of
tumorigenesis and metastasis in colorectal cancer. yu-lin hung.
6.
2058 RHOA inactivation enhances Wnt signaling and
promotes colorectal cancer. Paulo Rodrigues, Irati Macaya,
Sarah Bazzocco, Elena Andretta, Rocco Mazzolini, Higinio
Dopeso, Silvia Mateo-Lozano, Josipa Bilic, Fernando CartónGarcía, Rocio Nieto, Lucia Suárez-López, Elsa Afonso,
Stefania Landolfi, Javier Hernandez-Losa, Kazuto Kobayashi,
Santiago Ramón y Cajal, Josep Tabernero, Niall C. Tebbutt,
John M. Mariadason, Simo Schwartz Jr, Diego Arango.
7.
8.
2059 Novel roles for GNA13 and RHOA as tumor
suppressor genes. Morgan O’hayre, Asuka Inoue, Katiuchia
Sales, Irina Kufareva, Juan Luis Callejas Valera, Fukun Guo,
Constantinos Mikelis, Giovanni DiPasquale, Kira Finkel,
Junken Aoki, Yi Zheng, Thomas H. Bugge, J. Silvio Gutkind.
2060 DUSP6 phosphatase as a tumor suppressor in
non-small cell lung cancer. Rosario Perona, Veronica
Moncho-Amor, Inmaculada Ibanez de Caceres, Laura
Pintado-Berninches, Ester Martin, Miguel Quintanilla, María
Cortes-Sempere, Leandro Sastre, Cristobal Belda-Iniesta.
9.
2061 CHIP functions as tumor suppressor in prostate cancer
through suppression of ROS-inflammasome in a chaperonedependent mechanism. Neveen A. Said, James Larner.
10.
2062 Pre-analytical conditions strongly influence
molecular pattern in clinical biospecimen. Florian T. Unger,
Nicole Lange, Philipp Uhlig, Hartmut Juhl, Kerstin A. David.
11.
2063 A novel ELAVL1-TYK2 fusion protein drives
STAT3/5 activation and PIM-1 expression, survival and
growth in the MOLM-16 acute myeloid leukemia cell line.
Kristen McEachern, Erika Keeton, Keith Dillman, Minwei Ye,
Chloe Stengel, Huawei Chen, Suping Wang, Shaun
Grosskurth, Rosemary E. Gale, David C. Linch, Asim Khwaja,
Zhongwu Lai, Dennis Huszar.
12.
2064 GSK3 regulation of Mcl1 and beta catenin involves
I kappa B alpha. Vineshkumar Thidil Puliyappadamba, Nanda
Kumar Thudi, Markus Bredel.
13.
2065 TMEFF2 is a novel androgen receptor co-activator
in prostate cancer cells. Joshua Corbin, Thomas Green, Maria
J. Ruiz-Echevarria.
14.
2066 Aberrant upregulation of 14-3-3 gamma
promotes mononucleated polyploidization in human lung
cancers. Cecil J. Gomes, Michael Harman, Jesse Martinez,
Sara Centuori.
Poster
Board
Abstract
Number
15.
2067 Tid1 mediating cancer initiating properties of
head and neck squamous cell carcinoma. Li-Hao Cheng,
Jeng-Fan Lo.
16.
2068 Cyclooxygenase-1 gene expression contributes to
multiple oncogenic pathways in high grade serous ovarian
cancer. Andrew J. Wilson, Brian D. Lehmann, Jeanette
Saskowski, MD Jashim Uddin, Cristina Daniel, Brenda C.
Crews, Qi Liu, Shilin Zhao, Deok-Soo Son, Jennifer A.
Pietenpol, Lawrence J. Marnett, Dineo Khabele.
17.
2069 Stromal-epithelial crosstalk of Mig-6 has an
important role for tumor suppression via progesterone in
endometrial cancer. Tae Hoon Kim, Byung Gak Kim, JungYoon Yoo, Jae Hee Lee, Diego H. Castrillon, Jae-Wook Jeong.
18.
2070 Stxbp4 suppresses APC/C mediated turnover of
p63 and increases tumorigenicity and malignancy. Yukihiro
Otaka, Susumu Rokudai, Kyoichi Kaira, Kimihiro Shimizu,
Masashi Ito, Ami Ichihara, Reika Kawabata, Shinji Yoshiyama,
Arito Yamane, Takayuki Asao, Carol Prives, Masahiko
Nishiyama.
19.
2071 Disruption of TGF␤-mediated tumor suppression
in a Tpl2 model of cutaneous squamous cell carcinoma.
Lauren Falkenberg, J. Curtis Gwilliam, Katie L. DeciccoSkinner.
20.
2072 Ormeloxifene attenuates wnt/␤-catenin
signaling in colon cancer cells by modulation of PKD1 and
glycolytic pathways. Aditya Ganju, Rishi Gara, Sonam
Kumari, Man Mohan Singh, Subhash Chauhan, Meena Jaggi.
21.
2073 Histone deacetylase 8 impairs insulin sensitivity
and activates ␤-catenin signaling in NAFLD-associated
hepatocellular carcinoma. Yuan Tian, Ka F. To, Paul B. Lai,
Yue S. Cheung, Jun Yu, Vincent W. Wong, Henry L. Chan,
Alfred S. Cheng.
22.
2074 Selective inhibitor of nuclear export (SINE)
compounds show synergistic anti-tumor activity in
combination with dexamethasone in multiple myeloma.
Yosef Landesman, Trinayan Kashyap, Boris Klebanov, Sivan
Elloul, Marsha Crochiere, Sharon Friedlander, William
Senapedis, Robert Carlson, Michael Kauffman, Sharon
Shacham.
23.
2075 Signaling thresholds and negative B cell selection
in acute lymphoblastic leukemia. Zhengshan Chen,
Seyedmehdi Shojaee, Maike Buchner, Huimin Geng, Jae
Woong Lee, Lars Klemm, Eugene Park, Ying Xim Tan, Anne
Satterthwaite, Elisabeth Paietta, Stephen P. Hunger, Mignon
L. Loh, Jae U. Jung, John E. Coligan, Silvia Bolland, Tak W.
Mak, Andre Limnander, Hassan Jumaa, Michael Reth, Arthur
Weiss, Clifford A. Lowell, Markus Müschen.
24.
2076 RNF43 is a frequent mutational target in serrated
colorectal neoplasia. Vicki L. Whitehall, Catherine Bond,
Diane McKeone, Jonathan Ellis, Mark Bettington, Sally
Pearson, Barbara Leggett.
25.
2077 DLEU1 significantly alters programmed cell death
in chemoimmunotherapy-treated TALENs-induced DLEU1
knockout and DLEU1 overexpressing Burkitt Lymphoma
(BL): DLEU1 may act as a tumor suppressor gene in
pediatric BL. Sanghoon Lee, Changhong Yin, Janet Ayello,
Carmella van de Ven, Mitchell S. Cairo.
375
POSTER SESSION
Oncogenic Transcription Factors
Poster
:LJ[PVU
Poster
Board
Abstract
Number
1.
2078 A functional role for the MYC i-motif in
transcription. Caleb Sutherland, Laurence Hurley.
2.
2079 FGFR1/MAPK pathway regulates transcription
factor brachyury-driven epithelial-mesenchymal
transition in lung cancer. Yunping Hu, Wesley Hsu.
3.
2080 Differential transcription profile of epithelia in
fimbria versus the ampulla of the fallopian tube. Sophia H.
George, Anca Milea, Noor H. Salman, Patricia A. Shaw.
4.
2081 The CCCTC-binding factor (CTCF) functions to
downregulate the transcription of MGMT gene in human
glioblastoma cells. Kalkunte S. Srivenugopal, Mohammed I.
Al-Obaide.
5.
2082 Control and function of the PROX1 transcription
factor in malignant glioma. Kaveh M. Goudarzi, Tamador
Elsir, Monica Nistér, Mikael S. Lindström.
6.
2083 TFAP4 inhibits differentiation of MYCN-amplified
neuroblastoma. Shuobo Zhang, Gonzalo Lopez, Jiyang Yu,
Jose Silva, Angela Kadenhe-Chiweshe, Andrea Califano,
Darrell Yamashiro.
7.
2084 Genetic variation at a cis-acting C/EBPG binding site is
associated with allele-specific ERCC5 transcript expression.
Xiaolu Zhang, Jiyoun Yeo, Erin Crawford, James C. Willey.
8.
2085 Nicotine-mediated regulation of Sox2 and its
implications in the biology of non-small cell lung
adenocarcinoma stem-like cells. Courtney Schaal, Namrata
Bora Singhal, Smitha Pillai, Jonathan Nguyen, Srikumar
Chellappan.
9.
2086 Role of the transcription factor NFE2L3 in TNF␣
signaling pathway in colorectal cancer. Marina Bury, Volker Blank.
10.
2087 Regulation of p53 function by KLF5. Yizeng Yang,
Taicheng Zhou, Zhen Zong, Gwen Lomberk, Raul Urrutia,
Jonathan Katz.
11.
2088 PU.1 enrichment to intronic enhancers is required for
meis1 gene expression in both hematopoiesis and
leukemogenesis. Yajun Li, Bo Li, Qiang Li, Lixia Zhang, Ping Li.
12.
2089 Role of Cdx2 in maintainining differentiated chromatin
structure during tumor progression. Ansu O. Perekatt, Ritu
Rana, Namit Kumar, Michael Valdez, Michael Verzi.
13.
2090 GLI3 repressor levels determine Hedgehog pathway
activity and predict response to Smoothened antagonist in acute
myeloid leukemia. Parvesh Chaudhry, Mohan Singh, Tim
Triche, Aparna Jorapur, Parkash S. Gill, Akil Merchant.
14.
2091 IL-8 mRNA gene expression up-regulated level in
both primary culture cell and tissue biopsy from gastric
cancer patient without Helicobacter pylori infection and
down- regulated level predict clinical response after
chemotherapy treatment. Sirikan Limpakan (Yamada),
ML.Bandhuphat Chakrabandhu, Shunji Kato, Pattama
Wongsirisin.
15.
16.
376
2092 FOXO1/Sprouty2 pathway regulates vascular
tumor growth. Sriram Ayyaswamy, Wa Du, Christopher
Anderson, Thuy L. Phung.
2093 Regulation of c-Myc expression by aspirin and
salicylic acid in colon cancer cells through a novel
pathway. Guoqiang Ai, Rakesh Dachineni, Pratik Muley,
Hemachand Tummala, Jayarama B. Gunaje.
Poster
Board
8
Abstract
Number
17.
2094 GSK-3 is a novel target of CREB and GSK-3-CREB
signaling participates in cell survival in lung cancer. SinAye Park, Jong Woo Lee, Roy S. Herbst, Jaseok Peter Koo.
18.
2095 DEPTOR is a direct NOTCH1 target that regulates
proliferation, metabolism and glucocorticoid resistance in
T cell leukemia. Yufeng Hu, Hexiu Su, Qi Ye, Zhaojing Wang,
Liang Huang, Qian Wang, Shuangyou Liu, Suning Chen,
Jianfeng Zhou, Peng Li, Guoliang Qing, Hudan Liu.
19.
2096 High sensitivity of cutaneous T-cell lymphoma
(CTCL) to CABE, a component of propolis. Arumugam
Jayakumar, Radjendirane Venugopal, Rafal Zielinski,
Aleksandra Rusin, Izabela Fokt, Stanislaw Skora, Xiao Ni,
Madeleine Duvic, Waldemar Priebe.
20.
2097 Grainyhead-like 2 (GRHL2) regulates epithelial
plasticity and stemness in oral cancers. Wei Chen, Shebli
Mehrazarin, Ki-Hyuk S Shin, Yi-Ling Lin, Reuben H. Kim, NoHee Park, Mo K. Kang.
21.
2098 Genome-wide comparison of PU.1 and Spi-B
binding sites in a mouse B lymphoma cell line. Lauren A.
Solomon, Stephen K. Li, Jan Piskorz, Li S. Xu, Rodney P.
DeKoter.
22.
2099 FoxM1 drives a feed-forward STAT3-activation
signaling loop to promote the self-renewal and
tumorigenicity of glioblastoma stem cells. Sicong Zhang,
Ai-hua Gong, Ping Wei, Aidong Zhou, Jun Yao, Ying Yuan,
Frederick Lang, Ganesh Rao, Suyun Huang.
24.
2101 The transcription factor POU3F2 is expressed in
human gliomas and promotes tumorigenesis in vivo.
Mohummad A. Rahman, Lina Liess, Mohammad S. Lellahi,
Christiane H. Gjerde, Halala S. Saed, Ercan Mutlu, Huaiyang
Zhu, Jian Wang, Per Ø. Enger.
25.
2102 TBX2 promotes rhabdomyosarcoma (RMS)
tumorigenesis by repression of PTEN expression. Bo K.
Zhu, Judith K. Davie.
26.
2103 SOX2 suppresses PTEN expression via miR-19a in
esophageal squamous cell carcinoma. Yasuyuki Gen,
Kohichiroh Yasui, Tomoko Kitaichi, Osamu Dohi, Yoshito Ito.
27.
2104 Evidence for E2F/EWS-FLI1 oncoprotein
synergism using systems biology. Raphaela Schwentner,
Theodore Papamarkou, Maximilian Kauer, Vassilios
Stathopoulos, Fan Yang, Sven Bilke, Paul S. Meltzer, Mark
Girolami, Heinrich Kovar.
28.
2105 An EWS-FLI1/MRTF gene regulatory network in
Ewing sarcoma. Anna M. Katschnig, Maximilian Kauer,
Raphaela Schwentner, Dave N. Aryee, Elizabeth Lawlor,
Heinrich Kovar.
29.
2106 Twist1 regulates keratinocyte stem cell
proliferation and migration and is required for skin tumor
formation. Jaya Srivastava, Okkyung Rho, John DiGiovanni.
30.
2107 YAP protein expression and subcellular
localization in pediatric liver tumors. Michael J. LaQuaglia,
James Grijalva, Kaly Mueller, Antonio Perez-Atayde, Heung
Bae Kim, Ghazaleh Sadri-Vakili, Khashayar Vakili.
8
POSTER SESSION
Poster
:LJ[PVU
9
9
Post-Transcriptional and Translational Control
Poster
Board
Abstract
Number
1.
2108 Regulation of nucleotide metabolism by mutant
p53 contributes to its gain-of-function activities. Luis A.
Martinez, Madhusudhan Kollareddy.
2.
2109 Short isoform ARID5B protein is expressed in
endometrial cancer cell lines by usage of the second
translation initiation codon. Norihiko Kawamata, Keiichi
Itakuara.
3.
2110 Modulating NRAS mRNA translation by nucleic
acid clamp-mediated stabilization of the 5’- UTR Gquadruplex. Taisen Hao, Tracy A. Brooks.
2111 Regulation and localization of the cleaved form of
PAR-4 in ovarian and endometrial cancers. Kevin Brasseur,
Valérie Leblanc, Sophie Parent, Éric Asselin.
4.
5.
2112 A novel mechanism of NF-␬B regulation in
bladder cancer. Neelam Mukherjee, Rita Ghosh.
6.
2113 Targeting tumor-associated hypoxia to overcome
chemoresistance in pancreatic ductal adenocarcinoma
(PDA). Fernando F. Blanco, Masaya Jimbo, Liz Enyenihi,
Nicole Meisner-Kober, Eric Londin, Isidore Rigoutsos,
Makarand Risbud, Peter McCue, Charles Yeo, Jordan Winter,
Jonathan R. Brody.
7.
2114 Targeting c-Jun and c-Fos using microRNA’s has
a potential in contesting melanoma. Ahmad M. Alhendi,
Leonel Prado-Lourenço, Noel Whitaker.
8.
2115 Effect of small interfering RNA targeting HPV
E6/E7 gene on the regulation of TP53/Rb dynamic
behaviour in cervical cancer cells. Nirmal Rajasekaran, Hun
Soon Jung, Young Deug Kim, Deuk Ae Kim, Tae Kyung Ha,
Yoo Ha Na, Young kee Shin.
9.
2116 HDAC9 and 11 contribute to UV resistance in
melanoma cells. Elizabeth T. Chang, Palak R. Parekh,
Qingyuan Yang, France Carrier.
Poster
Board
Abstract
Number
16.
2123 Protein synthesis and its control in cancer
development, progression and treatment. Armen Parsyan.
17.
2124 Analysis of the functional relevance of novel
alternative splicing events in non-small cell lung cancer.
Fernando J. de Miguel, Ravi D. Sharma, Pablo Reclusa, María
J. Pajares, Angel Rubio, Ruben Pio, Luis M. Montuenga.
18.
2125 Cis-mediated regulation of mRNA translation
initiation of p53 family members. Alessandra Bisio, Alberto
Inga.
19.
2126 Comprehensive transcriptome analysis reveals
that nonsense-mediated mRNA decay is not globally
suppressed in lung adenocarcinomas. Xiangyin Kong.
20.
2127 HnRNP Q1 contributes to tumorigenesis through
the translational regulation of Aurora-A in colorectal
cancer. Liang-Yi Hung.
21.
2128 Phosphorylation of Id2 at the N-terminus
modulates Id2 degradation and mediates cell cycle
regulation in neural progenitor cells. Jaclyn Sullivan,
Matthew Havrda, Brenton Paolella, Arminja Kettenbach, Scott
Gerber, Mark A. Israel.
22.
2129 Translational regulation of Id1 expression in
glioma cells by the PI-3K pathway involves PPM1Gmediated dephosphorylation of 4E-BP1. Kaiming Xu,
Lanfang Wang, Hui-Kuo G. Shu.
23.
2130 The RNA-binding protein tristetraprolin controls
intestinal cell differentiation and tumorigenesis through
the Notch signaling pathway. Shufei Zhuang, Liangyan Hu,
Sandhya Sanduja, Shahid Umar, Shrikant Anant, Dan A.
Dixon.
24.
2131 The Arkadia-ESRP2 axis suppresses tumor
progression: Analyses in clear cell renal cell carcinoma.
Anna Mizutani, Daizo Koinuma, Hiroyuki Seimiya, Kohei
Miyazono.
10.
2117 Epigenetic mechanisms control switching
between metastatic and proliferative subtypes in the
SW13 adrenal adenocarcinoma cell line. McKale R. Davis,
Elizabeth E. Hull.
25.
2132 Mutant Kras associated protein oxidation in
pancreatic neoplasia. Michelle Schultz, Brian DeCant,
Andrew Diaz, Sharon Solman, Rital Shah, David Bentrem,
Paul J. Grippo.
11.
2118 Nonsense-mediated decay regulates the
expression of tumor suppressor transcripts and cancer
pathways in non-small cell lung cancer cell lines. Jayanthi
P. Gudikote, Hao Zhao, Jing Wang, Youhong Fan, Lixia Diao,
Lauren A. Byers, Uma Giri, Monique Nilsson, John V.
Heymach.
26.
2133 Investigating the molecular interaction between
KRAS mRNA and RNA binding protein CRD-BP. Sebastian J.
Mackedenski, Chow H. Lee.
27.
2119 Identification of a RNA binding protein, SSP1,
inducing cell growth in esophageal squamous cell
carcinoma (ESCC) through posttranscriptional regulation
of target genes. Issei Imoto, Kiyoshi Masuda, Katsutoshi
Shoda, Jyunichi Hamada.
2134 Standard immunohistochemistry efficiently
screens for ALK rearrangements in differentiated thyroid
cancer. Gahee Park, Tae Hyuk Kim, Hae-Ock Lee, Jung Ah
Lim, Jae-Kyung Won, Hye Sook Min, Kyu Eun Lee, Do Joon
Park, Young Joo Park, Woong-Yang Park.
28.
13.
2120 Not all ribosomes are created equal: How cancer
abuses the translational machinery. Ari L. Landon,
Parameswary Muniandy, Ronald B. Gartenhaus.
2135 Survivin is a novel target of the Hedgehog/GLI
signaling pathway in human tumor cell lines. Kateřina
Vlčková, Lubica Ondrušová, Jiri Réda, Jiri Vachtenheim, Petra
Žáková.
29.
14.
2121 Microtubule-regulated mRNA translation
signaling and therapeutic implications in cancer. Prashant
Khade, Paraskevi Giannakakou.
2136 Correlating the expression of protein kinase C
isozymes with the transformed phenotype in colorectal
cancer. Catríona M. Dowling, James J. Phelan, Mary Clare
Cathcart, Brian Mehigan, Paul McCormick, Tara Dalton, John
C. Coffey, Jacintha O’Sullivan, Patrick A. Kiely.
30.
15.
2122 RNA editing reveals new regulatory functions in
tumorigenesis. Landian Hu.
2137 The effect of the transcription factor MAZ on kRAS
transcription: a role for the G-quadruplex. Harshul Batra,
Tracy A. Brooks.
12.
377
POSTER SESSION
Ras, Raf, ERK, and PI3K Pathway Signaling
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
378
Abstract
Number
2138 RasGRP3 mediates MAPK pathway activation in
GNAQ mutant uveal melanoma. Xu Chen, Qiuxia Wu,
Philippe Depeille, Jeroen P. Roose, Boris C. Bastian.
2139 Wild type N-Ras, overexpressed in basal-like
breast cancer, promotes tumor formation by inducing IL8
secretion via JAK2 activation. Ze-Yi Zheng, Wen Bu, Lin
Tian, Cheng Fan, Xia Gao, Cuijuan Yu, Liu Jun, Xiaomei Zhang,
Yi-Hua Liao, Yi Li, Michael T. Lewis, Dean Edwards, Susan G.
Hilsenbeck, Daniel Medina, Thomas P. Zwaka, Charles M.
Perou, Chad J. Creighton, Xiang Zhang, Eric C. Chang.
2140 Dual Wnt and EGFR-MAPK dependency of
BRAFV600E-mutant colorectal cancer. Youzhen Wang,
Michael Palmer, Savina Jaeger, Linda Bagdasarian, Shumei
Qiu, Steve Woolfenden, Ronald Meyer, Guizhi Yang, John
Green, Shifeng Pan, Jun Liu, Hui Gao, Z. Alexander Cao,
Andrea Myers, Margaret E. McLaughlin.
2141 Rab25 and Rab-coupling protein (RCP)
coordinate H-Ras and EGFR post-Golgi vesicle trafficking,
plasma membrane targeting, and function in mammary
epithelial cells. Allison B. Herman, Jeremy G. Wurtzel,
Lawrence E. Goldfinger.
2142 Novel oncogenic BRaf deletions functioning as
BRaf homodimer and sensitive to inhibition by LY3009120,
a pan Raf and Raf dimer inhibitor . Shih-Hsun Chen, Sean
Buchanan, Youyan Zhang, Robert Van Horn, Tinggui Yin,
Vipin Yadav, Swee Seong Wong, Lysiane Huber, James
Henry, Ilaria Conti, James J. Starling, Gregory D. Plowman,
Sheng-Bin Peng.
2143 A 3D system to elucidate a direct role for
epiregulin mistrafficking in epithelial transformation.
Bhuminder Singh, Galina Bogatcheva, Robert J. Coffey.
2144 Kinetic mechanism of the lysine
methyltransferase SMYD3 using MAP3K2 protein
substrate. Thomas V. Riera, Tim J. Wigle, Jodi Gureasko, P.
Ann Boriack-Sjodin, Robert A. Copeland.
2145 Overexpression of c-Myc facilitates
hepatocarcinogenesis with altering lipid metabolism in
tumors induced by activated Akt and mutant Hras. Bing
Xin, Masahiro Yamamoto, Xi Chen, Kiyonaga Fujii, Takako
Ooshio, Yuji Nishikawa.
2146 RASSF1C modulation of Piwi-interacting RNAs
(piRNAs) in lung cancer. Yousef G. Amaar, Matthew Firek,
Mark E. Reeves, Mark E. Reeves.
2147 Correlating RAS oncogenic allele dependence
with drug sensitivity. Kanika Sharma, Katie Beam, Nicole
Fer, Matthew Holderfield.
2148 Ras-mediated evasion of detachment-induced
cell death involves differential signaling pathways for
metabolism and anoikis. Joshua A. Mason, Calli Versagli,
Amy Leliaert, Sienna Durbin, Cassandra Buchheit, Zachary
Schafer.
2149 N-deacetylase/N-sulfotransferase (heparan
glucosaminyl) 4, a novel tumor suppressor, suppresses
tumorigenesis and liver metastasis of colorectal cancer
cells in mice. Tzu-Ming Jao, Ming-Hong Tsai, Sheng-Tai
Tzeng, Ya-Chien Yang.
2150 Impact of co-occurring genetic events on RAS
signaling diversification in NF1-mutant lung
adenocarcinoma (LUAC). Ferdinandos Skoulidis, Pan Tong,
Jing Wang, John V. Heymach.
2151 Development of reference reagents to accelerate
research on the RAS pathway. Dominic Esposito.
2152 Oncolytic virus (RT3D) administration in
combination with cetuximab in head and neck squamous
cell cancer (HNSCC) models harboring active EGFR/RAS/
PI3K signaling. Amanda Psyrri, Panagiota Economopoulou,
Ioannis Kotsantis, Vassilios Ramfidis, Elena Vagia, George
Koutsontodis, Clarence Sasaki, Theodoros Rampias.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
10
Abstract
Number
2153 Kinome inhibitor screen identifies kinase
inhibitors that inhibit selectively the survival of mutant
K-Ras-dependent human cancer cells. Norbert Berndt,
Xiaolei Zhang, Rays H. Jiang, Said M. Sebti.
2154 ERK/MAPK pathway inhibits tumorigenesis and
cellular reprogramming of pancreatic cancer cells.
Benjamin le Calvé, Xavier Deschenes-Ximard, Filippos
Kottakis, Véronique Bourdeau, Frédéric Lessard, Karine
Moineau-Vallée, Emmanuelle Saint-Germain, Julien Fitamant,
Rushika M. Perera, Nabeel Bardeesy, Gerardo Ferbeyre.
2155 Inactivation of the tumor suppressor DLC1 by the
oncogenes SRC and ERK1 in lung adenocarcinoma.
Brajendra K. Tripathi, Xiaolan Qian, Tiera Grant, Philipp
Mertins, Dunrui Wang, Alex G. Papageorge, Steven A. Carr,
Douglas R. Lowy.
2156 FGFR2 regulates Mre11 expression and doublestrand break repair via the MEK-ERK-POU1F1 pathway in
breast tumorigenesis. Yuan-Ling Huang, Wen-Cheng Chou,
Chia-Ni Hsiung, Ling-Yueh Hu, Hou-Wei Chu, Chen-Yang
Shen.
2157 PI3K/AKT-induced stabilization of FUSE binding
proteins (FBPs) in liver cancer cells. Jana Samarin, Ilan
Stein, Elad Horwitz, Xin Chen, Mona Malz, Eli Pikarsky, Diego
Calvisi, Peter Schirmacher, Kai Breuhahn.
2158 PDK1-dependent activation of RSK is an absolute
requirement for PI3K oncogenic activity in the thyroid
gland. Arturo Orlacchio, Antonio Di Cristofano.
2159 Ikaros and Casein kinase II (CK2) regulate PI3K
pathway in pediatric leukemia. Chandrika Gowda, Chunhua
Song, Yali Ding, Sunil Muthusami, Xiaokang Pan, Dhimant
Desai, Shantu G. Amin, Kimberly J. Payne, Sinisa Dovat.
2160 PTEN deletion is associated with metastatic
disease and worse prognosis in pancreatic cancer. Martin
Wartenberg, Irene Centeno, Inti Zlobec, Alessandro Lugli,
Aurel Perren, Eva Karamitopoulou.
2161 Activation of the MAPK pathway in combination
with PTEN loss leads to aggressive primary tumor
formation. Keyata N. Thompson, Rebecca A. Whipple,
Jennifer R. Yoon, Monica S. Charpentier, Amanda E. Boggs,
Lekhana Bhandary, Kristi R. Chakrabarti, Stuart S. Martin,
Michele I. Vitolo.
2162 Loss of ATF3 promotes akt activation and
prostate cancer development in a pten knockout mouse
model. Ziyan Wang, Dong Xu, Chunhong Yan.
2163 Mapping SUMOylation sites of PTEN tumor
suppressor. Yubing Wang, Chiwai Wong, Mingfei Yan,
Penelope Or, Andrew M. Chan.
2164 Revisiting the mechanisms of PTEN loss in
melanoma. Keith Giles, Yang Li, Amel Salhi, Jinhua Wang,
Eric Robinson, Iman Osman.
2165 Concurrent BRCA2 and PTEN mutations are
associated with improved survival in endometrioid
endometrial cancer. Jean M. Hansen, Keith Baggerly, Ying
Wang, Cristina Ivan, Sherry Wu, Rebecca Previs, Behrouz
Zand, Heather Dalton, Wei Hu, Robert L. Coleman, Anil K.
Sood.
2166 Analyses of protein expression of PI 3-kinase/AKT
signaling in response to altered expression of motor
protein MYO1C. Kittichate Visuttijai, Katarina Ejeskär, Afrouz
Behboudi.
2167 Differential roles of palmitoylation on oncogenic
potential of NRAS and KRAS4A. Huanbin Zhao, Ruibao Ren.
10
POSTER SESSION
Poster
:LJ[PVU
11
11
Systematic Analysis of Omic Data
Poster
Board
Abstract
Number
1.
2168 BC-BET: an online bladder cancer biomarker
evaluation tool. Garrett Dancik.
2.
2169 Genomic analysis of 207 rectal cancer samples.
Yue Hu.
3.
2170 Microarray analysis reveals distinct gene set
profiles between gastric and intestinal gastrointestinal
stromal tumors. Hirotoshi Kikuchi, Ryuhei Hara, Shinichiro
Miyazaki, Yoshihiro Hiramatsu, Kinji Kamiya, Manabu Ohta,
Takanori Sakaguchi, Satoshi Baba, Haruhiko Sugimura,
Hiroyuki Konno.
4.
2171 Leveraging global gene expression patterns to
identify gene sets that predict expression of large
numbers of unmeasured genes. James Rudd, Rene A.
Zelaya, Eugene Demidenko, Casey S. Greene, Jennifer A.
Doherty.
5.
2172 Earth mover’s distance for the identification of
genes associated with drug resistance in cancer. Sheida
Nabavi, Daniel Schmolze, Mayinuer Maitituoheti, Andrew H.
Beck.
6.
2173 Robust estimation of mutation burden. Oscar
Westesson, Rasmus Nielsen, John St John, Aleah Caulin,
Nicholas Hahner, Stewart Stewart, Catherine Foo, Kimberly
Lung, Jeff Catalano, Mandy Lee, Petros Giannikopoulos, Will
Polkinghorn, Jonathan Wiessman, Aviv Regev, Trever
Bivona.
7.
2174 Identification of genetic factors contributing to
development of common cancers through tissue-specific
protein interaction analysis. David C. Qian, Jinyoung Byun,
Younghun Han, David J. Hunter, Brian E. Henderson, Rosalind
Eeles, Christopher A. Haiman, Douglas F. Easton, Rayjean J.
Hung, Christopher I. Amos.
8.
2175 A diagnostic gene expression assay for the
classification of pheochromocytoma. Aidan Flynn, Diana
Benn, Roderick Clifton-Bligh, Joshy George, Anthony J. Gill,
Rodney J. Hicks, Richard W. Tothill.
9.
2176 Joint structural variant analysis of colorectal
cancer whole genome sequencing data. Esa Pitkänen,
Tatiana Cajuso, Riku Katainen, Sofie Lundgren, Sari
Tuupanen, Outi Kilpivaara, Lauri A. Aaltonen.
10.
2177 Differential expression of stromal cell-related
genes between primary nasopharyngeal carcinoma and
distant metastasis. Liangru Ke*, Jinna Chen*, Lin Wang*,
Yahui Yu, Yanfang Ye, Weixiong Xia, Xing Lv, Jing Yang,
Xiang Guo, Yanqun Xiang#, Xinyuan Guan#.
11.
2178 Comparison and interpretation of variants in RNA
and DNA from sarcoma cancer sample. Bodil Øster, Anika
Joecker, Rupert Yip, Frank Schacherer, Douglas Basset,
Donald Salter, Richard L. Hayward, Ted R. Hupp.
12.
2179 Gene expression models for predicting
doxorubicin response in canine osteosarcoma. Jared S.
Fowles, Kristen C. Brown, Ann M. Hess, Dawn L. Duval, Daniel
L. Gustafson.
Poster
Board
Abstract
Number
13.
2180 Immune, keratinocyte, and fibroblast expression
signatures distinguish HNSCC samples by HPV status. Lada
A. Koneva, Yanxiao Zhang, William R. Swindell, Shama Virani,
Alisha Virani, Thomas E. Carey, Laura S. Rozek, Maureen A.
Sartor.
14.
2181 Differential expression of genes related to
autoimmunity and metabolism in Stage I NSCLC from
patients with COPD. Jill M. Siegfried, Kan Shang, Cavan
Reilly, Laura P. Stabile.
15.
2182 Reconstructing evolutionary models of tumor
progression from single-cell heterogeneity data. Salim A.
Chowdhury, E. Michael Gertz, Darawalee Wangsa, Kerstin
Heselmeyer-Haddad, Thomas Ried, Alejandro Schaeffer,
Russell Schwartz.
16.
2183 Expression patterns in pancreatic intraepithelial
neoplasms. Michael Ayars, Eileen O’Sullivan, Michael
Goggins.
17.
2184 Gene expression analysis of human
papillomavirus positive head and neck cancer primary
tumor samples reveals two distinct subgroups. Yanxiao
Zhang, Lada A. Koneva, Shama Virani, Alisha Virani, Katie M.
Rentschler, Thomas E. Carey, Laura S. Rozek, Maureen A.
Sartor, the University of Michigan Head and Neck SPORE.
18.
2185 Informatics framework for clustering and deriving
gene signatures for prognostic stratification of cancer
patients. Segun Jung, Yingtao Bi, Ramana V. Davuluri.
19.
2186 Validation of a 32-gene classifier for the
subtyping of carcinomas using the qNPA™ ArrayPlate
Platform. Bernard Omolo, Barbara Centeno, Timothy
Yeatman.
20.
2187 Pan-cancer identification and prioritization of
cancer-associated differentially expressed genes: A
biomarker discovery application. Daryanaz Dargahi,
Richard D. Swayze, Leanna Yee, Peter J. Bergqvist, Bradley
J. Hedberg, Alireza Heravi-Moussavi, Edie M. Dullaghan, Ryan
Dercho, Christopher Bond, Jianghong An, John S. Babcook,
Steven J. Jones.
21.
2188 Different gene expression between men and
women patients with lung adenoarcinoma reveals
enrichment of immune gene sets. Joseph A. Pinto, Jhajaira
M. Araujo, Alexandra Prado, Claudio Flores, Nadezhda K.
Cardenas, Mayer Zaharia, Gustavo Sarria, Alfredo Aguilar,
Silvia Neciosup, Henry Gomez, Luis Mas.
22.
2189 Molecular similarity of Barrett’s-associated and
gastro-esophageal junction adenocarcinomas. Daysha
Ferrer-Torres, Derek Nancarrow, Rork Kuick, Ernest Nadal,
Thomas D. Wang, Andrew Chang, Jules Lin, Rishindra M.
Reddy, David G Beer.
379
POSTER SESSION
Transcriptional Deregulation
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
12
Abstract
Number
1.
2190 Oncostatin M reduces SLUG expression in lung
adenocarcinoma cells through STAT1-PIAS4-dependent
histone deacetylation. Chih-Ming Pan, Mong-Lien Wang,
Cheng-Wen Wu.
16.
2205 Identification of transcript abundance difference
at lung cancer and COPD risk genes in normal bronchial
epithelial cells. Jiyoun Yeo, Xiaolu Zhang, Erin Crawford,
James Willey.
2.
2191 Transcriptome analysis demonstrates the ability
of the bromodomain inhibitor JQ1 to attenuate expression
of common oncogenes heterogeneously expressed among
chronic lymphocytic leukemia subsets. Austin Y. Shull,
Jeong-Hyeon Choi, Brian Buckley, Lirong Pei, Farrukh T.
Awan, Huidong Shi.
17.
2206 qPCR array of 84 cell cycle genes in oral
squamous cell carcinoma reveals differently expressed
genes in larger size tumors in relation to small tumors.
Carolina C. Gomes, Marina G. Diniz, Fabricio T. de Souza,
Jeane F. Correia-Silva, Ricardo S. Gomez.
3.
2192 Stress-induced reprogramming of epithelial
cancers toward a stem-like fate. Maricel C. Gozo, David A.
Cheresh, Mayra Yebra, Laetitia Sequin.
18.
2207 Elucidating mechanisms employed by NFIL3 to
impact cancer cell survival. Megan Keniry, Omar Caballero,
Itzel Flores, Andrea Salinas.
4.
2193 Hypoxia-induced G9a histone methyltransferase
is crucial for blunting RUNX3 tumor suppressor function.
You Mie Lee.
19.
5.
2194 p21Waf1/Cip1 dependent chromatin modifications
in colorectal tumor cells. Pablo Lennert, Katharina
Erlenbach-Wuensch, Carsten Kroeger, Sara Steinmann,
Kerstin Huebner, Sushmita Paul, Felix Rausch, Arndt
Hartmann, Regine Schneider-Stock.
2208 Interferon Consensus Sequence-Binding Protein
(ICSBP) regulates the transforming growth factor-beta
type I receptor expression in osteosarcoma cells. Jee
Young Sung, Hyeryeong Kim, Kyung-Sil Yoon, Yong-Nyun
Kim, Byung-Kiu Park.
20.
2195 A high-throughput chemical screen identifies
synergistic activity between crizotinib and transcriptional
CDK inhibitors in ALK-mutated neuroblastoma. Nathan F.
Moore, Edmond Chipumuro, Clark M. Hatheway, Tinghu
Zhang, Nathanael S. Gray, Rani E. George.
2209 Deregulation of the Ras-Erk signaling axis
modulates the enhancer landscape. Behnam Nabet, Pilib O
Broin, Jaime Reyes, Kevin Shieh, Charles Y. Lin, Christine M.
Will, Relja Popovic, Teresa Ezponda, James E. Bradner, Aaron
A. Golden, Jonathan D. Licht.
21.
2210 DNA methylation to identify non-coding gene
regulatory regions in tumor samples. Benjamin P. Berman.
6.
7.
8.
9.
10.
11.
22.
2196 Novel and selective histone deacetylase (HDAC) 1
& 2 inhibitors enhance differentiation of neuroblastoma
cells in combination with retinoic acid. David L. Tamang,
Emily Lurier, Olga Golonzhka, Steven N. Quayle, Simon S.
Jones, Min Yang.
2211 A comparative analysis of the cis-regulatory
landscape between human and mouse. Feng Yue, Yin Shen,
Zhen Ye, Bing Ren.
23.
2197 Effect of tolfenamic acid on the therapeutic
efficacy of chemotherapeutic drugs used in the treatment
of Ewing sarcoma. Umesh T. Sankpal, Anish Ray, Leslie
Tabor-Simecka, W Paul Bowman, Riyaz M. Basha.
2212 Super-enhancer landscapes specify molecular
subtypes and novel targets in acute myeloid leukemia.
Matthew Eaton, Ryan Corces-Zimmerman, Jeremy Lopez,
Christian Fritz, Eric Olson, Ravindra Majeti, Jakob Loven.
24.
2213 Evaluation of bias associated with high-multiplex,
target-specific pre-amplification. Steven T. Okino, Michelle
Kong, Yan T. Wang.
25.
2214 Dynamic transcriptome analysis of DNA damage
pathways under hypoxia. Winnie W. Lo, Gaetano Zafarana,
Robert G. Bristow.
26.
2215 Transcriptional co-regulation of Nox4 by p53 and
SMAD3. Howard E. Boudreau, Jonathan J. Park, Thomas L.
Leto.
27.
2216 A novel G-quadruplex formed in the proximal P1
promoter of bcl-2 gene is a gene suppressor. Buket Onel,
Megan Carver, Danzhou Yang.
28.
2217 Prognostic and predictive values of CD68+
macrophage and aberrant expression of cathepsin L, IL-12,
CTL4A genes in classic Hodgkin’s lymphoma. Abeer A.
Bahnassy, Ahmad E-S El-Bastawisi, Osama Hammad, Nasr M.
Ali, John E. Diks, Hend F. Yousif, Abdel-Rahman N. Zekri.
29.
2218 Qualitative and quantitative analysis of IDH1
mutation in progressive gliomas by allele-specific
quantitative RT-PCR and Western blot analysis. Marco
Timmer, Moritz Perrech, Gabriele Röhn, Lena Dreher, Roland
Goldbrunner.
30.
2219 Development of an assay to detect transcription
misincorporation errors in Escherichia coli. Jorge A.
Irizarry-Caro, Mary Ernst, Carolyn Court, Alison Rattray,
Mikhail Bubunenko, Ding Jin, Donald Court, Jeffrey Strathern.
2198 ERK5 inhibition potentiates the effects of
leukemia cell differentiation inducers by augmenting the
function of master transcription factors. Ruifang Zheng,
George Studzinski.
2199 Evaluation of critical residues in the C-terminal
binding protein (CtBP) dehydrogenase domain
contributing to substrate binding, catalysis, and oncogenic
activity. Benjamin L. Morris, Priyadarshan Damle, Zaid
Nawaz, Steven R. Grossman.
2200 A rational approach for discovery of inhibitors of YAPTEAD interaction. Claudia Fromond, Laurent Chene, Anne
Soude, Martine Barth, Christian Montalbetti, Pierre Broqua.
12.
2201 EGFR regulates the expression and activity of
ARID3B through phosphoinositide 3-kinase. William M.
Hallas, Karen Cowden Dahl.
13.
2202 Novel regulation of pro-migratory genes by
nuclear Src in pancreatic cancer cells. David Paladino.
14.
2203 Regulation of hedgehog signaling by Mixed
Lineage Kinase 3 (MAP3K11) in pancreatic cancer. Navin
Viswakarma, Gautam Sondarva, Rajakishore Mishra, Rakesh
Sathish Nair, Subhasis Das, Basabi Rana, Ajay Rana.
15.
2204 Integrin ␣6␤4 regulates expression of Areg and
Ereg through DNA repair-dependent mechanisms. Brittany
L. Carpenter, Kathleen L. O’Connor.
380
12
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
14
14
Cancer Stem Cell Signaling Pathways
Poster
Board
1.
2.
3.
4.
Abstract
Number
2220 Annexin A3 regulates MET-like aldehyde
dehydrogenase positive breast cancer stem cells. Yadwinder S.
Deol, Sean P. McDermott, David M. Lubman, Jenny C. Chang,
Song Nie, Tahra K. Luther, Yang Cong, Ebrahim Azizi, Justin
Colacino, Shawn G. Clouthier, Max Wicha.
2221 Transforming Growth Factor-beta (TGF-␤) directly
regulates breast cancer stem cell dynamics in vitro and in vivo.
Binwu Tang, Asaf Raviv, Dominic Esposito, Catherine Daniel,
Kathleen C. Flanders, Yu-an Yang, Lalage M. Wakefield.
2222 Possible involvement of senescence bypass in
mesenchymal stem cells for sarcomagenesis identified through a
comparative gene expression profiling in rat sarcoma model.
Kanya Honoki, Hiromasa Fujii, Akira Kido, Shinji Tsukamoto,
Toshio Mori, Yasuhito Tanaka, Toshifumi Tsujiuchi.
2223 C-terminal truncated hepatitis B virus X protein
promotes hepatocarcinogenesis through enhanced
stemness and resistance to therapy. Kai Yu Ng, Stella Chai,
Man Tong, Xin-Yuan Guan, Alfred S. Cheng, Stephanie Ma.
5.
2224 Functional role of NRF2 signaling in sphere
cultured carcinoma cells. In-geun Ryoo, Mi-Kyoung Kwak.
6.
2225 c-Myc and Frizzled 8 play a major role in the
regulation of cancer stem cells and drug resistance in
triple-negative breast cancer. Shuping Yin, Vino T.
Cheriyan, Arun K. Rishi, Kaladhar B. Reddy.
7.
2226 PLSCR1- a modifier of TGF␤ signaling. Margaret
Klauzinska, Hideaki Karasawa, Maria Cristina Rangel, Nadia
Castro, Alyson Baker, Daniel Bertolette, Julie Krask, David
Salomon.
8.
2227 Effects of cathepsin S in differentiated and stemlike glioblastoma cells. Robyn A. Foster, Shahnaz T. Al
Rashid, Roberta E. Burden, Christopher J. Scott, Kevin M.
Prise, Thomas J. Flannery.
9.
2228 Requirement of JNK signaling for self-renewal
and tumor-initiating capacity of ovarian cancer stem cells.
Manabu Seino, Masashi Okada, Keita Shibuya, Shizuka Seino,
Shuhei Suzuki, Hiroyuki Takeda, Tsuyoshi Ohta, Hirohisa
Kurachi, Kiyoshi Ito, Satoru Nagase, Chifumi Kitanaka.
10.
2229 CD117 expression and activation in prostate
cancer progression. Bethany Kerr.
11.
2230 Wnt signaling in prostate cancer stem like cells. Reena
Davda, Christopher Thrasivoulou, John Masters, Aamir Ahmed.
12.
2231 Type II transglutaminase is an epidermal squamous cell
carcinoma stem cell survival protein. Matt Fisher, Wen Xu,
Gautam Adhikary, Candace Kerr, Richard Eckert.
13.
2232 Down-regulation of dual-specificity tyrosine-(Y)phosphorylation regulated kinase 1A mediated by miR1246 and miR-1290 in multiple myeloma cancer stem-like
cells. Terry Hei Yan Wong, Coty H. Cheung, Natalie Pui Ha
Chan, Rosalina KL Ip, Chi-Keung Cheng, Kitty Ka Yan Ng,
Margaret H.L. Ng.
14.
15.
2233 The prostaglandin E receptor EP4 is upregulated
on breast cancer stem-like cells and regulates sensitivity
to Natural Killer cells. Amy M. Fulton, Namita Kundu,
Xinrong Ma, Tyler Kochel, Jocelyn Reader.
2234 Nrf2 regulates ALDH activity and tumorigenicity
of mesothelioma cells. Xiaoqing He, Liying Wang, Yongut
Rojanasakul.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2235 miR-200c reduces P-gp mediated MDR and
metastasis by targeting JNK2/c-Jun signaling pathway in
colon cancer. Qi Li.
2236 Emergence of epigenetic regulation of tight
junction genes in recurrent serous epithelial ovarian
cancer. Zhiqing Huang, Zachery Visco, Gregory Sfakianos,
Regina Whitaker,Andrew Berchuck, Susan K. Murphy.
2237 Involvement of Retinoic Acid Receptors RAR␤
and RAR␥ in growth, self-renewal and differentiation on
mammary cancer stem cells. Damian E. Berardi, Carolina
Flumian, Maria I. Diaz Bessone, Stefano M. Cirigliano, Elisa D.
Bal de Kier Joffe, Alejandro J. Urtreger, Laura B. Todaro.
2238 CD44/CD24/STAT3 axis Is essential for
orchestrating the cancer stem cell properties in
nasopharyngeal carcinoma. Chia-Yu Wang, Yao-An Shen,
Yann-Jang Chen.
2239 The tumor stem cell marker doublecortin-like
kinase (DCLK1) activates inflammatory and carcinogenic
signals in hepatocellular carcinoma. Naushad Ali,
Parthasarathy Chandrakesan, Charles B. Nguyen, Sanam
Husain, Allison F. Gillaspy, Mark Huycke, William L. Berry,
Randal May, Dongfeng Qu, Nathaniel Weygant, Sripathi M.
Sureban, Danny N. Dhanasekaran, Courtney W. Houchen.
2240 Progesterone receptor isoform ratio regulates the
stem cell population in the mouse mammary gland. Maria
S. Recouvreux, Rocio Sampayo, Marina Simian.
2241 MDM2 silencing promotes tumor-initiating cells in
osteosarcoma and breast cancer. David J. Olivos, Lindsey D. Mayo.
2242 Inhibition of acetyl-CoA carboxylase attenuates
lipidation and activity of oncogenic signaling pathways in
pancreatic cancer. Elissaveta Petrova, Arne Scholz, Andrea
Sturz, Juliane Paul, Franziska Siegel, Dominik Mumberg,
Ningshu Liu.
2243 Alterations in the binding of Meis proteins to
HoxB13 or to DNA promote prostate cancer progression.
Hannah J. Brechka, Masis Isikbay, Raj Bhanvadia, Donald
Vander Griend.
2244 Functional interactions between estrogenrelated-receptor ␤ (ESRRB) and transforming growth
factor-beta (TGF-␤) in the regulation of breast cancer
stem cell dynamics. Nellie Moshkovich, Misako Sato, Binwu
Tang, Yu-an Yang, Kathleen C. Flanders, Mitsutaka Kadota,
Howard Yang, Maxwell P. Lee, Lalage M. Wakefield.
2245 SIPA1 negatively regulates the survive in breast
cancer patients and promotes CD44 expression to drive
cancer cell stemness. Li Su, Jing Xia.
2246 Progesterone generates cancer stem cells
through membrane progesterone receptor-triggered
signaling in basal-like human mammary cells. Guillaume
Vares, Sei Sai, Bing Wang, Akira Fujimori, Mitsuru Nenoi,
Tetsuo Nakajima.
2247 SHP2 expression and function in different
subtypes of glioblastoma. Laura Roccograndi, Yingtao Bi,
Ramana Davuluri, Nadia Dahmane, Donald M. O’Rourke.
2248 Mechanism of action of RPL39 in breast cancer
initiation and metastasis. Bhuvanesh Dave, Jenny Chang.
2249 TERT promoter mutation as poor prognosis
marker in glioblastoma via sphere formation and selfrenewal capacity. Jae-Ho Lee, Hyunsu Lee, Seon Rang Woo,
Kyeung-Min Joo, KeonUk Park.
381
POSTER SESSION
Tumor Biology
Metastasis-Promoting Genes
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
382
Abstract
Number
2250 COX2-MMP1 pathway promotes brain metastasis
by tampering with blood-brain barrier and supporting
tumor initiating cells in the brain microenvironment. Kerui
Wu, Koji Fukuda, Fei Xing, Yingyu Zhang, Sambad Sharma,
Yin Liu, Kounosuke Watabe.
2251 Serglycin proteoglycan promotes progression
and metastasis of triple-negative breast cancers. Cameron
N. Johnstone, Nathaniel Harris, Marie Ranson, Anil K. Rustgi,
Robin L. Anderson.
2252 Overexpression of APOBEC3B enhances
invasiveness of hepatocellular carcinoma. Wei Ma, Daniel
Wai Hung Ho, Irene Oi Lin Ng.
2253 Cadherin 17 plays an important role in breast
cancer metastasis to bone marrow. Tomoko Okada, Mutsuo
Furihata, Atsushi Kurabayashi, Toru Imamura.
2254 CCL2/CCR2 axis signaling promotes metastasis of
nasopharyngeal carcinoma by activating ERK1/2 pathway
via upregulating MMP2 and MMP9. Jing Yang, Xing Lv,
Yanqun Xiang, Xiang Guo, Jina Chen, Xinyuan Guan.
2255 Mechanisms governing lung adenocarcinoma
metastasis. Jennifer J. Brady, Chen-Hua Chuang, Deborah R.
Caswell, Monte M. Winslow.
2256 GLI2 inhibition suppresses metastasis of HER2+
breast cancer. Parul Gupta, Alok Ranjan, Neel M. Fofaria,
Sanjay K. Srivastava.
2257 Multiple drug resistance-associated protein 4
(MRP4) may contribute to breast cancer metastasis by
exporting the COX-2 product PGE2. Tyler J. Kochel, Namita
Kundu, Xinrong Ma, Jocelyn Reader, Amy Fulton.
2258 Myc drives Pten/ p53-deficient proliferation and
metastasis due to Il6-secretion and Akt-suppression via
Phlpp2. Dawid G. Nowak, Hyejin Cho, Tali Herzka, Victoria M.
Wang, Serif Senturk, Daniel V. DeMarco, David Ding, Christof
Fellmann, Tumas Beinortas, David Kleinman, Kaitlin Watrud,
Muhan Chen, John E. Wilkinson, Mireia Castillo-Martin, Carlos
Cordon-Cardo, Brian D. Robinson, Lloyd C. Trotman.
2259 Requirement for BUB1B in tumor progression of
lung adenocarcinoma. honglin chen, James Lee, Noelyn M.
Kljavin, Benjamin Haley, Anneleen Daemen, YUXIN Liang,
Leisa Johnson.
2260 Defining molecular mechanisms linking
Endophilin A2 to metastasis in human breast cancer
models. Tomas Baldassarre, Kathleen Watt, Peter Truesdell,
Mark Schneider, Sandip Sengupta, Andrew W. Craig.
2261 DLGAP5, MAT1A, SKA3, and ZMYM5 are novel
susceptibility genes for aggressive prostate cancer.
Minnkyong Lee, Kendra A. Williams, Ying Hu, Jonathan
Andreas, Shashankkumar J. Patel, Suiyuan Zhang, Nigel P.
Crawford.
2262 Evidence that the translational initiation factor
DAP5 plays a critical role in breast cancer metastasis.
Amandine Alard, Fernanda Musa, Robert Schneider.
2263 Mitochondrial ATAD3A combines with GRP78 to
regulate the stability of the WASF3 metastasis-promoting
gene. yong teng, xiaoou ren, John Cowell.
2264 Dual effects of podoplanin on the regulation of
cancer cell gene expression and platelet CLEC-2 signaling
during cancer metastasis. Ching-Ping Tseng, Yao-Wen
Chang, Pei-Wen Hsieh, Ju-Chien Cheng.
2265 Stat3 and ErbB-2 interaction in breast cancer
metastasis. Leandro Venturutti, Lucía V. Romero, Alejandro
J. Urtreger, María F. Chervo, María F. Mercogliano, Rosalía I.
Cordo Russo, Matías G. Pereyra, Gloria Inurrigarro, María C.
Díaz Flaqué, Victoria Sunblad, Juan C. Roa, Pablo Guzmán,
Elisa Bal de Kier-Joffe, Eduardo H. Charreau, Roxana Schillaci,
Patricia V. Elizalde.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
15
Abstract
Number
2266 CEACAM6 promotes tumor angiogenesis and
vasculogenic mimicry in gastric cancer via FAK signaling.
Bingya Liu, Ming-de Zang, Jian-fang Li, Li-ping Su, Zhenggang Zhu,Min Yan.
2267 Defining roles of SIN3 isoforms in breast cancer
metastasis. Monica J. Lewis, Jianzhong Liu, Douglas R. Hurst.
2268 Tenascin C as an effector of prostate cancer
derived bone metastasis. Rebeca San Martin, David R.
Rowley, Kenneth J. Pienta.
2269 A novel molecular subset of metastatic lung
adenocarcinoma is defined by the function of the
proteoglycan receptor HMMR. Laura E. Stevens, Minghui
Zhao, Zongzhi Liu, Don Nguyen.
2270 RAGE-ligand signaling drives breast cancer
invasion and metastasis. Taekyoung Kwak, Katherine
Drews-Elger, Dekuang Zhao, Alexander Besser, Ayse Ergonul,
Joyce M. Slingerland, Marc E. Lippman, Barry I. Hudson.
2271 Peptidylarginine deiminase 2 as a novel
therapeutic target for breast cancer. Sachi Horibata, John L.
McElwee, David Sadegh, Katherine Rogers, Dalton McLean,
Scott A. Coonrod.
2272 A novel epigenetic regulator histone demethylase
NO66 promotes prostate cancer bone metastasis. Rozita
Bagheri-Yarmand, Sharmistha Lahiri, Xinhai Wan, Nora
Navone, Christopher J. Logothetis, Robert F. Gagel, Krishna
M. Sinha.
2273 Mechanistic and functional implications of FABP4
in ovarian cancer metastasis. Kshipra M. Gharpure, Susan L.
Tucker, Shelley M. Herbrich, Anna K. Unruh, Alpa M. Nick, Erin
K. Crane, Robert L. Coleman, Jamie Guenthoer, Heather J.
Dalton, Sherry Y. Wu, Rajesha Rupaimoole, Gabriel LopezBerestein, Bulent Ozpolat, Cristina Ivan, Wei Hu, Keith
Baggerly, Anil Sood.
2274 The dual role of fibronectin in lung cancer
progression. Hung-Chi Cheng, Ming-Min Chang, Yau-Lin
Tseng.
2275 S100A4/metastasin-1 promotes lung cancer cell
invasion and associates with decreased overall survival
among patients with adenocarcinoma. Rachel L. Stewart,
Brittany L. Carpenter, Dava S. West, Teresa Knifley, Chi
Wang, Heidi L. Weiss, Tamas S. Gal, Kathleen L. O’Connor,
Min Chen.
2276 Oncostatin M promotes breast cancer metastasis
to lung by affecting initial stages of metastasis. Ken
Tawara, Celeste Bolin, Jordan Koncinsky, Cheryl L. Jorcyk.
2277 Prognostic impact of enhancer of zeste
homologue 2 (EZH2) in patients underwent hepatectomy
for colorectal liver metastases who received preoperative
oxaliplatin-based chemotherapy. Mayuko Ohuchi, Yasuo
Sakamoto, Ryuma Tokunaga, Kenichi Nakamura, Yuki
Kiyozumi, Daisuke Izumi, Keisuke Kosumi, Kazuto Harada,
Junji Kurashige, Yukiharu Hiyoshi, Shiro Iwagami, Yoshifumi
Baba, Yuji Miyamoto, Naoya Yoshida, Hideo Baba.
2278 The hypusine cascade promotes cancer
progression and metastasis through the regulation of
RhoA in squamous cell carcinoma. Tomoki Muramatsu, Kenichi Kozaki, Seiya Imoto, Rui Yamaguchi, Hitoshi Tsuda,
Tatsuyuki Kawano, Maki Morishita, Satoru Miyano, Johji
Inazawa.
2279 The oncogenic role of TRPM7 in cell proliferation
and invasion of U87MG glioma cells. Mingli Liu.
15
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
16
16
Mouse Models of Human Cancer 1
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Abstract
Number
2280 A novel c-Myc transgenic model for human
cancers. Wei Wang, Jiangong Ren, Bingning Dong, Michael
M. Ittmann, David D. Moore, Feng Yang.
2281 Building mouse tumor derived allogragfts for
immune-oncology research. Xiaoyu An, Jinping Liu, Jie Cai,
Jean-Pierre Wery, Henry Q. Li.
2282 K-RasV12 bone marrow cell reconstitution causes
lung cancer in wild type mice. Elena Belloni, Ines MartinPadura, Elvira Gerbino, Stefania Orecchioni, Fulvia FusarImperatore, Paola Marighetti, Giovanni Bertalot, Pier
Giuseppe Pelicci, Francesco Bertolini.
2283 Novel mouse model for mature B cell lymphoma
reveals the requirement of Fas downregulation in
lymphomagenesis. Eiji Sugihara, Norisato Hashimoto,
Sayaka Ueno, Hideyuki Saya.
2284 Generation and characterization of a mouse
model of CRTC1-MAML2-induced mucoepidermoid
carcinoma (MEC). Zirong Chen, Jian-Liang Li, Shuibin Lin,
Dinglong Pan, Wei Ni, Chunxia Cao, Yumei Gu, Maria D.
Hurtado, Sergei Zolotukhin, Tao Sun, Frederic Kaye, Lizi Wu.
2285 Germline genetic variation modulates tumor
latency and response to therapy in a mouse model of
basal-like breast cancer. David Darr, Norman Sharpless,
Charles Perou, Fernando Pardo-Manuel de Villena, Darla
Miller, Katharine Bendt, Stephen D. Hursting.
2286 Spontaneous mammary cancer development in
genetically engineered mice with only one copy of Brca1
disrupted in combination with Trp53 haploinsufficiency.
Sahar Alothman, Svenja Groeneveld, Ahmad Alamri, Bhaskar
Kallakury, Priscilla A. Furth.
2287 A model system to treat T-cell acute
lymphoblastic leukemia with JAK inhibitors. Emilee
Senkevitch, Julie Hixon, Wenqing Li, Scott Durum.
2288 Lipoprotein(a) and vitamin C affect the
development of breast cancer tumors in Lp(a)+; Gulo-/mice. John Cha, M. W. Roomi, Aleksandra Niedzwiecki,
Matthias Rath.
2289 A novel mouse model of endometrial cancer:
epithelial specific Pten deletion with lactoferrin-iCre.
Takiko Daikoku, Jumpei Terakawa, Sudhansu K. Dey.
2290 More than a biomarker: Studying the role of
vimentin in lung cancer metastasis. Alessandra M.
Salgueiro, Melissa Gilbert-Ross, Lauren S. Havel, John Shupe,
Adam I. Marcus.
2291 Snai1 accelerates Kras driven lung tumorigenesis
by overcoming oncogene-induced senescence. Kekoa
Taparra, Hailun Wang, Katriana Nugent, Russell Williams,
Reem Malek, Jessica Cades, Dean Felsher, Phuoc Tran.
2292 The role of immature colon carcinoma transcript 1
during c-myc deregulation in fast-onset mouse
plasmacytoma. Amy K. Dahl, Ruedee Sakulratchata, Sabine
Mai.
2293 Deletion of Tid1 in hepatocyte promotes
steatosis, fibrosis, and tumorigenesis. Yu-Syuan Chen,
Jeng-Fan Lo.
2294 Sophorolipid-mediated inhibition of colorectal
tumor cell growth in vitro and in vivo. Breedge Callaghan,
Sophie Roelants, Niki Baccile, Helen Lydon, Inge Van Bogaert,
Ibrahim M. Banat, Roger Marchant, Christopher A. Mitchell.
2295 AMP-activated protein kinase (AMPK) signaling in
the context of gain-of-function mutant p53 in vivo. SeYoung Jo, Hye-Min Moon, ChuHee Lee, Se Jin Jang, YoungAh Suh.
2296 An isoform of BARD1, associated with many types
of cancer, is a driver of oncogenesis by inducing telomere
aberrations in vitro and in vivo. Maxim Pilyugin, PierreAlain Andre, Magdalena Ratajska, Irmgard Irminger-Finger.
Poster
Board
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2297 The role of calpains-1/2 in mammary
tumorigenesis. James A. MacLeod, Peter A. Greer.
2298 Profiling of syngeneic models by anti-PD1, antiCTLA4 immunotherapeutics and deep sequencing enables
better selection of models for immune targeted
combination therapy. Lan Zhang, Juan Zhang, Qian Shi.
2299 Generation and characterization of inducible
KIF5B-RET mouse model of non-small cell lung cancer.
Qingling Huang, Valentina E. Schneeberger, Noreen Luetteke,
Chengliu Jin, Domenico Coppola, Jie Wu.
2300 LIN28 cooperates with Wnt signaling to drive
invasive intestinal and colorectal adenocarcinoma in
mouse and human. Ho-Chou Tu, Sarah Schwitalla, Zhirong
Qian, Grace LaPier, Alena Yermalovich, Yuan-Chieh Ku,
Shann-Ching Chen, Srinivas R. Viswanathan, Hao Zhu, Reiko
Nishihara, Kentaro Inamura, Sun A. Kim, Reppi Morikawa,
Kosuke Mima, Yasutaka sukawa, Juhong Yang, Gavin
Meredith, Charles S. Fuchs, Shuji Ogino, George Q. Daley.
2301 The generation of colorectal cancer mouse model
based on microsatellite instability and the identification of
transforming growth factor-beta signal target. Masashi
Miguchi, Takao Hinoi, Manabu Shimomura, Tomohiro Adachi,
Yasufumi Saito, Hiroaki Niitsu, Masatoshi Kochi, Yusuke
Sotomaru, Hideaki Ijichi, Tsuneo Ikenoue, Kunitoshi
Shigeyasu, Kohji Tanakaya, Kazuhiro Sentani, Naohide Oue,
Wataru Yasui, Hideki Ohdan.
2302 Analysis of the role of CADM1 in suppression of
lung cancer using Cadm1-deficient mice. Takeshi Ito,
Masayoshi Nagata, Taketo Kawai, Mika Sakurai-Yageta,
Akihiko Ito, Akiteru Goto, Daisuke Matsubara, Yoshinori
Murakami.
2303 Impact of synbiotics administration on
tumorigenesis of colon cancer mouse model. Yasufumi
Saito, Takao Hinoi, Tomohiro Adachi, Manabu Shimomura,
Masashi Miguchi, Hiroaki Niitsu, Masatoshi Kochi, Hideki
Ohdan, Kazuhiro Sentani, Naohide Oue, Wataru Yasui.
2304 The role of methyltransferase, enhancer of zeste
homolog 2 (EZH2) in mouse hepatocyte and human
hepatocellular carcinoma. Woo Kyun Bae, Hyun Jeong
Shim, Sang Hee Cho, Ik-Joo Chung, In-Kyu Park, Lothar
Hennighausen.
2305 Differential efficacy of metformin versus
everolimus in the setting of obesity in a mouse model of
serous ovarian cancer. Weiya Z. Wysham, Yan Zhang,
Hallum K. Dickens, Kimberly M. Malloy, Xiaoyun Han, Hui Guo,
Paola A. Gehrig, Chunxiao Zhou, Victoria L. Bae-Jump.
2306 Quantitative assessment of one-side directed in
vivo angiogenesis. Gerald Prager, Matthias Unseld, Johannes
Breuss, Clemens Pausz, Gernot Schabbauer, Christoph
Zielinski, Pavel Uhrin.
2307 Targeted agents and chemotherapeutic
treatments of genetically engineered Basal-like breast
cancer mouse model. Cristina M. Contreras, Grace O. Silva,
Adam D. Pfefferle, Charles M. Perou.
2308 The role of LKB1 in development of lung
squamous cell carcinoma in mice. Jian Liu, Sung-Nam Cho,
Yiqun Zhang, Chad J. Creighton, Francesco J. DeMayo.
2309 Murine model of dual mTORC kinase inhibition
identifies CDK6 as a synergistic target in T-ALL. Joy M.
Gary, Jinfei Xu, John Simmons, Shuling Zhang, Benjamin
Gamache, Ke Zhang, Alexander Kovalchuk, Aleksandra
Michalowski, Jin-Qiu Chen, Michelle Herrmann, Wendy
Dubois, Joseph Testa, Beverly A. Mock.
383
POSTER SESSION
Tumor Biology
Stem Cells and Development
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
384
Abstract
Number
2310 Loss of 14-3-3zeta attenuates miR-126
expression and results in neonatal lethality. Sonali Joshi,
Jun Yang, Qingfei Wang, Ping Li, Hai Wang, Brian Pickering,
Yan Xiong, Jan Parker-Thornburg, Richard Behringer, Dihua
Yu.
2311 Targeting EMT and MET breast cancer stem cell
states through simultaneous inhibition of glycolytic and
antioxidant pathways. Ming Luo, April Davis, Sean
McDermott, Evelyn Jiagge, Michael Brooks, Elizabeth
Gheordunescu, Tahra Luther, Shawn G. Clouthier, Sarah
Conley, Douglas R. Spitz, Max S. Wicha.
2312 Identifying novel cancer stem cell target for
triple-negative breast cancer. Yi Liu, Dong Soon Choi,
Sergio Grandos-Principal, Wei Qian, Lacey Burey, Helen
Wong, Crisitian Rodriguez-Aguayo, Anil Sood, Zheng Li,
Stephen Wong, Heidi Weiss, Bhuvanesh Dave, Melissa
Landis, Jenny C. Chang.
2313 Characterizing intratumoral cellular
heterogeneity in human glioblastoma xenografts by 30+
parameter single-cell mass cytometry. Erin F. Simonds,
Garry P. Nolan, William A. Weiss.
2314 d16HER2 splice variant regulates the activity of
HER2-positive breast cancer-initiating cells. Lorenzo
Castagnoli, Ada Koschorke, Gaia C. Ghedini, Lorenzo Galvani,
Valentina Ciravolo, Cristina Ghirelli, Arianna Palladini, Alessia
Lamolinara, Manuela Iezzi, Pier Luigi Lollini, Tiziana Triulzi,
Patrizia Nanni, Elda Tagliabue, Serenella M. Pupa.
2315 The LGR5 monoclonal antibody BNC101 has antitumor and anti-cancer stem cell activity in pancreatic
cancer. Farbod Shojaei, Colin Walsh, Kristen Smith, Camino
Menendez, Pedro Lopez, John Norton, Jose Iglesias, Manuel
Hidalgo, Christopher Reyes, Peter Chu.
2316 Fasting protects mice from lethal DNA damage by
promoting small intestinal stem cell survival and by
inhibiting acute inflammation. Kelsey L. Tinkum, Kristina M.
Stemler, Lynn S. White, Andrew J. Loza, Sabrina Jeter-Jones,
Basia M. Michalski, Catherine E. Kuzmicki, Robert Pless,
Thaddeus Stappenbeck, David Piwnica-Worms, Helen
Piwnica-Worms.
2317 Cancer-associated fibroblast-derived HGF
regulates cancer stem cell-like properties in hepatocellular
carcinoma through c-Met/FRA1/HEY1 signaling pathway.
Yuen Ting Lau, Jessica Lo, Irene Oi Lin Ng, Terence Kin Wah
Lee.
2318 Genetic and functional diversity of propagating
cells in glioblastoma. Sara G. Piccirillo, Sue Colman, Nicola E.
Potter, Frederik W. van Delft, Suzanne Lillis, Maria-Jose
Carnicer, Lyndal Kearney, Colin Watts, Mel Greaves.
2319 Sulforadex targets breast cancer stem-like cells in
patient-derived cells and xenograft tumors. Bruno M.
Simões, Denis Alferez, Rachel Eyre, Kath Spence, Angélica
Santiago-Gomez, Iris Tanaka, Bertram Kohler, David Howat,
Sacha J. Howell, Robert B. Clarke.
2320 Prox1 marks a stem cell population that promotes
tumor progression in intestinal adenomas. Zoltan Wiener,
Jenny Högström, Ville Hyvönen, Pauliina Kallio, Sarika Heino,
Kari Alitalo.
2321 A hematopoietic stem cell factor drives brain
tumor initiating cell genesis through Notch signaling.
Sunghak Kim, Eun-Jung Kim, Park Cheol Gyu, Se-Yeong Oh,
Minata Mutsuko, Hyunggee Kim, Ichiro Nakano.
2322 The Hippo signaling pathway mediates BMP
inhibition of cancer stem cells. Cecile Chartier, Shirley Ma,
Dragana Antic, Elsa Quintana, Janak Raval, Min Wang,
Cristina Dee-Hoskins, Ann Kapoun, Tim Hoey, John Lewicki,
Austin Gurney.
Poster
Board
14.
15.
16.
17.
18.
19.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
17
Abstract
Number
2323 Tarextumab (Anti-NOTCH2/3) reverses NOTCH2
and NOTCH3-dependent tumorigenicity and metastases in
small cell lung cancer. Jalpa Shah, Gilbert O’Young, Jie Wei,
Marcus Fischer, Wan-Ching Yen, Belinda Cancilla, Ann
Kapoun, John Lewicki, Jennifer Cain, Timothy Hoey.
2324 The histone acetyltransferase inhibitor CPTH6
selectively targets lung cancer stem-like cells. Marta Di
Martile, Mariannna Desideri, Teresa De Luca, Chiara Gabellini,
Adriana Eramo, Michele Milella, Daniela Secci, Simone
Carradori, Simona Buglioni, Donatella Del Bufalo, Daniela
Trisciuoglio.
2325 Activated glucocorticoid signaling in pancreatitis
contributes to acinar-to-ductal metaplasia and KrasG12Ddriven tumorigenesis. Pei-Yu Lin, Chien-Chang Su, Chi-Che
Hsieh, Chia-Ning Shen.
2326 Sox10 promotes both stem-like and EMT
properties in mammary cells. Christopher Dravis, Geoffrey
M. Wahl.
2327 Placenta-derived mesenchymal stem cells and
their secreted exosomes inhibit the self-renewal and
stemness of glioma stem cells in vitro and in vivo. Chaya
Brodie, Edrat Buchris, Susan Finniss, Simona Cazacu, Cunli
Xiang, Hae Kyung Lee, Laila Poisson.
2328 Targeting self-renewal in human colorectal
cancer by inhibiting SUMOylation. Li Du, Yuan Chen.
2330 Activation of cancer stem cells by oncogenic KRas requires activated Wnt/␤-catenin signaling. ByoungSan Moon, Kug Hwa Lee, Kyounghwa Koo, Kang-Yell Choi.
2331 CD271 defines a cancer-initiating cell population
in hypopharyngeal cancer. Nobuyuki Tanaka, Takayuki Imai,
Mai Mochizuki, Keiichi Tamai, Kazunori Yamaguchi, Kennichi
Satoh, Kazuto Matsuura, Ikuro Sato, Shigeru Saijo, Kazuo
Sugamura.
2332 Converging molecular effectors of airway lineage
specification and metastasis in lung cancer. Don X. Nguyen.
2333 The tumor suppressive role of PRMT6 in
regulating the pathogenesis of hepatocellular carcinoma.
Lok Hei Chan, Kai Yu Ng, Stephanie Ma.
2334 Disruption of TGF-␤-regulated CTCF suppression
of telomerase links a human stem cell disorder to
tumorigenesis. Jian Chen, Jiun-Sheng Chen, Zhixing Yao,
Wilma Jogunoori, Bibhuti Mishra, Franklin H. Herlong, Yun
Seong Jeong, Nipun A. Mistry, Jianping Zhang, Xiaoping Su,
Asif Rashid, Marta Davila, John R. Stroehlein, Jerry W. Shay,
Lopa Mishra.
2335 Pancreatic cancer stem cell function is regulated
by HNF1A. Ethan V. Abel, Masashi Goto, Nikita Ramanathan,
Chandan Kumar, Lesa Begley, Michele L. Dziubinski, Lidong
Wang, Meghna Waghray, Sumithra Urs, Diane M. Simeone.
2336 AD1 promotes astroglial differentiation and
depletes glioblastoma stem cells. Raffaella Spina, Dillon M.
Voss, Andrew Sloan, Eli E. Bar.
2337 ADAM17 mediation of cancer stem cell-ness and
chemo-resistance in colorectal cancer. Rui Wang, Fan Fan,
Delphine Boulbes, Rajat Bhattacharya, Xiang-Cang Ye, Ling
Xia, Lee Ellis.
2338 Histone demethylase KDM3A: Epigenetic target
for pancreatic ductal adenocarcinoma (PDAC). Satheesh K.
Sainathan, Santanu Paul, Kanagaraj Palaniyandi,
Dharmalingam Subramaniam, Satish Ramalingam, Ossama
W. Tawfik, Tomoo Iwakuma, Danny R. Welch, Subhash B.
Padhye, Shrikant Anant, Animesh Dhar.
2339 IGFBP7 eradicates leukemic stem and progenitor
cells in acute myeloid leukemia. Han Verhagen, Marjon
Smit, David de Leeuw, Arjo Rutten, Mei-Ling Tsui, Fedor
Denkers, Monique Terwijn, Patrick Celie, Gert Ossenkoppele,
Gerrit Jan Schuurhuis, Linda Smit.
17
POSTER SESSION
Tumor Biology
Poster
:LJ[PVU
18
18
The Immune Microenvironment
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
2340 IL-15 increases NK functions in the PCalymphocyte microenvironment by a profound increase in
shedding of MICA from PCa cells - a novel paradigm.
Christina Alexandra Sakellariou, Oussama Elhage, Richard A.
Smith, Prokar Dasgupta, Christine Galustian.
2341 Characterization of macrophage behavior by 4dimensional label free, quantitative holographic imaging.
Ed Luther, Meghna Talekar, Qijun Ouyang, Mansoor Amiji.
2342 Characterization of inflammatory markers and
mast cells in association with prostate cancer. Heidi
Hempel, Ibrahim Kulac, Nathan S. Cuka, Toby C. Cornish,
Elizabeth A. Platz, Angelo M. DeMarzo, Karen S. Sfanos.
2343 Tumor microenvironment regulates the fate of
myeloid cells by controlling STAT3 activity. Vinit Kumar,
Pingyan Cheng, Thomas Condamine, Dmitry Gabrilovich.
2344 The PD-1:PD-L1 pathway in the context of the
osteosarcoma tumor microenvironment. Pratistha Koirala,
Jonathan Gill, Michael Roth, Sajida Piperdi, Amy Park,
Vincent Poon, Michael Fremed, Bang Hoang, Richard Gorlick.
2345 The collagen-dense tumor microenvironment
increases neutrophil recruitment in mouse mammary
carcinoma. Maria Gracia Garcia Mendoza, David Inman,
Suzanne M. Ponik, Patricia J. Keely.
2346 Targeting the tumor immune response for prosenescence therapy in prostate cancer. Diletta Di Mitri,
JingJing Chen, Andrea Alimonti.
2347 Multiplexed quantitative assessment and
prognostic value of TIL subtypes in non-small cell lung
cancer. Kurt A. Schalper, Cliff Hoyt, Chichung Wang, David
Rimm.
2348 Expression of CECR1 by activated M2-type
macrophages in glioma. Changbin Zhu, Marcel M. van der
Weiden, Adrea Scchetti, Thierry P. van den Bosch, Ihsan
Chrifi, Maarten M. Brandt, Dana A. Mustafa, Caroline Cheng,
Johan M. Kros.
2349 EGFR is transferred from triple negative breast
cancer cells to immune cells via trogocytosis and
expression of EGFR on immune cells is associated with
high tumor grade of triple negative breast cancer patients.
Eiji Suzuki, Ayane Yamaguchi, Tatsuki R. Kataoka, Masahiro
Hirata, Kosuke Kawaguchi, Mariko Nishie, Masakazu Toi.
2351 Characterization of Neutrophil elastase uptake in
breast cancer: implications for immunotherapy. Celine
Kerros, Satyendra C. Tripathi, Anne V. Philips, Gheath AlAtrash, Kathryn E. Ruisaard, Karen C. Dwyer, Elizabeth A.
Mittendorf, Samir Hanash, Jeffrey J. Molldrem.
2352 Investigation of the spatial interrelations among
multiple types of immune and immune related cells in
head and neck squamous cell carcinoma. James R.
Mansfield, Kenneth Oguejiofor, Henry Galletta, Christian
Slater, Richard J. Byers.
2353 Noncanonical NF-␬B activation mediates STAT3stimulated IDO up-regulation in myeloid-derived
suppressor cells in breast cancer. Jinpu Yu, Yue Wang, Hui
Li, Xiubao Ren.
2354 Insulin receptor substrate-1 regulates immune
cell content in lung adenocarcinoma. Heather Metz,
Stephanie E. Busch, Julia Kargl, Mark L. Hanke, Kyoung-Hee
Kim, A. M. Houghton.
2355 Marrow-derived macrophages mediate invasion
of pancreatic adenocarcinoma by RET activation. Moran
Amit, Shorook Na’ara, Yoav Binenbaum, Ziv Gil.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
2356 Pro-inflammatory macrophages promote
prostate cancer initiation and progression via NOX2mediated oxidative stress. Kia J. Jones, Latoya K. Bryant,
Cimona V. Hinton.
2357 Knockdown of neuropilin-1 in monocytes
impaired lymphocyte migration and anti-tumor activity in
a humanized mouse model. Kosuke Kawaguchi, Eiji Suzuki,
Isao Kii, Tatsuki R. Kataoka, Masahiro Hirata, Hironori Haga,
Masatoshi Hagiwara, Masakazu Toi.
2358 Quantifying PD-L1 spatial distribution signatures
for patient selection approaches. Joseph S. Krueger, Nathan
Martin, Anthony Milici, Holger Lange.
2359 Adrenergic regulation of MCP-1 leads to
enhanced macrophage recruitment and ovarian carcinoma
growth. Guillermo N. Armaiz-Pena, Vianey GonzalezVillasana, Archana S. Nagaraja, Cristian Rodriguez-Aguayo,
Piotr Dorniak, Rebecca Previs, Nouara Sadaoui, Rebecca
Stone, Koji Matsuo, Heather J. Dalton, Susan K. Lutgendorf,
Anil K. Sood, Gabriel Lopez-Berestein.
2360 Quantitative analysis of multiple subtypes of
immune system cells in cancer tissues. Mirza Peltjo, Carsten
Schnatwinkel, Nathan Martin, Holger Lange, Joseph S.
Krueger.
2361 TGF␤ signaling deficiency enhances tumor
associated inflammation in colon cancer. Daniel R. Principe,
Brian DeCant, Riley J. Mangan, Elizabeth A. Wayne, Andrew
M. Diaz, Dominic Vitello, Hidayatullah G. Munshi, Paul Grippo,
Barbara Jung.
2362 Tumour lymphocyte infiltration has prognostic
value in lymph node negative breast cancer patients with
high proliferation. Kristin Jonsdottir, Nina G. Egeland, Einar
Gudlaugsson, Ivar Skaland, Jan P. Baak, Emiel A. Janssen.
2363 Loss of Sparc in p53-null astrocytes alters
collagen deposition and promotes macrophage activation
and tumor phagocytosis. Stacey L. Thomas, Chad R. Schultz,
Ezekiell Mouzon, William A. Golembieski, Nancy Lemke, Laila
M. Poisson, Jorge A. Gutierrez, Sandra Cottingham, Sandra A.
Rempel.
2364 CD68+ immune cells show different infiltration
patterns in tissue samples from women with no clinical
breast disease and those who have benign breast disease.
Muhammad A. Arshad, Daniel W. Visscher, Tanya L. Hoskin,
Rushin D. Brahmbhatt, Alvaro Pena Jimenez, Melody L.
Stallings Mann, Erin E. Miller, Linda M. Murphy, Jodi M. Carter,
Stacey J. Winham, Keith L. Knutson, Derek C. Radisky, Amy C.
Degnim.
2365 Targeting M2-tumor associated macrophages
(M2-TAMs) in prostate cancer. Jelani C. Zarif, James R.
Hernandez, Kris F. Sachsenmeier, Robert E. Hollingsworth,
Kenneth J. Pienta.
2366 YB-1 an oncogenic transcription factor regulates
macrophage polarization and tumor microenvironment.
Mohammad Imran Khan, Abid Hamid, Vaqar M. Adhami,
Hasan Mukhtar.
2367 Tumor-infiltrating (TINKs) and tumor-associated
(TANKs) natural killer cells: a new player in the
inflammatory orchestration of tumor angiogenesis in colon
cancer. Antonino Bruno, Barbara Bassani, Silvia Zanellato,
Sara Canali, Lorenzo Dominioni, Luigi Boni, Cassinotti Elisa,
Giulia David, Katiuscia Dallaglio, Lorenzo Mortara, Douglas M.
Noonan, Adriana Albini.
2367A CSF1-dependent macrophage-stromal
fibroblast interactions determine tumor stability. Jeremy
B. Jacox, Ruslan Medzhitov.
385
POSTER SESSION
Tumor Biology
Tumor-Microenvironment Interactions
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
15.
386
Abstract
Number
2368 Differentiated gastric cancer cells have a
potential to induce cancer-associated fibroblasts.
Yuncheng Li, Hiroshi Tazawa, Nishizaki Masahiko, Yuuri
Hashimoto, Naoto Hori, Ryoichi Katsube, Shinji Kuroda,
Kazuhiro Noma, Shunsuke Kagawa, Toshiyoshi Fujiwara.
2369 SOX11 promotes protective microenviromental
nixes in agressive MCL. Virginia Amador.
2370 Tumor-associated stromal cells increase
malignancy of human colorectal cancers triggering the
induction of Epithelial-to-mesenchymal transition.
Valentina Mele, Manuele G. Muraro, Raoul Droeser, Daniel
Oertli, Markus Zuber, Raffaele Rosso, Ivan Martin, Michael
Heberer, Giulio C. Spagnoli, Giandomenica Iezzi.
2371 The number of CD163-positive cells in the
microenvironment and peripheral blood lymphocyte-tomonocyte-ratio (LMR) is associated with poor outcome in
patients with diffuse large B-cell lymphoma (DLBCL). Eri
Matsuki, Olga L. Bohn, Janine Pichardo, Andrew Zelenetz,
Anas Younes, Julie Teruya-Feldstein.
2372 Inflammatory cytokine induced TSLP from bone
marrow niches contributes to relapse of high risk TSLPR
overexpressing acute lymphoblastic leukemia. Christopher
D. Chien, Sang Nguyen, Haiying Qin, Terry J. Fry.
2374 Mir-29/Hsp47 regulate breast cancer progression
by modulating the ECM transcription network. Jieqing Zhu,
Gaofeng Xiong, Ren Xu.
2375 Endothelial cells isolated from colorectal
carcinoma exhibit tumor microenvironment-dependent
plasticity allowing the identification of SPARCL1 as a novel
endothelial cell quiescence factor. Andrea Liebl, Elisabeth
Naschberger, Vera S. Schellerer, Ute Schaal, Patrick Kölbel,
Sandra Grenz, Nathalie Britzen-Laurent, Tilman T. Rau,
Susanne Merkel, Barbara Dietel, Ludger Klein-Hitpass,
Werner Hohenberger, Roland S. Croner, Michael Stürzl.
2376 Interleukin-6 secreted by cancer-associated
fibroblasts promote endometrial cancer cell proliferation.
Kavita S. Subramaniam, Zahurin Mohamed, Noor Azmi Mat
Adenan, Yin Ling Woo, Ivy Chung.
2377 Bone-derived osteopontin mediates the
migration and stem-like properties of breast cancer cells.
Graciella M. Pio.
2378 The interaction of epithelial ␣5␤1 integrin and
stromal fibronectin is a candidate seed-and-soil
mechanism in prostate cancer and bone metastases.
Raghav Joshi, Edi Goihberg, Monika Pilichowska, Paul
Mathew.
2379 The lung microenvironment influences the
metastatic behavior of breast cancer cells in an innovative
3D ex vivo pulmonary metastasis model. Matthew
Piaseczny, David Goodale, Alison Allan.
2380 Integrin ␣v is necessary for skin tissue generation
and SCC tumor invasion, but dispensable for tissue
maintenance. Elizabeth K. Duperret, Ankit Dahal, Todd W.
Ridky.
2381 Epithelial-stromal network deconvolution
analysis reveals new targetable epithelial-stromal network
dependencies in breast cancer. Octavian Bucur, Laleh
Montaser-Kouhsari, Eun-Yeong Oh, Andrew H. Beck.
2382 Exploring the relationship between reelin
signaling and breast cancer metastasis. Elvira Khialeeva,
Joan Chou, Ellen M. Carpenter.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
19
Abstract
Number
2383 IL-6 and RANTES mediate the cross-talk between
tumor cells and CAFs in the esophageal tumor
microenvironment. Tatiana A. Karakasheva, Monica Soni,
Todd Waldron, Anil K. Rustgi.
2384 CD151-integrin complexes suppress ovarian
tumor growth by repressing slug-mediated emt and
canonical wnt signaling. Xiuwei H. Yang.
2385 Characterization of ECM remodeling in
disseminated ovarian cancer as a result of loss of HtrA1
and deregulated TGFB signaling. Megan Cooley, Jeremy
Chien, Anirban Mitra, Alfonso Baldi, Andras Czirok, Edina
Kosa.
2386 MMP processing of bone metastatic prostate
cancer-derived PTHrP yields novel osteogenic peptides.
Jeremy S. Frieling, Gemma Shay, Conor C. Lynch.
2387 Pre-adipocytes promote myeloma homing to and
growth in bone by secretion of soluble molecules. Timothy
N. Trotter, Patrick D. Rowan, Qianying Pan, Yang Yang.
2388 Interaction between connective tissue growth
factor and a disintegrin and metalloproteinase with
thrombospondin type I repeats 7 during cancer
development. Liya Pi, Bryon E. Petersen.
2389 Eps8: a negative regulator of myofibroblast
differentiation and function. Steven J. Frampton, Veronika
Jenei, Massimiliano Mellone, Christopher J. Hanley, Marta M.
Rucka, Joanne Tod, Karwan A. Moutasim, Emma V. King,
Gareth Thomas.
2390 The normal brain microenvironment reduces the
radiosensitivity of glioblastoma stem-like cells and
identifies additional targets for radiosensitization. Barbara
H. Rath, Amy Wahba, Kevin Camphausen, Philip Tofilon.
2391 Microglia-stimulated glioblastoma cell invasion is
dependent on the EGFR ligand amphiregulin. Bhavika
Desai, Uttama Rath, Jeffrey E. Segall, Salvatore J. Coniglio.
2392 Hyaluronan-dependent growth of human triple
negative breast cancer MDA-MB-468 in mouse xenograft
models. Chunmei Zhao, Mathieu Marella, Susan Zimmerman,
Lei Huang, H. Michael Shepard, Zhongdong Huang.
2393 PDAC cells release BAG3 that activates a
paracrine loop with stromal macrophages. Alessandra
Rosati, Anna Basile, Raffaella D’Auria, Morena d’Avenia,
Margot De Marco, Antonia Falco, Michelina Festa, Luana
Guerriero, Vittoria Iorio, Maria Pascale, Renato Franco,
Claudio Arra, Antonio Barbieri, Domenica Rea, Giulio
Menichini, Michael Hahne, Marteen Bijlsma, Daniela Barcaroli,
David A. Tuveson, Jelena Todoric, Michael Karin, Vincenzo De
Laurenzi, Maria Caterina Turco.
2394 Cancer-associated fibroblasts in invasive lobular
breast carcinoma. Mirjam C. Boelens, Ellen Wientjens, Eva
Schut, Sjoerd Klarenbeek, Karin E. de Visser, Jos Jonkers.
2395 Leptin induces an IL-6 mediated interaction
between macrophages and ovarian cancer cells that
prompted invasiveness and migration. Sumie Kato, Lorena
Abarzua-Catalan, Isidora Solar-Costabal, Karen García, Jorge
Branes, Gareth I. Owen, Mauricio A. Cuello.
2396 Hampering the crosstalk between fibroblasts and
tumor cells reveals the need for blocking both canonical
and non-canonical TGF␤ pathways. NATALIA GUILLEN,
REBECA SANZ-PAMPLONA, SAMUEL GONÇALVES, RAMON
SALAZAR, GABRIEL CAPELLA, DAVID G. MOLLEVI.
2397 Cross-talk of mouse lung fibroblasts with human
NSCLC cells in vitro and in vivo: Possible implications for
xenograft studies. Julia B. Schueler, Eva Oswald, Albin
Rudisch, Anne Loehr, Wolfgang Sommergruber.
19
POSTER SESSION
Clinical Research
Poster
:LJ[PVU
21
21
Circulating Free DNA 1
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
2398 Precision molecular biomarkers for the
surveillance of gynecologic malignancies: Rapid and
efficient pipeline for the design and highly sensitive
detection of circulating tumor DNA. Elena B. Pereira, Olga
Camacho-Vanegas, Sanya Anand, Chanpreet Singh, Andrew
Uzilov, Robert Sebra, David Chappell, Peter Dottino, John A.
Martignetti.
9.
2.
2399 Circulating tumor DNA (ctDNA) analysis of
PIK3CA and AKT1 mutations in patients enrolled onto the
Phase 1b study of the PI3K inhibitor taselisib (GDC-0032)
in solid malignancies. Timothy R. Wilson, Heidi Savage,
Junko Aimi, Jessica Jin, Hema Parmar, Jerry Hsu, Ian Krop,
Cristina Saura, Andres Cervantes, Jasgit Sachdev, Manish
Patel, Juan Cejalvo, Mafalda Oliveira, Eric Winer, Daniel Von
Hoff, Jose Baselga, Dejan Juric.
10.
2407 Multiplex KRAS G12/G13 mutation testing of 16ng
of unamplified cell-free DNA from plasma of patients with
advanced cancers using Droplet Digital PCR. Helen J.
Huang, Dawne N. Shelton, Siqing Fu, Sarina A. Piha-Paul,
Apostolia M. Tsimberidou, Ralph G. Zinner, Jennifer J. Wheler,
Aung Naing, David S. Hong, Gerald S. Falckook, Scott Kopetz,
Rajyalakshmi Luthra, Bryan K. Kee, George A. KarlinNeumann, Funda Meric-Bernstam, Filip Janku.
3.
2400 Circulating tumor DNA as a non-invasive
substitute to metastasis biopsy for targeted sequencing in
a prospective randomized trial for personalized treatment
in all tumor type: The SHIVA study. Jean-Yves Pierga,
Charles Decraene, Virginie Bernard, Maud Kamal, Anthony
Blin, Quentin Leroy, Thomas Rio Frio, Gaëlle Pierron, Céline
Callens, Ivan Bieche, Adrien Saliou, Jordan Madic, Etienne
Rouleau, François-Clément Bidard, Olivier Lantz, Marc-Henri
Stern, Ronald Lebofsky, Christophe Le Tourneau.
11.
2408 A novel multiplex droplet digital PCR approach to
KRAS mutation detection in circulating tumor DNA.
Alexandra Pender, Isaac Garcia-Murillas, Sareena Rana, David
Gonzalez de Castro, Nicholas Turner, Sanjay Popat, Julian
Downward.
12.
2409 Ultrasensitive detection of genomic alterations in
cell-free DNA by Droplet Digital PCR. Nga Wan Rachel Tam,
Teiko Sumiyoshi, Rajesh Patel, Sundari Sarma, Astrid
Kiermaier, Rajiv Raja.
13.
2410 Cell-free DNA derived from ascites: Detection of
copy number and somatic mutations using OncoScan
FFPE® Assay. Hatim Husain, Sumathi Venkatapathy, German
Gomez, Brian Woodward, Suzanna Lee, Lubena Khambaty,
Lily Chen, Radha Duttagupta, Eric T. Fung, Razelle Kurzrock.
14.
2411 Non-invasive analysis for T790M mutations of
EGFR using a selective amplification method. Shingo
Nishikawa, Hideharu Kimura, Hayato Koba, Taro Yoneda,
Takashi Sone, Chris Booth, Andrew Webb, Kazuo Kasahara.
15.
2412 Assessment of clinical applications of circulating
tumor DNA using an enhanced TAm-Seq platform. Andrew
R. Lawson, Vincent Plagnol, Abdelaziz Fahem, Tim Forshew,
James D. Brenton, Davina Gale, Nitzan Rosenfeld.
16.
2413 Rapid, automated BRAF mutation testing of cellfree DNA from plasma of patients with advanced cancers
using the novel Idylla platform. Filip Janku, Helen J. Huang,
Bart Claes, Gerald S. Falchook, Siqing Fu, Apostolia M.
Tsimberidou, David S. Hong, Aung Naing, Jennifer J. Wheler,
Sarina A. Piha-Paul, Daniel D. Karp, Vivek Subbiah, Ralph G.
Zinner, Nishma Ramzanali, Rajyalakshmi Luthra, Sapna P.
Patel, E. S. Kopetz, Erwin Sablon, Geert Maertens, Razelle
Kurzrock, Funda Meric-Bernstam.
17.
2414 Novel, ultra deep next-generation sequencing of
plasma cell-free DNA from patients with advanced
cancers. Filip Janku, Helen J. Huang, Nishma M. Ramzanali,
David S. Hong, Daniel D. Karp, Xuyu Cai, Yue Zhao, Neeraj
Salathia, Jill Waters, Li Liu, Rick Klausner, Funda MericBernstam, Jian-Bing Fan.
18.
2415 Development of a clinical cell-free DNA assay for
cancer molecular profiling. Travis Clark, Mark Kennedy,
Geneva Young, Lauren Young, Jie He, Roman Yelensky, Siraj
Ali, Geoff Otto, Doron Lipson, Vince Miller, Phil Stephens.
4.
5.
2401 Circulating cell-free tumor DNA (cfDNA) analysis
of 50-genes by next-generation sequencing (NGS) in the
prospective MOSCATO trial. Ecaterina Ileana, Cécile Jovelet,
Marie-Cécile Le Deley, Christophe Massard, Nelly Motté,
Antoine Hollebecque, Amélie Boichard, Charles Ferté, Sophie
Postel-Vinay, Silvia Rosellini, Maud Ngo-Camus, Thierry De
Baere, Philippe Vielh, Catherine Richon, Mélanie Laporte,
Siham Gouissem, Yohann Loriot, Rastilav Bahleda, Anas
Gazzah, Andrea Varga, Gilles Vassal, Alexander Eggermont,
Fabrice André, Jean-Charles Soria, Ludovic Lacroix.
2402 A research approach for the detection of somatic
mutations at 0.5% frequency from cfDNA and cTc DNA
using a multiplex sequencing assay targeting 2000 tumor
mutations. Dumitru Brinza, Dalia Dhingra, Charles Scafe,
Richard Chien, Fiona Hyland.
6.
2403 Biopsy-free comprehensive tumor profiling of
1,000+ consecutive cancer patients using CLIA-certified
commercial test and its clinical utility. Eric Collisson,
Stefanie Mortimer, Dragan Sebisanovic, Reza Mokhtari,
Somayeh Bakhtiari, Rene Lopez, Devi M. Gadde, Maria M.
Vidamo, Heena Patel, Bahram G. Kermani, Helmy Eltoukhy,
Richard B. Lanman, AmirAli Talasaz.
7.
2404 Quality assessment of circulating cell-free DNA
using multiplexed droplet-digital PCR. Tania ContenteCuomo, Muhammed Murtaza.
8.
2405 A method for comprehensive genomic analysis of
cell free DNA. Sonya T. Parpart-Li, Samuel V. Angiuoli, Bryan
Chesnick, Kevin Galens, Siân Jones, Maura Kadan, Lisa Kann,
Karli Lytle, Derek Murphy, Monica Nesselbush, Jillian Phallen,
David Riley, Manish Shukla, Theresa Zhang, Hatim Husain,
Victor E. Velculescu, Luis A. Diaz, Mark Sausen.
2406 Validation of a simple low-cost method to
monitor ctDNA in patients with solid cancers. Lucie
Benesova, Barbora Belsanova, Petra Minarikova, Tereza
Halkova, Jiri Pudil, Filip Pazdirek, Milos Pesek, Ondrej Fiala,
Jiri Hoch, Miroslav Zavoral, Bohus Bunganic, Miroslav Levy,
Ludmila Lipska, Lubos Petruzelka, Miroslav Ryska, Marek
Minarik.
387
POSTER SESSION
Clinical Research
Preclinical Targeted Therapy
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
22
Abstract
Number
1.
2416 Activity of sunitinib for lung adenocarcinoma
with RET rearrangement. June-Koo Lee, Soyeon Kim, JongYeon Shin, Miso Kim, Bhumsuk Keam, Tae Min Kim, DongWan Kim, Jong-Il Kim, Dae Seog Heo, Jeong-Sun Seo, SeHoon Lee.
10.
2425 An in vitro platform to dissect drug
responsiveness in refractory anemia with ringed
sideroblasts (RARS). Daniela Georgieva, Sheherzad Preisler,
Michael Churchill, Abdullah Mahmood Ali, Azra Raza,
Siddhartha Mukherjee.
2.
2417 Characterization of novel patient derived
melanoma xenografts and cell lines in response to
targeted therapies. Antoneicka L. Harris, Laura Marlow,
Adam Mathias, Louis Dawson, William Durham, Kenneth
Meshaw, Robert Mullin, Daniel Small, Aidan Synnott, Kevin
Wu, Dragana Milosevic, Brian Netzel, Stefan Grebe, Svetomir
Markovic, John Copland.
11.
2426 JAK inhibitors as new drugs for treatment of
paclitaxel-resistant anaplastic thyroid cancer. Tomoyuki
Fujita, Takayuki Sasaki, Zheng Wang, Kayoko Koshikawa,
Hajime Nishimura, Minoru Fujimori.
12.
2427 The difference of drug sensitivity between HPVpositive and HPV-negative head and neck squamous cell
carcinoma cell lines. Ming Zhang, Tuhina Mazumdar,
Shaohua Peng, Pan Tong, Vaishnavi Sambandam, Lauren A.
Byers, Jeffrey N. Myers, Jing Wang, Faye M. Johnson.
13.
2428 Translational study of F14512, a novel vectorised
epipodophyllotoxin, which demonstrates a marked
activity on ovarian cancer models from patients. Benoît
Thibault, Gregoire Zorza, Samuel Meignan, Nicolas Guilbaud,
Christian Bailly, Jean-Pierre Delord, Bettina Couderc, Anna
Kruczynski, Pierre Ferre, Jean-Philippe Annereau.
14.
2429 Nestin expression in tumor cells is associated with
BRCA1 positive genotype and a basal-like phenotype in
breast cancer. Kristi Krüger, Elisabeth Wik, Hawa Nalwoga,
Monica Mannelqvist, Ingunn M. Stefansson, Jarle B. Arnes,
Gøril Knutsvik, Turid Aas, William D. Foulkes, Lars A. Akslen.
15.
2430 Treatment sequence and molecular biomarker in
EGFR mutant lung cancer cells. Hannah Motes, Emma B.
Reyes, Jared Kevern, Chao H. Huang, Peter J. Van
Veldhuizen.
16.
2431 Co-targeting ROS and CLU-mediated stress
response using SMIP004 (a novel inducer of ROS and
cancer cell selective apoptosis) and OGX-011 in MDV3100resistant, castrate-resistant prostate cancer. Lucia Nappi,
Eliana Beraldi, Fan Zhang, Dieter Wolf, Martin Gleave.
17.
2432 A technology platform for personalized medicine
in melanoma. Maria R. Girotti, Dominic Rothwell, Amaya
Viros, Amit K. Mandal, Kok Haw J. Lim, Gabriela Gremel,
Simon Furney, Malin Pedersen, Jane Rogan, Jacqueline Swan,
Alberto Fusi, Ged Brady, Paul Lorigan, Caroline Dive, Richard
Marais.
18.
2433 A novel MDM2 inhibitor suppresses breast cancer
growth and metastasis. Jiang-Jiang Qin, Wei Wang, Sukesh
Voruganti, Ruiwen Zhang.
19.
2434 The anticancer activity of Japonicone A is
mediated by inhibiting NFAT1-MDM2 pathway. Sukesh
Voruganti, Jiang-Jiang Qin, Wei Wang, Ruiwen Zhang.
20.
2435 FGFR1 is associated with resistance to interaction
with estrogen receptor (ER) ␣ endocrine therapy in ER+/
FGFR1-amplified breast cancer. Luigi Formisano, Christian
D. Young, Neil Bhola, Jennifer M. Giltnane, Monica V. Estrada,
Carlos L. Arteaga.
21.
2435A Identification and treatment data of xenografts
representing TCGA-defined glioblastoma subtypes.
Stephen T. Keir, B. A. Rasheed, Katherine A. Hoadley, Martin
A. Roskoski, Danuta Gasinski, Madan M. Kwatra, Henry S.
Friedman, Darell D. Bigner.
3.
4.
5.
6.
7.
8.
9.
388
2418 A comparison of NVP-AUY-922 (AUY) and
Geldenamycin (G) in human tumor primary culture
microspheroids. Robert A. Nagourney, Paula J. Bernard,
Federico Francisco, Meghan Cule, Ryan Wexler, Steven S.
Evans.
2419 Predicting clinical response based on ex vivo
drug response in renal cell carcinoma using kinase activity
profiling. Rob Ruijtenbeek, Liesbeth Houkes-van Kerkhoff,
Maria Hilhorst, Peter Mulders, Jeannette Oosterwijk-Wakka,
Lambertus Kiemeney, Egbert Oosterwijk.
2420 The dual PI3K ␦/␥ inhibitor RP6530 in
combination with Brentuximab Vedotin (SGN-35)
synergistically induces cell death via inhibition of tubulin
polymerization in Hodgkin lymphoma cell lines. Silvia L.
Locatelli, Giuseppa Careddu, Srikant Viswanadha, Swaroop
Vakkalanka, Luca Castagna, Armando Santoro, Carmelo
Carlo-Stella.
2421 The genomic landscape of response to EGFR
blockade in colorectal cancer. Eniko Papp, Andrea Bertotti,
Siân Jones, Vilmos Adleff, Valsamo Anagnostou, Mark
Sausen, Jillian Phallen, Collin Tokheim, Noushin Niknafs,
Monica Nesselbush, Karli Lytle, Francesca Cottino, Giorgia
Migliardi, Eugenia R. Zanella, Dario Ribero, Nadia Russolillo,
Alfredo Mellano, Andrea Muratore, Gianluca Paraluppi, Mauro
Salizzoni, Silvia Marsoni, Michael Kragh, Johann Lantto,
Andrea Cassingena, Qing Kay Li, Rachel Karchin, Robert
Scharpf, Andrea Sartore-Bianchi, Salvatore Siena, Luis A.
Diaz, Victor E. Velculescu.
2422 Pan-pim kinases inhibitor, AZD1208 suppresses
tumor growth and synergistically interacts with an AKT
inhibitor in gastric cancer cells. Miso Lee, Kyung-Hun Lee,
Ahrum Min, Jungeun Kim, Seock-Ah Im, Seon-Gyeong Kim,
Hyemin Jang, Yae-Won Yang, Tae-Yong Kim, Sae-Won Han,
Do-Youn Oh, Tae-You Kim, Yung-Jue Bang.
2423 Signaling pathway profiling in multiple myeloma.
Jing Xu, Thomas Hielscher, Nicola Lehners, Elena Ellert,
Anthony D. Ho, Peter Schirmacher, Hartmut Goldschmidt,
Mindaugas Andrulis, Marc-Steffen Raab.
2424 Association between Chk1 inhibitor AZD7762mediated modulation of pharmacodynamic biomarkers
and potentiation of hypoxia-activated prodrug TH-302
antitumor efficacy in a human tumor xenograft model.
Jessica D. Sun, Fanying Meng, Qian Liu, Dharmendra
Ahluwalia, Wenwu Li, Yan Wang, Deepthi Bhupathi, Charles
P. Hart.
22
POSTER SESSION
Chemistry
Poster
:LJ[PVU
23
23
Chemical Biology and Structure-Function Studies of Cancer Mechanisms
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
2436 Understanding the molecular mechanism of
targeted kinase inhibitor resistance mediated by the
FGFR1 gatekeeper mutation. Christal D. Sohl, Molly Ryan,
BeiBei Luo, Kathleen Frey, Karen S. Anderson.
13.
2448 Towards structure-based drug design of 3phosphoglycerate dehydrogenase inhibitors. Judith E.
Unterlass, Nabila Aljufri, Sophie Bex, Celine Cano, Martin E.
Noble, Nicola J. Curtin.
2.
2437 Crystal structures of CARM1 bound to sinefungin
and diverse peptide substrates. Ann Boriack-Sjodin, Lei Jin,
Suzanne L. Jacques, Allison Drew, Margaret Porter Scott,
Scott Ribich, Oscar Moradei.
14.
3.
2438 Identification of the mitochondrial binding site on
the amino-terminal end of hexokinase II. Nadezda Bryan,
Michelle M. Hwang, Kevin P. Raisch.
2449 Targeting an “undruggable” RNA-binding
protein: Discovery of small molecule inhibitors of HuR for
novel breast cancer therapy. Xiaoqing Wu, Lan Lan, Amber
Smith, Rebecca Marquez, David Wilson, Steven Rogers, Philip
Gao, Scott Lovell, John Karanicolas, Dan Dixon, Jeffrey Aubé,
Liang Xu.
15.
4.
2439 Multiplexed chemoproteomic profiling as a tool
to decipher the intracellular interactions between proteins
and small molecules. Michael Ford, Richard Jones, Ravi
Amunugama, Danette Daniels, Rachel Ohana, Thomas
Kirkland, Marjeta Urh.
2450 Identifying novel substrates of PLK2 using a
chemical genetics approach. Poornima Ramkumar, Rebecca
S. Levin, Miriam Sansó, Shashidhar Jatiani, Arvin C. Dar,
Robert P. Fisher, Kevan M. Shokat, E Premkumar Reddy.
16.
2451 The nuclear-targeted gold nanoparticles inhibit
the tumor growth in mouse model as potential anticancer
agents. Xianghong Peng, Megan A. Macke, Hyung Ju C Shin,
Sreenivas Nannapaneni, Nelson Chen, Sungjin Kim, Zhuo
(Georgia) Chen, Mostafa A El-Sayed, Dong Shin.
17.
2452 Deorphanizing TLX: Implications for treatment of
glioblastomas. Cindy C. Benod, Rosa Villagomez, Paul Webb.
18.
2453 The role of p21 in the toxicity of mitomycin C and
decarbamoylmitomycin C. Elise Champeil, Shu-Yuan Cheng,
Bik Tzu Huang, Jiwon Seo.
19.
2454 Targeting the translational enhancer complex
MCT-1: DenR to disrupt NHL survival. Sean D. Stowe,
Michael C. Cavalier, Raquel Godoy-Ruiz, Kristen J. Varney,
Paul T. Wilder, Ronald B. Gartenhaus, David J. Weber.
20.
2455 Differences in dynamic modulation of CoQ10
redox status and intracellular localization between nondisease and cancer cell lines. Katerina Krumova, Sumit Garg,
Sirisha Dhavala, Vivek K. Vishnudas, Michael A. Kiebish,
Rangaprasad Sarangarajan, Niven R. Narain.
21.
2456 The transmembrane domain of prostate specific
membrane antigen: Deciphering the role of the SmallXXX-Small motif in oligomerization. Brianna S. Berg,
Brandan M. Cook, Jack R. Hyder, James I. Godfroy, Hubert
Yin, Jonel P. Saludes.
22.
2457 Mechanisms of membrane binding of K-Ras4B
farnesylated hypervariable region. Hyunbum Jang, Sherwin
J. Abraham, Tanmay S. Chavan, Ben Hitchinson, Lyuba
Khavrutskii, Nadya I. Tarasova, Ruth Nussinov, Vadim
Gaponenko.
23.
2458 Targeting membrane fluidity as a therapeutic
strategy in cancer using BPM 31510. Sumit Garg, Sirisha
Dhavala, Katerina Krumova, Vivek K. Vishnudas, Joaquin J.
Jimenez, Michael Kiebish, Rangaprasad Sarangarajan, Niven
R. Narain.
5.
2440 Evaluation of structural changes in SN79-derived
sigma-2 receptor modulators: effect on apoptotic efficacy
in SK-N-SH neuroblastoma. Hilary E. Nicholson, Walid
Alsharif, Christopher R. McCurdy, Wayne D. Bowen.
6.
2441 Engineering and mapping difficult proteins using
comprehensive mutagenesis. Cheryl Paes, Jason Goodman,
Melanie Wescott, Yana Thaker, Anu Thomas, Joseph Couto,
Joseph Rucker, Benjamin J. Doranz.
7.
2442 XPO1 is selinexor prime target: Validation by
mutating cysteine 528 on both XPO1 alleles using CRISPR/
Cas9 genome editing. Jasper E. Neggers, Thomas
Vercruysse, Maarten Jacquemyn, Els Vanstreels, Erkan
Baloglu, Sharon Shacham, Marsha Crochiere, William
Senapedis, Yosef Landesman, Dirk Daelemans.
8.
2443 Optides (optimized peptides), a new knottinbased cancer drug discovery platform. James M. Olson,
Roland Strong, Christopher Mehlin, Colin Correnti.
9.
2444 Directed evolution strategy for generating of
novel zinc finger peptides with affinity for gapped DNA.
Dylan Plaskon, Rachel M. Guerra, Connor P. McGuckin, Vania
Lopez Ruiz, Colin T. Sheehan, Ryan A. Weeks, Dylan Cincotta,
Kevin P. Rice.
10.
11.
12.
2445 DNA recognition by XR5944, a novel bisintercalator and potent anticancer drug. Clement Lin,
Raveendra I. Mathad, Neil Sidell, Danzhou Yang.
2446 Decoding phenotypic drug screening targets
using a novel chloroalkane capture tag. Rachel Friedman
Ohana, Thomas Kirkland, Carolyn Woodroofe, Sergiy Levin,
Robin Hurst, Paul Otto, Tetsuo Uyeda, Michael Ford, Richard
Jones, Danette Daniels, Marjeta Urh, Keith Wood.
2447 Development of Hsp90 paralog specific inhibitors
with mitochondrial drug delivery system. Byoung Heon
Kang.
389
POSTER SESSION
Immunology
Antibodies/Antibody Derivatives
Poster
:LJ[PVU
Poster
Board
Abstract
Number
Poster
Board
1.
2459 KIR3DL1 and HLA-B subtype combinations predict the
efficacy of 3F8 monoclonal antibody therapy for neuroblastoma.
Christopher J. Forlenza, Jeanette E. Boudreau, Junting Zheng, Glenn
Heller, Nai-Kong V. Cheung, Katharine C. Hsu.
16.
2.
2460 Dissecting the in vitro and in vivo mechanism of action of
obinutuzumab (GA101) in preclinical models using an immune
effector-dead version of obinutuzumab. Sylvia Herter, Frank Herting,
Gunter Muth, Erwin van Puijenbroek, Claudia Ferrara, Sabine Lang, Marina
Bacac, Ekkehard Moessner, Pablo Umana, Christian Klein.
2461 SYD985, a novel HER2-targeting antibody-drug conjugate,
shows strong antitumor activity in primary USC cell lines with low (1+)
and moderate (2+) HER2/Neu expression. Jonathan D. Black, Salvatore
Lopez, Emiliano Cocco, Stefania Bellone, Elena Bonazzoli, Carlton Schwab,
Diana English, Peter Goedings, Patrick Beusker, Miranda van der Lee,
Marco Timmers, Wim Dokter, Thomas Rutherfor, Peter Schwartz,
Alessandro Santin.
2462 In Vivo efficacy of a novel anti-CD33 targeted thorium
conjugate (TTC) in mouse models of acute myeloid leukemia (AML).
Urs B. Hagemann, Joergen Borrebaek, Adam O’Shea, Ellen Wang, Katrine
Wickstroem, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Alan
Cuthbertson.
2463 Enhanced anti-tumor activity of an Auristatin-based
antibody-drug conjugate in combination with PI3K/mTOR inhibitors or
taxanes: Translational implications and mechanistic insights. Puja
Sapra, Boris Shor, Maureen Dougher, Jennifer Kahler, Michelle Mack, Jane
Xu, Shuyan Lu, Eugene Melamud, Fang Wang, Edward Rosfjord.
2464 DART® molecules with enhanced DR5 agonistic activity for
improved cancer cell cytotoxicity. Jonathan C. Li, Kalpana Shah, Jill
Rillema, Francine Chen, Doug Smith, Steve Burke, Valentina Ciccarone,
Sergey Gorlatov, Ralph Alderson, James Tamura, Ezio Bonvini, Syd
Johnson, Paul A. Moore.
2465 Targeting HER2-positive brain metastases by incorporating
the brain-penetrant Angiopep-2 peptide to an anti-HER2 antibody and
anti-HER2 antibody drug conjugate. Michel Demeule, Sanjoy Das,
Christian Che, Gaoqiang Yang, Jean-Christophe Currie, Simon LordDufour, Sasmita Tripathy, Anthony Regina, Jean-Paul Castaigne, Jean E.
Lachowicz.
2466 Sequential tumor and immune targeted immunotherapy:
Anti-tumor activity of antibody drug conjugate Trastuzumab
Emtansine (T-DM1) with CD137 stimulation in HER-2+ breast cancer
therapy. Suparna Dutt, Narendiran Rajasekaran, Aurelien Marabelle, Roch
Houot, Mohith Sadaram, Jonathan Hebb, Idit Sagiv-Barfi, Sid Ambulkar,
Amanda Rajapaksa, Cariad Chester, Erin Waller, Holbrook Kohrt.
2467 Expression levels of CD38 and the complement inhibitors
CD46, CD55 and CD59 control the ability of anti-CD38 antibodies to
trigger complement dependent lysis of multiple myeloma cells. Zhili
Song, Guang Yang, David Harper, Lucas Bush, Daniel Ajona, Bruno Paiva,
Ti Cai, Joachim Theilhaber, Francisco Adrián.
2468 Antibody targeting soluble NKG2D ligand sMIC induces
regression of primary tumors and eliminates metastasis in multiple
pre-clinical cancer models. Jennifer D. Wu, Fahmin Basher, Mark
Rubinstein.
2469 Brentuximab vedotin-mediated immunogenic cell death.
Shyra J. Gardai, Angela Epp, Che-Leung Law.
2470 Anti-leukemic activity and tolerability of anti-human CD47
monoclonal antibodies. E. Christine Pietsch, Jianying Dong, Xiaochun
Zhang, Diana Chin, Rebecca Hawkins, Thai Dinh, Mimi Zhou, Brandy Strake,
Ping-Hua Feng, Meredith Rocca, Cedric Dos Santos, Xiaochuan Shan,
Gwenn Danet-Desnoyers, Elizabeth Kaiser, Hillary Quinn, Jeffrey A.
Nemeth, Ricardo Attar.
2471 EGFRvIII T-cell TandAbs are specific and highly potent drug
candidates for the treatment of a variety of solid tumors. Kristina
Ellwanger, Uwe Reusch, Ivica Fucek, Michael Weichel, Carmen Herbrecht,
Stefan Knackmuss, Erich Rajkovic, Vera Molkenthin, Eugene A. Zhukovsky.
2472 SEA-CD40, a sugar engineered non-fucosylated anti-CD40
antibody with improved immune activating capabilities. Shyra J. Gardai,
Angela Epp, Germein Linares, Lori Westendorf, May Sutherland, Haley
Neff-LaFord, Stanford L. Peng, Che-Leung Law.
2473 KIR3DL2 is a novel target for antibody-therapy of T cell
lymphomas. Cariad Chester, Sean Lim, Anne Marie-Cardine, Naren
Rajasekaran, Hélène Sicard, Youn Kim, Holbrook Kohrt.
17.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
390
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
25
Abstract
Number
2474 A rat monoclonal antibody against bone sialoprotein II
shows differential activity in MDA-MB-231 cells growing in vitro or in
vivo. Michael Zepp, Irina Berger, Heidegard Hilbig, Franz-Paul Armbruster,
Martin R. Berger.
2475 A novel class of fully human monoclonal anti-oxMIF
antibodies penetrates metastases and accumulates in tumor tissue.
Alexander Schinagl, Michael Thiele, Patrice Douillard, Deyaa Adib,
Xiaochun Liu, Salim Yazji, Friedrich Scheiflinger, Randolf Kerschbaumer.
2476 Bispecific redirected T-cell immunotherapy targeting Pcadherin expressing tumors. Timothy S. Fisher, Adam Root, Bryan Peano,
Allison Rohner, Justin Lucas, Mark Elliott, Konstantinos Tsaparikos, Hui
Wang, Jonathan Golas, Maria Gavriil, Susan Benard, Tao He, Tracey Clark,
Nahor Haddish-Berhane, Ralph Alderson, Yinhua Yang, Syd Johnson, Paul
Moore, Lioudmila Tchistiakova, Hans-Peter Gerber, Chad May.
2477 Engineered toxin bodies: A next-generation immunotoxin
scaffold with novel immuno-oncology functionality. Erin K. Willert,
Garrett L. Robinson, Sangeetha Rajagopalan, Brigitte Brieschke, Jennifer
Erdman, Jane Neill, Rodney Flores, Julia Foree, William Null, Jensing Liu,
Jack P. Higgins.
2478 A mAb with in vivo therapeutic activity against spontaneous
breast tumors in FVB-neuN mice recognizes SLP-2. Li-Xin Wang, Michael
Berk, Gregory E. Plautz.
2479 Obinutuzumab compared to Rituximab significantly
enhances cell death, antibody dependent cytotoxicity (ADCC) and
improves overall survival against CD20+ rituximab-sensitive/-resistant
Burkitt Lymphoma (BL) and precursor Lymphoblastic Leukemia (pre-BALL). Aradhana A. Tiwari, Janet Ayello, Carmella Vandeven, Mona
Elmacken, Matthew J. Barth, Christian Klein, Mitchell S. Cairo.
2480 MI130004, a new antibody-drug conjugate, induces strong,
long-lasting antitumor effect in HER2 expressing breast tumor models.
Pablo M. Aviles, Maria Jose J. Guillen, Alberto Gallardo, Maria V. Cespedes,
Ramon Mangues, Heiner Fiebig, Natalie Hartman, Juan M. Dominguez, Luis
F. Garcia, Carlos Galmarini, Carmen Cuevas.
2481 CEA TCB, a novel T-cell bispecific antibody with potent in
vitro and in vivo antitumor activity against solid tumors. Marina Bacac,
Tanja Fauti, Sara Colombetti, Johannes Sam, Valeria Nicolini, Nathalie
Steinhoff, Oliver Ast, Peter Bruenker, Ralf Hosse, Thomas Hofer, Ekkehard
Moessner, Christiane Jaeger, Jose Saro, Vaios Karanikas, Christian Klein,
Pablo Umana.
2482 Neutralizing CD47 in cancer cells with dual targeting kappa/
lambda bodies. Krzysztof Masternak, Lucile Broyer, Elie Dheilly, Stefano
Majocchi, Valéry Moine, Giovanni Magistrelli, François Rousseau, Ulla Ravn,
Franck Gueneau, Pauline Malinge, Sébastien Calloud, Maud CharretonGalby, Mireille Guerrier, Nessie Costes, Nicolas Bosson, Gérard Didelot,
Lucie Bernard, Vanessa Buatois, Laura Cons, Laurence Chatel, Anne
Papaioannou, Zoë Johnson, Walter Ferlin, Marie Kosco-Vilbois, Nicolas
Fischer.
2483 Met degradation by SAIT301, a Met monoclonal antibody,
reduces the invasion and migration of nasopharyngeal cancer cells via
inhibition of EGR-1 expression. Bok-Soon Lee, Sam Kang, Kyung-Ah Kim,
Yun-Jeong Song, Kwang Ho Cheong, Hyun-Young Cha, Haeng-Jun Kim,
Hye Sook Hwang, Yeon Soo Kim, Chul-Ho Kim.
2484 IR700-conjugated anti-CD44 monoclonal antibody for
phototherapy theranostics of triple-negative breast cancer. Jiefu Jin,
Balaji Krishnamachary, Hisataka Kobayashi, Zaver Bhujwalla.
2485 Novel monoclonal antibody targeting cancer stem cells. Jeff
Holderness, Amy Turner, Sam dolezal, Steve Wolpe, Michael Pierce,
Cohava Gelber.
2486 Site-specific antibody-drug conjugation through an
engineered glycotransferase and a chemically reactive sugar. Zhongyu
Zhu, Ramakrishnan Boopathy, Jinyu Li, Ponraj Prabakaran, Simona
Colantonio, Yang Feng, Yanping Wang, Marzena A. Dyba, Dimiter S.
Dimitrov.
2487 The antitumor efficacy of anti-BST2 antibody is significantly
increased in combination with CpG oligodeoxynucleotide in
endometrial cancer. Yusuke Takahashi, Satoshi Serada, Kosuke
Hiramatsu, Kouji Kobiyama, Minoru Fujimoto, Ken Ishii, Tetsuji Naka.
2488 FGFR4 as a potential therapeutic target for monoclonal
antibody based intervention in rhabdomyosarcoma. Sivasubramanian
Baskar, Nityashree Shivaprasad, Zhongyu Zhu, Dimiter Dimitrov, Mhairi
Sigrist, Poul Sorensen, Marielle Yohe, John Shern, John Maris, Crystal
Mackall, Javed Khan.
25
POSTER SESSION
Immunology
Poster
:LJ[PVU
26
26
Tumor Vaccines
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
2489 HER2 peptide-specific immunogenicity correlates with
pathologic response following HER2-pulsed dendritic cell
vaccination for early breast cancer. Megan E. Fracol, Jashodeep
Datta, Shuwen Xu, Lea Lowenfeld, Elizabeth Fitzpatrick, Carolyn Mies,
Paul J. Zhang, Robert E. Roses, Carla Fisher, Brian J. Czerniecki.
2490 CD40 ligand expressing recombinant vaccinia virus
(rVV40L) modulation of central memory CD8-mediated immune
response. Emanuele Trella, Evangelos Panopoulos, Nermin Raafat,
Chantal Mengus, Emmanuel Traunecker, Swantje Heidtmann, Michael
Heberer, Daniel Oertli, Giulio C. Spagnoli, Paul Zajac.
2491 Treatment with tumor lysate-pulsed autologous
dendritic cells prolongs survival in patients with recurrent
glioblastoma multiforme. Marnix Bosch, Robert Prins, Linda Liau.
2492 Eradication of breast cancer with bone metastasis by
autologous formalin- fixed tumor vaccine (AFTV) and radiation.
Fumito Kuranishi, Yoji Uemae, Tadao Ohno, Yusuke Sumi.
2493 Fractionated but not single dose radiation is an optimal
adjuvant for in situ tumor vaccination. Claire I. Vanpouille-Box,
Molykutty Aryankalayil, Karsten A. Pilones, Silvia C. Formenti,
Norman Coleman, Sandra Demaria.
2494 Vaccine-induced TNF alpha producing T cells synergize
with cisplatin in tumor eradication. Cornelis J. Melief, Tetje C. van
der Sluis, Sjoerd H. van der Burg.
2495 STING agonists formulated into cancer vaccines
(STINGVAX) can cure established tumor resistant to immune
checkpoint blockade by activating NK cells. Young Kim, Drew
Pardoll, Juan Fu, Tom Dubensky.
2496 Preclinical testing of a novel anti-angiogenic vaccine
targeting human VEGF. Madelon Q. Wentink, Peter Timmerman,
Hans J. van der Vliet, Tanja D. de Gruijl, Henk M. Verheul, Arjan W.
Griffioen.
2497 Immune checkpoint inhibitors enhance benefits of
modified vaccinia virus Ankara to improve survival in preclinical
models of cancer. Karola Rittner, Christelle Remy-Ziller, Julie
Hortelano, Isabelle Farine, Micael de Meyer, Virginie Nourtier, Murielle
Gantzer, Christine Thioudellet, Philippe Slos, Xavier Preville.
2498 The MVA viral platform for the treatment of cancer and
chronic infectious diseases: Clinical experience from four
randomized controlled phase II studies. Jean-Marc LIMACHER,
Elisabeth QUOIX, Heiner WEDEMEYER, Francisco GARCIA, Pekka
NIEMINEN, Gisèle LACOSTE, Delphine AGATHON, Geraldine HONNET,
Elizabeth CALLEJA, Isabelle DIDILLON, Berangère MARIE-BASTIEN.
2499 Clinical and immunopathological effects following
Image-guided intratumoral injection of activated, autologous
dendritic cells in patients with advanced solid cancers. Vivek
Subbiah, Ravi Murthy, David S. Hong, Robert E. Brown, Robert Prins,
Chitra Hosing, Mary McGuire, Aung Naing, Siquing Fu, Tina Chou,
Quan Lin, Richard P. Guevarra, Anthony Conley, Indreshpal Kaur,
Funda Meric-Bernstam, Marnix Bosch.
2500 Identification of promiscuous oncofetal antigen (IMP3)-derived long peptides, bearing both Th cell and CTL epitopes.
Masatoshi Hirayama, Akira Yuno, Yusuke Tomita, Mohammad A.
Sayem, Hirotake Tsukamoto, Atsushi Irie, Satoru Senju, Yoshihiro
Yoshitake, Daiki Fukuma, Masanori Shinohara, Eiji Yuba, Kenji Kono,
Koji Yoshida, Yusuke Nakamura, Hideki Nakayama, Yasuharu
Nishimura.
2501 Vaccination using epitopes with higher MHC class I
affinity elicits CD8+ T cells with increased PD-1 expression.
Christopher D. Zahm, Douglas McNeel.
2502 Immunization with minicircle and mini-intronic DNA
vectors induce LAG-3 expressing CD8+ T cells and inferior antitumor responses. Viswa Teja Colluru, Douglas G. McNeel.
2503 Efficient crosspresentation of oncofetal antigen
(Glypican-3)-derived long peptides encompassing CTL and
promiscuous Th cell epitopes using a novel liposome. Mohammad
A. Sayem, Yusuke Tomita, Akira Yuno, Masatoshi Hirayama, Atsushi
Irie, Hirotake Tsukamoto, Satoru Senju, Eiji Yuba, Toshiaki Yoshikawa,
Kenji Kono, Tetsuya Nakatsura, Yasuharu Nishimura.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2504 A therapeutic Her2-Neu cancer vaccine alone or in
combination with anti-Her2 mAb inhibits tumor growth in HLA-A2
transgenic mice. Thi Tran, Mariana De Oliveira Diniz, Estelle Dransart,
Alain Gey, Sylvie Godefroy, Craig Sibley, Ludger Johannes, Eric
Tartour.
2505 Therapeutic efficacy of the ZVex™ and GLAAS™
platforms in a B16-F10/hCAIX melanoma mouse model. David J.
Campbell, Rebecca S. Reeves, Patrick A. Flynn, Scott H. Robbins,
Peter Berglund, Jan H. ter Meulen.
2506 Preclinical characterization of LV305, a lentiviral vector
targeting tumors expressing NY-ESO-1. Tina C. Albershardt, David
J. Campbell, Andrea J. Parsons, Jan H. ter Meulen, Peter Berglund.
2507 Bivalent adenylate cyclase (CYA)-based therapeutic
vaccines: eradication of tumor cells expressing different antigens
over time. Michaël Esquerré, Marie Momot, Anne Goubier, Yolande
Misseri, Marie-Christine Bissery.
2508 Multi-modal treatment with peptide vaccine,
metronomic cyclophosphamide and anti-PD1 monoclonal
antibody provides effective control of tumors in multiple models.
Genevieve Weir, Olga Hrytsenko, Marianne Stanford, Mohan Karkada,
Neil Berinstein, Marc Mansour.
2509 Human anti-MUC1 antibodies elicited by a prophylactic
cancer vaccine for mAb and CAR-modified T cell immunotherapies.
Jason J. Lohmueller, Shuji Sato, Wan Cheung Cheung, Isabel Chu,
Lana Popova, Christopher A. Manning, Katherine Crosby, Christopher
Grange, James D. Ham, Roberto D. Polakiewicz, Olivera J. Finn.
2510 Immunotherapy targeting MASH2 antigen protects mice
against MASH2-expressing transplanted tumors and inhibits the
development of colorectal adenomas in APC +/Min-FCCC mice.
Clément Rioux, Margie Clapper, Harry Cooper, Jean Michaud, Natalie
St Amant, Hossein Koohsari, Laura Workman, Esther Kaunga,
Anthony Pilorget, Catherine Gerard.
2511 Therapeutic dendritic cell targeting MIP3␣-gp100 DNA
vaccination with immunomodulatory ␣IL-10 and ␣PD-1
antibodies significantly enhances survival in a mouse melanoma
model system. James Gordy, Richard B. Markham.
2512 Novel immunotherapy using a tumor lysate vaccine with
␣-gal epitopes against pancreatic cancer. Kenta Furukawa,
Masahiro Tanemura, Eiji Miyoshi, Hiroaki Nagano, Masaki Wakasugi,
Toru Masuzawa, Mitsuyoshi Tei, Kentaro Kishi, Hiroki Akamatsu,
Hidetoshi Eguchi, Katsuyoshi Matsunami, Masaki Mori, Yuichiro Doki.
2513 Anti-tumor therapeutic effects in mice treated with
Listeria monocytogenes (Lm)-LLO immunotherapy in combination
with PD-L1. Poonam Molli, Anu Wallecha.
2514 Activity of a novel Foxp3-tumor cell vaccine in a murine
model of renal cell carcinoma. Li Shen, Ashley Orillion, Remi
Adelaiye, Eric Ciamporcero, Swathi Ramakrishnan, Roberto Pili.
2515 Tumor presenting cells: a new strategy for cancer
immunotherapy. Fernando T. Kreutz.
2516 A new generation of dendritic cells to improve cancer
therapy shows prolonged progression-free survival in patients
with solid tumors. Iris Bigalke, Kirsti Honnashagen, Marianne
Lundby, Guri Solum, Lisbeth Skoge, Else M. Suso Inderberg, Julitta
Kasten, Stein Saboe-Larssen, Dolores J. Schendel, Gunnar Kvalheim.
2517 Effects of toll-like receptor 4 agonist on the anti-tumor
immune response to the GVAX vaccine. Michael J. Korrer, Jeff W.
Bulte, Hyam I. Levitsky.
2518 Effective vaccination against melanoma in an animal
study: Combination of laser-assisted dermal skin delivery and
cross-presenting XCR1+ dermal DCs targeting. Dorothea Terhorst,
Even Fossum, Anna Baranska, Samira Tamoutounour, Camille
Malosse, Mattia Garbani, Elmira Lechat, Reto Crameri, Roland
Winteler, Bjarne Bogen, Bernard Malissen, Sandrine Henri.
391
POSTER SESSION
Combination Chemotherapy 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
392
Abstract
Number
2519 The role of EGFR in the regulation of EZH2mediated differentiation process of OSCC. Wei-Chun Hu,
Kuo-Wei Chang, Cheng-Chieh Yang.
2520 Synergistic combination of lurbinectedin and
PARP inhibitors in breast cancer tumor cell lines. Gema
Santamaría, Sonia Avila, Victoria Moneo, Carmen Cuevas,
Luis F. García-Fernández, Carlos M. Galmarini.
2521 In vitro and in vivo antitumor efficacy of
sequentially combined vinorelbine and gefitinib in nonsmall cell lung cancer. Angela Alama, Maria Giovanna Dal
Bello, Irene Vanni, Anna Truini, Simona Coco, Erika Rijavec,
Carlo Genova, Federica Biello, Cecilia Marini, Gianluca
Bottoni, Gianmario Sambuceti, Francesco Grossi.
2522 Molecular and cellular mechanisms underlying the
therapeutic efficacy of the combination of JAK inhibitor,
ruxolitinib, PIM inhibitor, LGH447, and CDK4/6 inhibitor,
LEE011, in a preclinical model of myeloproliferative
neoplasia. Maria Pinzon-Ortiz, Tyler Longmire, Xianhui Rong,
Giordano Caponigro, Gary Vanasse, Benjamin H. Lee, Z.
Alexander Cao.
2523 Strong synergistic effects with APR-246 and
cisplatin in p53-mutant lung cancer cells. Nina Mohell, Åsa
Fransson, Jessica Alfredsson, Mikael von Euler, Ulf Björklund,
Lars Abrahmsen.
2524 Combination with vorinostat overcomes ABT-263
resistance of small cell lung cancer. Wataru Nakajima, Mark
A. Hicks, Kanika Sharma, Ngoc Le, Geoffrey W. Krystal,
Hisashi Harada.
2525 MLN4924 synergistically enhances cisplatininduced cytotoxicity via JNK and Bcl-xL pathways in
human urothelial carcinoma - In vitro and in vivo study.
I-Lin Ho, Kuan-Lin Kuo, Chien-Tso Chou, Chen-Hsun Hsu,
Yeong-Shiau Pu, Ju-Ton Hsieh, Kuo-How Huang.
2526 Detection of Ara-CTP following exposure to CPX351 and potentiation of action by fludarabine in leukemia
cell lines using a bioluminescent bacterial biosensor.
Lawrence D. Mayer, Elizabeth Anderson, Heather Bone,
Gareth Robinson, Garreth Reynolds, Vyvyan Salisbury.
2527 The drug combination sorafenib and quinacrine
targets the expression of Mcl-1 - an anti-apoptotic protein
and candidate prognostic factor in Anaplastic Thyroid
Cancer (ATC). Junaid Abdulghani, Jean-Nicholas Gallant,
Prashanth Gokare, Timothy Cooper, Tiffany Whitcomb,
Jiangang Liao, Jing Liu, David Goldenberg, Niklas K.
Finnberg, Wafik S. El-Deiry.
2528 Vardenafil is superior to idarubicin in treatment of
glioma. Abdelkader E. Ashour, Abdulrahman Z. Alzahrani,
Hala E. Abdel-Hamied, Khairy M. Zoheir, Sheikh F. Ahmed,
Salem S. Al-Rejaie, Adel R. Abd-Allah.
2529 Debio 1143 synergizes with taxanes,
topoisomerase and bromodomain inhibitors to inhibit
growth of lung adenocarcinoma. Casey G. Langdon, Norbert
Wiedemann, Matthew A. Held, James T. Platt, Ramanaiah
Mamillapalli, Pinar Iyidogan, Nicholas Theodosakis, Frederic
Levy, Denis Robichon, Claudio Zanna, Gregoire Vuagniaux,
Mel Sorensen, Shaomeng Wang, Marcus W. Bosenberg, David
F. Stern.
2530 Bcl-2 and Bcl-xL dual inhibitor, ABT-737,
circumvents JNK mediated upregulation of anti-apoptotic
molecules in cisplatin treated non-small cell lung cancer
models. Eun Young KIM, Arum Kim, Yoon Soo Chang.
2531 Fisetin enhances the efficacy of cabazitaxel: an in
vitro and in vivo study in prostate cancer. Eiman Mukhtar,
Vaqar M. Adhami, Mario Sechi, Hasan Mukhtar.
2532 Influence of survivin-targeted therapy on
chemosensitivity in the treatment of acute myeloid
leukemia. Jingcao Huang, Hui Lyu, Ying Wu, Bolin Liu.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
27
Abstract
Number
2533 SGI-110 priming sensitizes hepatocellular
carcinoma cells to oxaliplatin. Yuting Kuang, Anthony ElKhoueiry, Pietro Taverna, Mats Ljungman, Nouri Neamati.
2534 Sequenced combinations of platinum drugs and
phytochemicals towards overcoming drug resistance in
ovarian cancer. Safiah I. Althurwi, Jun Qing Yu,, Philip Beale,
Charles Chan, Fazlul Huq.
2535 Synergistic anti-tumor activity of the Notch
gamma secretase inhibitor BMS-906024 and paclitaxel in
the treatment of lung adenocarcinoma. Katherine M.
Morgan, Francis Lee, Erin Michaud, Joseph R. Bertino, Bruce
S. Fischer, Sharon R. Pine.
2536 Assessing combinations of FDA approved
chemotherapy in malignant peripheral nerve sheath tumor
(MPNST) cell lines. Elliott Kahen, Diana Yu, Christopher
Cubitt, Dan Sullivan, Damon R. Reed.
2537 CDK4/6 inhibition synergizes with KRAS-MAPK
pathway targeting in pancreatic cancer. Jason A.
Castellanos, Nagaraj Nagathihalli, Michael N. Van Saun,
Cameron Kasmai, Yanhua Xiong, Nipun Merchant.
2538 The dietary isoflavone biochanin-A in
combination with atorvastatin induces cell cycle arrest and
apoptosis in human pancreatic cancer cells. Alok Bhushan,
Ponniah Selvakumar, Satya Murthy Tadinada, James C. Lai.
2539 Targeting therapy-resistant gastric and
esophageal cancers with mTOR ATP site inhibitors.
Bhuvanesh Dave, Alexandria Phan.
2540 A new mathematical model and software, to
enable improved quantification and interpretation of
combinatorial drug effects. Giovanni Y. Di Veroli, Duncan I.
Jodrell, Frances M. Richards, Ian Goldlust.
2541 Preclinical results of SGN-CD19A in combination
with R-ICE or R-CHOP in non-Hodgkin lymphoma models.
Heather A. Van Epps, Kerry Klussman, Martha Anderson,
Weiping Zeng, Devra Olson, Maureen Ryan, Tina Albertson,
Che-Leung Law.
2542 Lurbinectedin (PM01183) synergizes in vivo the
antitumor activity of doxorubicin in SCLC tumor
xenografts. Maria J. Guillen, Oscar Cataluña, Mandy
Palomares, Raquel Lopez, Praxedes Nuñez, Carmen Cuevas,
Pablo M. Aviles.
2543 Akt and Myc cooperate to promote cell
proliferation in Lck-Dlx5 T-cell lymphomas. Yinfei Tan,
Eleonora Sementino, Joseph Testa.
2544 Combination of anti-cancer small molecule
tolfenamic acid and curcumin effectively inhibits colon
cancer cell growth. Umesh T. Sankpal, Ganji P. Nagaraju,
Myrna Hurtado, Sriharika R. Gottipolu, Bassel El-Rayes,
Mamoru Shoji, Christopher G. Jordan, Riyaz Basha.
2545 Effect of aldehydes in anthracycline cytotoxicity
in S. cerevisiae. Jana S. Miles, Tryphon K. Mazu, Hernan
Flores-Rozas.
2546 HDAC and Hsp90 inhibition as therapeutic
strategy for translocation renal cell carcinoma. Sheng-Yu
Ku, Swathi Ramakrishnan, Eric Ciamporcero, Bo Xu, Gissou
Azabdaftari, Richard Cheney, Roberto Pili.
2547 PEGPH20 enhances chemotherapy in patientderived and traditional cell-derived xenograft NSCLC
models. Jessica A. Cowell, Xiaoming Li, Ping Jiang, Susan
Zimmerman, Rebecca Symons, H. Michael Shepard, Daniel C.
Maneval, Curtis B. Thompson.
2548 Metformin and everolimus act synergistically with
paclitaxel against ovarian cancer. Nayara G. Tessarollo,
Isabella S. Guimaraes, Taciane Ladislau, Ian V. Silva, Leticia B.
Rangel.
27
POSTER SESSION
Poster
:LJ[PVU
28
28
DNA Damaging and Antimitotic Agents and Cytotoxicity Modulators
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
2549 Tyrosyl-DNA phosphodiesterase 1 (TDP1) is critical for
the repair of DNA breaks induced by sapacitabine, a nucleoside
antimetabolite in clinical trials targeted to ATM- and BRCAdeficient tumors. Muthana Al Abo, Xiaojun Liu, William Plunkett,
Yves Pommier.
2550 FANCA protein is involved in the homologous
recombination repair of sapacitabine-induced DNA damage.
Yingjun Jiang, Xiaojun Liu, William Plunkett.
2551 Brca1-deficient ovarian cancer cells are sensitized to the
DNA-strand-breaking nucleoside analog sapacitabine that
synergizes with PARP inhibition. Xiaojun Liu, Yingjun Jiang, Billie
Nowak, Dariya Tikhomirova, William Plunkett.
2552 Addition of repositioned-drug dexamethasone
improves anti-leukemia synergy between HDAC inhibitors and
nucleoside analogs. Hong Zhao, Jaime Mejia, Adriana E. Rosato,
Swaminathan P. Iyer, Jenny C. Chang, Roberto R. Rosato.
2553 Gemcitabine fails to radiosensitize normal intestinal
epithelial CCD841 cells at concentrations that promote excellent
radiosensitization in colorectal tumor cell lines. Sheryl A. Flanagan,
Jeffrey Ackroyd, Donna S. Shewach.
2554 Doxorubicin induced gender differences in tumorbearing spontaneously hypertensive rats, with an emphasis on
cardiotoxicity. Kaytee L. Pokrzywinski, Yanira Gonzalez, Leena M.
Chehab, Elliot T. Rosen, Vikrant Vijay, Varsha Desai, Jennifer S.
Dickey, V. Ashutosh Rao.
2555 The mechanism of action of bendamustine alone or in
combination with nucleoside analogs in chronic lymphocytic
leukemia. Sara E. Kost, Eric D. Bouchard, William S. Liang, Versha
Banerji, Spencer B. Gibson, Sachin Katyal, James B. Johnston.
2556 Trifluridine induces p53-dependent sustained G2 phase
arrest with its massive misincorporation into DNA and few DNA
strand breaks. Kazuaki Matsuoka, Makoto Iimori, Shinichiro Niimi,
Hiroshi Tsukihara, Sugiko Watanabe, Shinichi Kiyonari, Mamoru
Kiniwa, Koji Ando, Eriko Tokunaga, Hiroshi Saeki, Eiji Oki, Hiroyuki
Kitao, Yoshihiko Maehara.
2557 Efficacy of combination chemotherapy using a novel
oral chemotherapeutic agent, TAS-102, with oxaliplatin on human
colorectal or gastric cancers and 5-FU-resistant gastric cancer
xenografts. Mamoru Nukatsuka, Fumio Nakagawa, Kazuaki
Matsuoka, Hiroshi Tsukihara, Teiji Takechi.
2558 The mechanistic study on the effect of platinum-based
chemotherapy efficacy imposed by EGFR-TKI regulated ERCC1 in
non-small cell lung cancer (NSCLC). Hio Teng Cheong, Connie Wun
Chun Hui, Fei Xu, Tony Shu Kam Mok, Chi Hang Wong.
2559 Optimisation of EGFR TKI efficiency wild-type EGFR lung
cancer. Judith Raimbourg, Mathilde Cabart, Marie-Pierre Joalland,
Didier Decaudin, Ludmilla Deplater, Didier Lanoe, Jean-Yves
Douillard, Jaafar Bennouna, François Vallette, Lisenn Lalier.
2560 The cisplatin and Chal-24 combination synergistically
kills cancer cells through IAP and c-FLIP degradation,
Ripoptosome formation and autophagy-mediated apoptosis.
Shaoqing Shi, Qiong Wang, Jennings Xu, Mabel T. Padilla, Toru
Nyunoya, Chengguo Xing, Lin Zhang, Yong Lin.
2561 Contextual combination of PARP inhibitors with
p110beta inhibitors: Functional logistics to tame PTEN null tumors.
Jennifer H. Carlson, Yuliang Sun, Xiaoqian Lin, Pradip De, Brian
Leyland-Jones, Nandini Dey.
2562 Dianhydrogalactitol inhibits the growth of glioma stem
and non-stem cultures, including temozolomide-resistant cell
lines, in vitro and in vivo. Shaun D. Fouse, Anne Steino, Nicholas
Butowski, Jeffrey A. Bacha, Sarath Kanekal, Nancy D. Santos, Dennis
M. Brown, Joseph F. Costello.
2563 Modulation of DNA damage responses and cytotoxicity
of bleomycin by vitamin C. Blazej Rubis, Anatoly Zhitkovich.
2564 The anticancer molecule TPEN induces DNA damage in
human colon cancer cells. Hala Gali-Muhtasib, Omar Rahal,
Maamoun Fatfat, Carla Hankache, Bassam Osman, Hala Khalife,
Khaled Machaca.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2565 Aryl hydrocarbon receptor agonist 5F 203 induces
oxidative stress triggering DNA damage and cytoglobin upregulation in human breast cancer cells. Leah K. Rowland, Lancelot
S. McLean, Petreena Campbell, Cheri N. Watkins, Dain Zylstra, Louisa
H. Amis, Maheswari Senthil, Eileen Brantley.
2566 Combination of taxanes with mesothelin-targeted
immunotoxin RG7787 induces synergistic killing of pancreatic
cancer. Christine C. Alewine, Emily Kolyvas, Klaus Boslett, Ira Pastan.
2567 Cabazitaxel chemotherapy targets mitotic kinesins
resulting in multi-nucleation of prostate cancer cells: A novel
mechanism of cross-resistance with antiandrogens in advanced
CRPC. Sarah K. Martin, Hong Pu, Craig Horbinski, Zheng Cao, Natasha
Kyprianou.
2568 S49076, a MET, AXL, FGFR inhibitor, potentiates
radiation therapy in subcutaneous and orthotopic models of lung
cancer. Céline Clémenson, Cyrus Chargari, Michele Mondini, Charles
Ferté, Winchygn Liu, Mike Burbridge, Valérie Cattan, Anne JacquetBescond, Eric Deutsch.
2569 Synergistic antitumor interaction between valproic acid,
capecitabine and radiotherapy in colorectal cancer as a rationale
for the innovative V-shoRT-R3 trial in locally advanced rectal
cancer patients. Manuela Terranova Barberio, Biagio Pecori, Serena
Imbimbo, Alessandra Leone, Francesca Bruzzese, Maria C. Piccirillo,
Paolo Delrio, Franco Bianco, Luigi Aloj, Antonio Sorrentino, Fabiana
Tatangelo, Antonella Petrillo, Secondo Lastoria, Paolo Muto,
Francesco Perrone, Antonio Avallone, Alfredo Budillon, Elena Di
Gennaro.
2570 The mechanism of anti-tumor effect of metformin for
gemcitabine-resistant pancreatic adenocarcinoma. Keiichi Suzuki,
Osamu Takeuchi, Yoshiyuki Ishii, Masayoshi Osaku.
2571 Metformin inhibits proliferation and acts synergistically
with paclitaxel and doxorubicin in triple negative breast cancer
cell lines. Isabella S. Guimaraes, Nayara G. Tessarollo, Laura F.
Oliveira, Roger C. Zampier, Ian V. Silva, Cinthya Sternberg, Leticia B.
Rangel.
2572 Metronomic scheduling: a promising strategy to manage
intratumor heterogeneity and control treatment resistance. Manon
Carre, Maryna Bondarenko, Marie-Pierre Montero, Guillemette
Chapuisat, Assia Benabdallah, Marion Le Grand, Diane Braguer,
Nicolas Andre, Eddy Pasquier.
2573 Investigation of factors involved in the hypersensitivity
to KP1339-treatment. Beatrix Alte, Christine Pirker, Thomas Mohr,
Kushtrim Kryeziu, Bernhard K. Keppler, Petra Heffeter, Walter Berger.
2574 HIPEC for treatment of peritoneal carcinomatosis: 40°C
is the critical threshold temperature for potentiating
chemotherapy efficacy in vitro and in vivo. Lea Schaaf, Marina
Münch, Wolfgang Steurer, Walter E. Aulitzky, Thomas E. Mürdter,
Heiko van der kuip, Christoph Ulmer.
2575 Pharmacodynamic evaluation of the combination of
carboplatin and paclitaxel associated with either pioglitazone or
hydroxyurea, within a randomized phase 1 dose escalation clinical
trial in patients with advanced solid tumors. M. Teresa AgullóOrtuño, Carlos Pérez, C. Vanesa Díaz-García, Blanca Homet, Alba
Agudo-López, Analia Rodríguez Garzotto, Elena Prieto-García, Jorge
Adeva, María C. Riesco, Raquel Rodríguez, M. Luisa Durán, Elena
Laguna, Carmen Montalbán, Hernán Cortés-Funes, José A. LópezMartín.
2576 Enhanced antitumor efficacy by sequential application
of Wnt pathway antagonists in combination with taxanes. WanChing Yen, Marcus Fischer, Belinda Cancilla, Fiore Cattaruzza, Tracy
Tang, Pete Yeung, John Lewicki, Austin Gurney, Timothy Hoey.
2577 Aurora kinase inhibitors require PUMA to induce
apoptosis and preferentially kill KRAS-mutant colon cancer cells.
Jing Sun, Kyle Knickelbein, Kan He, Dongshi Chen, Jian Yu, Lin Zhang.
2578 Synthetic lethal approaches to aurora inhibition in
aggressive B-cell non-Hodgkin lymphoma. Daruka Mahadevan,
Carla Morales, Laurence Cooke, Manjari Pandey, Catherine Spier,
Wenqing Qi.
393
POSTER SESSION
MAPK, EGFR, and BTK Inhibitors
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
394
Abstract
Number
2579 Combination therapy with MEK inhibition is efficacious in
intracranial triple negative breast cancer models. Amanda E. Van
Swearingen, Marni B. Siegel, Maria J. Sambade, Shivani Sud, Samantha M.
Miller, Grace Silva, Ryan E. Bash, Charlene M. Santos, David B. Darr, Brian
Golitz, Joel S. Parker, C. R. Miller, Gary L. Johnson, Carey K. Anders.
2580 Screening of a mixture-based synthetic combinatorial
library identifies small molecules that inhibit the ability of GTP to
displace mant-GDP from mutant G12D KRas. Perry C. Kennedy, Marc C.
Guilanotti, Travis LsVoi, Said M. Sebti.
2581 Antitumor effect of Trametinib, a selective MEK inhibitor, in
combination with 4-methylumbelliferone, a hyaluronic acid synthesis
inhibitor, in Malignant pleural mesothelioma cell lines. Hiroyuki Cho,
Seiji Matsumoto, Yoshiko Fujita, Ayumi Kuroda, Masaki Hashimoto,
Teruhisa Takuwa, Toshi Menju, Makoto Sonobe, Nobuyuki Kondo, Hiroshi
Date, Seiki Hasegawa.
2582 Gefitinib [epidermal growth factor receptor (EGFR)
inhibitor] plus etoricoxib (COX-2 inhibitor) versus oral methotrexate in
advanced, recurrent head and neck squamous cell carcinoma (HNSCC):
results of a randomized pilot study. Hemant Malhotra, Archit Joshi,
Sandeep Jasuja, Ajay Yadav.
2583 Refinement of inhibitors of the KRAS-signaling naocluster
protein, CNKSR1, that block oncogenic KRAS signaling and growth. D.
Lynn Kirkpatrick, Martin Indarte, Mike Scott, Assael Madrigal, Geoffrey
Grandjean, Garth Powis.
2584 Specific antitumor activity of the splicing modulator
sudemycin and cooperation with ibrutinib in chronic lymphocytic
leukemia. Sílvia Xargay-Torrent, Mónica López-Guerra, Laia Rosich, Arnau
Montraveta, Jocabed Roldán, Vanina Rodríguez, Neus Villamor, Marta
Aymerich, Chandraiah Lagisetti, Thomas R. Webb, Elias Campo, Dolors
Colomer.
2585 Discovery of a potent covalent mutant-selective EGFR
inhibitor - the journey from high throughput screening to EGF816.
Gerald Lelais, Robert Epple, Pierre-Yves Michellys, Thomas H. Marsilje, Yun
Long, Matthew McNeill, Bei Chen, Wenshuo Lu, Badry Bursulaya, Michael
DiDonato, Yong Jia, Shailaja Kasibhatla, Chun Li, Igor Matushansky, Steven
Bender.
2586 ASP8273 selectively inhibits mutant EGFR signal pathway
and induces tumor shrinkage in EGFR mutated tumor models. Satoshi
Konagai, Hideki Sakagami, Hiroko Yamamoto, Hiroaki Tanaka, Takahiro
Matsuya, Shinya Mimasu, Yusuke Tomimoto, Masamichi Mori, Hiroyuki
Koshio, Masaaki Hirano, Sadao Kuromitsu, Masahiro Takeuchi.
2587 A novel covalent inhibitor of mutant but not wild-type (WT)
epidermal growth factor receptor (EGFR) has activity in vitro and in
vivo in non-small cell lung cancer (NSCLC) models. Pedro J. Beltran,
Jinghui Zhan, Petia Mitchell, Ryan P. Wurz, Liping Pettus, Tian Wu, Mary
Chaves, Darren L. Reid, Robert Radinsky, Keegan Cooke, Andrew Tasker.
2588 Anti-tumor effect of afatinib, an irreversible EGFR/HER2
dual inhibitor, in lung cancers harboring HER2 oncogene. Ken Suzawa,
Shinichi Toyooka, Masakiyo Sakaguchi, Tomoaki Ohtsuka, Mototsugu
Watanabe, Shinsuke Hashida, Yuho Maki, Hiromasa Yamamoto, Junichi
Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi.
2589 Investigations of covalent binding efficiency for thirdgeneration EGFR irreversible inhibitors AZD9291 and CO-1686. Zhen
Qin, Xuebing Sun, Ye Liu, Yunguang Du, Miao Wang, Nan Hu, Jiye Zhang,
Hao Peng, Lai Wang, Min Wei, Lusong Luo.
2590 KD019: Blood brain barrier penetrant HER2/neu, Src, and
EGFR inhibitor. James R. Tonra, Masha Poyurovsky, Kevin G. Liu, Jeegar
Patel, Nishta Rao, Robert Tilton, John L. Ryan, Mark S. Berger, Larry Witte,
Ji-In Kim, Samuel D. Waksal.
2591 Activity of MSC2156119J in non-small cell lung cancer
models with activating EGFR mutation. Friedhelm Bladt, Manja FrieseHamim, Andree Blaukat.
2592 Anti-tumor activity of icotinib (BPI-2009H) and BPI-403B in
the BxPC-3 pancreatic cancer cell line. Victoria L. Wilde, Don Zhang,
Jirong Peng, Michael A. Green, Michael N. Greco, Michael Costanzo.
2593 Combination therapy with EGFR-TKI and cMET-TKIs in nonsmall cell lung cancer: the golden duo. Nele Van Der Steen, Vanessa
Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Patrick
Pauwels.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
29
Abstract
Number
2594 Characterization of a novel irreversible third generation
EGFR TKI that targets T790M-mediated resistant EGFR-mutant NSCLC
while sparing wild type EGFR. Mike Zientek, Sangita Baxi, Henry Cheng,
Valeria Fantin, Jun Li Feng, Allison Given, Zelanna Goldberg, Jie Guo,
Michelle Hemkens, John Kath, Jennifer Lafontaine, Gary Li, Pramod Mehta,
Brion Murray, Sajiv Nair, Simon Planken, Chad Ray, Yuli Wang, Manli Shi,
Anand Sistla, Tod Smeal, Greg Stevens, Wei Tan, Paolo Vicini, Marlena
Walls, Liu Yang, Min-Jean Yin, Scott L. Weinrich.
2595 Efficacy of cetuximab and mutant selective EGFR inhibitor
WZ4002 in EGFR T790M and non-T790M models of erlotinib resistant
non-small cell lung cancer. Erin M. Tricker, Chunxiao Xu, Kwok-Kin Wong,
Pasi A. Janne.
2596 ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk)
inhibitor with improved selectivity and in vivo target coverage in
chronic lymphocytic leukemia (CLL) patients. Todd Covey, Tjeerd Barf,
Michael Gulrajani, Fanny Krantz, Bart van Lith, Elena Bibikova, Bas van de
Kar, Edwin de Zwart, Ahmed Hamdy, Raquel Izumi, Allard Kaptein.
2597 BGB-3111 is a novel and highly selective Bruton’s tyrosine
kinase (BTK) inhibitor. Na Li, Zhijian Sun, Ye Liu, Mingming Guo, Yilu
Zhang, Dongping Zhou, Bo Zhang, Dan Su, Shuo Zhang, Jing Han, Yajuan
Gao, Yunhang Guo, Zhiwei Wang, Min Wei, Lusong Luo, Lai Wang.
2598 Synergistic effect of ibrutinib and inhibitors targeting TLR
signaling in ABC subtype of diffuse large B-Cell lymphoma. Hsu-Ping
Kuo, Sidney Hsieh, Betty Chang.
2599 Discovery and pharmacological characterization of the
second generation of Btk inhibitors with improved target selectivity
and enhanced in vivo efficacy. Jiayin Zhang, Dong Liu, Ru Shen, Yinfa
Yan, Liuqing Yang, Minsheng Zhang, Jun Feng, Beibei Fu, Jerry Hu, Biao
Lu, Hong Wan, Lei Zhang, Weikang Tao, Lianshan Zhang, Jingsong Cao.
2600 Targeting cancer stem cell through blocking the Erk pathway
with Kazinol-E from Broussonetia kazinoki. Yu-Chae Jung, Seula Han, Li
Hua, Hui-Yuan Zhao, Cheol-Jung Lee, Yong-Yeon Cho, Raok Jeon, Jae-Ha
Ryu, Woo-Young Kim.
2601 A natural small molecule, catechol, induces c-Myc
degradation by directly targeting ERK2 in lung cancer in vitro and in
vivo. Do Young Lim, Seung Ho Shin, Margarita Malakhova, Mee-Hyun Lee,
Ann M. Bode, Zigang Dong.
2602 Identification of a novel Bruton’s tyrosine kinase (BTK)
inhibitor with anti-inflammatory and anticancer activities. Mukul R.
Jain, Abhijit Chatterjee, Jogeswar Mohapatra, Debdutta Bandhyopadhyay,
Krishnarup Ghoshdostidar, Upendra Bhatnagar, Harilal Patel, Vikram
Ramanathan, Rajesh Bahekar, Pankaj Patel, Ranjit Desai.
2603 Combination activity of the MEK inhibitor Pimasertib and the
hypoxia-activated prodrug TH-302 in pancreatic and biliary tract tumor
xenograft models. Jianguo Ma, Sakeena Syed, Lindsey Crowley, Jamie
Shaw, Janet Ogden, Brian Elenbaas, Samantha Goodstal.
2604 Preclinical anti-tumor efficacy and mode of action of a
novel, orally available, selective MKNK1 inhibitor [BAY 1143269].
Susann Santag, Franziska Siegel, Antje Margret Wegner, Claudia
Schneider, Ulf Boemer, Knut Eis, Florian Puehler, Martin Michels, Franz von
Nussbaum, Karl Ziegelbauer, Dominik Mumberg, Kirstin Petersen.
2605 The geranylgeranyltransferase I inhibitor GGTI-2418
suppresses multiple myeloma malignancy in the 5TMG1 mouse model.
Hua Yang, Michael F. Emmons, Christopher Cubitt, Ken Shain, Domenico
Coppola, Daniel Sullivan, Conor C. Lynch, Lori Hazlehurst, Said M. Sebti.
2606 Antitumor activity of the selective RAF inhibitor HM95573 in
melanoma. InHwan Bae, YoungGil Ahn, Namgoong GwangMo, SuHyeon
Kim, JiYeon Song, TaeHun Song, JaeHo Lee, KyuHang Lee, Young-Mi Lee,
YoungHoon Kim, KweeHyun Suh.
2607 Antitumor activity of the selective RAF inhibitor HM95573 in
solid tumors and hematologic malignancies. Young-Mi Lee, InHwan Bae,
Namgoong Gwang Mo, Jae Ho Lee, Suhyeon Kim, Ji Yeon Song, Kyu Hang
Lee, Tae Hun Song, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh.
2608 Ibrutinib significantly improves survival in a human Burkitt
lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a
potential adjuvant agent in the treatment of BL. Sanghoon Lee,
Changhong Yin, Timmy O’Connell, Matthew Barth, Janet Ayello, Lauren
Harrison, Carmella van de Ven, Rodney Miles, Paul Galardy, Stanton C.
Goldman, Megan Lim, Michelle Hermiston, Linda McAllister-Lucas, Lisa G.
Roth, Sherrie L. Perkins, Mitchell S. Cairo.
29
POSTER SESSION
Poster
:LJ[PVU
30
30
Novel Mechanisms of Drug Pharmacology and Toxicity
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
2609 Disruption of CAS scaffolds: A novel mechanism
for microtubule targeting agents. Nicholas F. DybdalHargreaves, Cristina C. Rohena, April L. Risinger, Susan L.
Mooberry.
11.
2619 Synergistic anticancer effect of Noscapine and
Camptothecin is mediated through apoptosis and cell
cycle arrest in A549 lung cancer. Ravi Doddapaneni, Ketan
Patel, Mandip Singh.
2.
2610 Identifying a lead compound for mitigation of
drug-induced PQTS. Lawrence Helson, Walter A. Shaw,
Stephen W. Burgess, George Shopp, Annie Bouchard, Dany
Savail, Muhammed Majeed.
12.
2620 Plumbagin induces growth inhibition of human
glioma cells by downregulating the expression and activity
of FOXM1. Xuejiao Liu, Wei Cai, Mingshan Niu, Rutong Yu.
3.
2611 A multi-parameter in vitro screen demonstrates
increased cardiac toxicity with pan-HER inhibitors afatinib
and neratinib when used in combination with
chemotherapy. Dominique R. Talbert, Kimberly Doherty,
Patricia Trusk, Diarmuid Moran, Sarah Bacus.
13.
2621 Preclinical systemic toxicity evaluation of
chitosan-solid lipid nanoparticles encapsulated aspirin,
curcumin and free sulforaphane (ACS) combinations in
BALB/c mice. Arvind Thakkar, Sushma Chenreddy, Jeffrey
Wang, Sunil Prabhu.
4.
2612 BET-protein bromodomain antagonist-based
combinations against ibrutinb-sensitive or resistant
human Mantle Cell Lymphoma cells. Baohua Sun, Bhavin
Shah, Warren Fiskus, Jun Qi, Santhana G. Devaraj,
Swaminathan P. Iyer, Sunil Sharma, James E. Bradner, Youli
Zu, Kapil N. Bhalla.
14.
2622 Fluorocyclopentenylcytosine (RX-3117) is
activated by uridine-cytidine kinase 2, a potential
biomarker. Godefridus J. Peters, Joris R. Julsing, Kees Smid,
Daniel De Klerk, Dzjemma Sarkisjan, Mi Y. Yang, Young B.
Lee, Deog J. Kim.
15.
5.
2613 STAT3 mediates C6-ceramide-induced cell death
in chronic lymphocytic leukemia via the MEK/ERK and PKC
pathway. Ushma Atul Doshi, Thomas P. Loughran, Mark
Kester.
6.
2614 Targeting heat shock protein 90 with Ganetespib
for the treatment of lymphoma. Zhigang Tu, Hanqing Liu,
Jingjing Zhao, Peishan Zhang, Zhiquan Liang, Lingling Ruan,
Yongjin Lu, Dongsheng Shang, Ying Sun, Lili Xu, Keping
Chen, Quji Danzeng.
2623 Molecular mechanism of synergy between BETprotein bromodomain antagonist (BA) and pTEFb kinase
inhibitor against human AML blast progenitor cells.
Santhana G. Devaraj, Bhavin Shah, Warren Fiskus, Baohua
Sun, Saikat Saha, Sai Ravi Pingali, Swaminathan P. Iyer, Sunil
Sharma, James E. Bradner, Kapil N. Bhalla.
16.
2624 Pre-clinical studies of a mutant p53 reactivating
drug in pancreatic cancer. Xin Yu, Ashley T. Tsang, Zhe Li,
Oliver S. Eng, Hongxia Lin, Murugesan Gounder, Darren R.
Carpizo.
17.
2625 Targeting prostate cancer stem cells (CSCs) with
the novel BET bromodomain (BRD) protein inhibitor
OTX015. Gianluca Civenni, Silvia Pedrani, Sara Allegrini,
Antonina Bruccoleri, Domenico Albino, Sandra Pinton, Ramon
Garcia-Escudero, L’Houcine Ouafik, Esteban Cvitkovic,
Giuseppina M. Carbone, Carlo V. Catapano.
19.
2627 Lapatinib promotes promoted the incidence of
hepatotoxicity by increasing chemotherapeutic agent
accumulation in hepatocytes. Chunling Dai, Shaolin Ma,
Zhesheng Chen, Kenneth To, Liwu Fu.
20.
2628 Mithramycin analogs with reduced toxicity for
EWS-FLI1 targeting. Joseph Eckenrode, Jamie Horn, JhongMin Chen, Jurgen Rohr, Markos Leggas.
21.
2629 Site-directed and random PEGylation of
retargeted tissue factor can improve the activity/toxicity
profile of the molecule. Caroline Zerbst, Janine Ring, Max
Fröhlich, Christoph Schliemann, Rolf M. Mesters, Wolfgang E.
Berdel, Christian Schwöppe.
7.
2615 Dual ErbB blockade with KTN3379 and cetuximab
yields enhanced antitumor activity by inhibiting parallel
signaling pathways in SCCHN. Diego Alvarado, Scott B.
Seibel, Gwenda F. Ligon, Jay S. Lillquist, Andrew Pierce,
Richard Gedrich, Theresa M. LaVallee.
8.
2616 Comparison of the cytotoxicity and increase of
reactive oxygen species and dihydroceramides of
fenretinide to its major metabolites (4-oxo- and 4methoxyphenyl fenretinide) in T-cell lymphoid
malignancy, neuroblastoma, and ovarian cancer cell lines.
Michael M. Song, Monish R. Makena, Ashly Hindle,
Balakrishna Koneru, Thinh H. Nguyen, Hwangeui Cho, Barry J.
Maurer, Min H. Kang, C. Patrick Reynolds.
9.
10.
2617 SUMOylation inhibition attenuates the cancer
stem cell population in glioblastoma and basal breast
cancer. Jung M. Park, Tong Wu, Sarah Van Dorin, Ronald
Weigel.
2618 Gemcitabine based peptide conjugates:
Overcoming the pitfalls of conventional therapies by
targeted approaches. Constantin Tamvakopoulos,
Theodoros Karampelas, Orestis Argyros.
395
POSTER SESSION
Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy
Poster
Board
Abstract
Number
1.
2630 Inhibition of angiogenesis contributes to
enhanced radiation response in tumors following MDM2
inhibition by AMG 232. Lauryn R. Werner, Shyhmin Huang,
Eric A. Armstrong, Fang Ma, Jude Canon, Paul M. Harari.
2.
2631 Discovery of SC110237, a highly potent, selective
and orally active FLT3 inhibitor for the treatment of acute
myeloid leukemia. Norman Kong, Daxin Gao, Heping Yang,
Yajun Yu.
3.
2632 The COX inhibitor, diclofenac induces mantle cell
lymphoma apoptosis independent of p53 status. Hesham
M. Hassan, Michelle L. Varney, Alia M. Attia, Shantaram S.
Joshi, Rakesh K. Singh, Bhavana J. Dave.
4.
2633 Vitamin D3 analog inecalcitol synergizes with
tyrosine kinase inhibitors (TKI) and selectively inhibit the
growth of chronic myeloid leukemia (CML) progenitors:
Development of a clinically applicable leukemic stem cell
targeting strategy. Ali G. Turhan, Hyacinthe Johnson Ansah,
Patricia Hugues, Camille Debord, Remi Delansorne, Agnes
Guerci-Bresler, Jean Francois Dufour Lamartinie, Annelise
Bennaceur-Griscelli.
Poster
Board
31
Abstract
Number
11.
2640 Small molecule compound NCI-8 induces ERK2dependent mutant-p53 protein degradation. Shengliang
Zhang, Lanlan Zhou, David T. Dicker, Wafik S. EL-Deiry.
12.
2641 Inhibition of Bcr-Abl in human leukemic cells with
a coiled coil protein delivered by a leukemia-specific cell
penetrating peptide. Benjamin J. Bruno, Carol S. Lim.
13.
2642 EF2-kinase (EF2K): A novel molecular target in
ovarian and pancreatic cancers. Ahmed Ashour, Alper
Erdogan, Sultan N. Alpay, Nermin Kahraman, Erkan Yuka,
Gabriel Lopez-Berestein, Bulent Ozpolat.
14.
2643 Small molecule identification for the restoration
of p53 pathway through p73 and by degradation of mutant
p53. Liz J. Hernandez Borrero, Shengliang Zhao, David T.
Dicker, Wafik El-Deiry.
15.
2644 Inhibition of PAK4 attenuates renal cell carcinoma
(RCC) growth. Omran Abu Aboud, William Senapedis, Yosef
Landesman, Erkan Baloglu, Robert H. Weiss.
16.
2645 Preclinical validation of Myc inhibition by a new
generation of Omomyc-based inhibitors. Marie-Eve
Beaulieu, Toni Jauset, Daniel Massó-Vallés, Jonathan
Whitfield, Erika Serrano, Martin Montagne, Pierre Lavigne,
Antonio Villaverde, Mireia Pesarrodona, Esther Vazquez,
Laura Soucek.
17.
2636 Myc vs. Akt therapy in RapidCap, a GEM model for
metastatic prostate cancer. Carlos E. Stahlhut, Kaitlin E.
Watrud, Alexandra J. Ambrico, Hyejin Cho, Lily Wang, Jun Qi,
Lewis C. Cantley, James Bradner, Lloyd C. Trotman.
2646 Targeting cancer stem cell pathways with cellpermeable peptide inhibitors. Verena Arndt, Annette
Friebe, Elena Meuser, Katharina Ross, Franziska Agerer,
Carmen Schulten-Schulz, Jens Waak, Daniel Friedrich, Hanjo
Hennemann, Jörg Vollmer.
18.
8.
2637 Mechanism of pertuzumab in combination with
trastuzumab plus docetaxel therapy in a breast cancer
xenograft model. Yoriko Yamashita-Kashima, Sei Shu, Keigo
Yorozu, Yoichiro Moriya, Naoki Harada.
2647 Anti-tumor activity of sHA8k, a HYAL1
hyaluronidase inhibitor, in bladder cancer cells. Andre R.
Jordan, Juan Chipollini, Luis Lopez, Travis Yates, Vinata
Lokeshwar.
19.
10.
2639 Preclinical evaluation and biomarker
identification for the anti-LGR5 mAb BNC101 in K-Ras
mutant CRC and other solid tumor indications. Peter Chu,
Kristen Smith, Farbod Shojaei, Colin Walsh, John Norton, Jose
Iglesias, Christopher Reyes.
2648 A novel dual inhibitor for AKT and EGFR signaling
inhibits the growth of lung cancer cells. Arokya M. Papu
John, Murali Ankem, Chendil Damodaran.
5.
2634 Investigating the chemotherapeutic effects of
aspirin in mutant PIK3CA breast cancer. Whitney Henry,
Alex Toker.
6.
2635 Targeting HER3 by interfering with its Sec61mediated cotranslational insertion into the endoplasmic
reticulum. Ana Ruiz-Saenz, Manbir Sandhu, Yazmin Carrasco,
Rebecca L. Maglathlin, Jack Taunton, Mark M. Moasser.
7.
396
Poster
:LJ[PVU
31
POSTER SESSION
Poster
:LJ[PVU
32
32
PI3K Pathway and Metabolism Modulators
Poster
Board
1.
2.
3.
4.
5.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Abstract
Number
2649 Inhibition of mTOR, but not PI3K, is required for the antitumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in
combination with MEK inhibitors. Aleisha M. Smith, Jessie Xiong, Lucas
Hunter, Jamie Jordan, Kelly Clark, David B. Darr, Sharpless Norman,
Charles M. Perou, William Y. Kim.
2650 PI 3-Kinase inhibitors enhance the synthetic lethality of Parp
inhibitors. Ashish P. Juvekar, Sina Yadegarynia, Hai Hu, Costas A.
Lyssiotis, Hui Liu, John M. Asara, Ralph Scully, Lewis C. Cantley, Gerburg M.
Wulf.
2651 MK2206 disrupts cytoplasmic AKT-p21 complex in mantle
cell lymphoma: Evidence of p21 coupled cell cycle arrest. Aloke K.
Sarkar.
2652 Pre-clinical activity and mechanism of action of the novel
dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. Chiara
Tarantelli, Eugenio Gaudio, Ivo Kwee, Andrea Rinaldi, Elena Bernasconi,
Luciano Cascione, Petra Hillmann, Anastasios Stathis, Laura Carrassa,
Massimo Broggini, Georg Stussi, Doriano Fabbro, Florent Beaufils, Anna
Melone, Thomas Bohnacker, Matthias P. Wymann, Andreas Wicki,
Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni.
2653 Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in
multiple myeloma. Jeremy T. Larsen, Vijay Ramakrishnan, Jessica Haug,
Teresa Kimlinger, Somdutta Sen, Dinesh Mahajan, Sundeep Dugar, S.
Vincent Rajkumar, Shaji K. Kumar.
2655 Determinants of sensitivity to PI3K inhibitors in PIK3CA
wildtype gastric tumor cells. Mei Ling Chong, Bhaskar Bhattacharya,
Dominic Voon, King Xin Koh, Hong Hui Low, Ti Ling Chang, Mengchu Wu,
Patrick B. Tan, Marie C. Loh, Touati Benoukraf, Huynh T. Hung, Oliver
Politz, Ningshu Liu, Richie C. Soong.
2656 Combined inhibition of MEK and PI3K elicits anti-tumor
activity in human cholangiocarcinoma. Jennifer Yang, Omar Elnaggar,
Thomas Mace, Matthew Farren, Gregory Young, Patrice Lee, Kaitlin
Keenan, Zheng Che, Jacob Kaufman, Denis Guttridge, David Carbone,
Cynthia Timmers, Tanios Bekaii-Saab, Gregory Lesinski.
2657 Elevated level of BCL-2 is the primary target for inhibition
during duvelisib (IPI-145) therapy: ABT-199 neutralizes the resistance
mechanism in chronic lymphocytic leukemia. Viralkumar M. Patel,
Kumudha Balakrishnan, Renato Guerrieri, William Wierda, Susan O’Brien,
Varsha Gandhi.
2658 Stromal microenvironment modulates mitochondrial
metabolism in chronic lymphocytic leukemia cells and is abrogated by
PI3K ␦ and ␥ inhibition. Hima V. Vangapandu, Kumudha Balakrishnan,
Mary L. Ayres, William G. Wierda, Michael J. Keating, Christine M.
Stellrecht, Varsha Gandhi.
2659 Discovery of CT365, a highly potent inhibitor of PI3K and
mTOR, for cancer treatment. Ning Xi, Yanjun Wu, Tingjin Wang, Heng
Wang, Zhiyong Li, Qingwei Meng, Jing Li, Zhaohe Wang, Yingjun Zhang.
2660 Synergistic effect of PI3K␦ inhibitor CAL-101 and JNK
inhibitor SP600125 on glioblastoma cell proliferation. Hua-Fu ZHAO,
Jing WANG, Shing-Shun T. TO.
2661 Bilateral blockade of MEK- and PI3K-driven pathways is
effective in the treatment of KAS mutant mucinous colorectal cancer
cells. Murali R. Kuracha, Peter Thomas, Brian W. Loggie, Venkatesh
Govindarajan.
2662 A dual PI3K/mTOR inhibitor as potential therapeutic option
for vulvar cancer. Iara Rodrigues, Bruna Rodrigues, Fernanda Giudice,
Glauco Baiocchi, Fernando A. Soares, Vilma Martins, Rafael M. Rocha.
2663 Idelalisib impacts cell growth through inhibiting translation
regulatory mechanisms in mantle cell lymphoma. Qingshan Yang, Lisa S.
Chen, Sattva S. Neelapu, Varsha Gandhi.
2664 PQR309: Structure-based design, synthesis and biological
evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor.
Vladimir Cmiljanovic, Natasa Cmiljanovic, Romina Marone, Florent
Beaufils, Xuxiao Zhang, Marketa Zvelebil, Paul Hebeisen, Marc Lang,
Juergen Mestan, Anna Melone, Thomas Bohnacker, Eugenio Gaudio, Chiara
Tarantelli, Francesco Bertoni, Reto Ritschard, Vincent Pretre, Andreas
Wicki, Doriano Fabbro, Petra Hillmann, Roger Williams, Bernd Giese,
Matthias P. Wymann.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2665 High dose intermittent scheduling of AZD8835, a novel
potent and selective inhibitor of PI3K␣ and PI3K␦, identifies potential
treatment strategies for PIK3CA-dependent cancers. Kevin Hudson, Urs
Hancox, Cath Trigwell, Phillippa Dudley, Lyndsey Hanson, Robert McEwen,
Alys Jones, Marie Cumberbatch, Urszula Polanska, Rebecca Ellston, Oona
Delpuech, Pablo Morentin Gutierrez, Lara Ward, Francisco Cruzalegui,
Stephen Green.
2666 PI3K inhibition induces homologous repair defects in
endometrioid endometrial cancer patient derived xenografts leading to
synergistic anti-tumor activity with PARP inhibitors. Bo Rueda, Celeste
Digloria, Tracilyn Hall, Rosemary Foster, Darrell Borger, Whitfield
Growdon.
2667 FP-208, a novel mTOR inhibitor with potent antitumor
activities. Zhenjian Du, Qi Ji, Bo Chen, Chunxiao Zhang, Ge Zhao, Xingmin
Zhang.
2668 Applying mechanistic PK/PD modeling to describe the
efficacy of AZD8835 (PI3Kalpha/delta inhibitor) in a mouse xenograft
breast tumor model at different dosing schedules. Pablo Morentin
Gutierrez, Kevin Hudson, Urs J. Hancox, Lara T. Ward, Urszula M. Polanska,
Marie Cumberbatch, Francisco H. Cruzalegui.
2669 Chaetoglobosin K, an Akt pathway inhibitor, prevents
proliferation and migration of prostate carcinoma cells. Amna Ali, Silvia
Caggia, Diane F. Matesic, Shafiq A. Khan.
2670 BKM120 and BYL719 (PI3K inhibitors) sensitize estrogen
receptor positive breast cancer cells to tamoxifen. I-Chun Chen, Ming
Gao, Lii-Ping Hsiao, Yi-Wen Huang, Huei-Chieh Yu, Ling-Chiun Yeh, AnnLii Cheng, Yen-Shen Lu.
2671 INCB050465, a novel PI3K␦ inhibitor, synergizes with PIM
protein kinase inhibition to cause tumor regression in a model of
DLBCL. Niu Shin, Holly Koblish, Maryanne Covington, Yanlong Li, Kathy
Wang, Qian Wang, Patricia Feldman, Leslie Hall, Sybil O’Connor, Xin He,
Kamna Katiyar, Yu Li, Eddy W. Yue, Thomas P. Maduskuie, Brent Douty,
Song Mei, Yun-Long Li, Chu-Biao Xue, Andrew Combs, Wenqing Yao,
Sharon Diamond-Fosbenner, Swamy Yeleswaram, Robert Newton, Kris
Vaddi, Reid Huber, Peggy Scherle.
2672 Characterization of the enhanced potency of PI3K inhibitor
taselisib (GDC-0032) in PI3K mutant cell lines and models. Kyle A.
Edgar, Michelle Nannini, Rebecca Hong, Charlie Eigenbrot, Stephen
Schmidt, Amy Young, Deepak Sampath, Jeffrey J. Wallin, Lori S. Friedman.
2673 Idelalisib has activity at clinically achievable drug
concentrations in a subset of ABC and GCB diffuse large B-cell
lymphoma and transformed follicular lymphoma cell lines. Jia Y. Liu,
Tom Kenney, Leslie Butterworth, Adam Kashishian, Sarah Meadows, Peng
Yue, Li Li, Kathleen Keegan, Christophe Quéva, Stacey Tannheimer.
2674 Activity of BAY1082439, a balanced PI3K␣/␤ inhibitor, in
gastric cancer. Huynh T. Hung, Richard Ong, Katja Haike, Elissaveta
Petrova, Mei Ling Chong, Marie Loh, Bhaskar Bhattacharya, Richie Soong,
Ningshu Liu.
2675 Biomarker and PK/PD analyses of first in class FASN
inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor
patients. Marie O’Farrell, Richard Crowley, Timothy S. Heuer, Doug
Buckley, Chris M. Rubino, William McCulloch, George Kemble.
2676 The MEK-inhibitor pimasertib is synergistic with PI3K-delta
and BTK inhibitors in lymphoma models. Eugenio Gaudio, Chiara
Tarantelli, Chiara Barassi, Elena Bernasconi, Ivo Kwee, Luciano Cascione,
Maurilio Ponzoni, Andrea Rinaldi, Anastasios Stathis, Samantha Goodstal,
Emanuele Zucca, Francesco Bertoni.
2677 Decrease in phospho-S6 expression under MEK inhibitor
(MEKi) treatment as a potential predictive biomarker of response to
MEKi alone or in combination with PI3K-mTOR pathway inhibitor in
pancreatic adenocarcinoma in vitro and ex vivo models. Cindy Neuzillet,
Annemilaï Tijeras-Raballand, Jérôme Cros, Pierre Bourgoin, Philippe
Bourget, Maria Serova, Armand De Gramont, Sandrine Faivre, Eric
Raymond, Philippe Ruszniewski, Pascal Hammel.
2678 Targeting prostate cancer metastasis with novel small
molecule agonists of EphA2. Bingcheng Wang, Aaron Petty.
397
POSTER SESSION
Resistance to Pathway-Targeted Therapeutics 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
398
Abstract
Number
2679 Overexpression of Mcl-1 confers resistance to
BRAFV600E inhibitors alone and in combination with
MEK1/2 inhibitors in melanoma. Neel M. Fofaria, Dennie T.
Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay K.
Srivastava.
2680 Cyclic AMP signaling in melanoma: Paradoxical
downregulation of pCREB upon activation of adenylate
cyclase confers resistance to MAPK inhibition. Carlos I.
Rodriguez, Vijayasaradhi Setaluri.
2681 Stromal neuregulin-1 promotes adaptive
resistance in mutant BRAF melanoma. Claudia Capparelli,
Sheera Rosenbaum, Adam Berger, Andrew E. Aplin.
2682 Melanoma phenotype switching to adapt to BRAF
inhibition. Lidia Robert, Jennifer Tsoi, Angel Garica Diaz,
Blanca Homet Moreno, Nhat Truong, Thomas Graeber, Antoni
Ribas.
2683 Simultaneous inactivation of TP53 and loss of
PTEN diminish response to targeted therapy in V600EBRAF
mutant melanoma. Elena Galvani, Kelly Brooks, Franziska
Baenke, Maria Romina Girotti, Gabriela Gremel, Amit Kumar
Mandal, Amaya Viros, Clare McManus, Matthew Smith, Kok
Haw Jonathan Lim, Rebecca Lee, Alberto Fusi, Paul Lorigan,
Richard Marais.
2684 An early innate stress response precedes acquired
drug resistance in melanoma. Dinoop Ravindran Menon,
Suman Das, Clemens Krepler, Adina Vultur, Gao Zhang,
Nikolas Haass, Peter H. Soyer, Brian Gabrielli, Rajasekharan
Somasundaram, Gerald Hoefler, Meenhard Herlyn, Helmut
Schaider.
2685 Paracrine effect of NRG1 and HGF drives
resistance to MEK inhibitors in metastatic uveal
melanoma. Hanyin Cheng, Mizue Terai, Takami Sato, Andrew
Aplin.
2686 In vivo ERK1/2 pathway reporting during
acquired resistance to combined RAF/MEK inhibition.
Ileine Sanchez, Andrew Aplin.
2687 Receptor tyrosine kinases can mediate
compensatory signaling and phenotype-switching
associated with resistance to BRAF inhibitors. Zhentao Li,
Rachel Ramsdale, Robert Jorissen, Karen Sheppard,
Amardeep Dhillon, Grant McArthur, Petranel Ferrao.
2688 The HSP90 inhibitor, onalespib (AT13387), delays
the emergence of resistance to erlotinib in an EGFR-driven
xenograft model. Aurélie Courtin, Tomoko Smyth, Keisha
Hearn, John Lyons, Neil Thompson, Nicola G. Wallis.
2689 Overcoming BRAF/MEK resistance using
vemurafenib with crizotinib or sorafenib in patients with
BRAF-mutant advanced cancers: phase I study. Shumei
Kato, Aung Naing, Gerald Falchook, Veronica R. Holley,
Vivianne M. Velez-Bravo, Sapna Patel, Ralph G. Zinner, Sarina
A. Piha-Paul, Apostolia M. Tsimberidou, David S. Hong,
Razelle Kurzrock, Funda Meric-Bernstam, Filip Janku.
2690 DCC-2618 is a potent inhibitor of wild-type and
mutant KIT, including refractory Exon 17 D816 KIT
mutations, and exhibits efficacy in refractory GIST and
AML xenograft models. Bryan D. Smith, Molly M. Hood, Scott
C. Wise, Michael D. Kaufman, Wei-Ping Lu, Thomas Rutkoski,
Daniel L. Flynn, Michael C. Heinrich.
2691 Role of trastuzumab in the combination treatment
for a HER2-positive trastuzumab-resistant gastric cancer
xenograft model. Sei Shu, Yoriko Yamashita-Kashima, Mieko
Yanagisawa, Yoichiro Moriya, Naoki Harada.
2692 High allele frequency of KRAS functional
mutations predicts resistance to MEK inhibitors: Evidence
from cell lines and human tumor xenograft models.
Anupama Reddy, Maria Pinzon-Ortiz, Adnan Derti, Joshua
Korn, David Ruddy, Guizhi Yang, John Green, Hui Gao, Joseph
Lehar, Giordano Caponigro, Z. Alexander Cao.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
33
Abstract
Number
2693 Overcoming MITF-conferred resistance through
dual AURKA/MAPK-axis targeting. Gaurav Pathria, Bhavuk
Garg, Kanika Garg, Viola Borgdorff, Christine Wagner, Giulio
Superti-Furga, Stephan N. Wagner.
2694 Esophageal cancer exhibits a resistance to the
chemical inhibition of IGF-1R with a maintained Ras-MAPK
activity. Munenori Takaoka, XiaoHong Bao, Huifang Hao,
Naomasa Ishida, Takuya Fukazawa, Tomoki Yamatsuji,
Minoru Haisa, Yoshio Naomoto.
2695 Using eicosapentaenoic acid to improve
cetuximab sensitivity in KRAS mutants. Chih-Wei Chen,
Li-Wei Kuo, Yeu-Jye Pang, Wai-Hung Leung, Wen-Hui Weng.
2696 Arenobufagin targets K-Ras downstream to
enhance the efficiency of gemcitabine in human pancreatic
carcinoma cells. Tianjiao Wang, Yuhui Yuan.
2697 The BTK inhibitor ibrutinib (PCI-32765)
overcomes paclitaxel resistance resulting from the
overexpression of ABCB1 and ABCC10 transporters. Hui
Zhang, Atish Patel, Yi-Jun Wang, Zhe-Sheng Chen, Li-Wu Fu.
2698 Combination strategies to target super enhancer
transcriptional activity by CDK9 and BRD4 inhibition in
acute myeloid leukemia. Brigham L. Bahr, Kyle S. Maughan,
Katherine K. Soh, Jeremiah J. Bearss, Wontak Kim, Peter
Peterson, Clifford Whatcott, Adam Siddiqui-Jain, Steve L.
Warner, David J. Bearss.
2699 Targeting GSK-3: a novel approach to enhance
glioblastoma chemosensitivity. Andrey Ugolkov, Oleksii
Dubrovskyi, Irina Gaisina, Alex Yemelyanov, Gennadiy
Bondarenko, Charles James, James Chandler, Thomas
O’Halloran, Alan Kozikowski, Jeffry Raizer, Andrew Mazar.
2700 The IAP inhibitor Debio 1143 reverses carboplatin
resistance in ovarian cancer cells by inducing both
apoptosis and necroptosis. Benoît Thibault, Ludivine Genre,
Clothilde Broca, Maryse Barbier, Claudio Zanna, Grégoire
Vuagniaux, Jean-Pierre Delord, Bettina Couderc.
2701 Characterization of acquired EPZ-5676 resistance
in cell line models of MLL rearranged leukemia. Scott R.
Daigle, Carly T. Campbell, Nigel J. Waters, Edward J. Olhava,
Robert A. Copeland, Stephen J. Blakemore, Roy M. Pollock,
Jesse J. Smith.
2702 Therapeutic potentials of STAT5 inhibitors in
overcoming bortezomib resistance in human T-cell
leukemia. Fu-Yu Chueh, Shahrooz Vahedi, Fu-Shin Chueh,
Chao-Lan Yu.
2703 Overcoming Lapatinib resistance by the fatty acid
synthase inhibitor HS-106. Yazan Alwarawrah, Philip
Hughes, Rachid Safi, Donald P. McDonnell, Neil L. Spector,
Timothy A. Haystead.
2704 RP6530, a dual PI3K ␦/␥ inhibitor, potentiates
ruxolitinib activity in the JAK2-V617F mutant
erythroleukemia cell lines. Swaroop Vakkalanka, Seeta
Nyayapathy, Srikant Viswanadha.
2705 AKT inhibition sensitizes tumor cells to rapamycin
by enhancing the repressive function of PRS40 on
mTORC1/4E-BP1 axis. Wenting Mi, Qing Ye, Side Liu, QingBai She.
2706 Inhibition of PFKFB3/glycolysis overcomes
chemoresistance in ovarian cancers. Susmita Mondal,
Debarshi Roy, Eleftheria Kalogera, Ashwani Khurana, Gilles H.
Tapolsky, Sucheta Telang, Jason Chesney, Viji Shridhar.
2707 Downregulation of cyclin D1 sensitizes cancer
cells to MDM2 antagonist Nutlin-3. Wenbin Ou, Weicai
Chen, Jiaqing Zhu, Grant Eilers, Xuhui Li, Peipei Yang, Hailong
Li, Fanguo Meng, Jonathan Fletcher.
2708 New approaches to overcome tyrosine kinase
inhibitor resistances in chronic myeloid leukemia.
Sebastian Halbach, Franziska U. Wöhrle, Sandra Braun,
Tilman Brummer.
33
POSTER SESSION
Carcinogenesis
Poster
:LJ[PVU
34
34
Carcinogenic Mechanisms 2
Poster
Board
Abstract
Number
1.
2709 The role of the phosphorylated RXR␣ on cellular
proliferation and liver tumorigenesis in mice. Hiroyasu
Sakai, Yohei Shirakami, Masahito Shimizu.
2.
2710 Tumorigenic activity of a novel KIF5B-RET fusion
gene. Jung-Young Shin, Min-Young Kim, Kyoung-Hwa Son,
Jeong-Oh Kim, Jin-Hyoung Kang.
3.
2711 Regulation of the IGF-1R signaling by angiotensin
signaling pathway. Hye-Jin Boo, Hyun-Ji Jang, Yujin Jung,
Hye-Young Min, Ho-Young Lee.
4.
2712 Influence of mitochondrial bioenergetics on the
development of estrogen-dependent breast cancer.
Mohannad Garoub, Deodutta Roy, Stanislaw Wnuk, Jayanta
Das.
5.
2713 Stem cell mutagenesis and carcinogenesis in the
colon of wild type and immune compromised mice. Barry
Gold, Ryan Whetstone.
6.
2714 Effects of endosulfan on COX-2 expression via
NADPH oxidase and the ROS, MAPK, and Akt pathways.
Eun Hee Han, Sang Mi Jun, Young Ho Chung.
7.
8.
9.
10.
2715 Hepatotoxicity and oxidative stress biomarker
study of peg-coated and non-coated gold nanoparticles in
Sprague-Dawley rats. Anita K. Patlolla, Myeisha Fountain,
Paul Tchounwou.
2716 Epstein-Barr virus-encoded BARF1
downregulates SMAD4 and increases miR-146a in gastric
carcinoma cells. Dong Ha Kim, Chan Jin Yoon, Jin, Kyung
Rho, Jaap M. Middeldorp, Jun Hee Woo, Mee Soo Chang.
2717 Epigenetic regulation of HPV16 early genes in a
model of cervical cancer. Adrien Morel, Aurélie Baguet,
Caroline Demeret, Eric Hervouet, Christiane Mougin, Jean-Luc
Prétet.
2718 Genomic and microRNAome subtraction identifies
pathogenic viral sequences in pancreatic ductal
adenocarcinoma. Mohanachary Amaravadi, Agnes HotzWagenblatt, Sandeep K. Botla, Pouria Jandaghi, Mehdi
Manoochehri, Nathalia Giese, Markus W. Büchler, Andrea S.
Bauer, Jörg D. Hoheisel.
Poster
Board
Abstract
Number
16.
2724 NMU induction of mammary tumors in
ovariectomized rats administered peroral estrogen and
progesterone. Hillary Stires, Mariana D. Saboya, Samantha P.
Globerman, Wendie S. Cohick.
17.
2725 Progesterone promotes estrogen induced
mammary tumorigenesis through the activation of nodal
and notch signaling. Diego A. Pedroza, Arunkumar
Arumugam, Sushmita Nandy, Ramadevi Subramani,
Thiyagarajan Boopalan, Rajkumar Lakshmanaswamy.
18.
2726 Dysregulation of host cellular genes targeted by
HPV integration contributes to HPV related cervical
carcinogenesis. Ruiyang Zhang, Xiangmei Chen, Fengmin Lu.
19.
2727 Molecular markers and pathway analysis of
Middle Eastern colorectal carcinoma. Shaham Beg, Sarita
Prabhakaran, Rong Bu, Mohammed Al-Assiri, Rami Sairafi,
Fouad Al-Dayel, Nasser Al-Sanea, Abdul K. Siraj, Shahab
Uddin, Khawla Al-Kuraya.
20.
2728 Correlation of p62/ubiquitin IHC expression with
clinicopathologic outcome in gastrointestinal carcinomas.
Amr Mohamed, Ayman AlKhoder, Wang Tengteng, Charles
Kovach, Ahmed Kaseb, Momin T. Siddiqui, Cynthia Cohen.
21.
2729 Chronic stress promotes lung cancer development
via IGF-1R pathway. Hyun-Ji Jang, Hye-Jin Boo, Yujin Jung,
Hye-Young Min, Ho-Young Lee.
22.
2730 Additional mutations in genes relevant to the Ras
signaling pathway promote the malignant characteristics
of NF1-associated malignant peripheral nerve sheath
tumor (NF1-MPNST) cells. Yoshimi Arima, Kenjiro Kosaki,
Chikako Hirose, Hideyuki Saya.
23.
2731 Establishment and characterization of
immortalized nasopharyngeal epithelial cells with stable
infection of Epstein-Barr virus. Lin Jia, Chi M. Tsang, Yim L.
Yip, Wai T. Law, Jun Zhang, George S. Tsao.
24.
2732 The role of protein P in hepatocellular carcinoma.
Hongyong Fu, Lianying Guo, Lin HUANG.
25.
2733 Development of novel monoclonal antibodies for
a cyclic DNA adduct derived from oxidation of ␻-6
polyunsaturated fatty acids. Marcin Dyba, Brandon Da Silva,
Jishen Pan, Fung-Lung Chung.
11.
2719 TCRP1 gene promotes NIH/3T3 cell
transformation by over-activating PDPK1 and Akt.
Chengkun Wang, Xiaorong Liu, Qinwei Qiu, Zhijie Zhang,
Jiang Yin, Guopei Zheng, Zhimin He.
12.
2720 Toll-like receptor 4 immunoreactivity in
mammary tumors chemically induced in female SpragueDawley rats. Joyce R. Zapaterini, Muriele B. Varuzza, Nelci A.
Moura, Maria A. Rodrigues, Luis F. Barbisan.
26.
2734 Ethanol potentiates tobacco smoke carcinogensinduced MAPK activation. Manoj K. Pandey, Jagat J.
Mukherjee, Dhimant H. Desai, Shantu G. Amin, Subodh
Kumar.
13.
2721 Induction of aberrant crypt foci in the colon of
mice exposed to tobacco carcinogen 2-amino-9Hpyrido[2,3-b]indole. Sangyub Kim, Jingshu Guo, Sabrina P.
Trudo, Daniel D. Gallaher, Robert J. Turesky.
27.
2735 Tributyltin alters the production and secretion of
inflammatory cytokines from human and mouse immune
cells. Shanieek T. Lawrence, Margaret Whalen, Samuel
Pellom, Anil Shanker.
14.
2722 Characterization of human lung enzymes involved
in the reduction of 4-(methylnitrosamino)-1-(3-pyridyl)1-butanone (NNK). Joseph Ashmore, Ying Liu, Amity
Peterson, Sabrina Fechtner, Gang Chen, Philip Lazarus.
28.
2736 Analysis of ROS concentration in serous ovarian
carcinoma. Shakeria L. Cohen, Sharifeh Mehbari, Edward E.
Partridge, Felix Aikhionbare.
29.
15.
2723 Ferric oxide nanoparticles (nFe2O3) induce
neoplastic transformation of primary human small airway
epithelial cells. Liying Wang, Donna C. Davidson, Raymond
Derk, Sudjit Luanpitpong, Georgios A. Sotiriou, Philip
Demokritou, Vincent Castranova, Yon Rojanasakul, Todd A.
Stueckle.
2737 Dynamics of Epstein-Barr virus loss in the live
epithelial cells. Yuan Zhou, George Tsao.
30.
2738 Mechanisms of cadmium carcinogenesis. Raghu G.
Nath, BR Sonawane, SV Vulimiri, YS Lin.
399
POSTER SESSION
Epidemiology
Familial Cancer: Exposures, Biomarkers, and Genetics
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
400
Abstract
Number
2739 Transcontinental characterization of the Hispanic BRCA1
3450del4 breast cancer founder mutation. Anna Marie D. Tuazon,
Carolina Ramirez, Mabel Bohorquez, Rodrigo Prieto, Paul Lott, Angel
Criollo, Ana Estrada, Gillbert Mateus, Alejandro Velez, Justo Ramirez,
COLUMBUS Consortium, Manuel Teixeira, Ana Vega, Conxi Lazaro,
Eva Tornero, Cristina Martinez, Mar Infante, Miguel De La Hoya,
Orland Diez, Pilar Carvallo, Magdalena Echeverry, Luis CarvajalCarmona.
2740 Familial Hodgkin lymphoma by relationship, sex, age
and histology: a joint study from five Nordic countries. Mahdi
Fallah, Elham Kharazmi, Eero Pukkala, Jørgen H. Olsen, Laufey
Tryggvadottir, Kristina Sundquist, Steinar Tretli, Kari Hemminki.
2741 The risk of cancer among children with birth defects.
Philip J. Lupo, Michael E. Scheurer, Sharon E. Plon, Logan E. Spector,
Beth A. Mueller.
2742 Potential burden of germline findings in targeted tumor
sequencing using matched normal DNA. Kasmintan A. Schrader*,
Donavan T. Cheng*, Joseph Vijai, Meera Prasad, Michael F. Walsh,
Ahmet Zehir, Tinu Thomas, Liying Zhang, Marc Ladanyi, Kenneth
Offit, Michael F. Berger, Mark E. Robson.
2743 Cancer risk in relatives of testicular cancer patients by
histology type and age at diagnosis: a joint study from five Nordic
countries. Elham Kharazmi, Kari Hemminki, Eero Pukkala, Kristina
Sundquist, Laufey Tryggvadottir, Steinar Tretli, Jørgen H. Olsen,
Mahdi Fallah.
2744 Familial multiple metastatic small intestine
neuroendocrine tumors: searching for genetic susceptibility. Mervi
Aavikko, Eevi Kaasinen, Iikki Donner, Kaisa Lehti, Erika Gucciardo,
Bideep Shrestha, Jukka-Pekka Mecklin, Järnhult Johannes, Kalle
Landerholm, Eero Pukkala, Camilla Schalin-Jäntti, Ari Ristimäki, Pia
Vahteristo, Lauri A. Aaltonen.
2745 Exome sequencing analysis of 41 patients with Familial
Colorectal Cancer Type X (FCCTX). Marilena Melas, Hung N. Luu,
Gad Rennert, Flavio Lejbkowicz, Stephen B. Gruber, Georgia L.
Wiesner, Leon Raskin.
2746 Significant evidence for linkage for lethal prostate
cancer on chromosome arm 4q in Utah high-risk pedigrees. Lisa A.
Cannon-Albright, craig C. TEERLINK, Robert A. Stephenson, Neeraj
Agarwal.
2747 Increasing age at first full-time pregnancy correlates to
use of oral contraceptives before age 20 in women with a family
history of breast cancer. Annelie Augustinsson, Carolina Ellberg, Ulf
Kristoffersson, Håkan Olsson.
2748 A population-based survey of excess cancers observed
in Ewing’s sarcoma and in their first-, second-, and third-degree
relatives. Diana Abbott, R. Lor Randall, Joshua Schiffman, Stephen
Lessnick, Lisa A. Cannon-Albright.
2749 Cumulative cancer risk in the NCI Li-Fraumeni Syndrome
Cohort. Phuong L. Mai, Philip S. Rosenberg, June A. Peter, Rosamma
DeCastro, Payal P. Khincha, Jennifer T. Loud, Renee Bremer, Sharon
A. Savage.
2750 Modulation of BRCA1 expression as a preventative
method for BRCA1-associated breast cancer. Rania Chehade,
Rachael Pettapiece-Phillips, Mohammad Akbari, Leonardo Salmena,
Steven Narod, Joanne Kotsopoulos.
2751 Identification of predisposition genes involved in
thyroid and breast carcinomas in patients with family history of
these tumors by whole exome sequencing. Maisa Pinheiro, Fabio
Marchi, Sandra Drigo, Patricia Reis, Luiz Lehmann Coutinho, Sonia
Andrade, Luis Paulo Kowaslki, Maria Isabel Achatz, Silvia Rogatto.
2752 Prevalence of BAP1 germline mutations in asbestosexposed malignant mesothelioma cases and controls. Mitchell
Cheung, Jacqueline Talarchek, Suzanne E. Howard, Timothy Howard,
Hongzhuang Peng, Mary Hesdorffer, Frank J. Rauscher, Jill A. Ohar,
Joseph Testa.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
36
Abstract
Number
2753 The germline TP53 p.R337H mutation: a putative
selective advantage. Kelvin C. Andrade, Ana Carolina Leite, Amanda
Nobrega, Sharon Savage, Maria Isabel Achatz.
2754 Novel germline copy number variations in patients with
hereditary colorectal carcinoma with no mutation in the mismatch
repair genes. Rolando André R. Villacis, Érika Maria M. Santos, Dirce
M. Carraro, Benedito M. Rossi, Silvia R. Rogatto.
2755 Germline copy number variations in melanoma families
with/without CDKN2A/CDK4 mutations. Xiaohong (Rose) Yang,
Jianxin Shi, Hunter Bennett, Laura Burke, Casey Dagnall, Laurie
Burdette, Belynda Hicks, Margaret Tucker, Alisa Goldstein.
2756 Whole-exome sequencing reveals a novel germline
variant in CEBPA-associated familial acute myeloid leukemia: 45year follow-up of a large family. Anand Pathak, Katja Seipel,
Alexander Pemov, Ramita Dewan, Christina Brown, Sarangan
Ravichandran, Brian T. Luke, Meredith Yeager, Richard A. Gatti, Neil
Caporaso, John J. Mulvihill, Lynn Goldin, Thomas M. Pabst, Mary L.
McMaster, Douglas R. Stewart.
2757 Evaluation of EYA4 as a candidate risk locus in familial
lung cancer families linked to 6q. Joan E. Bailey-Wilson, Claire L.
Simpson, Susan M. Pinney, Mariza de Andrade, Colette Gaba, Ping
Yang, Ming You, Elena Y. Kupert, Ann G. Schwartz, Diptasri Mandal,
Christopher I. Amos, Marshall W. Anderson.
2758 Cancer risk in relatives of nasopharyngeal carcinoma - A
register-based cohort study in Sweden. Zhiwei Liu, Fang Fang, Ellen
T. Chang, Weimin Ye.
2759 Possible later age of breast cancer onset for Hispanic
BRCA1 carriers with the protective rs140068132-G allele. Laura
Fejerman, Jeffrey N. Weitzel, Esther M. John, Cynthia Villarreal, Gary
Unzeitig, Darling Horcasitas, Charite Ricker, Adrian Daneri, Kayla
Castaneda, Alexander Miron, Ana Marie Tuazon, Magdalena
Echeverry, Pilar Carvallo, Carolina Alvarez, Teresa Tapia, Columbus
Consortium, Luis Carvajal-Carmona, Susan Neuhausen, Elad Ziv.
2760 Impact of race and age on choice of surgery in newly
diagnosed breast cancer patients who tested negative for BRCA
1/2 mutation. Siddhartha Yadav, Heidi Dreyfuss, Jennifer Fulbright,
Ashley Reeves, Sarah Campian, Dana Zakalik.
2761 Evaluation of the BOADICEA model for predicting BRCA1
and BRCA2 mutation carrier probabilities in high-risk US Hispanic
and Mexican families: A report from the Clinical Cancer Genetics
Community Research Network. Jessica Clague, Cynthia VillarrealGarza, Adrian Daneri Navarro, Alexandra J. Obregon-Tito, Sharon
Sand, Tanya A. Chavez, Bita Nehoray, Lacolle Robinson, Lenny
Gallardo, Azucena Del Toro, Rosa Alvarez, Kathleen R. Blazer, Blu
Yanez, Charité Ricker, Gary W. Unzeitig, Kai Yang, Jeffrey N. Weitzel.
2762 LFSpro: A risk assessment tool to estimate TP53
mutation status in families with Li-Fraumeni syndrome. Gang
Peng, Jasmina Bojadzieva, Mandy L. Ballinger, David M. Thomas,
Louise Strong, Wenyi Wang.
2763 Maternal folate intake at periconception and genomewide DNA methylation modifications at birth in children. Semira
Gonseth, Ritu Roy, E. Andres Houseman, Adam de Smith, Mi Zhou,
Seung-Tae Lee, Sébastien Nusslé, Amanda W. Singer, Margaret R.
Wrensch, Catherine Metayer, Joseph L. Wiemels.
2764 Cosegregating variants in chronic lymphocytic leukemia
(CLL) families that are located in loci discovered by genome wide
association studies (GWAS). Sara Beiggi, Daniel R. O’Brien, Sara J.
Achenbach, Kari G. Chaffee, Timothy G. Call, Neil E. Kay, Tait D.
Shanafelt, Julie Cunningham, James R. Cerhan, Celine M. Vachon,
Susan L. Slager.
2765 Evaluation of family history of cancer in first-degree
relatives and increased cancer risk: A multinational study. Laxmi
Modali, Teresa A. Lehman, Ramakrishna Modali, Luke D. Ratnasinghe.
2766 Advanced paternal age as a possible risk factor for
retinoblastoma. Vanniarajan Ayyasamy, Namrata Gaikwad,
Thirumalairaj Kannan, Aloysius A. Abraham, Veerappan
Muthukkaruppan, Usha Kim.
36
POSTER SESSION
Epidemiology
Poster
:LJ[PVU
37
37
Molecular and Genetic Epidemiology of Cancer 1: Breast
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
2767 Investigation of the relationship between crown-like
structures and adipose tissue hormone levels among postmenopausal
women with breast cancer. Maeve Mullooly, Hannah P. Yang, Roni T. Falk,
Sarah Nyante, Renata Cora, Ruth M. Pfeiffer, Derek C. Radisky, Daniel W.
Visscher, Lynn C. Hartmann, Amy C. Degnim, Frank Z. Stanczyk, Jonine F.
Figueroa, Montserrat Garcia-Closas, Jolanta Lissowska, Melissa T. Troester,
Louise A. Brinton, Mark E. Sherman, Gretchen L. Gierach.
2768 Relationships between mammographic density, microvessel
density, and breast biopsy diagnosis. Ashley S. Felix, Petra Lenz, Ruth M.
Pfeiffer, Stephen M. Hewitt, Jennifer Morris, Deesha Patel, Berta Geller,
Pamela M. Vacek, Donald L. Weaver, Rachael E. Chicoine, John Shepherd,
Amir P. Mahmoudzadeh, Jeff Wang, Bo Fan, Sally Herschorn, Jason
Johnson, Louise A. Brinton, Mark E. Sherman, Gretchen L. Gierach.
2769 Angiogenic profile in postmenopausal women is not
associated with breast cancer risk. Roni T. Falk, Annetine C. Staff, Gary
Bradwin, Ananth Karumanchi, Rebecca Troisi.
2770 Racial differences in quantitative measures of area and
volumetric breast density. Anne Marie McCarthy, Brad Keller, Marie
Synnestvedt, Emily Conant, Katrina Armstrong, Despina Kontos.
2771 Neutrophil specific mitochondrial DNA copy number as a
biomarker for breast cancer. Helene Barcelo, Nicholas J. Brady, Kathryn
L. Schwertfeger, Myron Gross, Bharat Thyagarajan.
2772 Hormone replacement therapy and genome-wide DNA
methylation among post-menopausal women. Kristina M. Jordahl, David
R. Doody, Yuzheng Zhang, Donghui Yan, Timothy W. Randolph, Lisa G.
Johnson, Christopher I. Li, Karl Kelsey, E. A. Houseman, Pei Wang,
Kathleen E. Malone, Parveen Bhatti.
2773 Association of ALDH1A1 gene expression with survival of
triple-negative breast cancer. Yan Liu, Qiuyin Cai, Ying Zheng, Michelle L.
Baglia, Yinghao Su, Sarah Nechuta, Ping-Ping Bao, William Blot, Wei
Zheng, Xiao-Ou Shu.
2774 Androgen receptor is an independent prognostic marker of
breast cancer in ethnically diverse women from Chicago. Abeer M.
Mahmoud, Umaima Al-alem, Virgilia Macias, Jacob K. Kresovich, Andre
Kajdacsy-Balla, Elizabeth L. Wiley, Garth H. Rauscher.
2775 Prognostic significance of triple miRNAs, miR-9, miR-221,
and miR-200c in breast cancer. Chun-Wen Cheng, Jyh-Cherng Yu, YiHsien Hsieh, Po-Ming Chen, Hsiao-Wei Wang, Hui-Chun Wang, Chen-Yang
Shen.
2776 Codon 72 and Intron-3 polymorphisms in TP53 are risk
factors for breast cancer. Trafina Jadhav, Jesus Salazar-Gonzalez, Shantel
Hebert-Magee, Michael Behring, Balananda-Dhurjati Putcha, Jeehyun
Helen Bae, Andra Frost, Isam-Eldin Eltoum, Sejong Bae, Upender Manne.
2777 Evaluation of miRNA-binding-site SNPs of MRE11A, NBS1,
RAD51 and RAD52 in HRR pathway genes and risk of breast cancer in
China. Chunhua Song, Kaijuan Wang, Zhenzhen Wu, Ye Hua, Peng Wang,
Yong Hong Zheng, Xiaoqin Cao, Songyuan Deng.
2778 Shared genetics of breast cancer risk factors across life
stages. Chi Gao, Rulla M. Tamimi, Peter Kraft, Sara Lindstrom.
2779 A genome-wide analysis of more than 160,000 individuals
identifies four novel pleiotropic risk loci shared between breast and
ovarian cancer. Siddhartha Kar, Kyriaki Michailidou, Jonathan Tyrer,
Deborah Thompson, Diether Lambrechts, Ovarian Cancer Association
Consortium (OCAC) and Breast Cancer Association Consortium (BCAC).
2780 Evaluation of genetic variants in high and moderatepenetrance breast cancer susceptibility genes in East Asians. Mi-Ryung
Han, Xiao-Ou Shu, Qiuyin Cai, Yu-Tang Gao, Ying Zheng, Kyriaki
Michailidou, Joe Dennis, Manjeet K. Bolla, Qin Wang, Ji-Yeob Choi, Mikael
Hartman, Daehee Kang, Artitaya Lophatananon, Hui Miao, Keitaro Matsuo,
Kenneth Muir, Sulee Sangrajrang, Chen-Yang Shen, Soo Hwang Teo, Anna
H Wu, Alison M. Dunning, Paul D. P. Pharoah, Douglas F. Easton, Wei
Zheng, Jirong Long.
2781 Genetic susceptibility to breast cancer in a Spanish
population. Manuela Gago-Dominguez, Maite Peña, Maria Torres, Jose L.
Soto-Vázquez, Miguel E. Aguado-Barrera, Sara Miranda, Manuel Calaza,
Alejandro Novo, Victor M. Muñoz, Angel Carracedo, M. Elena Martinez, J.
Esteban Castelao.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
2782 Risk loci for a breast-colon cancer phenotype: results from a
genome-wide association study. Mala Pande, Aron Joon, Sanjay Shete,
Abenaa M. Brewster, Cathy Eng, Wei V. Chen, Habibul Ahsan, Irene L.
Andrulis, Esther M. John, Yi Lin, Polly A. Newcomb, Noralane M. Lindor,
Christopher I. Amos, John Hopper, Patrick M. Lynch.
2783 Common functional mechanisms underlying pleiotropy at
the 19p13.1 breast and ovarian cancer cusceptibility locus. Kate
Lawrenson, Siddhartha Kar, Karoline Kuckenbaeker, Stacey Edwards,
Qiyuan Li, Jonathan Tyrer, Jonathan Beesley, Kyriaki Michailidou, Susan
Ramus, Alison Dunning, Fergus Couch, Alvaro Monteiro, Jacques Simard,
Matthew Freedman, Douglas Easton, Georgia Chenevix-Trench, Paul
Pharoah, Antonis Antoniou, Simon Gayther, OCAC, BCAC and CIMBA.
2784 Genetic analysis of breast cancer in admixed populations of
central Colombia. Paul C. Lott, Angel Criollo, Anna Marie Tuazon, Carolina
R. Alfonso, Ruta Sahasrabudhe, Ana Estrada, Elisha Garcia, Rodrigo Prieto,
John Williamson, Javier Torres, Mabel Bohorquez, Maria M. Echeverry de
Polanco, CHIBCHA Consortium, COLUBMUS Consortium, Luis G. CarvajalCarmona.
2785 Germ-line variant rs2228230 and breast cancer risk in Puerto
Rican women. Hector J. Diaz-Zabala, Luisa Morales, Jaime Matta, Julie
Dutil.
2786 Associations of erythrocyte ␻-3 fatty acids with breast
tissue ␻-3 and inflammation. Shuvro Roy.
2787 Exon sequencing of candidate genes for early onset ER
negative breast cancer risk reveals novel gene-level associations. Molly
Scannell Bryan, Muhammad G. Kibirya, Irene Andrulis, Jenny ChangClaude, Habibul Ahsan, Brandon Pierce.
2788 Comprehensive high-depth target sequencing in circulating
tumor DNAs of patients with inflammatory and non-inflammation
breast cancers. Hushan Yang, Xue Zhong, Qiang Wei, Zhaomei Mu, Zhong
Ye, Yinzhi Lai, Huei-Wen Lin, Rebecca Jaslow, Tiffany Avery, Laura Austin,
Zhaohui Sun, Shengrong Lin, Grace Zhao, Ling Fang Tang, Ronald E. Myers,
Juan P. Palazzo, Laura Biederman, Bingshan Li, Massimo Cristofanilli.
2789 Associations between insertional polymorphisms of human
endogenous retrovirus K113 and K115 and breast cancer risk in African
American and European American women. Li Tang, Steven R. Gregory,
David Tritchler, Gary R. Zirpoli, Song Yao, Warren Davis, Gregory L. Ciupak,
Yasmin Thanavala, Elisa V. Bandera, Christine B. Ambrosone.
2790 Gene-based analysis of the fibroblast growth factor receptor
signaling pathway identifies an association of the FGF1 gene with risk
of estrogen receptor-negative breast cancer: The AMBER consortium.
Edward A. Ruiz-Narvaez, Stephen Haddad, Christopher A. Haiman, Song
Yao, Lara E. Sucheston-Campbell, Jeanette T. Bensen, Kathryn L. Lunetta,
Andrew F. Olshan, Christine B. Ambrosone, Julie R. Palmer.
2791 Genetic variations associated with breast cancer-related
lymphedema in a prospective multiethnic cohort. Song Yao, Yali Zhang,
Valerie S. Lee, Janise M. Roh, Isaac J. Ergas, Lwarence H. Kushi, Christine B.
Ambrosone, Marilyn L. Kwan.
2792 Polymorphisms in vitamin D-related genes and risk of breast
cancer. Joy Shi, Anne Grundy, Harriet Richardson, Angela Brooks-Wilson,
John Spinelli, Kristan J. Aronson.
2793 Not HOXB13 p.G84E, but p.R217C appears to be associated
with increased breast cancer risk in the Dutch population. Jingjing Liu,
Wendy J. Prager-van der Smissen, Sten Cornelissen, Margriet J. Collee, Ans
W. van den Ouweland, Marjanka K. Schmidt, John W. Martens, Antoinette
Hollestelle.
2794 Genetic variations in vitamin D-related pathways and breast
cancer risk in African American women. Song Yao, Chi-Chen Hong,
Kathryn Lunetta, Stephen Haddad, Edward Ruiz-Narvaez, Qiang Hu,
Qianqian Zhu, Song Liu, Lara Sucheston-Campbell, Christopher Haiman,
Andrew Olshan, Julie Palmer, Christine Ambrosone.
2795 Replicating GWAS SNPs for breast cancer in Indian
population. Rajini T. Nagrani, Sharayu S. Mhatre, Rajendra Badwe, Rajesh
Dikshit.
2796 Single nucleotide variants in metastasis-related genes are
associated with breast cancer risk, by lymph node involvement and ER
status, in women with European and African ancestry. Michelle Roberts,
Lara E. Sucheston-Campbell, Gary R. Zirpoli, Elisa V. Bandera, Christine B.
Ambrosone, Song Yao.
401
POSTER SESSION
Prevention Research
Chemoprevention 1
Poster
:LJ[PVU
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
402
Abstract
Number
2797 Dietary administration of a ␥-tocopherol rich mixture of
tocopherols inhibits estrogen-mediated mammary tumorigenesis.
Soumyasri Das Gupta, Sudathip Sae-tan, Joseph Wahler, Jae Young
So, Larry C. Cheng, Min Ji Bak, Mao-Jung Lee, Yong Lin, Weichung
Joe Shih, Chung S Yang, Nanjoo Suh.
2798 Quercetin inhibits Cr(VI)-induced malignant
transformation of human lung epithelial cells by targeting miR-21Pdcd4 signaling pathway. Pratheeshkumar Poyil.
2799 Goniothalamin, a natural product, modulates the
inflammatory microenvironment on colitis and colitis-associated
cancer. Débora B. Vendramini Costa, Ralph A. Francescone, Oxana
Dmitrieva, Vivi Hou, David Posocco, Ronaldo A. Pilli, Sergei
Grivennikov.
2800 Dietary black raspberries (BRBs) inhibit tumor
progression in PTEN-deficient mouse model of prostate cancer.
Narayanan K. Narayanan, Gary D. Stoner, Daniel S. Peiffer, Karen
Galdanes, Eric Larios, Alu Mark, Lisa Maziniski, Luis Chiriboga,
Maarten C. Bosland.
2801 Resveratrol-Quercetin combination significantly inhibits
prostate cancer in TRAMP mice. Chandra K. Singh, Nihal Ahmad.
2802 Sulforaphane potentiates non-melanoma skin cancer in
UVB-treated Nrf2 knockout mice. Marlon D. Taylor, Jaroslav Janda,
Nikki Adams, Karen Blohm-Mangone, Timothy Bowden, Sally
Dickinson.
2803 Oral administration of an acid stable liposomal
formulation of docosahexaenoic acid (DHA) delivers DHA and its
LOX-metabolites to the circulation and the breast tissue of
sprague dawley rats. Christine G. Skibinski, Arunangshu Das, KunMing Chen, Neil Trushin, Bogdan Prokopczyk, Cesar Aliaga, Mark
Kester, Andrea Manni, Karam El-Bayoumy.
2804 The thiazolidinedione pioglitazone enhances the cancer
preventive activity of the rexinoid LG100268 in Her2/neu induced
breast cancer. Iván P. Uray, Jennifer M. Rodenberg, Yun Zhang,
Jamal L. Hill, Powel H. Brown.
2805 Preventive effect of a prostaglandin E receptor EP4
antagonist RQ-00015986 on rat colon tumorigenesis. Yohei
Shirakami, Hiroyasu Sakai, Takahiro Kochi, Takayasu Ideta, Tsuneyuki
Miyazaki, Masahito Shimizu, Mitsuru Seishima.
2806 Effect of ED-71, an analogue of Vitamin D3, on intestinal
neoplasia in the Apc+/Min-FCCC mouse model. Wen-Chi L. Chang,
Esther Kaunga, Harry S. Cooper, Lisa Vanderveer, Jing Peng,
Yongchao Zhang, Chen S. Suen, Margie L. Clapper.
2807 Oral silibinin inhibits tumorigenic potential of colon
cancer stem cells. Sushil Kumar, Dileep Kumar, Komal Raina, Natalie
J. Serkova, Chapla Agarwal, Rajesh Agarwal.
2808 Luteolin inhibits cell proliferation and induces cell
apoptosis via down-regulation of mitochondrial membrane
potential in esophageal carcinoma cells EC1 and KYSE450. Ping
Chen, Tao Hu, Yane Ma, Xiaoyu Chen, Liping Dai, Ningjing Lei, Ziming
Dong, Pei Li.
2809 Chemopreventive studies of multiple agents in the
methylnitrosourea-induced ER+ mammary cancer model in
animals on standard and Western diets. Clinton J. Grubbs, Mark S.
Miller, Vernon E. Steele, Fariba Moeinpour, Harold Seifried, Brandy M.
Heckman-Stoddard, Ronald A. Lubet.
2810 Identification of a natural compound as mammalian
target of rapamycin kinase inhibitor . Jeong-Hoon Jang, Cheol-Jung
Lee, Mee-Hyun Lee, Young-Joon Surh, Yong-Yeon Cho.
2811 Silver nanoparticles protect human keratinocytes from
deleterious effects of ultraviolet radiation: Implications for skin
cancer chemoprevention. Sumit Arora, Nikhil Tyagi, Arun Bhardwaj,
Lilia Rusu, Rohan Palanki, Ajay P. Singh, James E. Carter, Seema
Singh.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
38
Abstract
Number
2812 The chemo-prevention effect of statin on hepatocellular
carcinoma cell lines. Aram Ghalali, Javier Martin-Renedo, Johan
Högberg, Ulla Stenius.
2813 Chemoprevention of mammary cancer: Modeling
predictive values of short-term morphologic assays for efficacy in
animal tumor assays. Barbara K. Dunn, Vernon E. Steele, Richard M.
Fagerstrom, Carol F. Topp, Barnett S. Kramer.
2814 Inhibition of PhIP/DSS-induced colon carcinogenesis by
different forms of tocopherols in CYP1A-humanized mice. Chung S.
Yang, Jayson X. Chen, Anna B. Liu, Hong Wang, Marlon Lee, Siyuan
Yu, Chunfang Zhao, Ying-Yi Kuo, Eric Chi, Nanjoo Suh.
2815 Sulindac reversal of 15-PGDH mediated resistance to
colon tumor chemoprevention with NSAIDs. Stephen P. Fink, Dawn
M. Dawson, Yongyou Zhang, Adam Kresak, Earl G. Lawrence, Peiying
Yang, Yanwen Chen, Jill S. Barnholtz-Sloan, Joseph E. Willis, Levy
Kopelovich, Sanford D. Markowitz.
2816 2=-Hydroxyflavanone inhibits lung cancer growth by
inhibiting tumor cell proliferation and angiogenesis. Sharad S.
Singhal, James Figarola, Jyotsana Singhal, Lokesh Nagaprashantha,
Sanjay Awasthi.
2817 Dietary chemopreventive agent (curcumin),
hypomethylates 5’ promoter of DCLK1 gene in human colon cancer
cells and restores expression of long isoform of DCLK1.
Shubhashish Sarkar, Malaney O’Connell, Pomila singh.
2818 Paradoxical activity of topical rapamycin in UV-induced
murine nonmelanoma skin cancer. Sally E. Dickinson, Jaroslav
Janda, Jane Criswell, Erik R. Olson, Jack Zhang, Emanuel F. Petricoin,
Valerie S. Calvert, Karen A. Blohm-Mangone, Marlon D. Taylor,
Kathylynn Saboda, Chengcheng Hu, Zigang Dong, David S. Alberts, G.
Timothy Bowden.
2819 Targeting inflammation and pancreatitis blocks tumorinitiating stem cells and pancreatic cancer progression. Altaf
Mohammed, Naveena B. Janakiram, Venkateshwar Madka, Misty
Brewer, Rebekah L. Ritchie, Stan Lightfoot, Gaurav Kumar, Michael
Sadeghi, Jagan M. Patlolla, Hiroshi Yamada, Zobeida CruzMonserrate, Courtney W. Houchen, Vernon E. Steele, Chinthalapally
V. Rao.
2820 Omeprazole alone, or in combination with Aspirin
inhibits azoxymethane-induced colon adenoma progression to
adenocarcinoma and carcinoma invasion in F344 rat model. Altaf
Mohammed, Jagan M. Patlolla, Yuting Zhang, Laura Biddick,
Venkateshwar Madka, Qian Li, Stan Lightfoot, Ronald Lubet, Chen S.
Suen, Vernon E. Steele, Chinthalapally V. Rao.
2821 Joint relationship between iron and retinoids in patients
at high-risk for liver cancer. Yachana Kataria, Ryan Deaton, Erika
Enk, Milita Petrauskaite, Scott Cotler, Donald Jensen, Peter Gann.
2822 Aspirin and other non-steroidal anti-inflammatory drug
prescriptions after diagnosis and upper aerodigestive tract cancer
survival. Tatiana V. Macfarlane.
2823 Honokiol inhibits the invasive potential of melanoma
cells by targeting NADPH oxidase 1 and decreasing the binding of
core proteins. Ram Prasad, Santosh K. Katiyar.
2824 Evaluation of Ibuprofen loaded solid lipid nanoparticles
and its combination regimens for pancreatic cancer
chemoprevention. Arvind Thakkar, Sushma Chenreddy, Jeffrey
Wang, Sunil Prabhu.
2825 Prevention of breast tumor growth by an extract from
the muscadine grape. Patricia E. Gallagher, E. Ann Tallant.
2826 Equimolar vs. pharmacokinetics-guided dosing in anticancer efficacy assessment of precursor-product pairs: Example
with pyranocoumarins from Korean Angelica. Wei Wu, Manohar
Puppala, Suni Tang, Jinhui Zhang, Chengguo Xing, Cheng Jiang,
Junxuan Lu.
38
LATE-BREAKING POSTER SESSIONS
Monday, 1:00 p.m.-5:00 p.m.
Halls B-E, Pennsylvania Convention Center
Abstracts will be available online and in the Proceedings Part 2.
Section 40
Section 41
Late-Breaking Research: Clinical Research/Endocrinology
Late-Breaking Research: Tumor Biology 1
403
Monday, 1:30 p.m.-3:30 p.m.
What’s New in NCI’s Center for Cancer Genomics:
An Overview of Programs
Co-Chairpersons: Jaime Guidry Auvil, National Cancer Institute, Bethesda, MD; Jean C. Zenklusen,
National Cancer Institute, Bethesda, MD
The NCI Center for Cancer Genomics (CCG) unifies the NCI’s activities in cancer genomics. Support
begins with basic cancer genomics research, advances to technology to improve data accessibility,
and continues through clinical translation to targeted and molecularly informed treatments. The
Center for Cancer Genomics aims to synthesize research in different fields of cancer genomics –
structural, functional, and computational – with the goal of improving patient outcomes.
In this session, we will describe the various genomics initiatives supported by the CCG including
programmatic objectives and research efforts. We will also highlight the data, resources and tools
available to the research community from each program. CCG programs featured will include the
Cancer Driver and Development Program (CDDP), The Adjuvant Lung Cancer Enrichment Marker
Identification and Sequencing Trials (ALCHEMIST), Exceptional Responders Initiative, Burkitt
Lymphoma Genome Sequencing Project (BLGSP), HIV+ Tumor Molecular Characterization Project
(HTMCP), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), The
Cancer Genome Atlas (TCGA), and the Cancer Target Development and Discovery (CTD2) initiative. In
this session, we will also include updates on cloud-based storage of CCG data through the Genomics
Data Commons (GDC), as well as related the related NCI Cancer Genomics Cloud Pilots managed
through CBIIT (NCI Center for Bioinformatics and Information Technology). The session will close with
an overview of the new CCG website that will be launching shortly after the AACR Annual Meeting and
serve as a central portal to access information, data resources, and tools relating to each of the CCG
programs discussed.
1:30 p.m.
CCG Tumor Characterization Initiatives: TARGET pediatric cancer genomics initiative
and CGCI updates
Jaime Guidry Auvil, National Cancer Institute, Bethesda, MD
1:50 p.m.
CCG Tumor Characterization Initiatives: The Cancer Genome Atlas: A report on adult
cancer genomics
Jean C. Zenklusen, National Cancer Institute, Bethesda, MD
2:10 p.m.
Other CCG Initiatives: CDDP, ALCHEMIST, and exceptional responders
Roy Tarnuzzer, National Cancer Institute, Bethesda, MD
2:30 p.m.
Other CCG Initiatives: CTD2 network updates
Subhashini Jagu, Johns Hopkins University School of Medicine, Baltimore, MD
2:50 p.m.
Genomics data storage, access, and analysis for CCG Initiatives: Genomics data commons
Zhining Wang, National Cancer Institute, Bethesda, MD
3:10 p.m.
Genomics data storage, access, and analysis for CCG Initiatives: NCI cloud pilots
Tanja M. Davidsen, National Cancer Institute, Bethesda, MD
3:25 p.m.
Genomics data storage, access, and analysis for CCG Initiatives: The new CCG website
Emma J. Spaulding, National Cancer Institute, Bethesda, MD
404
Monday, 2:00 p.m.-2:45 p.m.
The National Cancer Institute: Challenges and Opportunities
Douglas R. Lowy, MD
Acting Director
National Cancer Institute, Bethesda, MD
MEET THE RESEARCH ICON (not eligible for CME credit)
Monday, 2:00 p.m.-3:00 p.m.
Meet the Research Icon
Waun Ki Hong, MD, DMSc (Hon.), FAACR
The University of Texas MD Anderson Cancer Center, Houston, TX
Formerly known as Meet the Research Pioneer, these informal sessions, organized by the Associate
Member Council, provide early-career scientists with the special opportunity to meet and hear from a
renowned senior researcher in a small-group setting. Throughout the course of each discussion,
attendees will gain career advice relevant to each speaker’s specific field and learn about the
speaker’s professional and personal experiences, vision for the future of their field, as well as key
decisions that shaped their career path. Meet Dr. Waun Ki Hong, American Cancer Society Professor,
Samsung Distinguished University Chair Emeritus, professor of the thoracic/head and neck medical
oncology department, and Fellow of the AACR Academy. Sessions are open to all graduate students,
medical students, residents, and clinical and postdoctoral fellows and will take place in the Associate
Member Resource and Career Center located in AACRcentral. Limited seating will be available on a
first-come, first-served basis. #AACRcentral
405
Monday, 2:30 p.m.-3:30 p.m.
Meet the 2015-2016 AACR President
José Baselga, MD, PhD, FAACR
Memorial Sloan Kettering Cancer Center, New York, NY
All Annual Meeting attendees are invited to meet AACR
President José Baselga, MD, PhD, FAACR. Dr. Baselga,
physician-in-chief and chief medical officer at Memorial
Sloan Kettering Cancer Center in New York, is an
internationally recognized physician and scientist who
focuses on the clinical development of novel molecularly
targeted agents for the treatment of cancer, particularly
breast cancer.
Dr. Baselga is a pioneer in the development of treatments
for women with HER2-positive breast cancer. He
conducted the initial clinical trial that demonstrated that
patients with advanced HER2-positive breast cancer
benefited from treatment with the anti-HER2 monoclonal
antibody trastuzumab. In addition, he led the clinical
development of the second anti-HER2 monoclonal
antibody to receive U.S. Food and Drug Administration
approval, pertuzumab (Perjeta). His most recent focus in
the laboratory and clinic is the identification of
mechanisms of resistance to anti-HER2 agents and the
clinical development of novel agents—including PI3 kinase
inhibitors and antiestrogen therapies.
Prior to becoming physician-in-chief and chief medical
officer at Memorial Sloan Kettering Cancer Center, Dr.
Baselga was the chief of the Division of
Hematology/Oncology and associate director of the
Massachusetts General Hospital Cancer Center, and
professor of medicine at Harvard Medical School in Boston.
He was also the director of medical oncology, hematology,
and radiation oncology and chairman of medical oncology
service at Vall d’Hebron University and Hospital, in
Barcelona, Spain, and professor of medicine at the
Universitat Autònoma de Barcelona. He had also served as
a faculty member of the Breast/Gynecological Oncology
Service at Memorial Sloan Kettering’s Memorial Hospital.
AACR’s high-impact scientific journal, Cancer Discovery. He
has served the AACR in many other key capacities, including:
Annual Meeting 2013 Program Committee chair; member of
the board of directors (2009-2012); and member of the
editorial boards of Clinical Cancer Research and Cancer
Prevention Research. In addition, Dr. Baselga has served on
numerous committees, including: chair of the Clinical Trials
Committee (2012-2013); chair of the Research Grant Review
Committee (2009); member of the Landon FoundationAACR INNOVATOR Award for International Collaboration in
Cancer Research Committee (2006-2008); the Pezcoller
Foundation-AACR International Award for Cancer Research
Committee (2004-2005); and the AACR Award for
Outstanding Achievement in Cancer Research Award
Committee (2002-2003). He was inaugurated into the 2014
class of fellows of the AACR Academy. Additionally, he is a
principal of the Stand Up To Cancer Dream Team, “Targeting
the PI3K Pathway in Women’s Cancers.”
Dr. Baselga has received numerous awards and accolades
for his work in cancer research, including the 32nd Annual
AACR Richard and Hinda Rosenthal Family Foundation
Award in 2008, the Queen Sofía Spanish Institute Gold
Medal in 2010, and the American Society of Clinical
Oncology (ASCO) Young Investigator and Career
Development awards. He is an elected member of the
Institute of Medicine, a past president of the European
Society for Medical Oncology, and has served on
the board of directors for ASCO and the European
Cancer Organisation.
Dr. Baselga received his medical and doctoral degrees from
the Universitat Autònoma de Barcelona and completed
residencies at Vall d’Hebron University Hospital and the State
University of New York Health Science Center at Brooklyn, as
well as a fellowship at Memorial Sloan Kettering.
Dr. Baselga has been actively involved in the AACR for
more than 20 years. Together with Lewis C. Cantley, PhD,
FAACR, Dr. Baselga is a founding editor-in-chief of the
406
Monday, 3:00 p.m.-4:00 p.m.
AACRcentral, MICR Networking and Resource Center, Halls B-E, Booth #725
Meet the 2015 AACR-MICR Jane Cooke Wright Lecturer
Organized by the Minorities in Cancer Research (MICR) Council
Lucile L. Adams-Campbell, PhD
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Please join us for informal discussion with AACR-Minorities in Cancer Research Jane Cooke Wright
Lectureship Tenth Annual Recipient Lucile Adams-Campbell, PhD. Dr. Adams-Campbell’s award lecture
will be presented on Sunday, April 19, from 3:15 p.m.-4:30 p.m. The lectureship is intended to give
recognition to an outstanding scientist who has made meritorious contributions to the field of cancer
research and who has, through leadership or by example, furthered the advancement of minority
investigators in cancer research.
407
Monday, 3:00 p.m.-4:30 p.m.
Associate Member Council Meet and Greet
The Associate Member Council (AMC) Meet and Greet is open to all graduate students, medical
students, residents, and clinical and postdoctoral fellows and will take place in the Associate Member
Resource and Career Center located in AACRcentral. This is an opportunity to meet the AMC and learn
more about their programs, including the three new AMC-led committees, as well as network with
other early-career scientists attending the Annual Meeting. Light refreshments will be provided.
#AACR15 #AACRAMC #AACRcentral
Chairperson:
Michelle Kinder, Janssen Research and Development, LLC, Wayne, PA
Chairperson-Elect:
Mark D. Stewart, Institute of Medicine of the National Academies, Washington, DC
Past-Chairperson:
Kerry L. Reed, Northern Ontario School of Medicine, Sudbury, ON, Canada
Council Members
Kenneth Dutton-Regester, Dana-Farber Cancer Institute, Broad Institute of Harvard MIT and QIMR
Berghofer Medical Research Institute, Cambridge, MA
Alexandra J. Greenberg, National Cancer Institute, Boston, MA
Wenji Guo, University of Oxford, Oxford, United Kingdom
Takashi Kobayashi, Kyoto University Graduate School of Medicine, Kyoto, Japan
Selena Lin, Drexel University College of Medicine, Doylestown, PA
Shih-Wen (Wenny) Lin, Genentech, Inc., South San Francisco, CA
Diana M. Merino, University of Toronto and The Hospital for Sick Children, Toronto, ON, Canada
Colles O. Price, University of Chicago, Chicago, IL
Richard L. Price III, Washington University, St. Louis, MO
Marijn (Mary) T.M. van Jaarsveld, Max Planck Institute for Molecular Genetics, Berlin, Germany
Anna Woloszynska-Read, Roswell Park Cancer Institute, Buffalo, NY
408
SU2C SPECIAL SESSION (not eligible for CME credit)
Monday, 3:00 p.m.-5:00 p.m.
SU2C Scientific Session: Genomics and Beyond–Bringing Personalized
Medicine to Cancer Therapy
Chairperson: Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT,
Cambridge, MA
Stand Up To Cancer (SU2C) is working with funding partners to support these presenting Dream
Teams and Translational Team with a focus on in-depth genomic and molecular tumor analysis to
personalize treatment and understand treatment resistance in individual patients. In this open session,
which is available to all attendees, Team members will discuss their projects and describe their current
and future work translating personalized medicine approaches to the clinic. A brief Q & A will follow
the presentation of the Dream Team and Team reports.
Opening remarks from the SU2C Scientific Advisory Committee Chairperson
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
Prospective use of DNA-guided personalized cancer treatment
Sta Op Tegen Kanker-Dutch Cancer Society (SU2C-KWF) Translational Team
Speaker: René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands
Personalized medicine for patients with BRAF wild-type (BRAFwt) cancer
SU2C-Melanoma Research Alliance Dream Team
Speaker: Aleksandar Sekulic, Translational Genomics Research Institute, Phoenix, AZ
Precision therapy of advanced prostate cancer
SU2C-Prostate Cancer Foundation Dream Team
Speaker: Arul M. Chinnaiyan, University of Michigan Center for Translational Pathology, Ann Arbor, MI
Targeting adaptive pathways in metastatic treatment-resistant prostate cancer
SU2C-Prostate Cancer Foundation Dream Team
Speaker: Joshua M. Stuart, University of California, Santa Cruz, CA
Tumor organoids: A new preclinical model for drug sensitivity analysis
Sta Op Tegen Kanker-Dutch Cancer Society (SU2C-KWF) Dream Team
Speaker: Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands
409
CLINICAL TRIALS MINISYMPOSIUM
Monday, 3:00 p.m.-5:00 p.m.
Clinical Trials of Novel Therapeutics
Co-Chairpersons: Lillian L. Siu, University Health Network Princess Margaret Hospital, Toronto, ON,
Canada, and Paul Haluska, Mayo Clinic, Rochester, MN
3:00 p.m.
Introduction
3:10 p.m.
CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate,
sacituzumab govitecan (IMMU-132): Key preclinical and clinical results
Alexander N. Starodub, Allyson J. Ocean, Aditya Bardia, Michael J. Guarino, Wells
Messersmith, Jordan Berlin, Vincent J. Picozzi, Sajeve S. Thomas, Gregory Masters, Linda
T. Vahdat, Ingrid A. Mayer, Rebecca Moroose, Jennifer S. Diamond, Scott T. Tagawa,
Manish A. Shah, Francois Wilhelm, William A. Wegener, Pius Maliakal, Robert M. Sharkey,
David M. Goldenberg.
3:30 p.m.
CT237: Preclinical characterization and first-in-human study of MM-141, a dual
antibody inhibitor of IGF-1R and ErbB3
Alexey A. Lugovskoy, Michel Curley, Jason Baum, Sharlene Adams, Sergio Iadevaia,
Victoria Rimkunas, Adam Camblin, Lin Nie, Gege Tan, Bryan Johnson, Sara Mathews,
Kerry Horgan, Chrystal U. Louis, Akos G. Czibere, Monica Arnedos, Jean-Charles Soria,
Rastilav Bahleda, Anthony Shields, Patricia M. LoRusso, Mansoor Saleh, Steven J. Isakoff.
3:50 p.m.
CT238: Phase I safety and biodistribution study of 124I-PEG-AVP0458 diabody in
patients with TAG-72 positive ovarian and prostate cancer
Andrew M. Scott, Timothy Akhurst, Fook-Thean Lee, Marika Ciprotti, Ian Davis, Andrew
Weickhardt, Hui Gan, Pece Kocovski, Nancy Guo, Linda Mileshkin, Scott Williams, Declan
Murphy, Rod Hicks, Kunthi Pathmaraj, Sze Ting Lee, Graeme O'Keefe, Sylvia Gong,
Maggie Oh, Michael Wheatcroft, Peter J. Hudson.
4:10 p.m.
CT239: Clinical and preclinical evidence of an immune modulating role for the
STAT3-targeting ASO AZD9150 and potential to enhance clinical responses to
anti-PDL1 therapy
Patricia E. Mccoon, Rich Woessner, Shaun Grosskurth, Chris Womack, Mason Yamashita,
Gene Hung, Robert MacLeod, Kirsten Bell, Mike Collins, Rachel DuPont, Vivian Jacobs,
Michele Johnstone, Margaret Veldman-Jones, Paul Lyne.
4:30 p.m.
CT240: Checkpoint kinase 1/2 inhibitor LY2606368 in a phase I dose-expansion study
in patients with squamous cell carcinoma of the head and neck
Johanna Bendell, Stefan Grant, Filip Janku, Jeffrey Infante, William N. William, Todd M.
Bauer, Sarina Piha-Paul, Ricardo Martinez, Sameera Wijayawardana, Ji Lin, Lisa Golden,
Aimee Bence Lin, David Hong.
4:50 p.m.
Discussion
410
MAJOR SYMPOSIUM
Monday, 3:00 p.m.-5:00 p.m.
AACR-JCA Joint Symposium:
Current and Evolving Treatment Strategies in Hepatocellular Cancer:
From Genomics to Stem Cells and HCV
Co-Chairpersons: Lopa Mishra, The University of Texas MD Anderson Cancer Center, Houston, TX;
Shuichi Kaneko, Kanazawa University School of Medicine, Kanazawa, Japan
The AACR and the Japanese Cancer Association (JCA) are pleased to jointly present this symposium
to discuss and review important advances in hepatocellular cancer. The rapidly increasing incidence
of hepatocellular carcinoma in the United States is a particular concern given the high prevalence of
risk factors such as hepatitis C and B, alcohol toxicity, and fatty liver, and the low median survival
after diagnosis.
This liver cancer symposium brings together leaders in clinical and basic science from institutions in
the United States and Japan. The symposium will cover risk factors, genomics, and mechanisms of
neoplasia and will feature both current treatment options and new therapeutic modalities.
3:00 p.m.
Trans-ethnic landscape of HCC genomes: From therapeutic targets to
new epidemiology
Tatsuhiro Shibata, National Cancer Center, Tokyo, Japan
3:25 p.m.
Discussion
3:30 p.m.
HCV therapy: A cure with cancer prevention
K. Rajender Reddy, Hospital of the University of Pennsylvania, Philadelphia, PA
3:55 p.m.
Discussion
4:00 p.m.
Beyond conventional diagnosis and treatment for HCC
Shuichi Kaneko, Kanazawa University School of Medicine, Kanazawa, Japan
4:25 p.m.
Discussion
4:30 p.m.
From the past to the future: From stem cells to targeted therapies in HCC
Lopa Mishra, The University of Texas MD Anderson Cancer Center, Houston, TX
4:55 p.m.
Discussion
411
MINISYMPOSIUM
Monday, 3:00 PM-5:00 PM
Chemistry
Clinical Research
Progress Toward New Drugs and New Drug
Technologies
Predictive and Prognostic Biomarkers
Chairperson: Steven D. Averbuch
Chairpersons: Matthew A. Marx and Katerina Leftheris
3:00 Introduction
3:00 Introduction
3:05 2827 Discovery of AP26113, a potent, orally active inhibitor
of anaplastic lymphoma kinase and clinically relevant mutants.
Wei-Sheng Huang, Feng Li, Lisi Cai, Yongjin Xu, Sen Zhang, Scott D.
Wardwell, Yaoyu Ning, Anna Kohlmann, Tianjun Zhou, Emily Y. Ye,
Xiaotian Zhu, Narayana I. Narasimhan, Tim Clackson, Victor M.
Rivera, David Dalgarno, William C. Shakespeare.
3:20 2828 Rapid identification of potent and highly selective, oral
PTEFb Inhibitor BAY 1143572 with first in class potential. Ulrich T.
Luecking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk
Kosemund, Rolf Bohlmann, Knut Eis, Mark Gnoth, Ildiko Terebesi,
Kirstin Meyer, Katja Prelle, Ray Valencia, Stuart Ince, Franz von
Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Bert Klebl, Axel
Choidas, Peter Nussbaumer, Matthias Baumann, Carsten SchultzFademrecht, Gerd Ruehter, Jan Eickhoff, Michael Brands.
3:35 2829 Discovery and in vitro and in vivo characterization of
aminopyrazoline-based SMYD2 inhibitors. Carlo Stresemann, Ingo
Hartung, Timo Stellfeld, Naomi Barak, Jeffrey Mowat, Clara Christ,
Antonius ter Laak, Silke Koehr, Jörg Weiske, Roman Hillig, Volker
Badock, Detlef Stoeckigt, Karl Ziegelbauer, Hilmar Weinmann,
Volker Gekeler.
3:50 2830
Discovery of AZD8835, a potent and selective inhibitor
of PI3K and PI3K for the treatment of PIK3CA-dependent
cancers. Bernard Barlaam, Sabina Cosulich, Benedicte Delouvrie,
Martina Fitzek, Herve Germain, Stephen Green, Craig S. Harris,
Kevin Hudson, Christine Lambert-van der Brempt, Maryannick
Lamorlette, Le Griffon Antoine, Remy Morgentin, Gilles Ouvry, Ken
Page, Georges Pasquet, Linette Ruston, Twana Saleh, Michel
Vautier, Lara Ward.
4:05 2831 Development of selective GRP94 inhibitors for the
treatment of cancer. Stefan O. Ochiana, Tony Taldone, Hardik J.
Patel, Pallav Patel, Yan Pengrong, Weilin Sun, Anna Rodina, Smit
Shah, Daniel T. Gewirth, Gabriela Chiosis.
4:20 2832 Targeting and depletion of circulating cancer cells by
lipophilic antibody-modified erythrocytes. Dmitri Simberg.
4:35 2833 Enhanced therapeutic efficacy of a combination of
gemcitabine and albumin-bound paclitaxel in multistage
nanovectors in pancreatic ductal adenocarcinoma: Evaluation of
transport phenomena. Carlotta Borsoi, Kenji Yokoi, Fransisca
Leonard, Mauro Ferrari, Biana Godin Vilentchouk.
4:50 Discussion.
3:05 2834 BH3 profiling predicts clinical response in a phase II
clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia.
Leah Hogdal, Brenda Chyla, Evelyn McKeegan, Joel Leverson, Jalaja
Potluri, Nancy Falotico, Justin Ricker, Rod Humerickhouse, Mack
Mabry, Glenna Foight, Amy Keating, Ilene Galinsky, Richard Stone,
Daniel DeAngelo, Marina Konopleva, Anthony Letai.
3:20 2835 MDM2 antagonist-based therapeutic response is
discriminated by a 4-gene signature in acute myeloid leukemia
patients. Hua Zhong, Gong Chen, Lori Jukofsky, David Geho, Sung
Won Han, Fabian Birzele, Sabine Bader, Lucia Himmelein, James
Cai, Zayed Albertyn, Mark Rothe, Laurent Essioux, Helmut
Burtscher, Steven A. Middleton, Lin-Chi Chen, Markus Dangl,
William E. Pierceall, Gwen Nichols.
3:35 2836 A discovery and validation set of breast cancer
preoperative clinical trials show an increase in immune score
upon brief-exposure to trastuzumab (T) and the HER2-enriched
subtype predict response to combination chemotherapy and T.
Vinay Varadan, Kristy L. Miskimen, Shikha Parsai, Ian E. Krop, Eric P.
Winer, Veerle Bossuyt, Maysa Abu-Khalaf, William Sikov, Lyndsay
N. Harris.
3:50 2837 A surrogate gene expression signature of tumor
infiltrating lymphocytes (TILs) predicts degree of benefit from
trastuzumab added to standard adjuvant chemotherapy in
NSABP (NRG) trial B-31 for HER2+ breast cancer. Seong-Rim Kim,
Patrick G. Gavin, Katherine L. Pogue-Geile, Nan Song, Melanie
Finnigan, Hanna Bandos, Jong-Hyeon Jeong, Priya Rastogi, Edward
H. Romond, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra
M. Swain, D. Lawrence Wickerham, Charles E. Geyer, Joseph P.
Costantino, Norman Wolmark.
4:05 2838 TP53 autoantibody can detect CA125 screen negative
ovarian cancer cases and can be elevated prior to CA125 in
preclinical ovarian cancer. Wei-Lei Yang, Archana Simmons, Zhen
Lu, Keith Baggerly, Karen Lu, Alex Gentry-Maharaj, Usha Menon, Ian
Jacobs, Robert C. Bast.
4:20 2839 Specific mutant tumor DNA can be detected in ovarian
cystic fluid of an unknown ovarian tumor cyst. Karin Sundfeldt,
Björg Kristjansdottir, Bert Vogelstein.
4:35 2840 Discovery and independent validation of prognostic
protein-coding and non-coding genomic meta-features in
rhabdomyosarcoma. Anirban P. Mitra, Sheetal A. Mitra, Jonathan
D. Buckley, James R. Anderson, Stephen X. Skapek, Douglas S.
Hawkins, Timothy J. Triche.
4:50 Discussion.
412
MINISYMPOSIUM
Molecular Mechanisms of Sensitivity or
Resistance to Pathway-Targeted Agents
PARP and DNA Repair Inhibitors
Chairperson: Yves G. Pommier
Chairperson: Paul Workman
3:00 Introduction
3:00 Introduction
3:05 2841 A co-clinical assessment of patterns of BRAF inhibitor
resistance. Lawrence N. Kwong, Genevieve Boland, Dennie
Frederick, Timothy Helms, Ahmad Akid, John Miller, Shan Jiang,
Zachary Cooper, Xingzhi Song, Sahil Seth, Jennifer Kamara, Alexei
Protopopov, Gordon Mills, Keith Flaherty, Jennifer Wargo, Lynda
Chin.
3:20 2842 Personalized pre-clinical trials in BRAF inhibitor
resistant patient derived xenograft models of melanoma identify
c-Met as an effective second line combination therapy target.
Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia Brafford,
Batool Shannan, Marilda Beqiri, Wei Xu, Bradley Garman, Katherine
L. Nathanson, Xiaowei Xu, Giorgos Karakousis, Gordon B. Mills,
Yiling Lu, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn
Schuchter, Meenhard Herlyn.
3:35 2843 Resistance to ERK inhibitors as a result of an acquired
novel P-loop mutation of ERK2. Paul A. Clarke, Toby Roe, Kate
Swabey, Craig McAndrew, Kathy Boxall, Isaac Westwood, Robert
van Montfort, Bissan Al-Lazikhani, Paul Workman.
3:50 2844 RNA interference kinome-wide screen reveals a role for
PDK1 in acquired resistance to CDK4/6 inhibition ER-positive
breast cancer. Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer,
Carlos L. Arteaga.
4:05 2845 Co-acquisition of T790M and EMT in resistant EGFR
mutant non-small cell lung cancer can be overcome by combined
irreversible EGFR and BCL-XL inhibition. Aaron N. Hata, Matthew
J. Niederst, Hannah L. Archibald, Hillary Mulvey, Jungoh Ham, Maria
Gomez-Caraballo, Anuj Kalsy, Anthony C. Faber, Jeffrey Engelman.
4:20 2846 Ultrasensitive detection of actionable subclones in
chronic myeloid leukemia. Michael W. Schmitt, Bella Aminov,
Jerald P. Radich, Lawrence A. Loeb.
4:35 2847 High complexity barcoding to study clonal dynamics in
response to cancer therapy. Hyo-eun C. Bhang, David A. Ruddy,
Viveksagar Krishnamurthy Radhakrishna, Rui Zhao, Iris Kao, Daniel
Rakiec, Pamela Shaw, Marissa Balak, Justina X. Caushi, Elizabeth
Ackley, Nicholas Keen, Michael R. Schlabach, Michael Palmer,
William R. Sellers, Franziska Michor, Vesselina G. Cooke, Joshua M.
Korn, Frank Stegmeier.
3:05 2848 Combination of DNA methyltransferase and PARP
inhibitors as a novel therapy strategy for poor prognosis acute
myeloid leukemia. Nidal E. Muvarak, Carine Robert, Eun Yong Choi,
Vu Duong, Ashkan Emadi, Rena Lapidus, Maria R. Baer, Stephen
Baylin, Feyruz Rassool.
3:20 2849 The combination of the PARP inhibitor talazoparib
(BMN 673) with the ATR inhibitor VE-821 overcomes the drug
resistance of Schlafen 11-deficient cells. Junko Murai, Yves
Pommier.
3:35 2850 Talazoparib (BMN-673) possesses greater PARP1
trapping activity than structurally distinct PARP inhibitors with
identical PARP1 binding properties. Todd A. Hopkins, Yan Y. Shi,
Enrico L. DiGiammarino, Sanjay C. Panchal, Gui-Dong G. Zhu,
Thomas D. Penning, Eric F. Johnson, David Maag.
3:50 2851 Preclinical characterization of NMS-P648, a novel and
potent PARP-1/-3 inhibitor. Alessia Montagnoli, Gianluca Papeo,
Sonia Rainoldi, Alessandra Cirla, Antonella Ciavolella, Clara
Albanese, Michele Modugno, Roberta Bosotti, Alessio Somaschini,
Giovanni Carapezza, Rosita Lupi, Dario Ballinari, Marina Ciomei,
Enrico Pesenti, Daniele Donati, Antonella Isacchi, Arturo Galvani.
4:05 2852 Torin2 suppresses ionizing radiation induced DNA
damage repair. Durga Udayakumar, Raj K. Pandita, Nobuo
Horikoshi, Clayton R. Hunt, Qingsong Liu, Kwok-Kin Wong,
Nathanael S. Gray, Tej K. Pandita, Kenneth D. Westover.
4:20 2853 Investigating DNAPK as a biomarker and a novel
therapeutic target in aggressive prostate cancer. Vishal Kothari,
Jonathan F. Goodwin, Shuang Zhao, Elai Davicioni, Jeffrey R.
Karnes, Robert B. Den, Rohit Mehra, Karen E. Knudsen, Felix Y.
Feng.
4:35 2854 Targeting error-prone alternative nonhomologous end
joining (A-NHEJ) DNA repair pathway to treat ESR1-mediated
therapy resistance. Samaya Krishnan, Binoj Nair, Gangadhara
Sareddy, Monica Mann, Ratna K. Vadlamudi.
4:50 Discussion.
4:50 Discussion.
413
MINISYMPOSIUM
Terrace Ballroom IV (400 Level), Pennsylvania Convention
Center
Immunology
Cancer Epigenetics
Immune Checkpoint Inhibition
Chairpersons: Feyruz V. Rassool and James M. Flanagan
Chairperson: Mario Sznol
3:00 Introduction
3:00 Introduction
3:05 2855 Immunomodulatory activity of nivolumab monotherapy
in patients with advanced melanoma. Walter J. Urba, Salvador
Martín-Algarra, Margaret Callahan, Jedd D. Wolchok, William H.
Sharfman, Jeffrey A. Sosman, Shailender Bhatia, Wen-Jen Hwu,
Thomas F. Gajewski, Craig L. Slingluff, Yun Shen, Christine E. Horak,
F Stephen Hodi.
3:20 2856 Unique changes in the TCR repertoire of tumorinfiltrating lymphocytes underlie the synergy of radiotherapy
with CTLA-4 blockade. Karsten Pilones, Graeme Koelwyn, Ryan
Emerson, Silvia Formenti, Harlan Robins, Sandra Demaria.
3:35 2857 Metastatic site and response to pembrolizumab (antiPD1 antibody) in melanoma. Paul C. Tumeh*, Michael Rosenblum*,
Nathan Handley, Katy Tsai, Robert Rodriguez S. Rodriguez, Niharika
Khurana, Christina Harview, Marko Spasic, Phillip J. Sanchez,
Jeremy Chang, I. Peter Shintaku, Emma Taylor, Bartosz
Chmielowski, Tristan Grogan, David A. Elashoff, Robert H. Pierce,
Adil Daud.
3:50 2858 Radiation and dual immune checkpoint blockade
overcome tumor resistance and distinctly improve immunity.
Andrew J. Rech, Christina Twyman-Saint Victor, Amit Maity,
Ramesh Rengan, Kristen E. Pauken, Erietta Stelekati, Joseph Benci,
Bihui Xu, Hannah Dada, Pamela M. Odorizzi, Ramin S. Herati,
Kathleen D. Mansfield, Dana Patsch, Ravi K. Amaravadi, Lynn M.
Schuchter, Hemant Ishwaran, Rosemarie Mick, Daniel Pryma,
Xiaowei Xu, Michael D. Feldman, Tara C. Gangadhar, Stephen M.
Hahn, E. J. Wherry, Andy J. Minn, Robert H. Vonderheide.
4:05 2859 Inhibition of PD-L1 by MPDL3280A leads to clinical
activity in patients with metastatic triple-negative breast cancer
(TNBC). Leisha A. Emens, Fadi S. Braiteh, Philippe Cassier, JeanPierre Delord, Joseph Paul Eder, Marcella Fasso, Yuanyuan Xiao,
Yan Wang, Luciana Molinero, Daniel S. Chen, Ian Krop.
3:05 2862 MBD3 regulates chromatin accessibility at active
promoters. Takashi Shimbo, Christopher Lavender, Sara A. Grimm,
Makiko I. Doi, Telmo Henriques, Kimberly R. Cannady, Kevin J.
Murphy, Daniel A. Gilchrist, Adam Burkholder, Jeffrey J. Hayes,
Karen Adelman, Trevor K. Archer, Kenneth S. Zaret, Paul A. Wade.
3:20 2863 DNA methylation dictates transcription factor binding
and gene activation in brain tumor. Shuli Xia, Qifeng Song, Jun
Wan, Yijing Su, Yaxue Zheng, Hongjun Song, Jiang Qian, John
Laterra, Heng Zhu.
3:35 2864 Acetylation regulates TET2 stability and enzymatic
activity. Yang Zhang, Yi Cai, Wenbing Xie, Hariharan Easwaran,
Stephen B. Baylin.
3:50 2865 Characterization of histone deacetylases in embryonal
rhabdomyosarcoma. Michael Phelps, Terra VleeshouwerNeumann, Jenna Bailey, Nicole Hickman, Eleanor Chen.
4:05 2866 Defining epigenetic vulnerabilities in synovial sarcoma.
Ana Banito, Nilgun Tasdemir, Marc Ladanyi, Scott W. Lowe.
4:20 2867 Inhibition of BET bromodomain proteins as a
therapeutic approach in small cell lung cancer. Anastasia Wyce,
BaoChau Le, Yuchen Bai, David Soong, Xi-Ping Zhang, Jeanne J.
Matteo, Susan Korenchuk, Michael F. Butticello, Ramona Plant,
Maureen R. Bleam, Yan Degenhardt, Charles F. McHugh, Christopher
Carpenter, Peter J. Tummino, Olena Barbash.
4:35 2868 SETDB1 accelerates non-small cell lung cancer (NSCLC)
tumorigenesis through WNT signalling pathway. Qiaoyang Sun,
Lingwen Ding, Jinfen Xiao, Lee Goodglick, David Chia, Vei Mah,
Mohammad Alavi, Ngan Doan, Jonathan W. Said, Henry Yang,
H.Phillip Koeffler.
4:50 Discussion.
4:20 2860 Improved clinical response in patients with advanced
melanoma treated with nivolumab combined with ipilimumab
compared to ipilimumab alone. F. Stephen Hodi, Michael A.
Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth
Grossmann, David McDermott, Gerald Linette, Nicolas Meyer,
Jeffrey Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S.
Ernstoff, David R. Minor, April Salama, Matthew H. Taylor, Linda
Rollin, Christine Horak, Paul Gagnier, Jedd D. Wolchok.
4:35 2861 High-level amplification of chromosome 9p24 targeting
PD-L1 and JAK2 correlates with worse DFS and OS in triple
negative breast cancer. Karen S. Anderson, Christine L. Klassen,
Amylou C. Dueck, Ann E. McCullough, Donald W. Northfelt,
Mariacarla Andreozzi, Barbara A. Pockaj, Michael T. Barrett.
4:50 Discussion.
414
MINISYMPOSIUM
Terrace Ballroom I (400 Level), Pennsylvania Convention
Center
Mechanisms of Cancer Initiation and New
Targets for Prevention
Non-Coding RNAs in Cancer Biology 2
Chairpersons:
Prevention Research
Chairpersons: Cory Abate-Shen and Andrew J.
Dannenberg
3:00 Introduction
3:05 2869 SChLAP1 mediated epigenetic modifications in prostate
cancer. Udit Singhal, Anirban Sahu, John R. Prensner, Qi Cao, Arul
M. Chinnaiyan.
3:20 2870 A novel metastasis-associating LincRNA destabilizes
tumor-suppressor mRNAs through cooperative action with
NF90/ILF3 binding. Zhengyu Jiang, Zhou Yan, Karthikeyan
Devarajan, Carolyn M. Slater, Mary B. Daly, Xiaowei Chen.
3:35 2871 Allele-specific modulation of cancer metabolism by a
long noncoding RNA. Roxana S. Redis, Cristina Ivan, Luz Vela,
Weiqin Lu, Cristian Rodriguez-Aguayo, Andre L. Ambrosio, Sandra
M. Gomes Dias, Ioana Berindan-Neagoe, George A. Calin.
3:50 2872 Estrogen withdrawal and breast cancer development in
the presence of the KRAS-variant. Song-Yi Jung, David Salzman,
Joanne B. Weidhaas.
4:05 2873 Identification of a new mechanism of microRNA
turnover from miR-106a-363 cluster leading to epithelial-tomesenchymal transition in prostate cancer. U-Ging Lo, Rey-Chen
Pong, Diane Yang, Jiancheng Zhou, Leah Gandee, Shu-Fen Tseng,
Jer-Tsong Hsieh.
4:20 2874 Regulatory role of miRNA-1246 and Wnt/␤-catenin
pathway interaction in CD133+ liver cancer stem cells-driven
hepatocellular carcinoma. Stella Chai, Kai Yu Ng, Man Tong, Siu
Tim Cheung, Xin-Yuan Guan, Stephanie Ma.
4:35 2875 p53 regulation of PDL1 is mediated through miR-34a.
Maria A. Cortez, David Valdecanas, Xiaohong Wang, Cristina Ivan,
Heidi Peltier, Huiping Ye, Luiz Araujo, David Carbone, Dipak K. Giri,
Ritsuko Komaki, Sunil Krishnan, Ferdinandos Skoulidis, John
Heymach, George Calin, Andreas G. Bader, James W. Welsh.
4:50 Discussion.
3:00 Introduction
3:05 2876 Supplemental estrogen protects against obesity
induced mammary gland inflammation in mice. Priya Bhardwaj,
Baoheng Du, Xi Kathy Zhou, Erika Sue, Dilip Giri, Michael D. Harbus,
Domenick J. Falcone, Clifford A. Hudis, Kotha Subbaramaiah,
Andrew J. Dannenberg.
3:20 2877 Exercise, alone and in combination with a whole tumor
cell vaccine reduces mammary tumor cell growth and enhances
anti-tumor immunity. William J. Turbitt, Donna Sosnoski, Andrea
Mastro, Connie Rogers.
3:35 2878 Development of the pre-cancer genome atlas (PCGA)
for squamous cell lung carcinoma. Jennifer E. Beane, Joshua
Campbell, Christopher Moy, Catalina Perdomo, Michael Schaffer,
Sarah Mazzilli, Yaron Geshalter, Jacob Kantrowitz, Liye Zhang,
David Jenkins, Mary Beth Pine, Samjot Dhillon, Gang Liu, Hanqiao
Liu, Sherry Zhang, Jessica Vick, Stefano Monti, Evan Johnson, Suso
Platero, Marc Lenburg, Mary Reid, Avrum Spira.
3:50 2879 Profiling of lung microbial communities in lung cancer
and chronic obstructive pulmonary disease patients. Yanhong
Liu, Nadim J. Ajami, Matthew C. Wong, Michael Scheurer, E. Susan
Amirian, Joseph F. Petrosino, Margaret R. Spitz, Melissa L. Bondy,
Farrah Kheradmand.
4:05 2880 Modulating disease susceptibility in a model of human
colon cancer by microbiome rederivation. James Amos-Landgraf,
Susheel Busi, Aaron Ericsson, Marina McCoy, Taybor Parker,
Rebecca Schehr, Miriam Hankins, Craig Franklin, Elizabeth Bryda.
4:20 2881 Systemic Chromosome Instability (CIN) resulted in
transcriptomic changes in metabolic and proliferation regulators
in colonic mucosal tissue of Sgo1-/+ mice. Chinthalapally V. Rao,
Saira Sanghera, Yuting Zhang, Laura Biddick, Arun Reddy, Stan
Lightfoot, Altaf Mohammed, Wei Dai, Hiroshi Y. Yamada.
4:35 2882 Calorie-induced silencing of the tumor suppressive
guanylin-GUCY2C paracrine axis underlies colorectal cancer in
obesity. Erik S. Blomain, Jieru E. Lin, Francheska Colón-González,
Gilbert W. Kim, Terry Hyslop, Tingting Zhan, Adam E. Snook, Scott
A. Waldman.
4:50 Discussion.
415
MINISYMPOSIUM
Tumor Biology
Tumor Biology
Epigenetic and Metabolic Regulation in the
Microenvironment
Mouse Models of Human Cancer 2
Chairperson: Anton Berns
Chairperson: Irene M. Ghobrial
3:00 Introduction
3:00 Introduction
3:05 2883 Genetic ablation of Smoothened in tumor-associated
fibroblasts promotes pancreatic tumorigenesis. Jason R. Pitarresi,
Jinghai Wu, Xin Liu, Veronica Bravo, Maria C. Cuitiño, Raleigh D.
Kladney, Sarah Woelke, Sarmila Majumder, Gustavo Leone, Michael
C. Ostrowski.
3:20 2884 Tumor-driven eutrophication of the tumor ecosystem
selects for cancer cell clones that overcome evolutionary inertia
leading to increased metastatic capacity. Sarah R. Amend,
Kenneth Pienta.
3:35 2885 Differential expression of long non-coding RNAs in
ovarian cancer-associated fibroblasts versus normal ovarian
fibroblasts. Emily K. Colvin, Fatemeh Vafaee, Samuel C. Mok,
Michael J. Birrer, Viive M. Howell, Goli Samimi.
3:50 2886 Epigenetic regulation of MUC1 in NF-kB target gene
expression of pro-inflammatory cytokines in colon cancer.
Sandra Cascio, Joshua Sciurba, Olivera Finn.
4:05 2887 Epigenetic silencing of the DNA repair genes, BRCA1
and MLH1, induced by hypoxic stress in a pathway dependent on
the histone demethylase, LSD1. Yuhong Lu, Adrian Chu, Narendra
Wajapeyee, Mitchell S. Turker, Peter M. Glazer.
4:20 2888 Metabolically activated macrophages in obesity
associated TNBC. Payal Tiwari, Kelly Schoenfelt, Swati Kulkarni,
Marsha Rosner, Lev Becker.
4:35 2889 Distinct microbiome in colorectal cancers with the CpG
Island Methylator Phenotype. Ang Sun, Matteo Cesaroni, Christian
Jobin, Carlos Barrero, Jaroslav Jelinek, Jacqueline D. Sautter,
Thomas E. Rams, Salim Merali, Jean-Pierre Issa.
4:50 Discussion.
3:05 2890 Single mouse trials, a concept using patient-derived
tumor xenografts for large scale in vivo screens. Christina Gredy,
Julia B. Schüler, Nina Zanella, Heinz-Herbert Fiebig, Thomas Metz.
3:20 2891 Chemokine-targeted models of human orthotopic
colorectal cancer in immunocompetant mice. Steven M. Lipkin,
Huanhuan Joyce Chen, Jian Sun, Zhiliang Huang, Harry Hou, Myra
Arcilla, Nikolai Rakhilin, Daniel Joe, Jiahn Choi, Poornima
Gadamsetty, Jeff Milsom, Govind Nandakumar, Randy Longman,
Kathy Zhou, Robert Edwards, Kai Yuan Chen, Pengcheng Bu, Lihua
Wang, Yitian Xu, Robert Munroe, Christian Abratte, Andrew Miller,
Zeynep Gümüş, Michael Shuler, Nozomi Nishimura, Winfried
Edelmann, Xiling Shen.
3:35 2892 A MYC-driven medulloblastoma model derived from
human induced pluripotent stem cells. Jonathan Sagal, Charles G.
Eberhart, Mingyao Ying.
3:50 2893 Sleeping Beauty uncovers cooperating driver genes in a
preclinical mouse model of myeloid leukemia. Karen M. Mann,
Justin Newberg, Nicholas Navin, David J. Adams, Nancy Jenkins,
Neal Copeland, Michael B. Mann.
4:05 2894 Notch signaling promotes survival and recurrence of
dormant mammary tumor cells following HER2/neu targeted
therapy. Daniel L. Abravanel, Meredith A. Collins, George K. Belka,
Tien-chi Pan, Dhruv K. Pant, Christopher J. Sterner, Lewis A.
Chodosh.
4:20 2895 Phosphorylation of EZH2 at T416 by CDK2 promotes
development of mammary tumors with basal-like phenotype. Lei
Nie, Yongkun Wei, Adam LaBaff, Cheng-Chieh Yang, Weiya Xia,
Longfei Huo, Dongping Liu, Yi-Hsin Hsu, Gabriel N. Hortobagyi, Jun
Yao, Celina G. Kleer, Mien-Chie Hung.
4:35 2896 A flexible mouse model of malignant pleural
mesothelioma. Jonathan Cooper, Filippo Giancotti.
4:50 Discussion.
416
AACR-PRINCESS TAKAMATSU LECTURE
Monday, 3:30 p.m.-4:30 p.m.
Ninth Annual AACR Princess Takamatsu Memorial Lectureship
Targeting PI3K for Cancer Therapy
Lewis C. Cantley, PhD, FAACR
Sandra and Edward Meyer Cancer Center at
Weill Cornell Medical College, New York, NY
The AACR Princess Takamatsu Memorial Lectureship was
established and first presented in 2007 in honor of the late
Princess Takamatsu of Japan. During her extraordinary life,
Her Imperial Highness Princess Takamatsu expended
tremendous efforts toward the public and humanitarian
cause of the eradication of cancer. She is an honored and
respected figure in Japan, the United States, and the
cancer research community worldwide.
The Lectureship recognizes an individual scientist whose
novel and significant work has had or may have a farreaching impact on the detection, diagnosis, treatment, or
prevention of cancer, and who embodies the dedication of
the Princess to multinational collaborations.
Dr. Lewis C. Cantley is honored for his discovery of the
phosphoinositide 3-kinase (PI3K) enzyme and the
subsequent work delineating the PI3K signaling pathway.
Dr. Cantley’s research has shown that this pathway is
commonly activated in cancer and has paved the way for
the development of therapeutics aimed at inhibiting PI3K
signaling. This work is already having a genuine impact on
cancer patients and perfectly captures the spirit of this
award. His laboratory demonstrated the importance of
activation of P13K and the downstream signaling pathway
and they developed novel of peptide libraries that revealed
the structural specificity of phosphorylation-dependent
protein networks that regulate this pathway and other
signaling pathways. Mutations that activate P13K are
among the most frequent genetic alterations in human
cancers. The first PI3K inhibitor for cancer therapy was
approved in 2014 and more than 20 PI3K inhibitors are
currently in clinical trials for a wide variety of cancers.
Dr. Cantley’s scientific accomplishments have been
recognized with numerous additional honors throughout
his career, including the inaugural Breakthrough Prize in
Life Sciences, the H.C. Jacobaeus Prize, the Pasarow Award
for Cancer Research, the Rolf Luft Award from the
Karolinska Institute, the Pezcoller Foundation-AACR
International Award for Cancer Research, and the
Caledonian Prize Lectureship in Biomedical Science from
the Royal Society of Edinburgh. Additionally, he is an
elected member of the National Academy of Sciences, the
Institutes of Medicine and the American Academy of Arts
and Sciences.
Dr. Cantley graduated from Wesleyan College and received
his PhD in biophysics from Cornell University. In 1992, he
assumed the position of chief of signal transduction at Beth
Israel Deaconess Medical Center and Harvard Medical
School. He currently occupies the position of Meyer Director
of the Sandra and Edward Meyer Cancer Center at Weill
Cornell Medical College/New York Presbyterian Hospital.
417
Monday, 3:30 p.m.-5:00 p.m.
Biospecimens to Support Cancer Research
Co-Chairpersons: Irina Lubensky, Danielle Carrick, and
Helen M. Moore, National Cancer Institute, Bethesda, MD
This session will present information regarding the
acquisition and utilization of cancer and normal
biospecimens for cancer research.
NCI Biospecimen Resources Available to the Research
Community
Moderators:
Irina Lubensky, Cancer Diagnosis Program, Division of
Cancer Treatment and Diagnosis, National Cancer Institute,
Bethesda, MD
Aniruddha Ganguly, Cancer Diagnosis Program, Division of
Cancer Treatment and Diagnosis, National Cancer Institute,
Bethesda, MD
The first part of the session will provide information about
two quality human biospecimen resources supported by
NCI and available to the researchers for discovery and
validation of biomarkers of diagnosis, prognosis and
response to therapy. The Cooperative Human Tissue
Network (CHTN) and NCI National Clinical Trials Network
(NCTN) Biospecimen Banks will be described in detail,
including the types of samples (paraffin embedded, fresh
frozen, blood, fluid, etc.) and the extent of clinical data
available. Access to biospecimens, application process and
evaluation, criteria for specimen distribution, fee structure
and examples of successful research projects using each
resource will also be discussed. NCI Specimen Resource
Locator tool for finding biospecimen resources will be
highlighted.
Speakers:
William Grizzle, University of Alabama, Birmingham, AL
Mark Watson, Washington University, St. Louis, MO
Utilizing FFPE Tissues in Genomic Research
Section Moderator: Danielle Carrick, Epidemiology and
Genomics Research Program, Division of Cancer Control
and Population Sciences, National Cancer Institute,
Bethesda, MD
The second part of the session will focus on how formalinfixed paraffin-embedded (FFPE) tissue may be acquired
and used as a reliable alternative to fresh frozen tissue for
genomic cancer research. While most population-based
molecular studies use whole blood or fresh frozen tissue
418
specimens, FFPE tissue is more widely available and more
easily obtained. The potential utility of FFPE tissue as a
source of DNA and RNA for next generation sequencing
(NGS) would greatly enhance population-based cancer
studies. Moreover, translation of these technologies may
require understanding challenges and limitations of using
FFPE samples processed in non-uniform manners in clinical
settings. Speakers will discuss challenges and
considerations for obtaining and using FFPE tissue and
potential approaches to overcome those challenges.
Speakers:
Rulla Tamimi, Harvard School of Public Health, Boston, MA
P. Mickey Williams, Frederick National Laboratory for
Cancer Research, Frederick, MD
Normal Biospecimens and Reference Genomic Data: The
GTEx Project
Section Moderator: Helen M. Moore, Biorepositories and
Biospecimen Research Branch (BBRB), Division of Cancer
Treatment and Diagnosis, National Cancer Institute,
Bethesda, MD
The third part of the session will provide information about
acquiring normal tissue for research studies. The session
will provide an overview of the NIH Genotype Tissue
Expression (GTEx) project and highlight the operational,
Informatics, biospecimen, and data resources that have
been developed. The GTEx Project is a Common Fund
Project of the NIH that was designed to build the resources
and infrastructure for researchers to address the question
of how variability in genotype influences gene expression
and phenotypic endpoints in normal, non-diseased
individuals. This project has addressed and overcome many
of the challenges of normal tissue collection and has
developed a unique set of resources including standard
operating procedures (SOPs) for the acquisition, storage,
use and distribution of biospecimens; an IT infrastructure
that allows a standardized approach for acquiring,
annotating and tracking biospecimens; a biobank with
biospecimens from over 25 organ sites from 900 individual
donors; and a large dataset of genomic data available for
researchers through dbGaP.
Speakers:
Judith Keen, National Cancer Institute-BBRB, Bethesda, MD
Latarsha Carithers, National Cancer Institute-BBRB,
Bethesda, MD
REGULATORY SCIENCE AND POLICY SESSION (not eligible for CME credit)
Monday, 3:30 p.m.-5:30 p.m.
Integrating Patient-Reported Outcomes (PROs) into Regulatory Evaluation
Chairperson: Paul G. Kluetz, U.S. Food and Drug Administration, Silver Spring, MD
Patient-Reported Outcomes (PROs) have been defined as “any report of the status of a patient’s
health condition that comes directly from the patient, without interpretation of the patient’s response
by a clinician or anyone else.” When integrated into clinical trials, accurate and carefully obtained PRO
data can provide additional patient-centered information to inform regulators, clinicians, and patients
on the risks and benefits of a therapeutic product. The U.S. Food and Drug Administration, (FDA) has
previously released guidance on “Patient-Reported Outcome Measures: Use in Medical Product
Development to Support Labeling Claims” to provide recommendations for the design of PRO
instruments and clinical trials. While the Guidance is meant to apply across therapeutic areas, it has
become clear that oncology trials present unique challenges for PRO including frequent open label
and single-arm trial designs, missing data, lack of statistical rigor, and therapies that often cause
significant toxicity. There has been a redoubling of efforts to address these challenges by FDA and
others. This session will explore efforts being made by all stakeholders to improve PRO data from
cancer clinical trials with the goal of increasing the amount of PRO data in FDA labels. Representatives
from the FDA, industry, academia, and the patient advocacy community will discuss the opportunities
and challenges in assessing PRO in cancer clinical trials. The challenge of missing data will be further
explored including methods to mitigate this common problem.
A panel discussion will be moderated by Paul G. Kluetz, U.S. Food and Drug Administration, and
audience Q and A will follow the presentations.
Speakers:
Paul G. Kluetz, U.S. Food and Drug Administration, Silver Spring, MD
Patricia Spears, Cancer Survivor and Patient Advocate, Raleigh, NC
Lori M. Minasian, National Cancer Institute-DCP, Rockville, MD
Alicyn Campbell, Genentech, Inc., South San Francisco, CA
Laura Lee Johnson, U.S. Food and Drug Administration, Silver Spring, MD
Arturo Molina, Janssen Research and Development, LLC, Menlo Park, CA
419
Monday, 4:00 p.m.-5:00 p.m.
Meet the Editor-in-Chief of Molecular Cancer Research
Karen E. Knudsen, PhD
Interim Director, Sidney Kimmel Cancer Center
Interim Chair and Hilary Koprowski Endowed Professor,
Department of Cancer Biology
Professor of Cancer Biology, Urology Radiation Oncology and Medical Oncology,
Sidney Kimmel Medical College, Thomas Jefferson University
Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of
broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes
analyses performed at the molecular and cellular level that reveal novel mechanistic insight into
pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis
include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin
regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor
suppressors; and signal transduction), in addition to studies describing new molecular mechanisms
and interactions that support cancer phenotypes. For full consideration, primary research submissions
must provide significant novel insight into existing pathway functions or address new hypotheses
associated with cancer-relevant biologic questions.
420
AACR-ROSENTHAL AWARD LECTURE
Monday, 4:30 p.m.-5:30 p.m.
Terrace Ballroom II-III (400 Level), Pennsylvania Convention Center
Thirty-Ninth Annual AACR Richard and Hinda Rosenthal Memorial Award
Systematic Identification of Cancer Targets
William C. Hahn, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
The American Association for Cancer Research and the Rosenthal Family Foundation originally
established this award in 1977 to recognize research that has made notable contributions to improving
clinically based cancer care. In an effort to honor and provide incentive to early investigators, the
foundation has restricted award recipients to the age of 50 years at the time the award is presented.
Dr. William C. Hahn is honored for his seminal contributions to the understanding of the mechanisms
underlying cancer initiation, maintenance, and progression. Dr. Hahn’s work has defined new
conceptual paradigms and provided a foundation for novel therapeutic approaches that are now being
tested in the clinic. Dr. Hahn has pioneered the use of systematic approaches to understand cancer
phenotypes and has been a singular innovator in creating the means to create experimental cancer
models of defined genetic composition.
Adapting genetice methods used in model organisms, Dr. Hahn has performed a series of studies to
identify genes whose expression/function is essential in particular genetic contexts. Identifying these
codependencies or synthetic lethal partners provides the means to decipher the wiring of cancer cells
and also o identitify novel approaches to target tumor suppressor genes and oncogenes. Dr. Hahn’s
laboratory recently demonstrated that specific memembers of the proteasome and spliceosome are
required in cells that exhibit hemizygous loss of these genes. This work, together with recent work
from the DePinho and Ashworth laboratories, provides a rationale for how targeting sememingly
essential processes leads to enhanced responses in cancer compared to normal cells.
Dr. Hahn’s laboratory has also discovered that the transcriptional regular YAP1 is required for the
survival of colon cancers that harbor constitutively active b-catenin/WNT signaling and that the
serine-theronine kinase TBK1 is synthetic lethal partner that acts to promote tumor cell survival in
cancers depenedent on KRAS. Onoing work in Dr. Hahn’s laboratory has identified an oncogienic
DRAS-driven cytokine loop regulated by TBK1 that is amendable to pharmacologic inhibition of TBK1.
Clinical trials involving this small molecule inhibitor of TBK1 (CYT387, momelotinib) have started for
patients with KRAS mutant pancreatic and lung cancers.
Dr. Hahn has been a member of the Harvard Medical School faculty throughout his career, which is
where he also received his bachelor’s, medical, and doctoral degrees. Additionally, he was a resident at
Massachusetts General Hospital, a clinical fellow at the Dana-Farber Cancer Institute/Partners Cancer
Care Program, and a postdoctoral fellow at the Whitehead Institute.
Dr. Hahn’s dedication and innovative approaches to cancer research are continuing to transform
the field.
421
FORUMS
Monday, 5:00 p.m.-6:30 p.m.
Bridging the Gap between Academia and
Industry in Drug Discovery
Controversies in RAS Signaling:
Wild Type RAS, Tumor Suppressor or
Partner in Tumorigenesis?
Moderator: William Pao, Roche Pharma Early Research and
Development, Basel, Switzerland
Experts will discuss perspectives on drug discovery from
academia and industry, with a focus on how both can work
effectively together.
Panel:
Mace L. Rothenberg, Pfizer, Inc., New York, NY
Charles L. Sawyers, Memorial Sloan Kettering Cancer
Center, New York, NY
The Cancer Epigenome: Is Epigenetic
Deregulation the Chicken or the Egg?
Moderator: Stephen B. Baylin, Johns Hopkins University
School of Medicine, Baltimore, MD
It is apparent over the past 15 or so years that epigenetic
alterations, involving DNA methylation, chromatin, or both,
are a constant feature of virtually all cancer types. There is
a building theme that at least some of these abnormalities
are key drivers for cancer initiation and progression.
However, when these occur, and their importance, with
respect to occurrence of genetic changes for cancer
initiation especially are still widely debated. These
questions are heightened now that we know that
mutations in genes encoding regulators of the epigenome
are frequent in most cancer types. The chicken or egg
question inherent to these issues will be addressed by the
speakers in this session.
Panel:
Christopher J. Kemp, Fred Hutchinson Cancer Research
Center, Seattle, WA
Jean-Pierre J. Issa, Fels Institute for Cancer Research and
Molecular Biology, Philadelphia, PA
Moderator: Julian Downward, Cancer Research UK,
London, United Kingdom
Mutation of RAS genes leads to dominant gain of function
oncogenic changes as a result of loss of GTP hydrolysis
activity. However, it has also been observed that many
tumors with RAS mutations have also lost expression of
wild type alleles of the gene, suggesting the possibility
that wild type RAS could have a tumor suppressive role. On
the other hand, evidence has recently been found that wild
type RAS signaling can continue to fulfil an essential role in
cancer cells that is distinct to that of mutant RAS. We will
discuss the latest thinking regarding the role of wild type
RAS proteins in RAS mutant cancers and whether or not
targeting wild type RAS proteins is likely to be beneficial or
harmful in this context.
Panel:
Kevin M. Shannon, University of California, San Francisco, CA
Minh D. To, University of Toronto, Toronto, ON, Canada
Dietary Supplements and Cancer Risk
and Prognosis
Moderator: Cornelia M. Ulrich, Huntsman Cancer Institute,
University of Utah, Salt Lake City, UT
A large proportion of men and women in the United States
and worldwide use dietary supplements. Motivations are to
improve general health, reduce cancer risk and, for cancer
patients, to aid recovery and improve chances of survival.
What is the evidence in support of these expectations and
what are the potential harms associated with dietary
supplement use? This forum will discuss findings to date on
the benefits and risks of dietary supplements in cancer risk
and prognosis – highlights will include antioxidants, folate
and vitamin D, among others. Gaps in our knowledge, as
well as future research strategies will be discussed.
Panel:
Marian L. Neuhouser, Fred Hutchinson Cancer Research
Center, Seattle, WA
Tim E. Byers, University of Colorado Cancer Center,
Aurora, CO
422
Is MET Still a Relevant Target in
Lung Cancer?
Moderator: Pasi A. Jänne, Dana-Farber Cancer Institute,
Boston, MA
MET signaling plays an important role in biological
properties in cancers including cell migration, metastases,
and resistance to targeted therapies. Several strategies to
inhibit MET have been developed and have been or are
undergoing clinical evaluation. Many of these have been
conducted in patients with lung cancer and to date the vast
majority of the studies have been negative in the clinic. In
this session we will review the biology of MET and evaluate
the various therapeutic approaches. We will dissect whether
the negative clinical results are due to incomplete
understanding of MET biology, or to ineffective strategies to
inhibit MET or due to wrong clinical trial designs.
Panel:
Paolo M. Comoglio, Institute for Cancer Research and
Treatment - IRCC, Candiolo (Torino), Italy
D. Ross Camidge, University of Colorado Denver, Aurora, CO
Convention Center
Opportunities and Challenges in the Use of
Animal Models for Cancer Target Validation
and Drug Development
Moderator: Robert T. Abraham, Pfizer Pharmaceuticals,
San Diego, CA
Cancer researchers now have access to a diverse array of
preclinical cancer models, including conventional human
cell line xenografts, patient-derived xenografts (PDX), and
genetically engineered mouse models. These in vivo
disease models have yielded fundamental insights into
tumor biology, and have proven indispensable for the
validation of cancer drug targets, the testing of drug
candidates and combinations, and biomarker identification.
However, each animal model bears certain biological and
technical limitations that, depending on the specific
experimental setting, have important implications for both
the practical application of the model, and the relevance of
the preclinical results to the clinical diseasel. For example,
panels of PDX models of a specific cancer subtype permit
an assessment of inter- and intratumoral heterogeneity on
disease biology and drug responsiveness, but the
immunocompromised state of the host limits their
usefulness for studies of tumor-host interactions and
immunotherapeutic drug candidates. This Forum will
provide an opportunity for an open discussion of the
current opportunities and challenges stemming from the
use of animal models of human cancer, and of technical
advances on the horizon that might further enhance the
predictive potentials of these models in academic and
pharmaceutical research.
5:00 p.m.
Introduction
Robert T. Abraham, Pfizer Pharmaceuticals,
San Diego, CA
5:05 p.m.
Terry A. Van Dyke. Frederick National
Laboratory, Frederick, MD
5:20 p.m.
Benoit J. Van den Eynde, Ludwig Institute for
Cancer Research, Brussels, Belgium
5:35 p.m.
Neal Goodwin, Champions Oncology, Inc.,
Sacramento, CA
6:05 p.m.
Panel Discussion
423
AACR/ASCO JOINT SESSION
Monday, 5:00 p.m.-6:30 p.m.
Terrace Ballroom I (400 Level), Pennsylvania Convention Center
AACR/ASCO Joint Session: Obesity, Insulin Resistance, and Cancer
Co-Chairpersons: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Peter Yu,
Palo Alto Medical Foundation, Sunnyvale, CA
Excess body weight has been associated with increased breast cancer risk. This relationship has been
attributed to higher estrogen levels in women with high BMI. However, obesity is also associated with
high insulin levels and inflammation, there is a well-recognized crosstalk between estrogen receptor
and insulin/IGFs signaling, and hyperinsulinemic states – such as diabetes – are also associated with a
higher risk of breast cancer. All these suggest that insulin levels might be a dominant mechanism.
Along these lines, use of hypoinsulinemic agents such as metformin, has been correlated with better
outcome in cancer patients treated with chemotherapy. Speakers in this session will review the
pathogenic mechanisms linking obesity, hyperinsulinemia, and inflammation to breast cancer risk and
progression, as well as epidemiological studies in this area and therapeutic interventions which may
interfere with this signaling axis, thus providing opportunities for cancer prevention and treatment.
5:00 p.m.
Metabolic syndrome, inflammation, and cancer: The hidden risks of obesity
Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY
5:25 p.m.
Discussion
5:30 p.m.
The insulin/IGF-axis and cancer risk
Howard Strickler, Albert Einstein College of Medicine, Bronx, NY
5:55 p.m.
Discussion
6:00 p.m.
How insulin resistance relates to current cancer treatments
Michael N. Pollak, McGill University and Segal Cancer Centre, Montréal, QC, Canada
6:25 p.m.
Discussion
424
SCIENCE POLICY SESSION
Monday, 5:00 p.m.-6:30 p.m.
Tobacco Control and Electronic Nicotine Delivery Systems (ENDS)
Moderator: Roy S. Herbst, Yale Cancer Center, New Haven, CT
Combustible tobacco use remains the leading preventable cause of premature mortality, killing more
than five million people worldwide every year. We know that tobacco use is causally associated with
18 different cancers, including lung, head and neck, stomach, pancreas, and cervical cancers, and alone
tobacco accounts for 30 percent of all cancer deaths. In the past few decades, the rate of combustible
tobacco product use has declined, but there has been a recent, rapid increase in the use of electronic
nicotine delivery systems (ENDS), which include electronic cigarettes, or e-cigarettes, devices that are
capable of delivering nicotine in an aerosolized form. These devices have been promoted as potential
cessation products and safer alternatives to combustible cigarettes. However, at the present time
definitive data are lacking on the health consequences of ENDS use and their value as tobacco
cessation aids. Additionally, unlike combustible cigarettes and other tobacco products, ENDS are not
currently regulated by the U.S. Food and Drug Administration (FDA). Additional research is needed to
inform the regulation of ENDS and there is also a need for policies to aid in the minimization of the
potential negative public health consequences of these products, particularly youth initiation of ENDS
use. In this session the speakers will discuss additional research needs to inform the regulation of
ENDS, as well as the policy recommendations outlined in the recently released joint American
Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO)
statement that provides recommendations seeking to guide policymakers in the regulation of ENDS,
especially youth-oriented ENDS use and marketing, without undermining the potential of these
products to reduce harm as a smoking cessation tool.
Speakers:
Roy S. Herbst, Yale Cancer Center, New Haven, CT
Michele Bloch, National Cancer Institute, Rockville, MD
Replacement Speaker: Rachel Grana
Matthew L. Myers, Campaign for Tobacco-Free Kids, Washington, DC
Replacement Speaker: Danny McGoldrick
Peter G. Shields, The Ohio State University Comprehensive Cancer Center, Columbus, OH
425
Monday, 5:00 p.m.-6:30 p.m.
Howe Room, 33rd Floor, Loews Philadelphia Hotel
AACR Radiation Oncology Task Force Open Forum and
Networking Reception
Chairperson: Theodore S. Lawrence, University of Michigan, Ann Arbor, MI
All Annual Meeting attendees are invited to participate in this forum hosted by the AACR Radiation
Oncology Task Force. Ongoing AACR programs and initiatives related to radiation science and
medicine, including the recent Inaugural AACR Think Tank on Radiation Oncology and all next steps
for the Radiation Oncology Task Force will be discussed. A networking reception will be held following
all forum presentations and discussion.
Speakers:
Dennis E. Hallahan, Washington University School of Medicine, St. Louis, MO
Quynh-Thu Le, Stanford Cancer Institute, Palo Alto, CA
426
MICR TOWN MEETING (not eligible for CME credit)
Monday, 5:00 p.m.-6:30 p.m.
Commonwealth Hall A-B (Second Floor), Loews Philadelphia Hotel
Minorities in Cancer Research Town Meeting
Chairperson: Chanita Hughes-Halbert, Medical University of SC Hollings Cancer Center, Charleston, SC
This session is a can’t-miss for MICR members and Annual Meeting attendees. The MICR Town Meeting
provides an opportunity for the MICR Council to present its members, agenda, and programs to AACR
members and Annual Meeting participants. This meeting gives participants a chance to share ideas,
voice concerns, and express views on a variety of related topics. All Annual Meeting attendees are
invited to attend.
427
AACR-G. H. A. CLOWES LECTURE
Monday, 5:30 p.m.-6:30 p.m.
Fifty-Fifth Annual AACR G. H. A. Clowes Memorial Award
Finding Therapeutic Targets for Aggressive Prostate Cancer
Owen N. Witte, MD, FAACR
University of California, Los Angeles, CA
This award was established in 1961 by AACR and Eli Lilly and Company to honor Dr. G.H.A. Clowes, a
founding member of AACR and past research director at Eli Lilly and Company. The award recognizes
an individual that has had outstanding recent accomplishments in the field of basic cancer research.
Dr. Owen N. Witte is recognized for his many contributions to the understanding of human leukemias,
immune disorders, and epithelial cancer stem cells. His innovative work has revolutionized modern
cancer treatment by defining tyrosine kinases as crucial drug targets in human disease. These studies
have led to the development of several approved targeted therapies, transforming the lives of patients
with Philadelphia chromosome-positive leukemias and B-cell malignancies.
Dr. Witte has played a major role in the discovery of the ABL fusion oncoproteins in leukemia, defining
their properties as tyrosine kinases and characterization of their properties as oncogenes in mouse
models of leukemia. At UCLA, Dr. Witte was the first to show that Philadelphia chromosome, positive
CML cells had an abberant ABL protein with associated tyrosine kinase activity. Later Dr. Witte showed
that this BCR-ABL oncogene was sufficient to cause leukemias in mouse models. Based on this, he
predicted that CML patients should benefit from inhibition of the BCR-ABL oncoprotein. As they say,
the rest is history. Dr. Witte has provided the basis of a now very successful therapy for patients with
CML. His work over the past 25 years serves as the most compelling case of target validation in human
cancer and illustrates the critical importance of research in fundamental disease mechanisms to guide
the development of specific therapies.
In studies on growth control of immature B cells, Dr. Witte and colleagues also identified a new
cytoplasmic tyrosine kinase (BTK) and showed that its loss could lead to a block in B cell development
and proliferation. These studies again predicted that BTK is a valuable target in certain lymphomas
and autoimmune diseases. Again, history repeats itself, his fundamental insights into the biology of
BTK has resulted in the approval of Ibrutinib in 2013 for Chronic Lymphocytic leukemia and
Mantle Cell Lymphoma.
Dr. Witte is a member of the National Academy of Sciences and the Institute of Medicine of the
National Academies. Among his many recognitions are the Milken Foundation Award in Basic Cancer
Research, the Rosenthal Award of the AACR. He was recently also elected as a fellow of the American
Association for Cancer Research Academy. To these recognitions, he can now add the 55th Annual
AACR G.H.A. Clowes Memorial Award.
428
Monday, 6:00 p.m.-8:00 p.m.
Grand Ballroom Salon H (Level 5), Philadelphia Marriott Downtown
Joint Cancer Immunology (CIMM)/Tumor Microenvironment (TME)
Working Groups Evening Scientific Session
The emerging success of tumor immunotherapy heralds a new chapter in the treatment of advanced
cancers. This session, “The TME: Impact on Immunotherapeutic Responses,” will discuss how the TME
modulates the local and systemic immune response and how immune-based interventions can
redefine the TME. The Chairpersons of the Cancer Immunology (CIMM) and Tumor Microenvironment
(TME) Working Groups invite you to attend this evening scientific session to hear leaders from both
fields present the most current information on this topic.
6:00 p.m.
Chairperson, TME: Opening Remarks
6:15 p.m.
Functional role of stroma and tumor immunity in pancreas cancer
6:45 p.m.
The role of TOSO in CLL progression and immunotherapy
Tak W. Mak, Campbell Family Institute for Breast Cancer Res., Toronto, ON, Canada
7:15 p.m.
Modulation of innate immune function by the TME
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY
7:45 p.m.
Chairperson, CIMM: Closing Remarks
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY
429
MEG TOWN MEETING (not eligible for CME credit)
Monday, 6:30 p.m.-8:00 p.m.
Grand Ballroom Salons A-B (Level 5), Philadelphia Marriott Downtown
Molecular Epidemiology (MEG) Working Group Town Hall Meeting
Co-sponsored by the American Institute for Cancer Research (AICR)
This Town Hall Meeting, co-sponsored with the American Institute for Cancer Research (AICR),
includes a discussion on “The Continuous Update Project: Challenges in keeping the evidence on
nutrition, physical activity, and cancer up to date,” featuring Edward L. Giovannucci, MD, ScD, of the
Harvard School of Public Health. Additionally, Timothy R. Rebbeck, PhD, of the University of
Pennsylvania School of Medicine, and CEBP Editor-in-Chief, will provide an update on this exciting
journal. Come learn about these and other important MEG initiatives; meet members of the working
group and steering committee, and the newest MEG Scholar-in-Training Award recipients, in addition
to learning more about joining the MEG Working Group. A networking reception will follow.
6:30 p.m.
Chairperson: Opening Remarks
Susan M. Gapstur, American Cancer Society, Atlanta, GA
6:40 p.m.
Chairperson-Elect: Remarks
Jo L. Freudenheim, SUNY at Buffalo, Buffalo, NY
6:50 p.m.
Update on the Journal Cancer Epidemiology, Biomarkers & Prevention
Timothy R. Rebbeck, University of Pennsylvania School of Medicine, Philadelphia, PA
7:10 p.m.
The Continuous Update Project: Challenges in keeping the evidence on nutrition,
physical activity, and cancer up to date
Edward L. Giovannucci, Harvard School of Public Health, Boston, MA
7:30 p.m.
Closing Remarks
Jo L. Freudenheim, SUNY at Buffalo, Buffalo, NY
430
PROFESSIONAL ADVANCEMENT SESSION (not eligible for CME credit)
Monday, 6:30 p.m.-8:45 p.m.
Regency Ballroom (Second Floor), Loews Philadelphia Hotel
MICR Professional Advancement Reception and Roundtable: Navigating the Road to a
Successful Career in Cancer Research
Co-Chairpersons: A. William Blackstock, Jr., Wake Forest University School of Medicine, Winston-Salem, NC; Christopher I.
Li, Fred Hutchinson Cancer Research Center, Seattle, WA
This exciting Professional Advancement Session organized by the Minorities in Cancer Research Council provides a
reception, followed by a forum in which students, postdoctoral candidates, and junior faculty discuss important career
development issues and survival skills with senior established scientists. This event includes mentored roundtable
discussions facilitated by senior researchers from a variety of sectors in the cancer community, including academia,
government, and industry.
For AACR members, all 2015 Professional Advancement Sessions are free with your Annual Meeting registration (except for
the Grant Writing Workshop) and are an added benefit of your membership. For nonmembers, there is an additional fee of
$50 ($95 for the Grant Writing Workshop) for attendance at each session. If you are not an AACR member, we strongly
encourage you to join and take advantage of the many benefits of membership, which include attendance at these
sessions. Participation is on a first-come, first-served basis, and space is limited. Nonmembers are required to pay onsite.
Careers in Cancer: Industry
J. Carl Barrett, AstraZeneca Pharmaceuticals LP, Waltham, MA
Survival Skills: Junior Faculty
Lisa Baumbach Reardon, TGen, Phoenix, AZ
How to Set Up a Lab and Management of Resources
and Personnel
Wayne D. Bowen, Brown University, Providence, RI
Effective Leadership, Communication, and
Negotiation Skills
Marcia Cruz-Correa, University of Puerto Rico
Comprehensive Cancer Center, San Juan, PR
Career Transitioning: From Fellow to Junior Faculty
LaCreis R. Kidd, University of Louisville, Louisville, KY
Careers in Cancer: Academia
K. Sean Kimbro, North Carolina Central University,
Durham NC
What to Look for in a Good Mentor
Rick A. Kittles, University of Arizona Cancer Center,
Tucson, AZ
Career Transitioning: From Medical School to
Careers in Research
Xavier Llor, Yale University School of Medicine,
New Haven, CT
Careers in Cancer: Government
Beverly D. Lyn-Cook, FDA-NCTR, Jefferson, AR
Career Transitioning: From Graduate School to Fellow
Gustavo Miranda-Carboni, The University of Texas Health
Science Center at San Antonio, San Antonio, TX
How to Get Your Papers Published in Journals with a
High Impact Factor
Electra Paskett, Ohio State University Comprehensive
Cancer Center, Columbus, OH
Career Objectives: Clinical Fellow
Manuel L. Penichet, UCLA, Los Angeles, CA
How to Be a Good Mentor
Camile C.R. Ragin, Fox Chase Cancer Center, Philadelphia, PA
Survival Skills: Postdoctoral Level
Brian Rivers, Moffitt Cancer Center and Research Institute,
Tampa, FL
Effective Management, Communication, and Negotiation
Skills (for Junior Investigators)
Victoria L. Seewaldt, Duke University Medical Center,
Durham, NC
Survival Skills: Graduate Level
Christopher Sistrunk, Duke University, Durham, NC
Career Transitioning: From Junior Faculty to Tenure
Danny R. Welch, University of Kansas Cancer Center,
Kansas City, KS
More to be announced
431

monday, april 20 at-a-glance - American Association for Cancer

Transcription

Similar documents

Exsanguination - Northern Health

Tumor Antigens and Cancer Vaccines

Johnny Tremain by Esther Forbes Objectives

Pharmacy Guild Portal Instructions

Making a Shepard Fairey Style Poster

Assessing Response to Chemotherapy in Bone and Soft Tissue

Marketplace of Homes Marketplace of Homes

experienced. focused. evolving. just like you.

Alexander Palmestål Portfolio 2016 alexanderpalmestal.com

Pleomorphic Hyalinizing Angiectatic Tumor